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Abstract 
Commercial weight loss programmes (CWLPs) are structured weight loss 
programmes, which are provided to the public by commercial organisations for 
profit. These programmes offer a weight management service for overweight or 
obese adults who are willing and able to pay for their participation. There are few 
studies that have shown CWLPs are more effective than either usual or standard care 
in various healthcare settings. The extent to which elements of CWLPs contribute to 
weight reduction is not clear from these studies.  
 
The studies presented in this thesis aimed to i) systematically review the 
effectiveness of CWLPs in randomised controlled trials and ii) to evaluate the 
effectiveness of a pharmacist-led weight management clinic, Boots Pharmacy 
Weight Loss Programme (BPWLP), in achieving meaningful weight loss of the 
initial body weight at three months in overweight and obese clients who received a 
combination of orlistat, and diet and exercise advice.  
 
The systematic review evaluated percentage weight loss or change and used a 
narrative synthesis. Nine electronic databases (1980-2011) were searched. The 
review studies published in English were included and their quality was assessed, 
including assessment of risk of bias. The number of total titles, abstracts and full 
articles reviewed were 8484, 772 and 153, respectively. The final number of papers 
included in the review was 20 randomised studies of CWLPs, which were selected 
based on the application of inclusion and exclusion criteria.  
 
The evaluation of the BPWLP involved analysis of data from randomly collected 
customer record forms (CRFs) for clients who participated in the programme from 
January 2006 to January 2009. Five hundred and fifty-seven records were collected 
from 10 Boots pharmacies. Demographics data, history information, biometric data 
and information about the supply of orlistat were collected. Change in body weight 
(kg) was compared at baseline and three months using Wilcoxon Signed Rank Test.  
 
 ii 
 
Seventy percent of the studies included in the systematic review were conducted in 
the US. There were three potential elements of effective CWLPs, which were calorie 
restriction, exercise and support. At 12 weeks, mean weight loss ranged from 3.3 to 
12.7 kg.  
 
The mean weight loss in the BPWLP was 5.8 kg (p < 0.001). Similarly, sensitivity 
analysis using last-observation-carried-forward (LOCF) showed a statistically 
significant weight loss (p < 0.001) associated with the BPWLP. Sixty-two percent of 
clients, who completed the BPWLP, lost at least 5% of their initial body weight at 
three months. Although the BPWLP had a high dropout rate (70%), clients mainly 
left the programme because they achieved their desired weight loss.  
 
The studies presented in this thesis have shown that CWLPs are effective in helping 
clients to lose weight. The systematic review shows that the combination of calorie 
restriction, structured exercise and support is an effective first-line strategy in obesity 
treatment. The BPWLP, which uses orlistat 120 mg in combination with advice and 
support on diet and exercise, was shown to be effective in achieving weight loss for 
clients and is considered a second-line treatment. Health care professionals and 
policy makers should acknowledge and adopt such strategies in order to tackle the 
problem of obesity. In particular, pharmacists have an important role to play in 
facilitating effective weight reduction through the provision of dietary and exercise 
advice and the prescribing of orlistat. Further study should focus on the factors which 
contribute to long-term weight maintenance and the cost-effectiveness of CWLPs.  
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Chapter 1 
Introduction and background 
 
This first chapter provides the background and rationale for the study and structure of 
the thesis. It also presents a review of the literature relevant to this research. The 
main topic areas covered are: health care systems in the UK, overview of obesity, 
principles of prevention and treatment of obesity, anti-obesity medicine, pharmacist-
led weight management clinics, pharmacist interventions, the role of the pharmacist 
in obesity management and pharmacy practice in the UK. Finally the aim and 
objectives of the study are described. 
 
1.1 Introduction  
Since the mid-1980s, obesity has become an important problem of global concern as 
there is a worldwide obesity epidemic with its resulting public health problems.1 The 
World Health Organisation (WHO) predicts that obesity affects approximately 400 
million adults worldwide and by 2015 will affect 700 million adults.2, 3 In the United 
States (US), the prevalence of being overweight or obese increased from 12.8% to 
22.5% between 1960 and 1994. The rise in obesity in the US is continuing; in 2005, 
31% of adults were obese.4, 5 Similarly in European countries, the prevalence of 
obesity has continually increased in both adults and children. In the United Kingdom 
(UK) obesity, which is one of the most common health problems, has tripled since 
1980 and also has the highest prevalence amongst European countries. In 2003 and 
2004, around 15% of men and 18% of women in England were obese.6-8 By 2007 
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almost one quarter (24%) of both were obese.9 However, the latest estimates predict 
obesity will double by 2050 when half the population will be obese. 
 
With such high levels of obesity in the UK many studies have advocated rigorous 
weight-loss interventions such as nutrition counselling, physical activity, behavioural 
modification and social support.10, 11 These interventions may be able to achieve and 
maintain weight loss in some individuals but they have not been widely 
implemented. Other studies suggest that pharmacological treatment can be an 
effective adjunct to dietary and lifestyle interventions in the treatment of obesity.12-14 
 
The first-line strategy in obesity guidelines recommends that people maintain a 
KHDOWK\ZHLJKWE\EDODQFLQJµFDORULHVLQ¶DQGµFDORULHVRXW¶ and eating a healthy diet. 
This strategy is to LPSURYHSHRSOH¶Vgeneral health and reduce the risk of developing 
diseases related to obesity.15 Other strategies to help people achieve and maintain a 
healthy weight include increasing physical activity levels, lifestyle or behavioural 
interventions which should be undertaken for at least three months for the effects to 
be seen. Where people are struggling to lose weight with lifestyle modification, then 
pharmacological treatment should be considered. Pharmacotherapy, alongside a 
restricted calorie diet and increased exercise, is a second line treatment. However, 
there are several options available to reduce weight including reduced-energy diets, 
physical activity, behaviour modification and surgery.16  
 
In the UK there are many providers of weight loss programmes. Such programmes 
can be either accessed through National Health Service (NHS) or commercial 
sources. Commercial weight loss programmes (CWLPs) provide an opportunity for 
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support in losing weight for patients who are prepared to pay to participate. Although 
the CWLPs are effective in achieving weight loss for overweight or obese people, it 
was essential to ascertain for health care providers whether or not CWLPs are more 
effective in weight reduction than either usual or standard care.17 The extent to which 
CWLPs could contribute to reducing the obesity epidemic is unclear.  
 
Community pharmacy is an ideal venue for weight management interventions. 
However, there is insufficient evidence as to the effectiveness of community 
pharmacy-based weight management interventions.18 To support effective weight 
loss in a community pharmacy, Boots Pharmacy Weight Loss Programme (BPWLP) 
was designed to support overweight or obese clients in losing weight. This CWLP 
involves the pharmacist providing the service which combines the supply of orlistat 
120 mg with advice and support about diet and physical activity.  
 
This thesis focuses on CWLP. CWLPs are defined as structured weight loss 
programmes initiated by organisations delivering the intervention for profit, and 
include where this is in the form of the provision of vouchers or partial subsidies. 
This study excluded non-commercial weight loss programmes (NCWLPs), which are 
defined as weight loss interventions offered free of charge to the user for both short- 
and long-term approaches, supported by government organisations, private health 
care provided as a part of health insurance, from charities or social enterprises. 
 
This thesis aims to investigate the effectiveness of CWLPs, using a systematic 
review and evaluation of a pharmacist-led weight management service in the UK.  
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1.2 Structure of the thesis 
There are the five further chapters in this thesis which are described below. 
 
Chapter two reports a systematic review of CWLPs. This study aims to assess the 
effectiveness of CWLPs in helping overweight and obese adults to lose weight. 
 
Chapter three describes a pilot study to evaluate a community pharmacy CWLP. The 
pilot study was conducted to test the data collection method and database, together 
with assessing the quality of the data held in pharmacies and to provide estimates for 
the sample size calculation for the main study. The amendments to the study method 
for the main study are then discussed. 
 
Chapter four describes a retrospective evaluation of a pharmacist-led weight 
management clinic. The aims of this phase of the study are to evaluate the 
effectiveness of a pharmacist-led weight management clinic in achieving weight loss 
for obese clients through a combination of orlistat supply, diet, exercise and advice.  
 
Chapter five presents the development and testing of a questionnaire to evaluate 
FOLHQWV¶YLHws of the Boots Pharmacy Weight Loss Programme (BPWLP).  
 
Chapter six, the discussion, draws together the findings and discussion from the two 
studies. Then the practical implications for health care professionals and policy, 
together with the strengths and limitations of the study, are discussed. 
Recommendations for further research in both providing evidence for CWLPs and 
improving them are presented.  
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1.3 Background 
1.3.1 Health care systems in England 
The NHS was the first state organization in the world to provide free universal 
healthcare. In the UK, health care is mainly provided by NHS free of charge at the 
point of service for patients, being funded from general taxation.19 Although health 
care in the UK is primarily provided by the NHS, private health care and a variety of 
alternative treatments are available for people who are willing and able to pay for 
them. 
 
1.3.1.1 Public health care 
Public health care provided by the NHS includes family doctors, specialists, dentists, 
pharmacists, opticians and the ambulance service. Services related to sight tests, 
dental treatment, prescriptions and many aspects of personal care are not free.19 The 
NHS provides for anyone who is resident in the UK including EU nationals, students 
(on courses longer than 6 months) and anyone with a British work permit. 
 
1.3.1.2 Private health care  
Private health care in the UK aims to help people make the right choice for any 
treatment. It is funded by private insurance and is used by less than 8% of the UK 
population. Where private health care is used, it is generally to top up NHS services. 
Recently, some of the unused private sector capacity has been used to increase NHS 
capacity.20 The involvement of the private health care sector remains comparatively 
small: 1.6% of Gross Domestic Product (GDP) in 201021 compared with the public 
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health care sector. Obesity treatment and weight management programmes are 
provided by both the private and public health care sectors.20  
 
1.3.2 An overview of obesity 
1.3.2.1 Definition and classification of obesity 
The worldwide obesity epidemic is an important problem of global concern.22, 23 
Obesity is defined using the body measurements, body mass index (BMI) and waist 
circumference (WC).22, 24 BMI is used to predict fat mass in the body which is 
calculated by dividing weight in kilogram (kg) by the square of height in metres 
(m2). The interpretation of BMI levels for adults, aged 18 years and over, is that a 
BMI of 30 kg/m2 or more defined as obesity ± see Table 1.1.  
 
Table 1.1 Classification of overweight and obesity based on BMI  
Weight category BMI (kg/m2) Obesity class 
Underweight <18.5 - 
Normal 18.5 to 24.9 - 
Overweight 25.0 to 29.9 - 
Obese 30.0 to 34.9 Class I 
Obese  35.0 to 39.9 Class II 
Extreme Obesity   Class III 
Source: Bjorntorp P. Definition and classification of obesity. Eating Disorders and Obesity, in C.G. Fairburn and 
K.D. Brownell (eds.). New York: The Guildford Press, 2002.23 
 
Measuring waist circumference (WC) is commonly used in adults as a measure of 
central adiposity as BMI cannot differentiate body fat mass and muscular physique. 
A WC greater than 102 cm for men and 88 cm for women is defined as overweight 
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or obese. A raised BMI, together with a high WC, indicates an increased impact of 
being overweight or obese on health and therefore a heightened risk of co-
morbidities.23, 24 Table 1.2 shows BMI and WC with the level of associated risk. 
 
Table 1.2 Relationship between measurements of obesity and level of associated risk for type 
2 diabetes mellitus, hypertension and cardiovascular disease 
Item BMI (kg/m2) 
Disease Risk Relative to Normal Weight and Waist 
Circumference 
0HQFPLQches), 
:RPHQFPLQches) 
Men >102 cm (>40 inches), 
Women >88 cm (>35 inches) 
Underweight <18.5 - - 
Normal 18.5 to 24.9 - - 
Overweight 25.0 to 29.9 Increased High 
Obesity I 30.0 to 34.9 High Very high 
Obesity II 35.0 to 39.9 Very high Very high 
Obesity III  Extremely high Extremely high 
Source: ASHP therapeutic position statement on the safe use of pharmacotherapy for obesity management in 
adults.24 
 
Obesity is also a risk factor for a number of conditions that result in increasing 
mortality. The BMI standards were developed using Western populations and these 
are the standards accepted in most obesity guidelines, including those of the WHO.  
 
The evidence from non-Western populations suggest that the standard applied should 
vary. The Japan Society for the Study of ObesiW\-$662FODVVLILHV%0,kg/m2 
as obese and China uses a BMI of greater than 28 kg/m2 to classify adults as obese.25 
Waist measurement standards are also different in some populations; in China a WC 
of over 85 cm in men and 80 cm in women conveys added risk of a raised BMI. A 
study by Woo et al.26 found that WC was a useful measure in predicting mortality 
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and cardiovascular risk in elderly people. Similarly Janssen et al.27 suggests waist 
measurement can explain the health risks; nevertheless BMI remains a significant 
predictor of the obesity-related health risks.28  
 
1.3.2.2 Causes and risks 
Causes of obesity can be divided into two main areas:29-31  
x At an individual level a combination of both environmental and genetic 
causes leads to obesity. Environmental causes include increasingly sedentary 
lifestyles, lack of physical activity, family influence and overconsumption of 
energy. Overconsumption may be due to eating too many calories, high fat 
intake, low energy expenditure compared with calories consumed and also 
socio-economic factors32-34 such as low family income, low education levels 
and married. Genetic causes, which influence obesity arise from processes in 
the body, such as reduced metabolic rate and raised blood glucose 
metabolism.  
x At societal level increasing rates of obesity are due to an easily accessible diet 
and the increased reliance on cars.  
 
Within both of these areas, contributors to the increase in obesity levels have been 
identified as insufficient sleep, decreased rates of smoking (due to the effect of 
smoking in suppressing appetite) and increased use of medication.29, 31 The co-
morbidities that increase morbidity and mortality in obese people are heart disease, 
type 2 diabetes, stroke and sleep apnoea ± see Table 1.3. People who have three or 
more co-morbidities will raise morbidity and mortality.29 
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Table 1.3 Co-morbidities associated with obesity  
Main co-morbidities Other co-morbidities 
Coronary Heart Disease  High blood pressure 
Type 2 diabetes mellitus Dyslipidemia: LDL* > 160 mg per dL/4.14 mmol 
per L, HDL** < 35 mg per dL/0.91 mmol per L 
Stroke Hypercholesterolemia 
Sleep apnoea Gastrointestinal cancers 
 Osteoarthritis 
 Respiratory diseases 
*LDL = low-density lipoprotein cholesterol, **HDL = high- density lipoprotein cholesterol 
Source: Berke EM, Morden NE. Medical Management of Obesity.29 
 
1.3.3 The obesity epidemic  
The WHO predicts that obesity affects approximately 400 million adults worldwide 
and by 2015 will affect 700 million adults.3 It is an increasingly important issue in 
both developed and developing countries.  
 
1.3.3.1 A worldwide problem 
In the US, the prevalence of being overweight or obese increased from 12.8% to 
22.5% between 1960 and 1994.4 The increased prevalence of obesity is seen in both 
men and women.35 The rise in obesity levels in the US is continuing: in 2005, 31% of 
adults were obese5 Similarly in European countries, obesity has increased since the 
mid-1980s ± see Table 1.4. 
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Table 1.4 Studies measuring the prevalence of obesity in both developed and developing 
countries  
Study 
(Year, 
Country) 
Method Sample Number of 
participants 
Age 
(years) 
The prevalence of 
obesity (%) 
Men Women Total 
North America  
Ogden, et al 
(2006, 
US)35 
NHANES 
Measured 
Multistage 
sample  
4,431 in  
1999-2000 
 
20+ 
 
27.5 
 
33.4 
 
30.5 
   2003-2004 20+ 33.9 40.1 37.0 
Mokdad, et 
al (2003, 
US)36  
Cross-sectional 
survey: Self-
reported 
Random digit 
telephone 
sample 
195,005 18+ 21.0 20.8 20.9 
Flegal, et al 
(1998, US)4 
National survey: 
Measured, self-
reported in 
1988-1994 
The complex, 
stratified and 
multistage 
probability 
cluster 
sampling  
1960-1962 
1971-1974 
1976-1980 
1988-1994 
20-74 
20-74 
20-74 
20-74 
10.4 
11.8 
12.3 
20.0 
15.0 
16.2 
16.5 
24.9 
12.8 
15.2 
14.5 
22.5 
Bélanger-
Ducharme, 
F. & 
Tremblay, 
A. (2005, 
Canada)37 
Cross-sectional 
survey: Self-
reported and 
measured 
weight and 
height 
Systematic 
sampling 
1970-1972 
1988-1992 
2003 
20-69 
20-69 
18+ 
8.0 
13.0 
15.9 
13.0 
15.0 
13.9 
10.5 
14.0 
14.9 
Europe  
Gallus, et al 
(2006, 
Italy)38 
Interview 
survey: Self-
reported 
Multistage 
stratified 
sampling 
1993-1994 
2,932 in 
2004 
15+ 
18+ 
- 
7.4 
- 
8.9 
7.0 
8.2 
Carmo, et al 
(2006, 
Portugal)39 
Cross-sectional 
survey: Self-
reported 
Systematic 
sampling  
 
4,328 in 
1995-1998 
6,411 in 
2003-2005 
18-64 
 
18-64 
12.9 
 
14.6 
15.4 
 
13.3 
14.1 
 
13.8 
Milewicz, et 
al (2005, 
Poland)40 
Observational 
study: No details 
of BMI 
measurement 
- 1993 
2003 
1993 
2003 
20-40 
20-40 
40-60 
40-60 
6.3 
6.5 
15.7 
23.6 
8.9 
15.0 
22.5 
36.1 
7.6 
10.7 
19.1 
29.8 
Martínez, et 
al (2004, 
Spain)41 
Cross-sectional 
survey: Self-
reported 
Systematic 
sampling  
9,885 in 
1990-2000 
25-60 13.4 15.7 14.5 
Note: - = Data unavailable  
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Table 1.4 (continued)  
Study 
(Year, 
Country) 
Method Sample Number of 
participants 
Age 
(years) 
The prevalence of 
obesity (%) 
Men Women Total 
Europe  
Neovius, et al 
(2004, 
Sweden)42 
The Survey of 
Living 
Conditions: 
Self-reported 
weight and 
height 
Random 
sample 
12,000-
15,000 in 
1988/1989 
 
16-84 
 
 
5.2 
 
 
5.6 
 
 
5.4 
 
   1996/1997 16-84 6.8 7.2 7.0 
   2002/2003 16-84 10.6 9.9 10.3 
Helmert, U. & 
Strube, H. 
(2004, 
Germany)43 
Cross-
sectional 
survey: No 
details of BMI 
measurement 
- 26,614 in 
1985-1998 
2002-2003 
 
25-69 
25-69 
 
16.2 
22.5 
 
 
16.2 
23.5 
 
16.2 
23.0 
Visscher, et al 
(2002, 
Netherlands)44 
Longitudinal 
survey: 
Measured 
Systematic 
sampling 
17,008 in 
1976-1980 
7,510 in 
1987-1991 
4,623 in 
1993-1997 
29,141 in 
1993-1997 
37-43 
 
37-43 
 
37-43 
20-59 
4.9 
 
7.4 
 
8.5 
8.5 
6.2 
 
7.6 
 
9.3 
9.6 
5.6 
 
7.5 
 
8.9 
9.1 
Lahti-Koski, 
et al (2000, 
Finland)45  
Cross-
sectional 
survey: 
Meaured 
Random 
sample 
24,604 in  
1982 
1987 
1992 
1997 
 
25-64 
25-64 
25-64 
25-64 
 
15.4 
17.5 
19.9 
19.8 
 
17.2 
20.2 
19.5 
19.4 
 
16.3 
18.9 
19.7 
19.6 
Gutiérrez-
Fisac, et al 
(2000, 
Spain)46  
Cross-
sectional 
survey: Self-
reported 
Multistage 
stratified 
sampling in the 
primary units  
Simple random 
sampling in the 
secondary 
units (census 
districts) 
14,676 in 
1987 
7,004 in 
1995/1997 
37-43 
 
37-43 
 
7.6 
 
12.3 
8.9 
 
12.1 
8.2 
 
12.2 
Note: - = Data unavailable 
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Table 1.4 (continued) 
Study 
(Year, 
Country) 
Method Sample Number of 
participants 
Age 
(years) 
The prevalence of 
obesity (%) 
Men Women Total 
Europe  
Maillard, et 
al (1999, 
France)47  
Cross-sectional 
survey: Self-
reported 
Multilevel 
stratified 
random 
sample 
13,942 in 
1980 
15,106 in 
1991 
20+ 
 
20+ 
6.4 
 
6.4 
6.3 
 
7.8 
6.35 
 
7.1 
Other developed countries 
Thorburn, 
A.W. (2005, 
Australia)48 
Cross-sectional 
survey: 
Measured 
Systematic 
sampling 
1980 
11,247 in 
1999-2000 
25-64 
25+ 
- 
19.3 
- 
22.2 
7.1 
20.8 
Kanazawa, 
et al (2002, 
Japan)25 
Japan Society 
for the Study of 
Obesity 
(JASSO): 
Measured 
- 150,000 in 
1997 
15+ 1.6 2.7 2.2 
The developing countries 
Rguibi, M. 
& Belahsen, 
R. (2007, 
Morocco)49 
National 
survey: 
Measured 
Random 
sample 
41,526 in 
1984/1985 
14,028 in 
1998/1999 
20+ 
 
20+ 
1.6 
 
4.3 
6.4 
 
16.0 
4.1 
 
10.3 
Madanat, et 
al (2007, 
Jordan)50 
Cross-sectional 
survey: 
Measured  
Random 
sample 
2003 
800 in 2004 
18+ 
18+ 
- 
- 
13.0 
18.5 
- 
- 
Wu, Y. 
(2006, 
China)51 
National 
Nutrition and 
Health Survey: 
No details of 
BMI measured 
- 140,022 in 
2002 
18+ - - 7.1 
Grabauskas, 
et al (2003, 
Lithuania)52 
Cross-sectional 
survey: Self-
reported 
Random 
sample 
 
3,000 in 
2002 
20-64 16.2 15.8 16.0 
Galal, O.M. 
(2002, 
Egypt)53 
Cross-sectional 
survey: 
Measured  
Systematic 
sampling 
5395 in 
1994  
4,883 in 
1998-1999 
20+ 
 
20+ 
- 
- 
20.0 
(U) 
6.0 
(R) 
41.7 
(U) 
27.6 (R) 
45.2 
(U) 
20.8 (R) 
- 
- 
32.6 
 
13.4 
Note: - = Data unavailable 
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Table 1.4 (continued)  
Study 
(Year, 
Country) 
Method Sample Number of 
participants 
Age 
(years) 
The prevalence of 
obesity (%) 
Men Women Total 
The developing countries 
Puoane, et al 
(2002, South 
Africa)54 
Cross-sectional 
survey: 
Measured 
Stratified 
and 
systematic 
sampling 
13,089 in 
1998 
15+ 9.7 22.1 15.9 
Ismail, et al 
(2002, 
Malaysia)55 
National Health 
Morbidity 
Survey: 
Measured  
Systematic 
sampling 
28,737 in 
1996 
20+ 4.0 7.6 5.8 
Abdul-
Rahim, et al 
(2001, 
Palestine)56 
Cross-sectional 
survey: 
Measured 
Systematic 
sampling 
485 (U) 30-65 30.0 48.8 39.4 
Misra, et al 
(2001, 
India)57 
Cross-sectional 
survey: 
Measured* 
Systematic 
sampling 
532 (U) 18+ 13.3 15.6 14.5 
Monteiro, et 
al (2000, 
Brazil)58 
National survey: 
Measured 
Multistage 
stratified 
clustering 
sampling 
15,585 in 
1989 
10,680 in 
1997 
20+ 
 
20+ 
4.7 
 
6.9 
12.0 
 
12.5 
8.4 
 
9.7 
Note: - = Data unavailable, U = Urban, R = Rural, * = BMI > 25 kg/m2 
 
1.3.3.2 A UK issue 
Obesity has tripled in the UK since the mid-1980s59 resulting in the UK having the 
highest prevalence of obesity among European countries, thus it is a major problem 
facing the country ± see Table 1.5. Obesity has risen in both men and women. In 
1995 the proportion of the Scottish population that was obese was 1% higher in both 
men and women, compared with England. This trend has continued and in between 
2003 and 2004, Scotland60 had a higher prevalence of obesity than both England6 and 
Wales.8   
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Table 1.5 The prevalence of obesity in the UK  
Study 
(Year, 
Country) 
Method Sample Number of 
participants 
Age 
(years) 
The prevalence of 
obesity (%) 
Men Women Total 
The United of Kingdom 
NHS (2009, 
UK)9  
The Health 
Survey for 
England (HSE): 
Measured 
Random 
sample  
198059 
- 15,284 in  
1993/1994 
- 6,328 in 
2005 
- 11,920 in 
2007 
16+ 
16+ 
 
16+ 
 
16+ 
6.0 
13.2 
 
22.1 
 
24.0 
8.0 
16.4 
 
21.9 
 
24.0 
 
7.0 
14.8 
 
22.0 
 
24.0 
 
Wardle, J. & 
Boniface, D. 
(2008, 
England)61 
The Health 
Survey for 
England (HSE): 
Measured 
Random 
sample  
- 20,246 in 
1993/1994 
- 11,708 in 
2002/2003 
18+ 
 
18+ 
13.4 
 
22.7 
15.8 
 
22.4 
14.6 
 
22.6 
Joint Health 
Survey Unit 
(2008, 
England)62  
The Health 
Survey for 
England (HSE): 
Measured and 
self-reported 
Random 
sample  
- 24,115 in 
2006 
16+ 24.0 
 
24.0 
 
24.0 
 
Department 
of Health 
(2005, 
England) 63 
The Health 
Survey for 
England (HSE): 
Measured 
Random 
sample  
- 84,626 in 
2004 
16+ 23.0 
 
24.0 
 
23.5 
 
The Scottish 
Executive 
(2005, 
Scotland)60  
The Scottish 
Health Survey: 
Measured and 
self-reported 
Random 
sample  
- 13,375 in 
2003 
16+ 22.0 26.0 24.0 
Welsh 
Assembly 
Government 
(2008, 
Wales)64 
Welsh Health 
Survey: Self-
reported 
Random 
sample  
2005/2007 16+ 20.0 20.0 20.0 
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1.3.3.3 Summary of the worldwide prevalence of obesity 
Many countries, especially developed countries such as the US, saw an increase in 
obesity between the 1970s and the mid 2000s that was generally greater for women 
than for men.4, 35, 37, 65 Since 2000, several European countries have observed an 
increase in obesity similar to the US.38, 40, 42, 43 In the UK,61 the recent data shows a 
similar prevalence in both genders,66, 67 similar to Finland.45 All studies cited also 
suggested that obesity changed over time according to gender and age differences.68  
 
1.3.4 Principles of prevention and treatment in obesity management 
The principles of prevention and treatment in obesity management are to achieve and 
maintain healthy weight in individuals. Prevention strategies aim to help people 
maintain a healthy weight, and treatment aims to achieve and sustain weight loss in 
those who are already overweight. Public health policy for obesity is based on health 
promotion and combines many approaches such as encouraging environmental 
changes, educating obese people to balance healthy eating with physical activity, and 
identifying effective and culturally appropriate interventions. These approaches 
attempt to improve the prevention and treatment of obesity so that people are more 
likely achieve the healthy benefits of being a normal weight.  
 
1.3.4.1 Principles of prevention in obesity 
The rationale of obesity prevention is to tackle the development of either overweight 
RU REHVH LQGLYLGXDOV¶ RYHU WLPH DQG WKH KHDOWK FRQVHTXHQFHV DVVRFLDWHG ZLWK
obesity.66 One approach, which is related to whole communities, is the population 
approach.69 This population approach is based on health education programmes 
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promoting healthier lifestyles such as a reduction of saturated fat intake, smoking 
cessation, reducing serum cholesterol and reducing blood pressure. This approach 
also involves the cooperation of agricultural producers, food manufacturers and 
marketing companies in order to persuade consumers to make better choices. 
Additionally, it also requires healthcare professionals to be providing education on 
the appropriate behavioural changes needed to reduce risk of weight gain, especially 
advice targeted at local food preferences and the promotion of leisure facilities to 
improve exercise habits.66, 70  
 
1.3.4.2 Principles of treatment in obesity 
The goals of obesity treatment are to achieve and to maintain weight loss. The 
requirement for REHVLW\ WUHDWPHQW LV EDVHG RQ DQ DVVHVVPHQW RI SDWLHQWV¶ QHHG WR
UHGXFH WKHLUZHLJKW3DWLHQWV¶ WUHDWPHQW VHOHFWLRQ Ior obesity is guided not only by 
WKH LQGLYLGXDOV¶ %MI and health condition but also by their previous weight loss 
attempts. Patients should select their treatment options with consideration of safety, 
efficacy and cost.  
 
This treatment recommendation can be seen as a three-stage process:70 
1. Stage One: Classification decision 
People are divided into four levels of BMI classification. 
2. Stage Two: Stepped-Care decision 
When one approach is unsuccessful a more intensive intervention may be 
justified, such as a weight loss programme, taking into consideration cost as 
risk of side effects.  
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3. Stage Three: Matching decision 
This stage is a final treatment selection that is EDVHG RQ WKH LQGLYLGXDOV¶
previous weight loss attempts, treatment preferences and need for weight 
reduction.  
 
In addition, selecting treatment is also dependent RQSDWLHQWV¶SUHYLRXVZHLJKW ORVV
attempts which requires a multimodality approach through both reducing energy 
intake and increasing energy output.70 Strategies for reducing energy intake consist 
of diets and medicines.  
 
Diets 
The diet approach aims to reduce fat consumption and provide low energy density in 
the diet. For example, low carbohydrate diets are using foods with a lower glycemic 
index or lower glycemic load thus reducing the total amount of carbohydrate. High 
protein diets are part of low-fat intake that could enhance weight maintenance. Very 
low-calorie diets (VLCD) or very low energy diets are formulated to substantially 
reduce the caloric intake. The lower the energy intake, the more rapid the weight 
loss. This approach is used for long-term weight loss and weight maintenance, and 
also can be used in combination with reducing total fat intake, reducing portion size, 
reducing energy density, reducing calories and increasing fruit and vegetable 
intake.70  
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Anti-obesity medicines 
Anti-obesity medicines are less commonly used and are yet to be established as 
acceptable in the context of the long-term safety.70 When weight-loss medicines are 
stopped, weight may be regained. This approach is used when patients become less 
motivated or find it difficult to persist with the long-term changes in eating and 
activity, and they need to lose weight and avoid weight regain to reduce their health 
risks.71  
 
Exercise 
Exercise is the single best predictor of long-term weight maintenance but is less 
likely to predict weight loss in the short term.70 Patients who aim to achieve the long-
term weight maintenance should be physically active for 30-60 minutes per day on a 
least five days per week.70 
 
In addition, the treatment of obesity involves FKDQJLQJ SDWLHQWV¶ ORQJ-term 
behaviour, changes that will include self-monitoring, environmental modification 
and social support70 ± see Table 1.6. 
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Table 1.6 Behaviour change for weight loss 
Behaviour change 
techniques 
Example Suggestions for implementation 
Self-monitoring Monitor energy intake Calorie counting/restriction, 
daily food record 
 Keep track of exercise activity Set realistic goals for time and 
distance walked e.g. increase 
walking in the daily life or using 
stairs instead of a lift 
Environmental modification Permanent change in eating habits Eating more fruits and 
vegetables, limiting sweetened 
drinks/not adding sugar to 
drinks 
 Be mindful of weight loss goals 
while grocery shopping 
Buy fruits and vegetables 
 Reduce consumption of food 
outside the home 
Avoiding take away food, 
avoiding eating out at 
restaurants 
 Increase physical activity Increase walking in the daily 
life, going to the gym or using 
stairs instead of a lift 
Social supports Family A family can help to increase 
exercise and avoid temptation. 
 General practice or other health 
care professionals 
Refine optimistic strategies, 
facilitate follow-up appointment 
Source: Thompson WG, et al. Treatment of Obesity.70 
 
A combination of the weight loss strategies is more likely to succeed than any single 
strategy alone. GPs DQGRWKHUKHDOWKFDUHSURIHVVLRQDOVFDQDVVLVWSDWLHQWV¶HIIRUWs to 
reduce portion size, count food calories and plan menus. To increase the chances of 
success, strategies for weight loss should be tailored to the patient through discussion 
between the patient and their GP.70 
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1.3.5 Anti-obesity medicine 
Since 1998, there has been a dramatic increase in the prescribing of anti-obesity 
medicines. Anti-obesity medicines are not first line treatments but are recommended 
for patients who have not been successful with other treatments, such as lifestyle 
modification. A management pathway for the appropriate prescribing of anti-obesity 
medicines is shown in Figure 1.1.16  
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Figure 1.1 A management pathway for the appropriate prescription of anti-obesity medicine 
Source: Anti-obesity Drugs: Guidance on Appropriate Prescribing and Management: A report of the Nutrition 
Committee of the Royal College of Physicians of London.16 
 
  
Primary intervention:
- Diet
- Physical activity
- Behaviouralmanagement
Start of episode of care
Drug treatment
(following specific 
licence requirements)
- Continue drug treatment
- Monthly monitoring of 
weight loss/weight 
maintenance
- Duration of treatment 
determined by success and 
product license
5% or greater weight loss
- Drug treatment discontinued
- Other advice reinforced
- Other treatment options 
considered
Less than 5% weight loss
- Failure to achieve 5-10% 
weight loss goal
- Consider drug treatment if : 
BMI 30 kg/m2 or greater, or 
BMI 27 kg/m2 or greater with 
risk factors
- Fulfill medical criteria for 
drug treatment
12 weeks
Weight regain
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1.3.5.1 Orlistat 120 mg (Xenical®) 
Currently, there is only one recommended anti-obesity medicine which acts on the 
gastrointestinal system. Orlistat 120 mg72, 73 was launched in the UK in December 
199874 ± see Table 1.7.  
 
Table 1.7 Orlistat used in the treatment of obesity 
 Orlistat 120 mg (Xenical®) 
Indications A potent inhibitor of both gastric and pancreatic lipase, reduces the 
absorption of approximately 25% of dietary fat. The approved indication is 
alongside a reduced-calorie, low-fat diet and exercise programme.  
Overweight or obese adults aged 18-75 years with a 
1. BMI of 28 kg/m2 or more in the presence of significant comorbidities  
2. BMI of 30 kg/m2 or more.  
Lose an initial minimum of 2.5 kg with diet and physical activity 
Within 3 months, weight loss should be around 5% of body weight and 
10% after 6 months  
Can be continued longer than 12 months after a discussion between patient 
and professional 
Cautions May impair absorption of fat-soluble vitamins 
Contra-indications Chronic malabsorption syndrome, cholestasis, breastfeeding and pregnancy 
Interactions Fat-soluble vitamins such as vitamins A, D, E, K and beta-carotene take at 
bedtime to help ensure adequate vitamin intake 
Oral anticoagulants including warfarin, thyroid medicines, amiodarone, 
oral contraceptives and antidiabetic agents 
Side-effects Altered bowel habits: Include fatty oily stool (steatorrhea), gas with oily 
spotting, faecal urgency and faecal incontinence  
Vitamin malabsorption 
Dose Adults over 18 years: Take orlistat during or up to an hour after each meal 
containing fat  
Daily dose: 120 mg 3 times daily 
Note: The dose of orlistat can be omitted when patients miss a meal or food 
contains no fat. 
Source: Midland Therapeutic Review & Advisory Committee (MTRAC). Summary Sheet for: Orlistat (Xenical®) 
for the treatment of obesity: Department of medicines management, Keele University, March 2001.74 
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There has been a study examining the effectiveness of using orlistat 120 mg in 
combination with a non-pharmacological intervention, which suggested that the 
group of patients who received a personalised reduced energy diet in discussion with 
a family physician and dietician as well as orlistat, achieved a greater percentage 
weight reduction than the group of patients who only received the reduced energy 
diet. This shows that prescribing orlistat in combination with other approaches is 
effective in the management of obesity.13 
 
1.3.5.2 Supply of prescription anti-obesity medicines 
The previous studies reviewed, that discussed the supply of prescription anti-obesity 
medicines, were mainly in relation to NCWLPs ± those offered free of charge to the 
user (as defined on page 3).  
 
A study by Kaya et al.75 found that the efficacy of sibutramine, orlistat or 
combination of both medicines on short-term weight management in obese patients 
was significantly better than dietary regimens alone. However, they were not able to 
establish whether one therapy was superior to the other. A US study of anti-obesity 
medication use by Stafford and Radley76 found that orlistat prescribing was higher 
than sibutramine, even when it was newly released in 1999. Additionally, patients 
demonstrated increases in heart rate and blood pressure as side effects of 
sibutramine.76 However, sibutramine,77 which acts on the central nervous system, 
was withdrawn in the European Union in early 2010.78  
 
Similar studies in the UK have shown that orlistat is the most frequently prescribed 
anti-obesity medication in the UK. The number of prescriptions written for orlistat 
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rose 36-fold from 17,800 to 646,700 between 1998 and 2005 compared with 
sibutramine where the increase was 4-fold from 53,393 to 227,000 between 2001 and 
2005.79 Until recently orlistat has only been available on prescription or under a 
patient group direction (PGD) in pharmacist-led weight management clinics. In April 
2009, orlistat 60 mg was reclassified in the UK as a pharmacy medicine (P).  
 
Derosa et al.80 found that in obese patients with hypercholesterolemia, orlistat 
significantly reduced BMI, waist circumference (WC), body weight (BW), systolic 
blood pressure and diastolic blood pressure at 6 and 12 months compared with 
baseline.80 A study adding orlistat to a weight management programme (personal diet 
and meetings with physicians and dieticians) resulted in patients being more likely to 
achieve their weight reduction goals than those on the programme alone.13 In contrast 
Poston et al.81 found no differences in patients on orlistat alone compared with 
combining this with brief counselling. Orlistat has also been shown to improve 
physical ability in patients with chronic kidney disease (CKD) after 12 months, 
alongside reductions in BW and WC.82 Similarly in overweight patients with type 2 
diabetes other benefits in addition to weight loss have been found for orlistat - 
namely reductions in fasting blood glucose, low-density lipid (LDL) cholesterol and 
blood pressure.83, 84 Overweight patients who achieved weight loss of RIWKHLU
initial weight with orlistat at 12 months, continued to lose more weight at 18 
months.14  
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Patients who used orlistat and achieved a considerable weight reduction also 
benefited from decreased BW, blood pressure and fasting blood glucose at three and 
six months.75, 80 Most studies measured those changes before and after treatment, and 
also followed up at 12 months as the end point.  
 
1.3.5.3 Supply of over-the counter Orlistat 60 mg (Alli®) 
Orlistat 60 mg (Alli®) has been approved for OTC supply in the management of 
obesity.85 It was launched in the US in 2007 and has been used by millions of 
people.86 In the European Union, orlistat 60 mg was approved in October 2008 and 
marketed in the UK from April 2009. OTC orlistat is licensed for use in overweight 
people (BMI of 28 kg/m2 or over), aged 18 years old or over and taken in 
conjunction with a mildly hypocaloric diet and low fat diet. Efficacy is similar to 
orlistat 120 mg ± see Table 1.8. Patients taking orlistat 60 mg mostly lost at least 5% 
body weight within the first year of treatment although this weight loss was less 
likely than if treated with orlistat 120 mg. It could be concluded that the efficacy of 
prescription strength orlistat is not different from OTC strength orlistat in the 
treatment of obesity. Pharmacists have been issued with guidance about sale of OTC 
orlistat which includes eliciting information from patients, ensuring the medicine will 
be safely used and advising about adverse effects87 ± see Table 1.8.  
 
OTC orlistat is available for pharmacists to supply directly to their patients. OTC 
orlistat is another product where community pharmacists can become involved with 
ORQJHUWHUPWKHUDS\DQGPRQLWRULQJSDWLHQWV¶SURJUHVV7KH27&DYDLODELOLW\DOORZV
patients to have more choice in the methods used to reduce their weight and 
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furthermore governments can potentially save health service costs related to 
reductions in prescribing.88-90  
 
Table 1.8 Summary of the efficacy of orlistat 60 mg TID in the treatment of obesity 
Study No. of patients 
Dose 
(mg) 
Duration 
(mo) 
BMI 
(kg/m2) 
% of Patients 
ZLWK
weight loss 
Comments 
Hauptman, 
et al.91 
212 P 
213 O  
210 O 
 
 
 
60 
120 
 
0-12 
 
30-44 31 
49 
51 
 
Patients treated taking 
orlistat 120 mg were more 
likely to lose 5% of their 
initial weight than those 
taking orlistat 60 mg in 
year 1. However, both 
groups lost significantly 
more weight than placebo. 
 122 P 
154 O 
151 O 
 
60 
120 
12-24 30-44 24 
34 
34 
In year 2, patients in both 
groups lost the same 
percentage of body 
weight. 
Rössner, 
et al.92  
244 O  
242 O 
243 P 
120 
60 
0-12 28-43 63 
63 
44 
Patients taking orlistat 120 
mg and 60 mg 
significantly lost 5% from 
the first weight more than 
those with placebo. 
 159 O 
140 O 
136 P 
120 
60 
12-24 28-43 65 
56 
38 
Patients with both orlistat 
120 mg and 60 mg 
significantly increased the 
weight loss in year 2. 
Hill, et 
al.93 
    Body weight 
regain (%) 
Patients treated with 
orlistat 120 mg regained 
less weight than others. 
 181 O 
173 O 
187 O 
188 P 
120 
60 
30 
 
 
0-12 
 
 
28-43 
32 
47 
53 
56 
 
Anderson, 
et al.94 
    % of baseline 
weight lost 
The efficacy of orlistat 
was greater than placebo.  
 196 O 
195 P 
60 4 25-28 4.2 (3.6 kg) 
2.6 (2.2 kg) 
 
Note: O = Orlistat, P = Placebo 
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Orlistat 60 mg (Alli®) is unlike other products available without prescription for 
weight loss because it is a proven medicine that has been shown to be effective 
alongside a reduced-calorie, low-fat diet and exercise programme.95, 96 Studies of 
orlistat found that patients who used this drug following the dosing directions 
tolerated the medicine well and the safety was similar to the prescription dose.94 
Although patients reported gastrointestinal (GI) effects such as diarrhoea, abdominal 
pain, flatulence, nausea/vomiting, rectal discharge and faecal incontinence, they still 
reported high satisfaction with orlistat in weight loss therapy. Orlistat is not only 
recommended as a safe and effective medicine in treating obesity but for its benefit 
in improving quality of life of those patients.97, 98  
 
1.3.5.4 Supply via Patient Group Direction  
Definition of Patient Group Direction 
A Patient Group Direction (PGD)99 is a written direction relating to supply and/or 
administration of a licensed medicine or prescription only medicine (POM) to 
persons and is signed by a doctor or dentist and a pharmacist.  
 
Treatment issued under a PGD can be provided by a specified range of health care 
professionals such as a pharmacist or nurse, without the patient first seeing a doctor 
or dentist. PGDs are usually a local arrangement between groups of health care 
professionals looking after the health needs of the local area; however they can also 
be national arrangements. Services using PGDs can be developed in the private 
sector, as in Boots pharmacies.99 The BPWLP is a national PGD which aims to assist 
clients to lose weight. PGDs are required to set out in detail the conditions under 
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which a POM can be supplied without prescription including the details of the health 
care professionals who have made the agreement ± see Box 1.1.  
 
A PGD contains information as follows:  
x The name of the body to which the direction applies 
x The date that direction comes into force and expires 
x A description of the medicine  
x The clinical conditions 
x A description of patients who are excluded from the treatment under the direction 
x A description of the circumstances under which further advice should be sought from a doctor 
(or dentist, as appropriate) and arrangements for referral made 
x Appropriate dosage and maximum total dosage, quantity, pharmaceutical form and strength, 
route and frequency of administration, and minimum or maximum period of the medicine should 
be administered 
x Relevant warnings including potential adverse reactions 
x Details of any follow-up action and the circumstances 
x A statement of the records to be kept for audit purposes 
Box 1.1 Information required in private Patient Group Directions IRUSKDUPDFLVWV¶
authorisation to supply medicines 
Source: Boots. Boots Pharmacy Weight Loss Programme (BPWLP) overview.99 
 
Boots Private Patient Group Direction of Orlistat 120 mg 
The purpose of the PGD is to enable pharmacists to provide orlistat to patients within 
the setting of a pharmacy authorised by the independent medical agency (IMA). 
Boots pharmacies have been able to provide customers with greater access to 
treatments through private PGDs since registering as an IMA with the Healthcare 
Commission (HCC) in 2003. To deliver private PGDs, a pharmacist must receive 
authorisation from the IMA after completing specific training and being assessed by 
an authorised sign-off person (ASP).99  
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Boots pharmacy offers private PGDs to provide easier access for customers to 
appropriate and effective treatments for a wide range of conditions and to extend the 
SKDUPDFLVW¶s and team members roles to further develop their skills and knowledge 
in order to offer a new professional service.99 Customers can have access to well 
trained healthcare professionals offering a high standard of service and advice and 
following-up appointments at the end of month one, three, six, 12, 18 and 24 ± see 
Appendix 1.  
 
1.3.6 Pharmacy practice in the UK 
Over 90% of both healthy and ill people visit community pharmacies in the UK.24, 100 
Community pharmacies are the most accessible site for healthcare services such as 
health promotion in the community.101 As a consequence, pharmacy has the potential 
to maintain the combination of safety, accessibility and reliability of medicine supply 
to extend the role of the pharmacist.102  
 
1.3.6.1 The traditional role of the pharmacist 
Pharmacists can assist patients in making healthy lifestyle choices due to their 
credibility as health professionals and their accessibility in the community 
pharmacy.103 In the UK community pharmacists provide both NHS and commercial 
services.104 Anderson104 reviewed how the role of the community pharmacist has 
been changed in professional practice and also found that pharmacists were involved 
in health promotion and training for their future role. In pharmacy practice, health 
issues have increasingly been promoted by pharmacist105, 106 ± see Table 1.9.  
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Table 1.9 Examples of traditional and newer roles of the pharmacist 
Traditional roles of the pharmacist Newer roles of the pharmacist 
- Dispensing prescriptions written by doctors 
- Supplying quality medicines 
- Ensuring medicines supplied and prescribed is 
legal and appropriable 
- Advising patients about medicines that included 
taking medicines and interactions with drug and 
food 
Essential services 
- Dispensing, repeat dispensing via electronic 
prescription service (EPS) 
- Disposal of medicines 
- Promotion of healthy lifestyles and self care for 
patients with minor ailments 
- Advising and signposting other healthcare 
professionals about safe and effective medicines 
use for patients 
- Supervising the production and preparation of 
medicines  
Advanced services: Providing services to patients 
such as medicine review, smoking cessation, 
blood pressure, cholesterol measurement, etc. 
Enhanced services:107 Providing local services 
such as minor ailment schemes, supplementary 
prescribing, sexual health care 
 
In order for pharmacists to achieve some of these future roles they will need to work 
more closely with GPs and other health professionals. Examples of such services 
are:102  
x Health checks in pharmacies ± since 2004 Boots pharmacies have offered 
cardiovascular health checks by monitoring people who have been diagnosed 
with a cardiovascular condition by their GP.  
x Medicines supply services such as smoking cessation support with NRT 
(Nicotine Replacement Therapy) supply, influenza vaccinations and 
Chlamydia screening and treatment. 
x Self-care support. Medicine use reviews and Internet support for public 
access about health. 
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1.3.6.2 The role of the pharmacist in obesity management 
Pharmacists can play an important role in obesity management. Obesity is considered 
an area where pharmacists can contribute to the health of both individuals and the 
population ± see Box 1.2.  
 
The role of the pharmacist in combating obesity has been described as follows:  
x Providing advice on risks from therapy, benefits of treatment, selection of weight-loss agents, 
appropriate counselling and behavioural change such as healthy eating and increasing daily 
activity 
x Supporting people to lose weight and promotion of healthy lifestyles to prevent people becoming 
overweight and obese  
x Communicating with customers about the health advantages of losing weight 
x Being sympathetic to people who are suffering from chronic disease 
x Reinforcing the importance of changing their lifestyle to improve and maintain weight loss 
x Increasing frequency of people contact that can improve the success of weight loss and 
maintenance efforts 
x Signposting by informing patients of other resources such as the relevant websites about weight 
loss products and making referrals if necessary as having high blood pressure or blood glucose 
level 
x Providing the safe supply of anti-obesity medicines:  
o Warning about adverse effects, drug interactions, the potential impurities of herbal products 
and product utilization 
o Identifying and monitoring appropriate individual to use weight-loss medicines to maximise 
safety and efficacy 
x Collaborating with other health care professionals 
Box 1.2 The role of the pharmacist in obesity 
Source: Bottorff M. Role of the Pharmacist.108 Chambers R, et al. Supporting Self Care in Primary Care. Oxford: 
Radcliffe Publishing Ltd, 2006.109 
 
Boots have additional requirements for their employed pharmacists providing weight 
management consultations. Pharmacists are required to become familiar with the 
process which involves counselling and paperwork, a clearly understanding of record 
keeping and the till process, learning how to effectively manage their time and 
requiring store as What Good Looks Like (WGLL).99  
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Pharmacy providing the service should comply with What Good Looks Like 
(WGLL) requirements as set out by Boots. The WGLL checklist includes:99  
x The consultation room: Appropriate and ready for use 
x Support staff: Adequately trained and aware of the programme 
x Dispensary staff: Clearly make the necessary records 
x All necessary equipment: Available 
x Appointment diary: In place 
x Patient records: Filed appropriately and confidentially 
x Pharmacist: Appropriate clinical training and understanding the PGD 
complaints procedure 
x Engaging customers by advertising (including leaflets) or through promotion 
by a satisfied customer or partner, pharmacist, team member, or healthcare 
professional.  
 
Pharmacists provide the full obesity management consultation under four categories, 
which are 1) customer service: welcome and general conduct during consultation, 2) 
management of the consultation: smooth flow of the consultation with target times 
met, 3) consent and customer understanding: proper consent from patients and ensure 
their understanding and 4) information: delivering, seeking and recording.99  
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1.3.6.3 Pharmacy medicines 
The 1968 Medicines Act defined pharmacy medicines that can be obtained without a 
prescription form under the supervision of a qualified pharmacist. Since 2009, 
politicians have responded to a perceived public demand for readier access to 
medicines, and increasing numbers of medicines have been reclassified from POM 
(prescriptions-only medicines) to P (pharmacy medicines). Only pharmacies can sell 
pharmacy medicines, and pharmacists must supervise the sale.110 
 
Most pharmacy medicines are used in the treatment of minor ailments or injuries, for 
health promotion and to assist patients in making healthier lifestyle choices such as 
orlistat for obesity.110  
 
1.3.6.4 Pharmacist-led weight management clinics 
In the UK, obesity is a huge public health issue and reducing obesity is a health 
promotion priority. The 2008 Government White Paper potentially included the 
community pharmacy as a source for weight loss programmes.111 Pharmacists 
contribute to weight management as a part of a health check in height, weight, blood 
pressure and blood sugar, and the provision of advice and support by following the 
scheme of using patient group directions to facilitate the supply of prescription-only 
medicine. 
 
A systematic review by Gordon et al.18 found that the effectiveness of long-term (12 
months) community pharmacy weight management interventions showed a mean 
weight loss from 1.1 to 4.1 kg. They also reported the clinically significant weight 
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loss was five to six percent of the initial body weight at three and six months. Studies 
in this review showed unclear evidence for the effectiveness of weight management 
programmes in the community pharmacy. All weight loss interventions were 
delivered by at least one pharmacist with or without support staff involvement. This 
review also indicated some studies with high-quality of community pharmacy-based 
weight management. 
 
1.3.7 Weight loss programmes 
1.3.7.1 Weight loss strategies  
Weight loss occurs when there is a negative energy balance, that is, energy 
expenditure is greater than energy intake from food and drink. There are a wide 
range of weight loss strategies available from health professionals to help patients 
lose weight. Table 1.10 provides the advantages and disadvantages of the most 
common weight loss strategies that include CWLP such as Weight Watchers (WW) 
and Jenny Craig (JC).112  
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Table 1.10 Summary of weight loss strategies 
Weight loss strategies Advantages Disadvantages 
Low carbohydrate diet  
(< 20 g/day) 
Increase in protein intake 
Show a greater weight loss than low 
fat diets at 6 months 
Increase malnutrition because of 
cutting out some of the core food 
elements 
Not recommended in patients with 
osteoporosis, kidney disease or 
LDL cholesterol 
Low fat diet  
(30-50 g/day) 
Decrease dietary fat intake without 
reducing volume of food intake 
Reduce good fats as well as bad 
fats 
May increase sugar content and 
glycaemic index 
Portion control (calorie 
controlled for all foods) 
Use portion plates and select smaller 
packages 
Provide the pictorial guides to 
simply educate overweight or obese 
people for all food levels 
May face to the oversized 
packaging, dinnerware and 
utensils 
Require education in appropriate 
portion sizes 
Meal replacement:  
- Low energy diet:     
3.4-5.0 mj/day 
- Very low diet:             
< 3.4 mj/day 
Good for such people who have 
difficulty choosing or preparing 
meals and controlling portions 
Well designed programme for a 
comprehensive weight loss 
programme 
Lack of following up from some 
weight loss programme 
May not improve long term 
dietary behaviours 
Reducing energy intake makes 
metabolism slow and needs to 
compensate metabolic 
mechanisms 
Exercise Regular exercise is good for health 
Can be free and enjoyable 
Decrease risk of mortality that 
related to BMI 
Unable to achieve weight loss if 
standing alone 
Exercise over an hour of brisk 
walking per day may be 
impractical without dietary 
modification 
Behavioural intervention This strategy is suited to individual 
needs 
Need dietary change 
Medicine e.g. Orlistat Be effective when using in 
conjunction with diet, exercise and 
lifestyle modification 
Need to combine with other 
therapies 
Need evidence for long term 
safety and effectiveness 
Side effects 
Expensive 
Source: Clark A, et al. Overweight and obesity ± use of portion control in management.112 
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1.3.7.2 Commercial weight loss programmes  
Defining commercial weight loss programmes 
CWLPs are defined as structured commercial weight loss programmes provided to 
the public by an organisation delivering the intervention for profit, including the 
provision of vouchers or partial subsidies. Examples include: 
x US: WW, JC, Health Management Resources (HMR), Nutrisystem, 
eDiets.com,113 LEARN 
x UK: Slimming World (SW), Rosemary Conley (RC), LighterLife (LL) 
x European country: Weight Balance (Finland) 
 
US commercial weight loss programme 
In the US, approximately 55% of Americans were considered overweight or obese in 
1998.114 Millions participated in commercially available weight loss programmes.115 
In 1987, there were approximately 13,000 US weight loss programmes and products 
such as commercial weight loss clinics, physician-supervised programmes, low-
calorie foods, artificial sweeteners and diet books.114 These programmes are directly 
purchased by consumers or provided through health insurance cover. 
 
In the US, there are Federal Trade Commission116 guidelines for providers of CWLPs 
± these cover content, pricing and effectiveness of programmes.114, 115 
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In the US many commercial programmes involve diet and exercise such as Weight 
Watchers (WW) and Jenny Craig (JC) or meal replacement such as Health 
Management Resources (HMR), eDiets.com and LEARN. Examples of these 
programmes are described below.  
 
Weight Watchers 
WW is the largest worldwide CWLP and aims to help members succeed in achieving 
their weight loss goals. This programme not only provides dietary counselling and 
group support through weekly meetings but also has a range of food products which 
clients can purchase in supermarkets. WW additionally provides support via 
electronic applications such as computers or smart phone. Meeting leaders are 
trained by the company for at least 6 weeks about setting weight loss goals, 
achieving and maintaining weight loss, the use of dietary supplements and increasing 
exercise. After training, group support leaders are able to advise their clients and 
refer clients to their physicians, if needed. Costs of WW are covered by a 
membership fee and weekly meeting fees. 
 
Jenny Craig  
JC is the second largest CWLP and aims to help clients to succeed in their weight 
loss by changing their lifestyle and eating habits. This commercial programme also 
provides individual dietary counselling and pre-packaged meals. Once clients reach 
their weight loss target, they no longer need to rely on the programmes or 
consultations in order to maintain their healthy lifestyle. Nevertheless, they may 
continue to attend this programme for their weight maintenance. The standard plan of 
this programme lasts one year. Additionally, the programme offers telephone support 
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24 hours a day, 7 days a week. Costs of JC are covered by a membership fee and 
daily food purchases from the company. 
 
Health Management Resources  
HMR is a meal replacement weight loss programme introduced in 1983 and aims to 
establish medical and behavioural weight loss interventions in hospitals, medical 
schools and medical practices. This programme offers three dietary options for 
weight loss which includes a VLCD, a combination of meal replacements and 
conventional foods, and a telephone-based programme. The costs of HMR are 
covered by fees for the 12 week treatment programme, fees for the initial history, 
physical examination, physician visits, laboratory tests and programme classes, in 
addition to the meal replacement purchases that clients make. 
 
eDiets.com  
eDiets.com is an Internet-based commercial programme that offers professional 
dietary, nutritional and exercise advice through the website. This programme also 
prescribes an individualised hypocaloric diet for 12 weeks. Clients who participate in 
this programme are required to purchase and prepare their own meals while the 
programme provides additional services within the 13-week membership package, 
weekly online chats and individualized e-mail counselling from experts.114 
 
LEARN  
The LEARN programme for weight control is a lifestyle behaviour-change 
programme. LEARN stands for the five key components which are Lifestyle, 
Exercise, Attitudes, Relationships and Nutrition. The LEARN programme also 
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provides supplements to other weight management programmes including 
commercial ones. The LEARN programme consists of 16 weekly lessons that 
address different aspects of weight control, following a commencement lesson 
(including a master list of 158 lifestyle change techniques, the Weight Loss 
Readiness Test and a comprehensive index) and offers group programmes with 
health professional instructors and one-on-one counselling.117 This programme is the 
first training and certification programme to offer multidisciplinary training in both 
weight and stress management. It has also been used as a self-study or self-help 
programme in support groups with a professional counsellor or in individual face-to-
face counselling with a health professional. 
 
Summary of US commercial weight loss programmes 
US CWLPs include the programme components (diet, physical activity and 
behaviour modification), effectiveness of the programme and costs.116 All CWLPs 
mentioned about price because people can consider price and ultimate benefits if/as 
they prepare themselves to attend the programme.  
 
UK commercial weight loss programmes 
In the UK, CWLPs are a widely available option for overweight and obese people.17 
Weight loss programmes have also been delivered in partnerships with NHS primary 
care organizations such as Slimming World (SW),118 Rosemary Conley (RC) and 
LighterLife (LL).119  
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Slimming World  
SW is a commercial slimming organization with weekly group sessions led by 
consultants.118 Members are able to lose weight through a combination of its µFood 
Optimising¶ eating plan, moderate activity WKURXJK WKH µBody Magic¶ programme, 
group support and shared experience with other slimmers by encouraging behaviour 
change. The cost of being a member of Slimming World is approximately £4.95 per 
week.120  
 
Rosemary Conley 
RC is the name of an English business woman who is the founder and president of 
RC Diet and Fitness Clubs.121 This weight management club is one of biggest three 
weight loss organizations alongside SW and WW.122 This CWLP aims to provide 
overweight and obese people with assistance to help them lose weight and to 
encourage both groups to adopt a healthy lifestyle. This programme also includes 
diets and physical activity. Prices of RC depend on membership status and treatment 
duration.122  
 
LighterLife 
LL simply aims to assist overweight and obese people to lose weight. This 
programme combines nutritionally balanced weight loss foods with VLCD meal 
plans and motivation by counselling. The initial phase lasts for 100 days and during 
this time people use the food packs provided and attend weekly counselling sessions. 
If they wish to lose more weight after the initial phase, they can continue with this. 
When they have achieved their target weight, there is a long-term weight 
maintenance programme where they slowly return to conventional food whilst 
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reducing reliance on and use of the food packs. Costs of LL include food packs and 
counselling sessions, and cost members approximately £66 per week.123  
 
Summary of UK commercial weight loss programmes 
UK CWLPs emphasise diet, physical activity and maintenance support. Details of 
three CWLPs above have included price because people can consider costs and 
ultimate benefits before they decide whether or not to attend the programme.  
 
Commercial weight loss programme in other countries 
Lastly, CWLPs in other countries include programmes such as the Finnish provided 
Weight Balance® programme.  
 
Weight Balance 
Weight Balance is a mobile phone-operated weight-loss programme, launched in 
Finland in 2001.124 This programme provides a daily calculated diet and physical 
activity plan for energy requirements of participants. Weight Balance also advises on 
UHGXFLQJSDUWLFLSDQWV¶IRRGLQWDNHE\OHDYLQJRXWXQQHFHVVDU\IRRGVParticipants set 
their weight loss goal for 12 weeks and after they have reached their target, they can 
switch to a weight maintenance programme.  
 
In the UK, little research has been conducted to evaluate the effectiveness of 
CWLPs. The effects on weight reduction, changes in BMI, blood pressure, blood 
glucose and presence or absence of risk factors still have to be established. There is a 
gap in the literature concerning research assessing the provision of CWLPs from 
community pharmacies. There are currently pharmacist-led clinics for weight 
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management. For example, many larger Boots stores offer a weight management 
programme which includes the provision of lifestyle advice, regular weight checks 
and the supply of orlistat via a private PGD. The next section describes the Boots 
Pharmacy Weight Loss Programme. 
 
1.3.7.3 Boots Pharmacy Weight Loss Programme  
BPWLP99 is a programme designed to help medically overweight or obese customers 
lose weight and is led by a pharmacist. This CWLP uses orlistat 120 mg in 
combination with advice and support on diet and physical activity. Customers who 
participate in this programme can decide to attend consultations at the pharmacy at 
monthly or 3 monthly intervals. The cost of the BPWLP to the patient is £62.50 and 
£125.00 for four and 12 weeks, respectively. There is no membership fee; however, 
if customers have a Boots Advantage Card, they will receive discounts for attending 
this programme99 ± see Table 1.11. This programme can be used as a model for 
weight management in community pharmacies, using PGDs to supply orlistat 120 
mg outside the scope of the NHS.125  
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Table 1.11 Comparison of Boots Pharmacy Weight Loss Programme and NICE obesity 
treatment recommendations 
NICE pathway for the appropriate 
prescription of anti-obesity medicine 
Boots Pharmacy 
Weight Loss 
Programme 
How BPWLP meets NICE 
standards 
Considering drug treatment if:     
BM,kg/m2 or greater, or      
%0,kg/m2 or greater with risk 
factors 
9 +DYLQJ%0,kg/m2 RU
kg/m2 with at last one co-
morbidity related to risk factors  
Fulfilling medical criteria for drug 
treatment (orlistat 120 mg) 
9 Providing supply of orlistat via 
private PDG combination with 
SKDUPDFLVW¶VFRQVXOWDWLRQ 
Having exclusion criteria such as 
pregnant, breast-feeding, insulin-
dependent diabetes, any present 
liver; gall bladder or jaundice, 
surgery for weight loss, 
gastrointestinal malabsorption 
problems, sensitivity to orlistat 
and any concomitant medication  
Weight loss < 5% of the initial 
weight 
- Drug treatment discontinued 
- Other advice reinforced 
- Other treatment options considered 
9 Customers who failed to achieve 
their minimum weight loss 
required discontinuing the 
programme and could attend this 
programme after 12 weeks.  
:HLJKWORVVRIWKHLQLWLDO
weight 
- Continue drug treatment 
- Monthly monitoring of weight 
loss/weight maintenance 
- Duration of treatment determined 
by success and product license 
9 Customers decided to continue the 
weight loss programme if they had 
their weight loss at least 5% of the 
initial weight and have followed-
up maximum two years. 
3DWLHQWV¶DJH\HDUVDQGROGHU 9 3DWLHQWV¶DJHEHWZHHQDQG
years  
 
BPWLP was launched in May 2005 and has been available in over 200 stores since 
13 July 2009 in the UK offering the service which consists of: 
x A consultation and assessment by an authorised pharmacist 
x Comprehensive support and advice on healthy eating and physical activity 
x Supply of a prescription only medicine (orlistat 120 mg, Xenical®) 
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x Discount on Boots branded low calorie products (Shapers) and Exercise 
equipment for Advantage card holders only 
 
Based on the criteria of Boots Pharmacy Private PGD, customers eligible for 
BPWLP should have a BMI equal to or greater than 30 kg/m2 or 28 kg/m2 with at 
least one co-morbidity related to risk factor. Exclusion criteria are pregnancy, breast-
feeding, insulin-dependent diabetes, liver disease; gall bladder or jaundice, surgery 
for weight loss, gastrointestinal malabsorption problems, sensitivity to orlistat and 
any concomitant interacting medicines such as amiodarone, acarbose or ciclosporin.  
 
All customers who met the inclusion criteria had the service explained before 
deciding whether or not to participate. At the initial visit, the pharmacist recorded 
each FXVWRPHUV¶ KLVWRU\ RI DQ\ SUHYLRXV ZHLJKW ORVV DWWHPSWV LQFOXVLRQ DQG
exclusion criteria, advice given for orlistat, outcome of consultation, blood pressure, 
blood glucose, height (metres/feet and inches), weight (kg/lbs), BMI, minimum 
weight loss required at three months (5% of the initial weight at programme entry), 
FXVWRPHUV¶FRQVHQWGDWHRIYLVLWVGDWHDQGDPRXQWRIWKHVXSSO\RIRUOLVWDWDQGGDWH
of the follow-up visit. The pharmacist followed customers with monthly 
appointments and monitored their weight loss, BMI, diet, exercise and side effects. 
 
After 12 weeks customers can decide to continue the weight loss programme if their 
weight loss was at least 5% of the initial weight. However, customers who failed to 
achieve this minimum weight loss were required to stop the programme. The 
baseline and follow-up consultations with customers were performed by the 
pharmacists, with referral to a doctor if appropriate.  
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Managing obesity in Boots Pharmacy Weight Loss Programme 
The four elements, which are provided for pharmacists to guide them in the provision 
of the BPWLP, consist of: 
x Details of the measurement and recording of data the initial consultation 
together with the type of advice to be offered 
x Guidance on the information to be provided to the clients about orlistat 
including how it works and how to take it 
x Details of measurements and records to be made at follow-up visits  
x Information about ongoing weight loss advice and how to continue to 
motivate clients to lose weight  
 
7KH FOLHQW¶V MRXUQH\ WKURXJK WKH %3:/3 LV VKRZQ LQ Figure 1.2. This guide is 
available for store staff to help them guide clients through the service. 
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Figure 1.2 COLHQW¶V journey of Boots Pharmacy Weight Loss Programme 
3. Customers engaged 
in store by Pharmacist 
or Healthcare assistant
1. Customers engaged 
by advertising
2. Customers referred 
by satisfied customer 
or partner, Health 
Professional
4. Customers 
request treatment
5. Assistant issues leaflet 
and explains service
8. Refer customers to other options using 
RWKHUZHLJKWORVVVROXWLRQV¶OHDIOHW
6. Customer uses BMI 
machine to get print out
7.  Is customers 
%0,30 or 28 if 
co-morbidities?
Yes
No
Patient takes leaflet away
13. Give customers an 
appointment card and check in 
customer when they arrive and 
inform pharmacist recheck BMI 
12. Make an appointment 
for customers 
11. Is 
pharmacist 
available?
10. Does the 
customer wish to 
attend the 
programme?
9. Assistant explains 
details of PGD offer 
using service leaflet and 
what happens next
Refer customer to other options 
using other weight loss 
solution leaflet 
14. An assistant takes customer to 
consultation area to fill in section A of CRF
Yes
YesNo
Key:  Customer/Patient
 Healthcare assistant
 Pharmacist 
15 Pharmacists conductinitial
consultationanswering
questionsandsetreview 
baseline and explainbenefits 
ofprogrammesideeffects and
whathappensnext
No
16. Refercustomertoother
optionsusingotherweight
losssolutionleaflet
Ifcontraindicated
Ifeligible
17 ConfirmpatientsuitablyforXenical
18 Take BP and BG level, explain
costandpurchaseoptionsandagree
plan, fillinweightmanagement
recordforms
19 Fill in dosage details 1- and 3-month
Medicationdispensedandrecordfiled: 
Fillincustomerreview andsupplycard, 
recordsupplyinPrivatePrescription
Register, completethecustomerlogfor
allnewcustomers
20 GPsentcopyofrecord
21 Patientreceives 
weightmanagement
packMedicinePIL
Allinformation and 
returns at monthly for 
repeat purchase
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1.3.7.4 Summary 
The literature review elucidated the health care system in the UK including weight 
management services. The prevalence of obesity in the UK has increased during the 
last two decades. Many studies included in this literature review have advocated 
rigorous weight-loss interventions such as nutrition counselling, physical activity, 
behavioural modification and social support. Also, previous studies have suggested 
that pharmacological treatment is an effective adjunct to dietary and lifestyle 
interventions in the treatment of obesity. 
 
There are several options available to reduce weight, including reduced-energy diets, 
physical activity/exercise, behaviour modification, pharmacological intervention and 
surgery. One approach for overweight or obese adults to help manage weight loss is 
the participation in weight loss programmes. Many weight loss programmes provide 
strategies for the public to successfully achieve weight loss goals.  
 
Treatments for obesity aim to help patients both lose and maintain weight loss. Many 
different health care providers may be involved in providing weight management 
services. Pharmacists provide both advice to obese customers on weight loss and 
structured programmes for them to follow. Pharmacotherapy, alongside a restricted 
calorie diet and increased exercise, is recommended a second line treatment for 
obesity by NICE.  
 
BPWLP is not only a pharmacist-led weight management clinic but also where 
appropriate involves the supply of orlistat via a PGD to overweight or obese clients 
to help them lose weight. It consists of: 1) a consultation and assessment by a 
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pharmacist, 2) comprehensive support and advice on healthy eating and physical 
activity, 3) supply of a prescription only medicine (orlistat 120 mg, Xenical®) and 4) 
discount on Boots branded low calorie products and exercise equipment for 
Advantage card holders only. This programme is available to customers with a BMI 
equal to or greater than 30 kg/m2 or 28 kg/m2 with at least one co-morbidity related 
to risk factors.  
 
As a result of the high prevalence of obesity, health commissioners are interested in 
determining which methods of weight loss programmes are more effective, whether 
they are CWLPs or NCWLPs. Although there is some evidence for NCWLPs, in the 
short- and long-term treatment of obesity, the evidence for commercial programmes 
is less clear and therefore this thesis considers CWLPs. The CWLP is an option for 
those overweight and obese patients who are willing and able to pay for such 
programmes. Thus, this thesis describes a systematic review of CWLPs to determine 
which factors are associated with successful programmes. Additionally, the thesis 
presents a before and after study of a CWLP delivered through pharmacies which 
determined the effectiveness of the programme. 
 
1.4 Rationale for the study 
Obesity and its resultant health problems have become an issue of global concern.1 In 
the UK, obesity is a huge public health issue the incidence of which, in England, has 
tripled between 1980 and 2007 from around 7% to 24% of the general population.  
 
Weight management services aim to reduce weight in individuals who are either 
overweight or obese. CWLPs can assist by not adding to NHS expenditure and also 
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by offering a variety of structured programmes where for-profit commercial 
organisations deliver weight loss interventions. Overweight and obese people who 
have participated in the CWLP have done so, in part, because they are willing and 
able to pay for such health benefits. A published study found that CWLPs were more 
effective than primary care based services in assisting clients to lose weight.126 To 
offer supporting evidence of CWLPs, a systematic review was conducted, as one part 
of this thesis, to provide guidance for health care providers about successful 
programmes and their attributes.  
 
Currently, there is only one available anti-obesity medicine; orlistat. In the UK 
orlistat was only available on prescription or via a PGD in pharmacist-led weight 
management clinics until 2009, when the 60 mg strength was licensed as a pharmacy 
medicine. 
 
Studies of weight loss management services also have assessed the success of the 
programmes. Management through a combination of anti-obesity medicines with diet 
and exercise was significantly better than dietary regimens alone. However, with 
ever increasing numbers of obese people, a range of weight loss strategies may be 
necessary for the population, including preventative campaigns. Pharmacist-led 
weight management clinics, involving the supply of orlistat via PGD, have not been 
evaluated to determine whether or not they are effective in assisting people to lose 
weight and so the evaluation of one such service comprises the second part of this 
thesis.  
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Pharmacists contribute to weight management as a part of health promotion 
priorities.111 The NHS and the Government White Paper potentially included 
community pharmacy as an ideal venue for weight loss programmes. There is little 
information about the reasons for clients participating in pharmacy-based weight loss 
programmes, how they attempted to control their weight in the past and their 
experiences of community pharmacy-based weight loss programmes. Therefore, to 
complement the evaluation of the effectiveness study a questionnaire was designed to 
explicit clients¶ views.  
 
1.5 Aims and objectives 
This study aimed to evaluate the effectiveness of commercial weight loss 
programmes in overweight and obese adults. The overall aims of this study were: 
x To systematically review the effectiveness of commercial weight loss 
programmes in helping overweight and obese adults to lose weight. 
x To evaluate the effectiveness of a pharmacist-led weight management clinic 
in achieving weight loss in obese clients through a combination of orlistat 
supply and advice. 
 
1.5.1 Systematic review objectives 
The objectives of the study were to:  
x Systematically review the literature in order to describe the effectiveness of 
CWLPs in overweight and obese adults 
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x Determine whether there were particular characteristics of such programmes 
that indicated the success of CWLPs 
 
1.5.2 Evaluation of Boots Pharmacy Weight Loss Programme 
objectives 
1.5.2.1 Pilot study 
The objectives of the pilot study were to:  
x Test the data collection method and database 
x Test the quality of the records in BPWLP  
x Determine sample size calculation for the main study  
 
1.5.2.2 Main study 
The objectives of the main study were to:  
x Describe the characteristics of clients who participated in the weight loss 
programme in terms of: 
o The length of time clients remained in the programme  
o The rate of unwanted effects based on the consultation notes 
o Reasons for dropout from the programme 
x Determine the effect of the programme on body weight and BMI at three 
months  
x Determine any associations between clieQWV¶ ELRPHWULF data at the initial 
visit and gender, age and length of time in the programme 
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x Determine characteristics associated with  
o Weight reduction at three months  
o Clients who achieved at least 5% weight loss 
 
1.5.2.3 Questionnaire study 
The survey study aimed to develop a questionnaire to determine the views of clients 
who participated in the BPWLP about the programme and other weight loss attempts. 
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Chapter 2 
A systematic review of the effectiveness of 
commercial weight loss programmes 
 
This chapter presents a systematic review of the effectiveness of commercial weight 
loss programmes (CWLPs) in helping overweight and obese adults to lose weight. 
 
At the time of undertaking this current review, I was aware of only one previous 
systematic review of this subject, published in 2005 and containing only US 
studies.116 However, this review did not provide information about the global, as 
opposed to national, effectiveness of CWLP and so an up-to-date systematic review 
covering the global literature sources was needed. Moreover, there is a lack of 
studies comparing weight management interventions within CWLPs in the UK. 
Many overweight and obese adults know little about the effectiveness of CWLPs116 
in their own countries. Therefore, this review will assist in identifying such 
successful weight management programmes. 
 
2.1 Why this review matters 
It has been reported that in the UK, the medical costs associated with obesity-related 
diseases will be £648 million each year by 2020 and £2 billion each year by 2030. By 
lowering the proportion of the UK population who are overweight or obese, the 
treatment costs associated with obesity-related diseases can be reduced.127 
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In the light of the rising prevalence of obesity, the need to find ways to assist people 
in losing weight has become increasingly important. Various weight management 
programmes and services offer to assist overweight and obese adults to lose weight. 
The programmes offered can be broadly divided into two groups, commercial weight 
loss programmes (CWLPs) and non-commercial weight loss programmes 
(NCWLPs). CWLPs are structured programmes which involve a for-profit 
commercial organisation delivering the weight loss intervention. These types of 
programmes are for those people who are willing and able to pay for the service. 
NCWLPs include organisations where weight loss interventions are offered free-of-
charge, such as from government organisations, private health care provided as a part 
of health insurance, charities or social enterprises. 
 
Very little is known about the effectiveness of CWLPs in facilitating weight loss in 
the many overweight and obese adults who take part in these programmes. The one 
previous systematic review on this subject was published in 2005 and only included 
US studies.116  
 
2.2 Aim and objectives 
The aim of this review was to assess the effectiveness of CWLPs in helping 
overweight and obese adults to lose weight. 
 
The objectives of the review were to: 
1. Describe the effectiveness of CWLPs in overweight and obese adults 
2. Consider findings in the context of evidence published  
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2.3 Methods 
2.3.1 The review team 
The review team included the main (first) reviewer, Sukhumaphorn Sriwisit (SS); 
other reviewers included Helen Boardman (HB) and Anthony Avery (AA). 
 
2.3.2 The review process 
The review comprised five steps:128 1) framing the questions, 2) identifying relevant 
literature, 3) assessing the quality of the literature, 4) summarising the evidence 
(Results) and 5) interpreting the findings. A review protocol was developed to guide 
the review process.  
 
2.3.2.1 Framing questions 
The review question was framed in terms of the population (P), interventions (I) or 
comparators (C), outcomes of the studies (O) and study design (S).129 
 
Population 
The review used the WHO definition of µoverweight¶ as a Body Mass Index (BMI)  
25 kg/m2 and µobesity¶ as a BMI  30 kg/m2.3 BMI is defined as the weight in 
kilograms divided by the square of the height in meters (kg/m2). BMI provides the 
most useful population-level measure of the classifications of overweight and obesity 
for both genders and adults of all ages.  
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Intervention or comparison 
A CWLP intervention was defined as a structured weight loss programme initiated 
by organisations delivering the intervention for profit, and where this is in the form 
of the provision of vouchers or partial subsidies. This review excluded NCWLP 
studies that, as stated in Chapter 1 (page 3), were offered free of charge to the user 
supported by government organisations, private health insurance, charities or social 
enterprises. 
 
Outcome 
The review included studies that collected, analysed and presented the effects of 
weight loss programmes on either weight or BMI.  
 
Study design 
The review incorporated interventions that used randomised controlled trials (RCTs) 
and randomised trials to assess intervention effect.  
 
Defining these components allowed a framework to be developed for establishing the 
inclusion and exclusion criteria for studies included in the review. These preliminary 
inclusion and exclusion criteria are summarised in Table 2.1. 
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Table 2.1 Preliminary inclusion and exclusion criteria for identification of studies  
Inclusion criteria Exclusion criteria 
Participants 
Participants aged 18 years or older  
Participants who were overweight and obese  
Participants aged younger than 18 years 
 
Intervention/comparison 
Commercial weight loss programmes  Non commercial weight loss programmes  
Outcome  
Main outcomes: Changes in weight (kg or %) 
and/or BMI (kg/m2 or %) 
Main outcomes: Did not report weight and BMI 
changes  
Study design 
Randomised controlled trials (RCTs), randomised 
trials, systematic reviews 
Non-systematic reviews, controlled before and 
after study, before and after study or time series 
analysis  
Published in the English language only Not published in a language other than English 
Published between 1 January 1980 and 31 
December 2011 
Published before January 1980 and after 
December 2011 
 
2.3.2.2 Identifying relevant literature  
Data sources 
A multiple database search was used to identify studies for the review because one 
database cannot embrace all studies. Therefore, nine bibliographic databases were 
used to identify the literature for inclusion in the systematic review ± see Table 2.2. 
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Table 2.2 A list of electronic databases searched for the systematic review 
Database Information provided Searched for database 
1. CENTRAL (The Cochrane 
Central Register of Controlled 
Trials, Clinical Trials) 
Full text of regularly updated 
systematic reviews prepared by the 
Cochrane collaboration of completed 
reviews and protocols 
Via The Cochrane 
Library 
2. Medline (Medical Literature 
Analysis and Retrieval System 
Online) 
Journal citations and abstracts for 
medicine, nursing, pharmacy, dentistry, 
psychiatry, veterinary and health care  
Via OVID 
3. EMBASE (Excerpta Medica 
Database) 
The most comprehensive biomedical 
database on the internet, consisting of 
biomedical and pharmaceutical studies 
Via OVID 
4. CINAHL (Cumulative Index 
of Nursing and Allied health 
Literature) 
The most comprehensive resource for 
nursing and allied health literature  
Via EBSCO 
5. IPA (International 
Pharmaceutical Abstracts) 
Abstracts in clinical studies including 
study design, number of patients, 
dosage, dosage forms and dosage 
schedule  
Via OVID 
6. Scopus (SciVerse Scopus) Abstracts and citations for academic 
peer-reviewed journal articles in the 
scientific, technical, medical and social 
sciences  
Via SciVerse 
7. WOS (Web of Science) Multiple databases, cross-disciplinary 
research and in-depth exploration of 
specialized subfields within an 
academic or scientific discipline 
Via Web of 
Knowledge 
8. PsycINFO (Psychological 
Information Database) 
Abstracts of literature in psychology 
and health care disciplines related 
Via OVID 
9. HMIC (Health Management 
Information Consortium) 
Data related to health management and 
services, social care, service 
development or NHS organisation and 
administration 
Via OVID 
 
Search strategies 
Search terms used were based on the four components of the review: 1) overweight 
or obese, 2) interventions: CWLP, 3) changes in weight or BMI and 4) study design. 
Searches were made using Medical Subject headings (MeSH), keywords or text 
words. Free text words which incorporated the use of wildcard truncations were used 
to help compile the search terms. Details of the terms used and how these were 
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combined were provided ± see Appendix 2. The search strategy was tested and 
refined in order to try and achieve maximum sensitivity for obtaining relevant studies 
without generating an unmanageable number of references for review. 
 
The criteria and process for excluding titles and abstracts, and including articles, is 
explained below. All stages of the process of selecting studies for this review were 
conducted by two reviewers (SS and HB). Any disagreements were resolved by 
discussion, if necessary involving a third reviewer (AA). 
 
Defining criteria and the process of exclusion for titles 
The titles of papers identified through the search were reviewed to eliminate those 
that were not relevant, using the terms of the following three components: 
- Participants: The study did not include overweight or obese adults.  
- Intervention: The study was not about weight loss.  
- Study type: The study was not a systematic review, randomised trial or 
randomised controlled trial. 
 
If there were insufficient details in the title, or the reviewer was unsure, the title was 
retained at this stage.  
 
The process of reviewing the titles involved systematically selecting every 8th title, n 
= 1,060 (13%) to be reviewed by both reviewers. Ideally, at least 10% of samples are 
required to be checked.130 However, sampling every 8th title was decided as a 
pragmatic number as that was approximately 1,000 titles. Following this, the titles 
included and excluded by both reviewers were compared. There was disagreement 
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on 48 (4.0%) of the titles. This was discussed and resulted in 19 titles being included 
and 29 titles excluded, based mainly on the reason that the research did not have 
weight loss as a primary outcome. The main reviewer (SS) analysed the remaining 
titles (n = 7,424), resulting in 772 titles being retained for inclusion in the process of 
abstract review (see flow diagram ± Figure 2.2, page 72).  
 
Exclusion criteria and process of exclusion of abstracts  
After eliminating the article titles, the main reviewer (SS) applied the exclusion 
criteria to the remaining abstracts. The following exclusion criteria were used: 
- Studies were excluded if they focused on the following groups of participants: 
o Normal weight or underweight adults  
o Aged younger than 18 years  
o Pregnant women or breast-feeding mothers 
o With an eating disorder or previous obesity surgery such as gastric 
banding, bariatric surgery or intragastric balloon 
- Intervention: Studies were excluded if they were not about weight loss, weight 
change, weight reduction, weight control or weight management. In addition, 
studies focusing on the following interventions were excluded: 
o Non-commercial weight loss programmes funded by health care systems 
(government or public sector) 
 NHS, Medicaid, Medicare 
 Army or military 
 Hospitals both inpatients and outpatients 
 Primary care, general practice or health centre 
 
Chapter 2 Systematic review 
61 
 
o Drugs withdrawn from the market such as Sibutramine (UK and Europe,78 
US131 and Canada,132 Australia133 and New Zealand134 markets) or 
Rimonabant (UK and Europe).135 Disease specific diets e.g. for severe 
liver disease where the primary aim is not weight reduction  
- Outcomes: Studies were excluded if the main outcome did not report weight 
loss, weight change or weight reduction (measured in kilograms or percentage 
change). 
- Study type: Studies of the following types were excluded: qualitative studies, 
expert opinion, case studies, case series, case reports, symposium reports, non-
systematic literature reviews, narrative reviews, comments, guidelines or 
questionnaire surveys. 
 
As with reviewing titles, if there was insufficient detail in the abstract, or the 
reviewer was unsure, the papers were not excluded at this stage. 
 
The process of reviewing the abstracts involved systematically selecting every 7th 
abstract, n = 110 (14%) to be reviewed by both reviewers. Ideally, at least 10% of 
samples are required to be checked.130 However, sampling every 7th abstract was 
decided as a pragmatic number as this was approximately 100 abstracts. Following 
this, the abstracts included and excluded by both reviewers were compared. There 
was agreement on 100% of the abstracts. Two reviewers agreed on 51 (46.4%) 
papers to be included, and 59 (53.6%) papers to be excluded. Reasons of the 59 
excluded titles were not having weight loss as a primary outcome (17), and criteria 
(28) and study type (14) for CWLPs. The main reviewer (SS) reviewed the 
remaining abstracts (n = 662). The total number of abstracts retained for the process 
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of a full article review was 153 (see flow diagram ± Figure 2.2, page 72).  
 
Inclusion and exclusion criteria and process of selecting full articles 
After eliminating certain papers by reviewing their abstracts, the inclusion and 
exclusion criteria for full articles were applied to the remaining articles. The 
inclusion and exclusion criteria, shown in Table 2.3 were used. 
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Table 2.3 The criteria of inclusion and exclusion for full articles 
Characteristics of the study Inclusion criteria Exclusion criteria 
Participants At least 80% of the participants in 
this study were:  
- Overweight adults as having BMI 
kg/m2 RUkg/m2 in Asian 
people  
- 2EHVHDGXOWVDVKDYLQJ%0,
kg/m2 RUkg/m2 in Asian 
people 
Participants were younger than 
18 years old. 
Interventions   
Nature of interventions Commercial weight loss 
programme (CWLP) 
The only difference between 
intervention and control is a 
product or supplement. 
Organisation - A structured programme 
- Organisation delivering the 
intervention is for a profit 
commercial organisation and in the 
form of the provision of vouchers 
or partial subsidies 
- Government organisation 
- Private health care provided as 
a part of health insurance 
- Charity 
- Social enterprise 
Duration of programme 4 weeks and longer Less than 4 weeks 
Outcomes Primary outcome was weight loss 
or weight change expressed as:  
- Mass change 
- BMI change  
- Percentage change  
The main outcome did not 
report weight loss, weight 
change or weight reduction  
Study types - Randomised controlled trial 
- Randomised trial 
- Controlled trial 
- Time series analysis  
 
- Conference abstract 
- Study protocol 
- Commentary 
- Before and after study 
- Systematic review 
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The process of reviewing all full articles (n = 153) involved both reviewers using a 
checklist form ± see Figure 2.1. Following this, all full articles included and excluded 
by both reviewers were compared. The reviewers agreed 100% with the 21 (14%) 
articles to be included and 132 (86%) articles to be excluded. Reasons for exclusion 
and results for full articles excluded were shown in Figure 2.2, page 72. There were 
21 full articles retained for the data extraction and quality assessment.  
 
 
Chapter 2 Systematic review 
65 
 
 
Figure 2.1 A check list form for inclusion and exclusion of full articles 
  
 Article identification:  5HYLHZHU¶VLQLWLDOV 
Author and year:  Country:  
 Met the criteria for 
 Inclusion  Exclusion  
Participants: At least 80% of the participants in this study were    
Overweight adults as having BMI NJP2 RUNJP2 in Asian 
people  
   
Obese adults as having %0,NJP2 or NJP2 in Asian 
people 
   
Interventions   
Nature of intervention   
1. Commercial weight loss programme  X 
2. The only difference between intervention and control is a product. X  
Organization   
1. A structured programme  X 
2UJDQL]DWLRQGHOLYHULQJWKHLQWHUYHQWLRQLVDµIRUSURILW¶
commercial organization 
 X 
3. Government organization X  
4. Private health care company and the programme is provided as a 
part of health insurance 
X  
5. Charity X  
6. Social enterprise X  
Duration of programme    
,IZHHNV  X 
If < 4 weeks X  
Outcomes: If primary outcome was weight change expressed as   
Mass (weight) change  X 
Percentage change in weight   X 
BMI change  X 
Percentage BMI change  X 
Study types   
Randomized controlled trial   Controlled trials     
Before and after study   Time series analysis      
Systematic reviews   ,QHOLJLEOHVWXG\«««     
Initial decision   
Final agreed decision between reviewers   
Comments: 
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2.3.2.3 Data extraction and assessing quality of literature 
Data extraction 
All relevant data were extracted from the full articles which met the inclusion 
criteria. A data extraction form was developed by SS ± see Appendix 3. This data 
extraction form was adapted from the Cochrane reviews by Higgins and Green,136 
CONSORT (Consolidated Standards of Reporting Trials) statement of randomised 
trials of non-pharmacological treatment137 and systematic reviews by Khan et al.128 
The data was then summarised into data extraction tables by SS. These summaries 
were checked by the second reviewer (HB) for accuracy. Any disagreement or 
queries arising from data extraction were discussed among the team, and information 
was clarified and/or corrected accordingly. 
 
CONSORT is a checklist for reporting randomised controlled trials (RCTs) which 
may also be used for reviewing of RCTs.138 CONSORT defines standards for RCTs 
to ensure quality in reporting and covers area such as randomisation, blinding and 
generalisability. The purpose of CONSORT in this review was to aid data extraction 
and to provide a clear and consistent description from the randomised trials.128 All 
variables on the CONSORT checklist were extracted from the studies where 
possible. In addition, the source of funding was added to the data extraction form 
(Appendix 3).  
 
Quality assessment  
Studies within this review may contain reporting bias, which can result where the 
authors report their study in such a way that it overestimates the effect of the 
intervention.128, 136 Bias may result from inadequacies in the study design (such as the 
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flaws in allocation concealment), outcome assessment or use of statistical 
methods.139 It was not possible to determine to what extent bias affected the methods 
(internal validity) and results of the studies; however the risk of bias is acknowledged 
as a potential influence in this review. In order to assess bias consistency for all 
studies a risk of bias tool was used136 ± see Appendix 4.  
 
In this review, the purpose of the risk of bias tool was to assist in describing 
heterogeneity (methodological diversity such as differences among studies in terms 
of allocation concealment and blinding) in the design and results of the included 
studies.136 For the design of the included studies, blinding was not always possible to 
achieve for the weight loss interventions because participants would be aware of 
their diet and any exercise taken. Whilst blinding would normally be a desirable 
characteristic of a RCT, it was felt inappropriate to judge weight loss interventions 
that did not incorporate blinding as being interventions of a low quality because of 
the difficulty in achieving blinding. However, this does not mean that such 
interventions were un-biased.136  
 
Using risk of bias is preferable in assessing quality as this tool does not use quality 
scales to yield a summary score. The use of quality scales can be unreliable as they 
have been designed for specific types of trials and are not always suitable for other 
trial types. For example, two widely used tools for assessing quality are the Jadad 
scoring system140 and Evidence-based behavioural medicine system (EBBM).141 The 
Jadad scoring system140 does not include a score related to allocation concealment 
which is one of the most important potential biases in randomised trials.136 This tool 
also gives a high weighting to blinding which is rarely possible in diet and exercise 
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trials. EBBM141 tool focuses on behavioural interventions assessing training, 
supervision, preference and manner of treatment providers including treatment 
adherence. In this systematic review the effectiveness of the intervention was the 
primary outcome and therefore the EBBM tool would not assess the relevant areas 
for the study. Therefore, the risk of bias is the most suitable tool to assess the quality 
of the studies for this review. 
 
The risk of bias tool comprises a description and a judgement on the standard risk of 
bias by reviewing intervention components such as sequence generation, allocation 
sequence concealment, blinding, incomplete outcome data, selective outcome 
reporting and other potential sources of bias ± see Table 2.4.136, 142 This assessment 
tool provides a brief free text description or summary of the relevant trial 
characteristics and involves assigning a judgement of high, low or unclear risk for 
each item. For example, where a positive response to a question indicated a suitable 
procedure to minimise bias (e.g. whether or not the allocation was adequately 
concealed) this was translated into a low risk of bias. On the other hand, where a 
negative response to a question indicated a lack of an unsuitable procedure to 
maximise bias, this was translated into a high risk of bias.  
 
The risk of bias of each study was assessed by SS and checked by a second reviewer 
(HB). In comparing the two assessors¶ judgements of the risk of bias, any 
disagreements were resolved by discussion, if necessary involving AA. There was 
disagreement on eight articles in a domain of random sequence generation. This was 
discussed and informed to AA with the result that a low risk of bias in a domain of 
random sequence generation has been changed to an unclear risk of bias. 
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Table 2.4 Classification scheme for bias assessment 
Type of bias Source of bias Support for judgement 5HYLHZDXWKRUV¶MXGJHPHQW 
Selection 
bias 
Sequence 
generation 
Describe the method used to generate 
the allocation sequence in sufficient 
detail to allow an assessment of 
whether it should produce 
comparable groups 
Was the allocation sequence 
adequately generated? 
 Allocation 
concealment 
Describe the method used to conceal 
the allocation sequence in sufficient 
detail to determine whether 
intervention allocations could have 
been foreseen before or during 
enrolment  
Was allocation adequately 
concealed? 
Performance 
bias 
Blinding of 
participants 
and personnel*  
Describe all measures used. If any, to 
blind trial participants and 
researchers from knowledge of which 
intervention a participant received.  
Provide any information relating to 
whether the intended blinding was 
effective 
Was knowledge of the 
allocated intervention 
adequately prevented during 
the study? 
Detection 
bias 
Blinding of 
outcome 
assessment** 
Describe all measures used. If any, to 
blind outcome assessment from 
knowledge of which intervention a 
participant received.  
Provide any information relating to 
whether the intended blinding was 
effective 
Was knowledge of the 
allocated intervention 
adequately prevented during 
the study? 
Attrition 
bias 
Incomplete 
outcome data 
Describe the completeness of 
outcome data for each main outcome 
including attrition and exclusions 
from the analysis.  
State whether attrition and exclusions 
were reported, the numbers in each 
intervention group (compared with 
total randomised participants), 
reasons for attrition or exclusions 
where reported, any reinclusions in 
analysis for the review  
Were incomplete outcome 
data adequately addressed? 
Reporting 
bias 
Selective 
reporting 
State how selective outcome 
reporting was examined an what was 
found  
Are reports of the study free 
of suggestion of selective 
outcome reporting? 
Other bias Anything else, 
ideally 
prespecified 
State any important concerns about 
bias not covered in the other domains 
in the tool  
Was the study apparently 
free of other problems that 
could put it at a high risk of 
bias? 
*In reality it is very hard to blind participants in this type of trials as they will know what they are eating 
and how much exercise they take. However the data collection can be blinded to the trial arm and therefore 
we considered blinding in the assessment of the risk of bias. **Assessments should be made for each main 
outcome or class of outcomes. 
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2.3.2.4 Data synthesis  
Data synthesis was used to conduct a narrative review, with tabulation of results, for 
all studies included. Information about each of the three main intervention 
components of diet; diet and exercise; and meal replacement were discussed as 
described below:  
1. Diet:143 where a reduced-energy diet was the primary focus of the 
intervention, along with behavioural modification with or without a peer or 
group support or verbal or written advice on how to lose weight or 
participation in group meetings. This intervention also included very low 
calorie diets143 which typically are less than 800 kcal per day, commonly in a 
form of a liquid diet and used as the initial weight loss intervention. 
2. Diet and exercise:143 a reduced-energy diet along with behavioural 
modification, with a recommended-specific goal for physical activity and 
with a peer or group support or with verbal or written advice on how to lose 
weight or participation in group meetings. 
3. Meal replacement:143 having two or more replacement meals per day as an 
adjunct to a reduced-energy diet with or without a peer or group support or a 
given verbal or written counselling on how to lose weight or participate in a 
meeting session 
 
The effectiveness of CWLPs was assessed by comparing results from the pooled data 
and the different comparator groups. The studies were not combined in a meta-
analysis due to differences in the interventions, comparators and populations in all 
studies included. 
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2.4 Results 
2.4.1 Summary of the evidence 
2.4.1.1 Studies retrieved 
16,356 citations were obtained from the initial database search, from which 153 full 
articles were obtained for further scrutiny. From these, 132 articles were rejected 
leaving 21 articles to be retained for inclusion in the review. However, one study 
reported the same data as a previous study so that the final total was of 20 studies to 
be included in this review ± see Figure 2.2.  
 
Regarding the excluded articles, reasons for exclusion are shown in Figure 2.2. Focus 
on a non-commercial weight loss programme was the main reason for exclusion of 
full articles (n = 81, 61%). Other reasons for exclusion include study type (systematic 
review or before and after study) and entry criteria for BMI not being stated. 
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Figure 2.2 Study identification process 
  
Potentially relevant citations identified through 
comprehensive electronic searching of 9 electronic databases
citations with titles and abstracts n = 16356 
CENTRAL (2492), Medline (4442), EMBASE (4594), 
PsyncINFO (999), HMIC (193), IPA (206), CINAHL (909), 
Scopus (2376), WOS (145)
Duplicates removed n = 7872
Title retained n = 8484
Titles excluded n = 7712
Abstracts retained n = 772
Full copies of articles 
retrieved and assessed n = 153
Articles included in the 
review n = 21 studies
Articles included in the 
review n = 20 studies
Duplicate publication excluded 
n = 1 (but reported all studies)
Excluded n = 132
- Non-commercial weight 
loss programme (81)
-Ineligible study type (26: 
10 Systematic reviews, 8 
Before and after studies, 8 
others)
-Not stated the entry criteria  
for BMI (11)
-Not met the BMI criteria  
(6)
-Drug trial (6)
- Duration of programme (2)
Abstracts excluded n = 619
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2.4.1.2 Summary of studies reviewed 
The 20 studies in the final review involved a combined total of 5,522 overweight or 
obese adult participants. Seventy percent of studies (14/20)11, 113, 117, 119, 144-155 were 
conducted in the US ± see Table 2.5. 
 
Table 2.5 Studies included in the review 
First author Year Country Outcomes 
Anderson144 2011 US Weight loss 
Dansinger11 2005 US Weight change 
Djuric145 2002 US Weight loss 
Donnelly146 2007 US Weight loss 
Foster147 2009 US Weight and BMI changes 
Gardner117 2007 US Weight loss 
Gold148 2007 US Weight change 
Green149 2005 UK, US Weight loss 
Haapala124 2009 Finland Weight change 
Heshka150, 151 2000 and 2003 US Weight and BMI changes 
Jebb152 2011 US Weight loss 
Jolly17 2011 UK Weight loss 
Luszczynska156 2007 UK, Poland Weight and BMI changes 
Rock153 2007  US Weight loss 
Rock154 2010 US Weight loss 
Rolland119 2009 US Weight loss 
Shuger155 2011 US Weight and BMI changes 
Truby126 2006 UK Weight change 
Van Wier157 2011 Netherlands Weight loss 
Womble113 2004 US Weight change 
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Seventeen (85%) of the studies included both men and women participants. three 
(15%) studies only had women participants. The mean age in the majority of studies 
(70%) was between 40 and 50 years. The mean age of participants was younger than 
40 years in one study and over 50 years in another. There were four studies that did 
not report mean age at baseline ± see Table 2.6.  
 
Thirteen (65%) studies had participants with a mean BMI at baseline in obesity class 
I, five studies (25%) had those in obesity class II and the last two (10%) studies had a 
mean BMI indicating overweight participants ± see Table 2.6.  
 
Table 2.6 3DUWLFLSDQWV¶FKDUDFWHULVWLFVRIVWXGLHVLQFOXGHGLQWKHUHYLHZ 
Criterion Category Number  Studies (First author) 
Gender Both men and women 17 Anderson,144 Dansinger,11 Djuric,145 
Donnelly,146 Foster,147 Gold,148 Green,149 
Haapala,124 Heshka,150 Jebb,152 Jolly,17 
Luszczynska,156 Rolland,119 Shuger,155 
Truby,126 Van Wier,157 Womble113  
 Only women  3 Gardner,117 Rock153 and Rock154 
Mean age at 
baseline 
< 40 years 1 Haapala124 
 40-49.9 years 14 Anderson,144 Dansinger,11 Gardner,117 Gold,148 
Heshka,150 Jebb,152 Jolly,17 Rock,153, 154 
Rolland,119 Shuger,155 Truby,126 Van Wier,157 
Womble113  
 50 years and older 1 Foster147  
 Mean age not reported 4 Luszczynska,156 Donnelly,146 Green,149 
Djuric145  
Mean BMI at 
baseline 
25-29.9 kg/m2 2 Green,149 Van Wier157  
30-34.9 kg/m2 13 Donnelly,146 Gardner,117 Gold,148 Haapala,124 
Heshka,150 Jebb,152 Jolly,17 Luszczynska,156 
Rock,153 Rock,154 Shuger,155 Truby,126 
Womble113  
 35-39.9 kg/m2 5 Anderson,144 Dansinger,11 Djuric,145 Foster,147 
Rolland119 
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2.4.1.3 Study design 
Most of the studies took place in a primary care or community-based setting, with 
about a quarter of the studies (n = 5)119, 126, 146, 150, 151 being conducted in settings such 
as a weight management clinics or Weight Watchers clinics ± see Table 2.7. In 15 
(75%) studies, participants were involved in the weight loss programme for over 
three months, whilst those in the remaining studies (25%) participated for up to three 
months. 
 
Recruitment methods for almost half of the studies were media advertisements. 
Seven (35%) studies recruited participants by mail and others included website 
programmes (e-mail distributors), interviews, obesity clinics, community events, 
worksites, press releases or brochures. Four (20%) studies recruited participants from 
referrals by health care providers, whilst the remaining studies recruited patients by 
selecting from records of participants already attending the programme and sending 
out a questionnaire.  
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Table 2.7 Characteristics of studies included in the review (n = 21) 
Criterion Category Number  Studies (First author) 
Setting Primary care 4 Anderson,144 Dansinger,11 Jebb,152 Jolly17 
 Secondary care 4 Djuric,145 Haapala,124 Heshka,150 Rolland119  
 Community setting (Not 
health care) 
4 Green,149 Gardner,117 Shuger,155 Truby126 
 Work place 2 Van Wier,157 Womble113 
 Not clear 1 Foster147  
 Others, including weight 
management clinics and 
Weight Watchers clinics 
5 Donnelly,146 Gold,148 Luszczynska,156 
Rock153, 154  
Length of 
treatment 
More than 3 months 15 Anderson,144 Dansinger,11 Djuric,145 
Gardner,117 Gold,148 Haapala,124 Heshka,150 
Jebb,152 Rock,153 Rock,154 Rolland,119 
Shuger,155 Truby,126 Van Wier,157 
Womble113 
 Up to 3 months 5 Donnelly,146 Foster,147 Green,149 Jolly,17 
Luszczynska156  
Recruitment* Media advertisements 9 Anderson,144 Dansinger,11 Foster,147 
Gardner,117 Green,149 Haapala,124 Rock,154 
Shuger,155 Truby126 
 Mailing and others 7 Djuric,145 Donnelly,146 Gold,148 Haapala,124 
Rock,153 Van Wier,157 Womble113  
 Referred by health care 
providers 
4 Foster,147 Jebb,152 Jolly,17 Rolland119  
 Selected from records 1 Heshka150  
 Already attending 1 Luszczynska156 
*Many studies had more than one method of recruitment. 
 
2.4.1.4 Intervention 
The majority (80%) of interventions delivered compared CWLPs involving diet and 
exercise. The remaining studies were focussed on diet and meal replacement. Three 
key elements in all diet groups are restriction on calorie level (total kcal/day), 
exercise (daily or optional) and support (description of support) ± see Table 2.8. 
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Thirteen studies were supported by health care providers including dieticians, 
counsellors, doctors, therapists, nurses, food advisors, group support, trained workers 
and facilitators. Group support was evident in 11 studies. Internet and telephone 
support was found in eight and seven studies, respectively, whilst external support, in 
the form of a book, was provided in two studies.  
 
The main outcome reported was weight loss in 11 (55%) studies and weight change 
in six (30%) studies. Only three (15%) studies presented both weight and BMI 
changes as main outcomes. Four (20%) studies reported adverse events whilst the 
remainder did not report adverse events.  
 
There was a total of 46 interventions in the 20 studies. Most groups had dropout rates 
of between 11% and 49% for either intervention or control groups. Three studies had 
a dropout rate higher than 50% for the intervention group, whilst none of the studies 
had a high dropout rate for the control group.  
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Table 2.8 Components of interventions in studies included in the review  (n = 21) 
Criterion Category Number  Studies (First author) 
Intervention 
delivery 
Diet and exercise  16 Dansinger,11 Djuric,145 Foster,147 Gardner,117 
Gold,148 Haapala,124 Heshka,150 Jebb,152 Jolly,17 
Luszczynska,156 Rock,153 Rock,154 Shuger,155 
Truby,126 Van Wier,157 Womble113  
 Diet  2 Green,149 Rolland119  
 Meal replacement  2 Anderson,144 Donnelly146  
Support* All providers 13 Anderson,144 Djuric,145 Donnelly,146 Foster,147 
Gardner,117 Jolly,17 Rock,153 Rock,154 
Rolland,119 Shuger,155 Truby,126 Van Wier,157 
Womble113  
 Group 11 Foster,147 Gardner,117 Gold,148 Green,149 
Heshka,150 Jebb,152 Jolly,17 Luszczynska,156 
Rolland,119 Truby,126 Womble113 
 Internet 8 Gold,148 Haapala,124 Jolly,17 Rock,153 Rock,154 
Rolland,119 Van Wier,157 Womble113  
 Telephone 7 Djuric,145 Haapala,124 Jolly,17 Rock,153 Rock,154 
Rolland,119 Shuger,155 Van Wier157 
 External (book) 2 Dansinger,11 Truby126 
 No support (control 
group) 
2 Djuric,145 Truby126  
Outcomes Weight loss 11 Anderson,144 Djuric,145 Donnelly,146 Gardner,117 
Green,149 Jebb,152 Jolly,17 Rock,153 Rock,154 
Rolland,119 Van Wier157  
 Weight change 6 Dansinger,11 Foster,147 Gold,148 Haapala,124 
Truby,126 Womble113  
 Weight and BMI 
changes 
3 Heshka,150 Luszczynska,156 Shuger155  
Adverse 
events 
Report 4 Anderson,144 Dansinger,11 Heshka,150 Jebb152  
Did not report 16 Djuric,145 Donnelly,146 Foster,147 Gardner,117 
Gold,148 Green,149 Haapala,124 Jolly,17 
Luszczynska,156 Rock,153 Rock,154 Rolland,119 
Shuger155 Truby,126 Van Wier,157 Womble113  
*Many studies had more than one method of support. 
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Table 2.8 (continued) 
Criterion Category Number  Studies (First author) 
Dropout rate 
Intervention** 
 
 
 
4 
 
Dansinger,11 Djuric,145 Rolland,119 Jolly17  
 11-49% 36 Anderson,144 Donnelly,146 Gardner,117 Gold,148 
Haapala,124 Heshka,150 Jebb,152 Jolly,17 Rock,154 
Truby,126 Van Wier,157 Womble113  
 d 10% 4 Foster,147 Haapala,124 Rock,153 Shuger155  
 Did not report 2 Green,149 Luszczynska156 
Control  - - 
 11-49% 37 Anderson,144 Dansinger,11 Djuric,145 
Donnelly,146 Gardner,117 Gold,148 Haapala,124 
Heshka,150 Jebb,152 Shuger,155Truby,126 Van 
Wier,157 Womble113  
 d 10% 3 Foster,147 Rock,153 Rock154  
 Did not report 4 Djuric,145 Green,149 Jolly,17 Luszczynska156 
**Many studies had more than one intervention. 
 
2.4.2 Quality assessment of the studies 
The risk of bias was assessed for a study across outcomes (each of the seven 
methodological criteria), an outcome within a study (across domains) and a review as 
a whole.  
 
2.4.2.1 Risk of bias for a study across outcomes  
Risk of bias for studies across outcomes was summarised by the total number of key 
domains for each study, each of the seven domains represents a different risk of bias. 
Low risk of bias suggests a plausible bias is unlikely to seriously alter the results; 
unclear risk of bias raises some doubt about the results. High risk of bias is perceived 
bias that seriously weakens confidence in the results.  
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A lack of blinding of participants and personnel was the main area where many 
studies (n = 19, 90.5%) had a high risk of bias. Blinding of the outcome assessment 
and allocation concealment had the highest number of studies where the bias was 
unclear. Other bias and random sequence generation were where most studies had a 
low risk of bias ± see Table 2.9. 
 
Table 2.9 Summary assessments of the risk of bias for all domains across studies (n = 21) 
Key domains across studies 
Risk of bias, number of studies and studies (First author) 
Low  Unclear  High  
Random sequence 
generation 
13 8 - 
Anderson,144 
Dansinger,11 
Foster,147 Gardner,117 
Heshka,150, 151 Jebb,152 
Jolly,17 
Luszczynska,156 
Rock,154 Shuger,155 
Truby,126 Van Wier157 
Djuric,145 
Donnelly,146 Gold,148 
Green,149 Haapala,124 
Rock,153 Rolland,119 
Womble113 
- 
Allocation concealment 7 14 - 
 Gardner,117 
Haapala,124 
Heshka,150, 151 Jebb,152 
Jolly,17 Van Wier157 
Anderson,144 
Dansinger,11 
Djuric,145 
Donnelly,146 
Foster,147 Gold,148 
Green,149 
Luszczynska,156 
Rock,153, 154 
Rolland,119 Shuger,155 
Truby,126 Womble113 
- 
Blinding of participants and 
personnel  
2 - 19 
Heshka,150 
Luszczynska156 
- Anderson,144 Dansinger,11 
Djuric,145 Donnelly,146 
Foster,147 Gardner,117 Gold,148 
Green,149 Haapala,124 
Heshka,151 Jebb,152 Jolly,17 
Rock,153, 154 Rolland,119 
Shuger,155 Truby,126 Van 
Wier,157 Womble113  
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Table 2.9 (continued) 
Key domains across studies 
Risk of bias, number of studies and studies (First author) 
Low  Unclear  High  
Blinding of outcome 
assessment 
4 15 2 
Dansinger,11 
Gardner,117 
Heshka,150 
Luszczynska156  
Anderson,144 
Djuric,145 
Donnelly,146 
Foster,147 Gardner,117 
Gold,148 Green,149 
Haapala,124 
Heshka,151 Jebb,152 
Rock,153 Rolland,119 
Shuger,155 Truby,126 
Van Wier,157 
Womble113 
Jolly,17 Rock154  
Incomplete outcome data 12 5 4 
 Gardner,117 Gold,148 
Foster,147 Heshka,150, 
151
 Jebb,152 Rock,153, 
154
 Shuger,155 
Truby,126 Van 
Wier,157 Womble113 
Djuric,145 
Donnelly,146 Jolly,17 
Luszczynska,156 
Rolland119 
Anderson,144 
Dansinger,11 
Green,149 Haapala124 
Selective reporting 19 - 2 
 Anderson,144 
Dansinger,11 
Djuric,145 Foster,147 
Gardner,117 Gold,148 
Haapala,124 
Heshka,150, 151 Jebb,152 
Jolly,17 
Luszczynska,156 
Rock,153, 154 
Rolland,119 Shuger,155 
Truby,126 Van 
Wier,157 Womble113  
- Donnelly,146 Green149 
Other bias 19 - 2 
 Anderson,144 
Dansinger,11 
Djuric,145 Foster,147 
Gardner,117 Gold,148 
Haapala,124 
Heshka,150, 151 Jebb,152 
Jolly,17 
Luszczynska,156 
Rock,153, 154 
Rolland,119 Shuger,155 
Truby,126 Van 
Wier,157 Womble113 
- Donnelly,146 Green149  
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2.4.2.2 Risk of bias for the review as a whole 
Risk of bias for this review as a whole was summarised by the percentage of risk of 
bias across both studies and domains. Over 90% of studies were at a low risk of bias 
for selective reporting and other bias, whilst 90% of studies were approximately at 
high risk of bias for blinding of participants and personnel. Over 70% of studies were 
at an unclear risk of bias for blinding of outcome assessment whilst 50% of studies 
were approximately at low risk of bias for incomplete outcome data. For selection 
bias, 62% and 38% of studies were at low and unclear risk of bias respectively for 
random sequence generation whilst 33% and 67% of studies were approximately at 
low and unclear risk of bias for allocation concealment, respectively ± see Figure 2.3. 
 
 
Figure 2.3 Risk of bias graph for all included studies 
 
  
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
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2.4.2.3 Risk of bias across domains 
Risk of bias across domains within each study shows variation in the quality of 
studies. Heshka and colleagues150 study was at low risk of bias for all domains unlike 
Green149 and Donnelly146 whose studies had no domains at low risk of bias. Two 
studies150, 156 had no domains at high risk of bias whereas two studies146, 149 had three 
or four domains at high risk of bias ± see Figure 2.4. 
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Dansinger 2005         
Djuric 2002         
Donnelly 2007         
Foster 2009         
Gardner 2007         
Gold 2007         
Green 2005         
Haapala 2009         
Heshka 2000         
Heshka 2003         
Jebb 2011         
Jolly 2011         
Luszczynska 2007         
Rock 2007         
Rock 2010         
Rolland 2009         
Shuger 2011         
Truby 2066         
Van Wier 2011         
Womble 2004         
         
Figure 2.4 Risk of bias summary of all included studies 
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The appraisal of methodological quality did not allow for all 21 randomised trials to 
be considerHG³EHVW´RU ³ZRUVW´ LQ WHUPVRI ULVN of bias. However this review was 
able to separately assess the low risk of ELDV6WXGLHVZHUHDVVHVVHGDV µDQXQFOHDU
ULVNRIELDV¶ZKHQWRRIHZGHWDLOVZHUHDYDLODEOH WRPDNHDMXGJHPHQWRIDKLJKRU
low risk of bias. However, most studies have combined the unclear and high 
domains.136 These will report that the average bias in results will reveal fewer studies 
at a high risk of bias. This current review found that 17 (81%)11, 17, 113, 117, 124, 126, 144, 
147, 148, 150-157
 studies were associated with a low risk of bias, whilst the remaining 
studies were associated with an unclear (n = 3, 14%)119, 145, 146 and high (n = 1, 
5%)149 risk of bias, respectively.  
 
2.4.2.4 Reporting of strengths and limitations in the studies 
Strengths 
There were reports of strengths in three studies of Gold and colleagues,148 Jolly and 
colleagues17 and Van Wier and colleagues.157  
 
The strengths of the Gold and colleagues148 study was that it was the first study to 
investigate a commercial online weight loss programme without additional 
professional contact compared with a traditional face-to-face programme. Subjects 
who were involved with the online structured behaviour weight loss website could 
achieve their weight loss.  
 
Jolly and colleagues17 reported their study was a robust evaluation of commercial 
weight loss services which included a diversity of ethnic groups and tested SHRSOH¶V
willingness to pay to participate in such programmes, whilst Van Wier and 
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colleagues157 reported using a theory-based intervention in a Dutch occupational 
setting. 
 
Limitations 
There were similar limitations in several studies. More than half of the studies had 
limitations in terms of a small sample size. The remaining limitations were 
principally around them being a short-term treatment, unknown effects of self-
reporting, low recruitment rates and high loss to follow-up. Three studies did not 
report limitations ± see Table 2.10. 
 
Table 2.10 Summary of limitation of studies included in the review 
Limitations Number Studies (First author) 
Small sample size  11 Anderson,144 Dansinger,11 Foster,147 Gardner,117 
Green,149 Haapala,124 Luszczynska,156 Rock,153 
Rolland,119 Truby,126 Womble113 
Short term study 8 Foster,147 Green,149 Haapala,124 Heshka,150, 151 Jebb,152 
Jolly,17 Rolland,119 Shuger155 
Others 
- Unknown effects from self-
reporting 
 
2 
 
Donnelly,146 Jolly17 
- Low recruitment rates  
- Loss to follow-up 
1 
1 
Jolly17  
Van Wier157 
No limitations reported 31 Djuric,145 Gold,148 Truby126 
 
2.4.3 Description of included studies and their findings 
The 20 studies were categorised by three main intervention components. Sixteen 
studies consisted of diet and exercise programmes11, 17, 113, 117, 124, 126, 145, 147, 148, 150-157 
whilst two studies each focussed on diet119, 149 and meal replacement.144, 146 All 
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studies are described in Appendix 5 that follows the full information by alphabetical 
study. 
 
2.4.3.1 Diet  
There were two RCTs for where the main intervention was diet. Lengths of the 
studies were eight weeks149 and nine months119 ± see Table 2.11. 
 
Green and colleagues149 investigated whether the dieting were related to cortico-
steroid secretion in the early stages of weight loss, by comparing three groups which 
consisted of supported and unsupported dieters, and a control group. They found that 
SDUWLFLSDQWV¶ PHDQ ZHLJKW ORVVHV LQ WKH VXSSRUWHG and unsupported dieters, and 
control were -2.65 kg (-3.3%), -2.16 kg (-2.9%) and -0.05 kg (-0.007%) respectively, 
however there was no significant difference between the three groups. 
 
Rolland and colleagues119 evaluated the effectiveness of a low-carbohydrate/high-
protein diet (LCHP), a commercial very low-calorie diet (VLCD) or LighterLife 
programme (LL), and a 600 kcal-deficient (CDD) diet in an obese population. 
3DUWLFLSDQWV¶ZHLJKWORVVLQ//ZDVKLJKHUWKDQWKDWLQ/&+3-11.6 kg (-9.5%) vs -
2.8 kg (-2.5%) at 3 months, -15.1 kg (-12.3%) vs -2.0 kg (-1.8%) at 9 months, p = 
0.007.  
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Table 2.11 Study details of interventions for diet  
Study Participants Interventions Weight or BMI changes 
Green et al.149 
2005, UK, US 
N = 55 
RCT 
Settings: Community in 
Birmingham, UK 
Age 20-45 years,     
BMI 25-29 kg/m2 
Both women and men 
Mean weight 76.54 kg 
Mean BMI 28.1 kg/m2  
Completers: 16 participants 
in control group 
25 participants -
unsupported dieters 
14 participants - supported 
dieters 
Duration: 8 weeks 
Control:* -0.05 r 2.84 kg 
(-0.07%) 
Unsupported dieters:* -
2.16 r 7.24 kg (-2.9%) 
Supported dieters:*          
-2.65 r 3.28 kg (-3.3%) 
NS** 
Rolland et al.119 
2009, UK 
N = 72 
Randomised 
controlled 
clinical trial 
Settings: Specialist 
Obesity Clinic 
Age older than 18,    
%0,kg/m2 
61 women, 11 men 
Mean age 42.7 years 
Mean weight 117.1 kg 
Mean BMI 39.9 kg/m2  
34 patients in LighterLife 
(LL) 
38 patients in low-
carbohydrate/high-protein 
diet (LCHP) 
Duration: 9 months 
At 3 and 9 months weight 
loss,  
LL: -11.6 r 12.9 kg        
(-9.5%) and -15.1 r 21.1 
kg (-12.3%), respectively 
LCHP: -2.8 r 4.5 kg       
(-2.5%) and -2.0 r 5.0 kg 
(-1.8%), respectively 
p-value = 0.007 
 *mean r SE, **No significant difference 
 
2.4.3.2 Diet and exercise  
There were 16 RCTs for diet and exercise, with or without support, with the length of 
treatment varied from 12 weeks to 24 months ± see Table 2.12. 
 
Dansinger and colleagues11 examined the effectiveness of four popular diets ± 
Atkins, Zone, Weight Watchers (WW) and Ornish ± on weight loss. At one year, 
RYHUZHLJKWRUREHVHSDUWLFLSDQWV¶PHDQZHLJKW ORVVHVwith Atkins (-2.1 kg, -2.1%), 
Zone (-3.2 kg, -3.2%), WW (-3.0 kg, -3.0%) and Ornish (-3.3 kg, -3.2%) indicated 
statistically significant differences within groups (p < 0.01). However, there was no 
statistically significant difference between groups (p = 0.40).  
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Djuric and colleagues145 assessed the effects of combining weight-loss counselling 
with the WW plan on weight loss for obese women with breast cancer. The weight 
loss in participants receiving the individualised counselling and attending WW 
weekly meetings was highest at 12 months, -9.4 kg. There was a significant 
difference from the control group (-0.85 kg), p < 0.05. 
 
Foster and colleagues147 evaluated the effects of two CWLPs on weight and glycemic 
control among obese patients with type 2 diabetes. The first involved a prepackaged, 
portion-controlled diet plan (PCD: NutriSystem® DTM PCD) and the second a 
diabetes support and education (DSE) SURJUDPPH $W WKUHH PRQWKV SDUWLFLSDQWV¶
weight loss with the NutriSystem® DTM PCD programme was -8.2 kg (95% CI: 9.5 
to -6.7, -7.1%) compared with -0.6 kg (95% CI: -2.0 to 0.8, -0.4%), p < 0.0001. For 
mean BMI at three months, PCD and DSE were -2.6 kg/m2 and -0.4 kg/m2, p < 
0.0001.  
 
Gardner and colleagues117 examined the effects of four weight loss diets ranging 
from low to high carbohydrate intake on weight loss among overweight and obese 
pre-menopausal women. At 12 months, the Atkins group (-4.7 kg, -5.5%) resulted in 
greater weight loss than the other three groups which were LEARN (-2.2 kg, -2.6%), 
Ornish (-2.6 kg, -1.9%) and Zone (-1.6 kg, -1.9%). Comparing Atkins and Zone diets 
showed in a statistically significant difference (p = 0.01). However, there were no 
statistically significant differences among Zone, LEARN and Ornish.  
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Gold and colleagues148 demonstrated the effects of a structured behavioural weight 
loss website (VTrim) compared with a commercial weight loss website (eDiets.com). 
The structured behavioural weight loss website (VTrim) consisted of a 6-month on-
line therapist-led weight loss programme and 6-month on-line weight maintenance 
programme. Commercial weight loss website (eDiets.com) provided a calorie-
controlled meal plan tailored to individual preferences, encouraged overweight or 
obese participants to follow their meal plan (my diet), recipe instructions and menu-
specific grocery lists, supported exercise (my fitness) to provide progress weekly and 
monitored by experts and peers in Support central. After six months, weight change 
in eDiets vs VTrim was -4.1 kg (-4.4%) vs -8.3 kg (-8.9%), p = 0.004. 
 
Haapala and colleagues124 evaluated the short- and long-term effectiveness of weight 
loss in a mobile phone weight-loss programme in healthy overweight adults. At 12 
mRQWKVWKHFRPSOHWHGVXEMHFWV¶PHDQZHLJKWORVVLQWKHH[SHULPHQWDOJURXS:HLJKW
Balance® (-4.5 kg, -5.4%), was greater than control group (-1.1 kg, -1.3%). 
Consequently, weight loss between groups at 12 months was of a statistically 
significant difference (p = 0.006).  
 
Heshka and colleagues151 compared the effectiveness of a self-help programme and a 
WW weight loss in overweight and obese adults. Participants in WW received 
vouchers worth $9.00 to attend WW sessions. Subjects in the self-help programme 
had 20-minute consultations with a dietician at the first session and week 12 visits, 
received printed material about dietary principles and physical activity guidelines for 
weight loss and were offered other resources of weight loss information such as 
public library materials, web sites on the Internet and telephone numbers of health 
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promotion organisations. Average weight losses at 26 weeks, 1 and 2 years in WW 
compared with self-help participants were -4.8, -4.3 and -2.9 kg (-5%, -4.6% and -
3.1%) vs -1.4, -1.3 and -0.2 kg (-1.5%, -4.6% and -3.1%), respectively, p < 0.01 at 26 
weeks, p DWDQG\HDUV7KHUHIRUHDWZHHNVSDUWLFLSDQWV¶PHDQ%0,
in WW, compared with self-help participants was 1.7 vs 0.5 kg/m2. At 1 and 2 years, 
SDUWLFLSDQWV¶PHDQ%0,LQ::compared with self-help participants was 1.6 and 1.1 
kg/m2 vs 0.5 and 0.2 kg/m2.150  
 
Jebb and colleagues152 compared weight loss of overweight or obese participants 
who had at least one additional risk factor for obesity-related disease in primary care 
referral to WW with standard care. Results showed that at 12 months, weight change 
in WW vs standard care was -5.06 kg (-5.8%) vs -2.25 kg (-2.6%), p < 0.0001. 
 
Jolly and colleagues17 evaluated the effectiveness of a range of weight loss 
programmes on weight loss. This involved eight interventions: WW, Slimming 
World (SW), Rosemary Conley (RC), Size Down (SD), Choice and Comparator (C), 
general practice (GP) and pharmacy (P)$WZHHNVSDUWLFLSDQWV¶PHDQZHLJKWORVV
in WW was -4.4 kg (-4.7%), Rosemary Conley -4.2 kg (-4.5%), Slimming World -
3.6 kg (-3.8%), Choice -3.3 kg (-3.6 %), Size down -2.4 kg (-2.5%), Pharmacy -2.1 
kg (-2.3%), Comparator (Exercise) -2.0 kg (-2.1%) and general practice -1.4 kg (-
1.5%). Overweight or obese participants in WW (-2.4 kg, -2.5%, p < 0.001) and 
Rosemary Conley (-2.2 kg, -2.2%, p < 0.05) recorded statistically significant 
differences in mean weight loss when compared to a comparator group. 
Consequently, CWLPs were more likely to be effective than comparators; WW was 
the most successful of the eight weight loss interventions.  
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Luszczynska and colleagues156 investigated the effects of the implementation 
intention prompt (IIP) on weight reduction. This study provided Weight Watchers 
(WW) with implementation intention prompt (IIP) conditions and found that at two 
PRQWKVRYHUZHLJKWRUREHVHZRPHQ¶VZHLJKW ORVV LQ::ZLWK,,3compared with 
control group was -4.2 kg (-4.7%) vs -2.1 kg (-2.4%) as well as BMI decrease 1.91 
kg/m2 vs 0.53 kg/m2, p < 0.05.  
 
Rock and colleagues153 investigated whether a multifaceted commercial weight loss 
programme (Jenny Craig, JC) promotes greater weight loss in overweight or obese 
women compared with usual care$WPRQWKVSDUWLFLSDQWV¶PHDQZHLJKW ORVVLQ
JC vs usual care control group (UC) was -7.3 kg (-7.8%) vs -0.7 kg (-0.7%), p < 
0.01. Therefore, participants in the JC group lost significantly more weight than 
those in the UC group. 
 
Rock and colleagues154 studied whether a free prepared meal and incentivised 
structured weight loss programme as centre-based (CB) or telephone-based (TB) 
intervention promotes greater weight loss in overweight and obese women compared 
with usual care (UC). Participants in both CB (-8.2 kg, -8.9%) and TB (-6.7 kg, -
7.2%) interventions reported significantly greater weight loss than those in the UC 
group.  
 
Shuger and colleagues155 study examined the effects of continuous self-monitoring 
and feedback of SenseWearTM Armband (SWA) alone and in combination with 
group weight loss (GWL) to improve weight loss over a 9-month period in sedentary 
overweight or obese adults3DUWLFLSDQWV¶PHDQZHLJKW ORVV LQDOO WKUHH LQWHUYHQWLRQ
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groups, GWL (-1.86 kg, -1.83%), SWA alone (-3.55 kg, -3.5%) and GWL plus SWA 
(-6.6 kg, -6.6%), was statistically significantly different from Standard Care (-0.9 kg, 
-0.9%). As a consequence, participants who participated in GWL plus SWA 
experienced greater weight loss than those in other groups. 
 
Truby and colleagues126 compared the effectiveness of four commercial weight loss 
diets ± WW, RC, Atkins and Slim-fast 7KH JUHDWHVW SDUWLFLSDQWV¶ PHDQ ZHLJKW
change was seen in the WW intervention group (-6.6 kg, -7.3%); weight change for 
Rosemary Conley was (-6.3 kg, -7.0%), Atkins (-6.0 kg, -6.2%), Slim-fast (-4.8 kg, -
4.9%) and control (-0.6 kg, -0.7%). Although there were no statistically significant 
differences of mean weight loss over time, a significant difference was found when 
compared with the control group at p < 0.001. 
 
Van Wier and colleagues157 study examined the effects of a weight-management 
programme with personal counselling by phone or e-mail. Compared with a control 
JURXSRYHUZHLJKWRUREHVHSDUWLFLSDQWV¶ZHLJKWORVVLQWKHphone group was -0.8 kg 
whilst that in e-mail group was -1.7 kg over the 2-year study. The phone group in 
this study recorded a lower weight loss than e-mail group in the Rock and 
colleagues154 study during the same period of trial. 
 
Womble and colleagues113 evaluated the effectiveness of eDiets.com (a commercial 
Internet weight loss programme) to improving weight. Two treatment groups were 
eDiets.com and Weight loss manual (a copy of LEARN programme); the average 
percentage of weight loss at 12 months in eDiets vs LEARN was -1.1% vs -4.1%, p 
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< 0.005. Therefore, participants in the manual group lost significantly more weight 
than those in eDiets.com. 
 
Table 2.12 Study details of interventions for diet and exercise   
Study Participants Interventions Weight or BMI changes 
Dansinger et 
al.11 2005, US 
N = 160 
Single-centre 
randomised 
trial 
Settings: Academic 
medical centre in 
Boston, Massachusetts 
Age 22-72 years,     
BMI 27-42 kg/m2 
81 women, 79 men 
Mean age 49 years 
Mean weight 100 kg 
Mean BMI 35 kg/m2  
40 participants each 
assigned to Atkins, Zone, 
Weight Watchers (WW) 
and Ornish 
Duration: 1 year 
Atkins: -2.1 r 4.8 kg      
(-2.1%) 
Zone: -3.2 r 6.0 kg        
(-3.2%) 
WW: -3.0 r 4.9 kg         
(-3.0%) 
Ornish: -3.3 r 7.3 kg      
(-3.2%)  
p < 0.01 within group 
p = 0.4 among groups 
Djuric et al.145 
2002, US 
N = 48 
Randomised 
pilot study 
(prospective 
trial) 
Settings: Single-centre 
(Secondary care) 
Age 18-70 years  
Both women and men 
Age 36-70 years 
Mean weight 95.4 kg 
Mean BMI 35.5 kg/m2  
12 participants each in 
control (1), Weight 
Watchers: WW (2), 
individualised counselling 
(3), and combination of 
WW and individualised 
counselling (4)  
Duration: 12 months 
Group 1: -0.85 r 6.0 kg 
Group 2: -2.6 r 5.9 kg 
Group 3: -8 r 5.5 kg 
Group 4: -9.4 r 8.6 kg 
p < 0.05 
 
Foster et al.147 
2009, US 
N = 69 
Randomised 
study 
Settings: Temple 
University 
Age 21-75 years,       
BMI 30-50 kg/m2 
49 women, 20 men 
Mean age 52.5 years 
Mean weight 111.2 kg 
Mean BMI 39 kg/m2  
35 patients in A 
commercially available 
weight loss programme: 
A prepackaged, portion-
controlled diet plan 
(PCD: NutriSystem® 
DTM PCD) 
34 patients in diabetes 
support and education 
(DSE) 
Duration: 3 months 
PCD: -8.2 kg              
(95% CI: 9.5 to -6.7),        
-7.1% 
DSE: -0.6 kg              
(95% CI: -2.0 to 0.8),        
-0.4% 
BMI decreased 
PCD: 2.6 kg/m2, 6.6% 
DSE: 0.4 kg/m2, 1.0% 
p < 0.0001 
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Table 2.12 (continued) 
Study Participants Interventions Weight or BMI changes 
Gardner et al.117 
2007, US 
N = 311 
Randomised 
trial 
Settings: Local 
community in the US 
Age 25-50 years,       
BMI 27-40 kg/m2 
Only premenopausal 
women 
Mean age 41 years 
Mean weight 85 kg 
Mean BMI 32 kg/m2  
77 participants in Atkins 
group, 79 participants in 
Zone group, 79 
participants in LEARN 
group, 76 participants in 
Ornish group  
Duration: 12 months 
Atkins: -4.7 kg           
(95% CI: -6.3 to -3.1),      
-5.5% 
Zone: -1.6 kg             
(95% CI: -2.8 to -0.4),       
-1.9% 
LEARN: -2.2 kg        
(95% CI: -3.6 to -0.8),      
-2.6% 
Ornish: -2.6 kg           
(95% CI: -3.8 to -1.3),      
-1.9% 
p = 0.01 
Gold et al.148 
2007, US 
N = 124 
RCT Face-to-
face 
intervention 
Settings: Website weight 
loss programme 
Age 18 years and older, 
BMI 25-39.9 kg/m2 
101 women, 23 men 
Mean age 47.7 years 
Mean weight 91.1 kg 
Mean BMI 32.4 kg/m2  
62 participants each in 
eDiets and VTrim groups 
Completers: 48 in 
eDiets.com, 40  in 
VTrim  
Duration: 12 months  
The first 6-month: 
Weight loss programme 
The last 6-month: 
Weight maintenance 
programme 
At 6 months, 
eDiets: -4.1 r 6.2 kg         
(-4.4%), VTrim: -8.3 r 7.9 
kg (-8.9%)  
p = 0.004 
At 12 months,  
eDiets: -3.4 r 5.8 kg        
(-3.7%), VTrim: -7.8 r 7.5 
kg (-8.6%) 
p = 0.034 
Haapala et al.124 
2009, Finland 
N = 124 
RCT 
Settings: University 
hospital, Kuopio Finland 
Age 25-44 years,       
BMI 25-36 kg/m2 
96 women, 28 men 
Mean age 38.05 years 
Mean weight 87 kg 
Mean BMI 30.5 kg/m2  
62 subjects each in 
experimental and control 
groups  
Completers: At 12 
months,  
42 subjects in 
experimental group (EG: 
Weight Balance)  
40 subjects in control 
group (CG) 
Duration: 12 months 
EG: -4.5 r 5.0 kg (-5.4%) 
CG: -1.1 r 5.8 kg (-1.3%) 
p = 0.006 
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Table 2.12 (continued)    
Study Participants Interventions Weight or BMI changes 
Heshka et al.150, 
151
 2000, 2003 
US 
N = 423 
RCT 
Settings: Multicentre (6 
clinical research centres) 
Age 18-65 years,       
BMI 27-40 kg/m2  
358 women, 65 men 
Mean age 44.5 years 
Mean weight 93.7 kg 
Mean BMI 33.7 kg/m2  
211 subjects in 
commercial programme 
(Weight Watchers) 
212 subjects in self-help 
group 
Duration: 26 weeks 
Commercial programme:  
-4.8 r 5.6 kg (-5.0%) 
Self-help group: -1.4 r 4.7 
kg (-1.5%) 
BMI decreased: 
Commercial programme: 
1.7 kg/m2 
Self-help group: 0.5 kg/m2 
p < 0.01 
Heshka et al.150, 
151
 2000, 2003 
US 
N = 423 
RCT 
Settings: Multicentre (6 
clinical research centres) 
Age 18-65 years,       
BMI 27-40 kg/m2  
358 women, 65 men 
Mean age 44.5 years 
Mean weight 93.7 kg 
Mean BMI 33.7 kg/m2  
211 subjects in 
commercial programme 
(Weight Watchers) 
212 subjects in self-help 
group 
Duration: 24 months 
At year 1 and 2, 
commercial programme:*   
-4.3 r 0.4 kg (-4.6%) and  
-2.9 r 0.5 kg (-3.1%) 
Self-help group:*               
-1.3 r 0.4 kg (-1.4%) and  
-0.2 r 0.4 kg (-0.2%) 
At year 1 and 2, BMI 
decreased:  
Commercial programme: 
1.6 and 1.1 kg/m2 
Self-help group: 0.5 and 
0.2 kg/m2, respectively 
p < 0.001 
Jebb et al. 
2011,152 UK 
N = 772 
Multicentre, 
RCT with a 
parallel design 
Settings: Primary care 
practices in Germany, 
Australia and UK 
Age at least 18 years, 
BMI 27-35 kg/m2  
668 women, 104 men 
Mean age 47.4 years 
Mean weight 86.7 kg 
Mean BMI 31.4 kg/m2  
378 participants in 
commercial programme 
(Weight Watchers) 
395 participants in 
standard care  
Duration: 12 months 
Commercial programme:* 
-5.06 r 0.31 kg (-5.8%) 
Standard care:*                  
-2.25 r 0.21 kg (-2.6%) 
p < 0.0001 
*mean r SE 
  
Chapter 2 Systematic review 
97 
 
Table 2.12 (continued)    
Study Participants Interventions Weight or BMI changes 
Jolly et al.17 
2011, UK 
N = 740 
8-arm RCT 
Settings: 17 primary care 
trust in South 
Birmingham, England 
AJHG\HDUV 
White Europeans and all 
ethnic groups: %0,
kg/m2 with comorbidities 
in RU%0,kg/m2 
without comorbidities 
South Asians: %0,
kg/m2 with comorbidities 
RU%0,kg/m2 
without comorbidities 
495 women, 245 men 
Mean age 49.3 years 
Mean weight 93.3 kg 
Mean BMI 33.6 kg/m2  
100 participants of each 
group for Weight 
Watchers (WW), 
Slimming World (SW), 
Rosemary Conley (RC), 
Size Down (SD), Choice 
and Comparator (C) 
70 participants of each 
group for general 
practice (GP) and 
pharmacy (P) 
Duration: 12 weeks 
WW: -4.4 kg                
(95% CI: 3.6-5.3), -4.7% 
SW: -3.6 kg                 
(95% CI: 2.7-4.4), -3.8% 
RC:a -4.2 kg               
(95% CI: 3.2-5.2), -4.5% 
SD: -2.4 kg                 
(95% CI: 1.7-3.1), -2.5% 
Choice: -3.3 kg            
(95% CI: 2.5-4.1), -3.6% 
C: -2 kg                          
(95% CI: 1.2-2.8), -2.1% 
GP: -1.4 kg                 
(95% CI: 0.4-2.3), -1.5% 
P: -2.1 kg                   
(95% CI: 1.0-3.2), -2.3% 
p d 0.01, ap < 0.05 
Luszczynska et 
al.156 2007, UK, 
Poland 
N = 55 
RCT 
Settings: Warsaw, 
Poland 
Age 18-76 years,    
BMI > 25 kg/m2 
Both women and men 
Mean weight 89 kg 
Mean BMI 33.2 kg/m2  
29 participants in control 
27 participants in Weight 
Watchers with 
implementation intention 
prompt (IIP) conditions  
Duration: 2 months 
Control: -2.1 kg          
(95% CI: 1.11-3.09),         
-2.4% 
IIP: -4.2 kg                 
(95% CI: 3.19-5.07),         
-4.7% 
BMI decreased: 
Control: 0.53 kg/m2 
IIP: 1.91 kg/m2 
p < 0.05 
Rock et al.153 
2007, US 
N = 70 
RCT 
Settings: San Diego 
Age 18 years and older, 
BMI 25-40 kg/m2 
Only women 
Mean age 41 years 
Mean weight 92 kg 
Mean BMI 34 kg/m2  
35 participants each in 
intervention group 
(Jenny Craig: JC) and 
usual care control group 
(UC).  
At 12 months, 32 
participants in 
intervention group  
33 participants in usual 
care control group 
Duration: 12 months 
JC: -7.3 r 10.4 kg (-7.8%) 
UC: -0.7 r 5.6 kg (-0.7%) 
p < 0.01 
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Table 2.12 (continued)    
Study Participants Interventions Weight or BMI changes 
Rock et al.154 
2010, US 
N = 442 
RCT 
Settings: US institutions 
at 4 study sites that 
consisted of 3 
universities as University 
of California, Arizona, 
and Minnesota and one 
centre of health research, 
Oregon 
Age 18 years or older, 
BMI of 25 to 40 kg/m2  
Only women 
Mean age 44.3 years 
Mean weight 92 kg 
Mean BMI 33.9 kg/m2  
167 participants in 
centre-based intervention 
(CB: Jenny Craig) 
164 participants in 
telephone-based 
intervention (TB) 
111 participants in usual 
care group (UC) 
Completers: 151 
participants in CB 
153 participants in TB 
103 participants in UC  
Duration: 24 months 
CB: -8.2 kg                 
(95% CI: -9.5 to -6.8),      
-8.9% 
TB: -6.7 kg                
(95% CI: -8.2 to -5.2),      
-7.2% 
UC: -2.1 kg                 
(95% CI: -3.6 to -0.7),       
-2.3% 
p < 0.05 
 
Shuger et al.155 
2011, US 
N = 197 
RCT 
Settings: The greater 
Columbia, South 
Carolina area 
Age 18-64 years,       
BMI 25-45 kg/m2 
161 women, 36 men 
Mean age 46.9 years 
Mean weight 92.8 kg 
Mean BMI 33.3 kg/m2  
50 participants for 
standard care (SC) 
49 for Group-based 
behavioural weight loss 
programme (GWL) 
49 for Combined GWL 
and SWA group (GWL + 
SWA) 
49 for SenseWearTM 
Armband alone group 
(SWA alone) 
Duration: 9 months 
SC: -0.9 kg (-0.9%) 
GWL: -1.86 kg (-1.83%) 
GWL + SWA: -6.6 kg     
(-6.6%), p < 0.0001 
SWA alone: -3.55 kg       
(-3.5%), p = 0.0002 
BMI decreased,  
SC: -0.36 kg/m2 
GWL: -0.7 kg/m2,             
p = 0.03 
GWL + SWA: -2.28 
kg/m2, p < 0.0001 
SWA alone: -1.17 kg/m2, 
p = 0.0005 
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Table 2.12 (continued)    
Study Participants Interventions Weight or BMI changes 
Truby et al.126 
2006, UK 
N = 293  
Multicentre 
randomised 
unblinded 
controlled 
parallel dietary 
intervention 
Settings: Community 
based sample of healthy 
overweight and obese 
adults, 5-region centres 
at Surrey University, 
Bristol University, 
Nottingham University, 
Ulster (Caleraine) 
University and Queen 
Margaret University 
College, Edinburgh) 
Age 18-65 years,       
BMI 27-40 kg/m2 
214 women, 79 men 
Mean age 40.2 years 
Mean weight 89.4 kg 
Mean BMI 31.7 kg/m2  
57 participants in Atkins 
(A) 
58 participants in Weight 
Watchers (WW) 
59 participants in Slim-
fast (SF) 
58 participants in 
Rosemary Conley (RC) 
61 participants in Control 
(C) 
Duration: 6 months 
A: -6.0 r 6.4 kg (-6.2%) 
WW: -6.6 r 5.4 kg           
(-7.3%) 
SF: -4.8 r 5.6 kg (-4.9%) 
RC: -6.3 r 6.1 kg (-7.0%) 
Control: -0.6 r 2.2 kg      
(-0.7%) 
p < 0.001 
 
Van Wier et 
al.157 2011, 
Netherlands 
N = 1386 
RCT 
Settings: 7 Dutch 
service-sector companies 
$JH\HDUV
%0,kg/m2 
457 women, 929 men 
Mean age 43 years 
Mean weight 93.2 kg 
Mean BMI 29.6 kg/m2  
462 participants in phone 
464 participants in 
Internet 
460 participants in 
control 
Completers: 263 in 
phone, 263 in Internet, 
266 in control 
Duration: 2 years 
Compared with control 
group:  
Phone lost 0.8 kg       
(95% CI: -1.5 to 0.03) 
p = 0.059 
Internet lost 1.2 kg     
(95% CI: -1.9 to -0.4) 
p = 0.004 
 
Womble et 
al.113 2004, US 
N = 47 
RCT 
Settings: University of 
Pennsylvania 
Age 18-65 years,       
BMI 27-40 kg/m2 
Both women and men 
Mean age 43.8 years 
Mean weight 90.7 kg 
Mean BMI 33.5 kg/m2  
23 participants in 
eDiets.com 
24 participants in 
LEARN (Weight loss 
manual) 
At week 16 and 52, 23 
participants each in both 
eDiets.com and LEARN 
(Weight loss manual) 
Duration: 12 months 
At week 16 and 52,  
eDiets lost 0.9 r 3.2 % 
(0.8 kg) and 1.1 r 4.0 % 
(1.0 kg), respectively 
LEARN lost 3.6 r 4.0 % 
(3.2 kg) and 4.0 r 5.1 % 
(3.5 kg), respectively 
p < 0.05 
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2.4.3.3 Meal replacement  
There were two RCTs for meal replacement with treatment lengths of 12 and 24 
weeks ± see Table 2.13. 
 
Anderson and colleagues144 compared effects of a standardised behavioural 
intervention using meal replacements (MRs), fruits and vegetables (MR-FV) and 
increased physical activity with a usual-care intervention on body weight change. 
The intervention group provided meal replacements, fruits and vegetables (MR-FV) 
as a low-energy diet whilst a control group received usual-care weight-loss 
counselling from an experienced or a registered dietician. At 24 weeks, obese 
SDUWLFLSDQWV¶ PHDQ ZHLJKW LQ 05-FV vs control group was -13.9 kg vs -0.7 kg (-
13.9% vs -0.7%).  
 
Donnelly and colleagues146 compared the effectiveness of a phone-based and a 
traditional face-to-face clinic approach using meal replacement to achieve 10% 
weight loss at 12 weeks. Results of phone and clinic groups showed greater weight 
loss than the control group (-0.2%). This study confirmed that both a phone approach 
and the traditional weight management clinic yielded similar success at 10% weight 
loss of the initial weight at baseline.  
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Table 2.13 Study details of interventions for meal replacement  
Study Participants Interventions Weight or BMI changes 
Anderson et 
al.144 2003, US 
N = 38 
RCT 
Settings: University 
medical centre 
Age 20-65 years,       
BMI 30-39.9 kg/m2 
29 women, 9 men 
Mean age 48 years 
Mean weight 99.5 kg 
Mean BMI 35.4 kg/m2  
16 participants in control 
group 
22 participants in meal 
replacements, fruits and 
vegetables (MR-FV)  
Duration: 24 weeks 
Control:* -0.7 r 1.1 kg     
(-0.7%) 
MR-FV:* -13.9 r 1.1 kg   
(-13%) 
p < 0.0001 
Donnelly et 
al.146 2007, US 
N = 96 
RCT 
Settings: Weight 
management clinic 
Age 25-68 years,       
BMI 33.2 r 3.8 kg/m2 
72 women, 24 men 
Median age: 53 years in 
phone, 52 years in clinic, 
46 years in control 
groups 
Median weight: 102.5 kg 
in phone, 95.6 kg in 
clinic, 88.2 kg in control 
groups 
25 participants in phone 
group 
27 participants in clinic 
group 
22 participants in control 
group 
Duration: 12 weeks 
Median weight loss 
(range, %) in 
Phone: -10.6 kg          
(16.6, -10.4%) 
Clinic: -12.7 kg         
(19.9, -13.7%) 
Control: -0.25 kg          
(5.6, -0.2%) 
p < 0.05 
*mean r SE 
 
2.4.4 Synthesis of findings 
The synthesis of findings revealed that the potential elements which are important in 
effective weight loss were: 1) structure of interventions via diet and exercise, 2) 
support, 3) length of treatment and 4) other considerations such as adverse events 
and dropout rate. 
 
This review compared the percentage weight loss across studies, particularly 
focusing on calorie restricted diets, exercise and support in the intervention groups. 
Those three elements are the essential criteria of any weight loss strategy, in order for 
CWLPs to be effective.  
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The diet was considered in terms of calorie restriction per day (total kcal/day). This 
element was primarily associated with the effectiveness of weight loss. Exercise and 
support are the complementary components in weight management. Exercise was 
associated with weight loss which, in addition to diet, was either taken as daily 
exercise or was optional. Providing support can encourage overweight or obese 
SDUWLFLSDQWVWRORVHZHLJKWYLDDVVLVWDQFHIURPSURYLGHUVDVZHOODVWKHSDUWLFLSDQWV¶
ability at self-monitoring. All three elements will be considered with relevant 
examples from the review ± see Table 2.14 and Table 2.15. 
 
In this review of all weight loss interventions, there were 46 intervention arms, which 
included four arms consisting of a diet group;119, 149 39 arms consisting of a diet and 
exercise group;11, 17, 113, 117, 124, 126, 145, 147, 148, 150-157 and three arms consisting of a meal 
replacement group144, 146 ± see Table 2.14 and Table 2.15. The effectiveness of 
CWLPs was evaluated using the percentage weight loss of at least 5% of the initial 
body weight for up to or more than three months. Where the weight loss 
interventions showed a weight loss of less than 5% this was taken to indicate an 
ineffective CWLP. This criterion was based on the NICE obesity guidelines.15  
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2.4.4.1 Structure of interventions: diet and exercise 
Calorie restriction 
Several CWLPs which specified calorie restriction per day appeared to be more 
effective than those with non-specified calorie restriction per day, in both short- and 
long-term treatments. Calorie restricted meal replacement programmes144, 146 (1,200 
kcal/day) and LL119 (550 kcal/day) achieved weight loss of more than 5%. 
Nutrisystem restricted calories to 1,550 and 1,250 kcal each day for men and women, 
respectively.147 Meanwhile SW,17 RC,17, 126 Zone,11, 117 Ornish11, 117 and LEARN,113, 
117
 did not restrict total calorie intake per day and were shown to produce weight 
losses of less than 5%.  
 
The most effective weight loss strategy for both a short- and long-term treatment was 
that of meal replacement programmes, yielding losses of 13.7%146 and 13.9%,144 
respectively. This weight loss intervention consists of a very low or low calorie diet 
(HMR shakes, fruits and vegetables using a low energy diet with 5 meal 
replacements and 5 servings of fruit or vegetables). HMR (1,200 kcal/day) had a 
slightly lower calorie level than almost all diet and exercise groups (1,200-2,300 
kcal/day) other than LL119 (550 kcal/day). It can be seen that HMR would be more 
effective in producing weight loss than the remaining CWLPs.  
 
Nutrisystem147 (7.1%) was the only programme that restricted intake to 1,550 
kcal/day in men and 1,250 kcal/day in women with mean age older than 50 years. 
Comparing Nutrisystem with a control, weight loss percentage from the Nutrisystem 
was significantly more when compared with a diabetes support and education 
programme (DSE, 0.4%).147 This showed that DSE failed to achieve meaningful 
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weight loss. The reason for this is likely to be that DSE included only lessons about 
diet and exercise support. Such support was ineffective as participants possibly due 
to lower adherence in this programme compared with the weekly support provided 
by the Nutrisystem, resulted in minimal weight loss by DSE participants.  
 
Regarding the remaining weight loss interventions for long-term treatment, seven 
interventions, which restricted total calorie intake per day, were effective, but not 
more so than meal replacement. These were JC153, 154 (7.8% and 8.9%), VTrim148 
(8.9%), telephone-based programme154 (7.2%), RC126 (7.0%), GWL and SWA155 
(6.6%) and Weight Balance124 (5.4%), respectively. JC154 low-calorie diet restriction 
was 1,200-2,300 kcal/day whilst VTrim148 consisted of reducing energy intake by 
1,000 kcal/day. RC126 included a low-calorie exchange diet (1,200 kcal/day) based 
on telephone-based intervention154 which consists of a low- or very low-calorie diet 
(1,200-2,000 kcal/day) with reducing fat intake by 20%-30%. Lastly, Weight 
Balance124 reduces food intake by 800-1,500 kcal/day. All four interventions of JC, 
VTrim, RC and telephone-based weight loss interventions included daily exercise 
and weekly individual support. Only Weight Balance included quarterly support ± 
see Table 2.15.  
 
Weight loss interventions which failed to achieve meaningful weight loss, such as 
Zone and Ornish,11, 117 may have done so because such programmes did not restrict 
SDUWLFLSDQWV¶in total calorie level per day. 
 
Similarly, a telephone-based weight loss intervention (1.5%)157 had a weight loss 
lower than 5% of the initial weight. The reason for this may be that participants in 
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this intervention received information on nutrition and exercise in the form of a 
workbook. Although participants had weekly one-to-one contact, via telephone, with 
health care providers, there were no restrictions on diet or exercise. It is therefore 
possible to conclude both the restriction of calorie and structured exercise is likely to 
lead to greater weight loss. 
 
Structured exercise 
Either high-impact or low-impact exercise, added to diet for weight loss, appeared to 
be another important component for the success of CWLPs. With exercise offered for 
participants as an optional activity appearing to be less effective than in programmes 
that encouraged weekly exercise (2,000 kcal/week)144, 146 especially when 
participants were expected to record the calories burned in physical activity. This 
restricted exercise may be a reason why meal replacement was found to be more 
effective than other programmes. For the remaining weight loss interventions, 
physical activity was prescribed, such as, 30-60 minutes per day on 5-7 days each 
week. Therefore, the effectiveness of meal replacement and the diet and exercise 
group was greater than in the diet group, except for one intervention (LL)119 which 
provided high restriction of total calorie level intake per day.  
 
In summary, those CWLPs which resulted in an effective weight loss of at least 5% 
of the entry body weight involved total calorie restriction per day, daily exercise and 
weekly support. In contrast, those CWLPs that resulted in a weight loss of less than 
5% of the initial body weight tended to have no calorie restriction per day on diet, 
optional exercise and offered only monthly or quarterly support. 
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Table 2.14 Key elements of weight loss interventions for short-term treatment 
Study and 
Programme  
Types of providers  Calorie restriction (Total kcal/day)  Exercise (Daily 
or Optional) 
Description of support  Dropout 
(%) 
Weight 
change (%)  
Diet       
Green149       
Supported dieters Dietician Calorie restricted and Balanced diet: 
Low fat, Low carbohydrate 
DNR* Weekly group session DNR* 3.3** 
Unsupported dieters No provider Calorie restricted and Balanced diet: 
Low fat, Low carbohydrate, planned by 
participants 
DNR* Weekly group session DNR* 2.9** 
Control DNR* Non-dieting DNR* Weekly group session DNR* 0.07** 
Diet and exercise       
Foster147       
Nutrisystem Physician Portion-controlled diet plan, prepakaged 
Nutrisystem DTM PCD (Women: 1250, 
Men: 1550) 
Daily principal 
walking start at 
week 4 
Weekly group session led by 
health care professional 
2.9 7.1 
Diet support and 
education (DSE) 
- - Daily principal 
walking start at 
week 16 
Monthly group session led by 
health care professional 
0 0.4 
*DNR = Did not report 
**Not significant difference between groups 
Chapter 2 Systematic review 
107 
 
107 
Chapter
 2 System
atic
 review
 
Table 2.14 (continued)  
Study and 
Programme  
Types of providers  Calorie restriction (Total kcal/day)  Exercise (Daily 
or Optional) 
Description of support  Dropout 
(%) 
Weight 
change (%)  
Luszczynska156       
WW + 
Implementation 
intention prompt 
Group supporter Low-calorie, exchange diet, clients 
prepare own meals (1200-1600) 
Daily Behaviour weight control 
methods: Weekly group and 
social support + Implementation 
intention prompt 
DNR* 4.7 
Weight Watchers 
(WW) 
Dietician  Low-calorie, exchange diet, clients 
prepare own meals (1200-1600) 
Daily Behaviour weight control 
methods: Weekly group and 
social support 
DNR* 
 
2.4  
Jolly17       
Weight Watchers Dietician  Low-calorie, exchange diet, clients 
prepare own meals (1200-1600) 
Daily Behaviour weight control 
methods: Weekly group and 
social support 
30 4.7 
Slimming World 
(SW) 
Food advisor, other 
members 
Eat low energy dense food, control high 
energy dense food, extra fibre 
Daily Email, telephone and group 
support, individual support , 
weekly contact 
40 3.8 
Rosemary Conley 
(RC) 
Food advisor, other 
members 
Low-calorie, exchange diet Daily Role modelling, group, telephone, 
website and individual support, 
weekly contact 
50 4.5 
Size down Trained worker Balanced diet Daily NHS group based programme, 
biweekly contact 
50 2.5 
*DNR = Did not report 
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Table 2.14 (continued)  
Study and 
Programme  
Types of providers  Calorie restriction (Total kcal/day)  Exercise (Daily 
or Optional) 
Description of support  Dropout 
(%) 
Weight 
change (%)  
Jolly17 (continued)      
Choice DNR* Choose 1 of 6 interventions Optional DNR 26 3.6 
General practice 
(Public) 
General practitioner Reducing calorie intake Daily Self-monitoring, weekly contact 54 1.5 
Pharmacy (Public) Pharmacist Reducing calorie intake Daily Self-monitoring, weekly contact 46 2.3 
Comparator 
(Exercise) 
- - Daily No appointment and individual 
advice and support 
DNR* 2.1 
Meal replacement       
Donnelly146       
Phone group Licensed physician 
and other health 
care providers 
Low-calorie or very low calorie diet, MR 
products (1200-1500) 
Daily (2000 
kcal/week) 
Weekly one-to-one contact with 
telephone  
16 10.4 
Clinic group Licensed physician 
and other health 
care providers 
Low-calorie or very low calorie diet 
(1200-1500) 
Daily (2000 
kcal/week) 
Group session, weekly classes 15 13.7 
*DNR = Did not report 
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Comparing all weight loss interventions with their controls, over four-fifths of all 
interventions produced statistically significant differences in weight loss compared 
with control groups. Three key elements in controls were different from the active 
interventions. The percentage weight change of controls in 20 studies ranged from 
0.07%-2.1% for a short-term treatment to 0.7%-4.4% for a long-term treatment. For 
example, the control groups in four studies failed to achieve any meaningful weight 
loss e.g. low-carbohydrate/high-protein diet119 (1.8%), WW156 (2.4%), LEARN113 
(4%), eDiets148 (4%). However, the percentage weight loss in two controls was 
greater than that in the interventions. Those controls were found in Womble and 
colleagues113 study (4% in LEARN vs 1.1% in eDiets) and Jolly and colleagues17 
(2.1% in comparator vs 1.5% in General Practice). Possible reasons for such results 
are described below. 
 
Although eDiets and LEARN failed to achieve meaningful weight loss, it was useful 
to compare their elements in terms of effectiveness.113 Considering key elements in 
eDiets, its structure was not step-by-step as with LEARN. Participants in LEARN 
needed to keep food records and count calories, whilst participants in the eDiets 
programme self-monitored and were not asked to record their total calorie intake per 
day; therefore, these activities in LEARN brought about a greater weight loss than 
those in eDiets. If participants in the Internet weight loss intervention had been 
required to keep daily records for total calorie intake per day in combination with 
exercise and the similar support, the results would probably have been similar. 
Therefore, this study showed that total calorie restriction per day and daily exercise 
with support are the main elements in any effective weight loss programme. 
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In the study of Jolly and colleagues,17 although General Practice included reducing 
calorie intake, daily exercise and weekly contact with a general practitioner, 
SDUWLFLSDQWV¶ SHUFHQWage weight change in this intervention was lower than the 
comparator (exercise). Additionally, there was no individual advice and support 
provided for the comparator group. Participants in this comparator group registered 
greater weight loss than those in the General Practice programme. This study claimed 
that participants in the comparator group were more likely to exercise and to highly 
adhere to this programme ± resulting in losing weight. Meanwhile participants in 
General Practice may be less inclined to take exercise, which affected their weight 
loss. 
Chapter 2 Systematic review 
111 
 
111 
Chapter
 2 System
atic
 review
 
Table 2.15 Key elements of weight loss interventions for long-term treatment 
Study and 
Programme  
Types of providers  Calorie restriction (Total kcal/day)  Exercise (Daily 
or Optional) 
Description of support  Dropout 
(%) 
Weight 
change (%)  
Diet       
Rolland119       
LighterLife (LL) Trained LL 
counsellor 
Very low calorie diet (550): 36% 
carbohydrate, 36% protein, 28% fat 
Daily  Long-term behaviour 
modification with group, 
telephone and email support, 
monthly contact 
58.8  9.5, 12.3 (3 
and 9 
months) 
 
Low-
carbohydrate/high-
protein diet (LCHP) 
Dietician, doctor Low-carbohydrate/high-protein diet 
(800-1500): 20% carbohydrate, 40% 
protein, 40% fat 
Daily Alternative approach by LCHP or 
prescription medication 
47.4 2.5, 1.8 (3 
and 9 
months) 
1.8 
Diet and exercise       
Dansinger11       
Atkins Dietician and 
physician advice 
Carbohydrate restriction: Low 
carbohydrate 
Daily Supplements, exercise and 
external support, weekly contact 
48 
 
2.1* 
 
Zone Dietician and 
physician advice 
Macronutrient balance: 40% 
carbohydrate, 30% fat, 30% protein 
Daily Supplements, exercise and 
external support, weekly contact 
50 3.2* 
 
*Not significant difference between groups 
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Table 2.15 (continued)       
Study and 
Programme  
Types of providers  Calorie restriction (Total kcal/day)  Exercise (Daily 
or Optional) 
Description of support  Dropout 
(%) 
Weight 
change (%)  
Dansinger11 (continued)      
WW Dietician and 
physician advice 
Low-calorie, exchange diet, clients 
prepare own meals (1200-1600) 
Daily Behaviour weight control 
methods: Weekly group and 
social support 
53 3.0* 
Ornish Dietician and 
physician advice 
Fat restriction Daily Supplements, exercise and 
external support, weekly contact 
25 3.2* 
Djuric145       
WW Dietician  Low-calorie, exchange diet, clients 
prepare own meals (1200-1600) 
Daily Behaviour weight control 
methods: Weekly group and 
social support 
72 
  
2.6 
 
Individualised 
counselling 
Registered dietician Low-calorie, exchange diet, clients 
prepare own meals (1200-1600) 
Daily Weekly 1-3 months, biweekly 3-6 
months, Monthly after 6 months 
one-to-one counselling using 
Bandura's social cognitive theory 
DNR** 8 kg (Did 
not report 
the initial 
weight) 
WW + Individualised 
counselling 
Dietician and 
physician advice 
Low-calorie, exchange diet, clients 
prepare own meals (1200-1600) 
Daily Behaviour weight control 
methods: Weekly group and 
social support + individualised 
counselling using Bandura's 
social cognitive theory 
53 9.4 kg (Did 
not report 
the initial 
weight) 
*Not significant difference between groups 
**DNR = Did not report 
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Table 2.15 (continued)       
Study and 
Programme  
Types of providers  Calorie restriction (Total kcal/day)  Exercise (Daily 
or Optional) 
Description of support  Dropout 
(%) 
Weight 
change (%)  
Djuric145 (continued)      
Control - 5HFHLYHG³$FWLRQ*XLGHWR+HDOWK\
(DWLQJ´DQG³)RRG*XLGH3\UDPLG´
pamphlets (no dietary instructions) 
No exercise 
instructions 
- DNR** 0.85 
Gardner117       
Atkins Dietician and 
physician advice 
Carbohydrate restriction: Low 
carbohydrate 
Daily Supplements, exercise and 
external support, weekly contact 
12 5.5* 
Zone Dietician and 
physician advice 
Macronutrient balance: 40% 
carbohydrate, 30% fat, 30% protein 
Daily Supplements, exercise and 
external support, weekly contact 
23 1.9* 
Ornish Dietician and 
physician advice 
Fat restriction Daily Supplements, exercise and 
external support, weekly contact 
22 1.9* 
LEARN Registered dietician The LEARN Manual for Weight 
Management: 55-60% carbohydrate, 
10% fat 
Daily Specific energy restriction goal, 
weekly contact 
24 2.6* 
*Not significant difference between groups 
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Table 2.15 (continued)       
Study and 
Programme  
Types of providers  Calorie restriction (Total kcal/day)  Exercise (Daily 
or Optional) 
Description of support  Dropout 
(%) 
Weight 
change (%)  
Gold148       
eDiet Company-trained 
counsellor and 
company dietician 
Low-calorie diet, modified eating by 
virtual dieticians, clients prepare own 
meals (1200-1300) 
Daily Individual and group online 
support, weekly contact 
35 
 
4.4 
 
VTrim Therapist Modified eating: Reduced energy intake 
up to 1000 kcal/day 
Daily exercise 
up to 1000 
kcal/day 
Individual and group online 
support, weekly contact 
23 8.9 
Haapala124       
Weight Balance Nurse Reducing food intake (800-1500) Daily Modified phone-operated weight 
loss programme, quarterly visit 
27 5.4 
Control No provider No specific diet instruction No specific 
exercise 
instruction 
No intervention 35 1.3 
Heshka150, 151       
WW Dietician  Low-calorie, exchange diet, clients 
prepare own meals (1200-1600) 
Daily Behaviour weight control 
methods: Weekly group and 
social support 
16  
 
5.0, 4.6, 3.1 
(H at 26 
weeks, 1 
and 2 
year)150, 151 
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Table 2.15 (continued)       
Study and 
Programme  
Types of providers  Calorie restriction (Total kcal/day)  Exercise (Daily 
or Optional) 
Description of support  Dropout 
(%) 
Weight 
change (%)  
Heshka150, 151 (continued)      
Self-help Dietician Guideline for diet Guideline for 
exercise 
Counselling at the first visit and 
week 12 
16 1.5, 1.4, 0.2 
(26 weeks, 
1 and 2 
years) 
Jebb152       
WW Dietician  Low-calorie, exchange diet, clients 
prepare own meals (1200-1600) 
Daily Behaviour weight control 
methods: Weekly group and 
social support 
39 
  
5.8 
 
Standard care Primary care 
professional 
Diet advice  Exercise advice  Used national clinical guideline 46 2.6 
Rock153       
Jenny Craig (JC) Company-trained 
counsellor 
Low-calorie diet, prepackaged JC meals 
only (1200-2300) 
Daily Individual sessions, weekly 
contact 
8.6  7.8 (12 
months) 
Usual care Dietician Received diet guideline without 
instruction 
Received 
exercise 
guideline 
without 
instruction 
Consultation at the initial visit and 
at week 16 
5.7 0.7 (12 
months) 
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Table 2.15 (continued)       
Study and 
Programme  
Types of providers  Calorie restriction (Total kcal/day)  Exercise (Daily 
or Optional) 
Description of support  Dropout 
(%) 
Weight 
change (%)  
Rock154       
Jenny Craig (JC) Company-trained 
counsellor 
Low-calorie diet, prepackaged JC meals 
only (1200-2300) 
Daily Individual sessions, weekly 
contact 
 4.7  8.9 (24 
months) 
Telephone-based Licensed physician 
and other health 
care providers 
Low-calorie or very low calorie diet 
(1200-2000), low fat (20-30%) 
Daily Weekly one-to-one contact with 
telephone 
6.7 7.2 (24 
months) 
Usual care Dietician Received diet guideline without 
instruction 
Received 
exercise 
guideline 
without 
instruction 
Consultation at the initial visit and 
at week 16 
8.8 2.3 (24 
months) 
Shuger155       
Group-based 
behaviour weight 
loss programme 
(GWL) 
Programme 
facilitator 
Healthy eating Optional Group-based behaviour 
modification, monthly contact 
30 1.8 
SenseWear Armband 
(SWA) alone 
Programme 
facilitator 
Healthy eating Daily Personalised weight management, 
monthly contact 
30 3.5 
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Table 2.15 (continued)       
Study and 
Programme  
Types of providers  Calorie restriction (Total kcal/day)  Exercise (Daily 
or Optional) 
Description of support  Dropout 
(%) 
Weight 
change (%)  
Shuger155 (continued)       
GWL + SWA Programme 
facilitator 
Healthy eating Daily Group-based behaviour 
modification and personalised 
weight management, monthly 
contact 
30 6.6 
Standard care No provider Healthy eating Daily Received self-directed weight loss 
manual 
48 0.9 
Truby126       
Atkins Dietician  Carbohydrate restriction: Low 
carbohydrate 
Daily Supplements, exercise and 
external support, weekly contact 
30 6.2 
WW Dietician  Low-calorie, exchange diet, clients 
prepare own meals (1200-1600) 
Daily Behaviour weight control 
methods: Weekly group and 
social support 
29.8 7.3 
Rosemary Conley 
(RC) 
Food advisor, other 
members 
Low-calorie, exchange diet (1200) Optional Role modelling, group, telephone, 
website and individual support, 
weekly contact 
19 7.0 
Slim-fast DNR** Low-calorie or very low calorie diet, MR 
products (1200) 
Optional Support pack with group session, 
weekly classes 
19 4.9 
Control DNR** Maintained diet Maintained 
exercise 
No intervention 34.4 0.7 
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Table 2.15 (continued)       
Study and 
Programme  
Types of providers  Calorie restriction (Total kcal/day)  Exercise (Daily 
or Optional) 
Description of support  Dropout 
(%) 
Weight 
change (%)  
Van Wier157       
Telephone-based Dietician, physical 
activity scientist 
Received information on nutrition in the 
workbook form 
Received 
information on 
exercise in the 
workbook form 
Weekly one-to-one contact with 
telephone 
43 1.5 
Internet Dietician, physical 
activity scientist 
Accessed programme online without 
prescription of diet 
Accessed 
programme 
online without 
prescription of 
exercise 
Self-monitoring, goal setting, 4 
months per contact 
46.7 2.0 
Control No provider Self-help diet Self-help 
exercise 
Self-help 46.5 1.8 
Womble113       
eDiets Company-trained 
counsellor and 
company dietician 
Low-calorie diet, modified eating by 
virtual dieticians, clients prepare own 
meals (1200-1300) 
Daily Individual and group online 
support, weekly contact 
34 1.1 
LEARN Registered dietician The LEARN Manual for Weight 
Management: 55-60% carbohydrate, 
10% fat 
Daily Specific energy restriction goal, 
weekly contact 
34 4.0 
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Table 2.15 (continued)       
Study and 
Programme  
Types of providers  Calorie restriction (Total kcal/day)  Exercise (Daily 
or Optional) 
Description of support  Dropout 
(%) 
Weight 
change (%)  
Meal replacement       
Anderson144       
Meal replacement, 
fruits and vegetables 
(MR-FV) 
Licensed physician 
and other health 
care providers 
Low-calorie or very low calorie diet, MR 
products (1200) 
Daily (2000 
kcal/week) 
Group session, weekly classes 18 13.9 
Usual care  Dietician Nutritional balance DNR** Counselling monthly 18 0.7 
**DNR = Did not report 
Chapter 2 Systematic review 
120 
 
2.4.4.2 The role of support 
Although support is not the most essential element when deciding the effectiveness 
of a weight loss programme, it is certainly a component of sound weight 
management.158 Support is an approach for monitoring weight reduction in individual 
or group meetings.  
 
Most weight loss interventions were supported by health care providers (dieticians 
and other health care professionals), groups and media based efforts. Sixty-three 
percent of all programmes were supported by dieticians or other health care 
providers ± see Table 2.16.  
 
Table 2.16 Key supports for all 20 studies classified by head-to-head intervention delivery 
Intervention 
delivery* 
Total 
number  
Studies were supported by No 
support Providers Group Internet Telephone External 
Diet 8 2 2 2 2 - - 
Diet and exercise 45 13 11 7 7 5 2 
Meal replacement 1 1 - - - - - 
Total 54 16 13 9 9 5 2 
*Many studies had more than one type of support. 
 
Sixteen studies of interventions delivering diet and exercise (83% of these including 
support in some form) received support through the health care provider, group or 
social support, the Internet, telephone and external (book) support, respectively. 
There were 46 interventions in all studies, 3611, 17, 113, 117, 119, 124, 126, 144-154, 156, 157 of 
which were supported by health care professionals, whilst seven interventions17, 119, 
153-156
 were supported by non-health care professionals such as a group supporter, 
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trained worker or company counsellors and programme facilitators. Two 
interventions17, 126 had no report of support, whereas no provider was reported in one 
intervention.149 These data would appear to recommend health care providers 
(dieticians or physicians) offer support via counselling and advice, which can affect 
weight loss improvement. However, it is possible to conclude the combination of 
support with both the restriction of calorie intake and structured exercise is likely to 
lead to greater weight loss. This may reflect that support from health care providers 
is an important component when aiming to maintain weight loss in combination with 
diet and exercise.  
 
In the diet and exercise group, participants received several types of support, 
depending on the particular diet and exercise programme. For example, VTrim148 and 
JC153, 154 encouraged participants via the Internet, to communicate with health care 
providers so that they could avail themselves of counselling. Although eDiets113, 148 
advised participants via the Internet, this intervention had a lower weight loss than 
VTrim at the end of one year. ThHOLNHO\UHDVRQIRUWKLVGHILFLWZDVWKDWWKHH'LHWV¶
programme was supported by company-trained counsellors whilst VTrim was led by 
a therapist. The eDiets programme did not specifically ask participants to record their 
calorie intake; nor did they require records of daily calorie intake to be kept,113 unlike 
VTrim which provided bi-weekly meetings and support components via the website. 
7KLV ZRXOG VXJJHVW WKDW KHDOWK FDUH SURYLGHUV¶ VXSSRUW WKURXJK WKH ,QWHUQHW LV an 
important component for maintaining weight loss in the diet and exercise group.  
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2.4.4.3 Length of treatment 
2QH RI WKH NH\ YDULDEOHV LQ DQ\ ZHLJKW ORVV SURJUDPPH LV WKH LVVXH RI µOHQJWK RI
WUHDWPHQW¶LQRWKHUZRUGVKRZORQJDQ\JLYHQSDUWLFLSDQWNHHSVWRWKat programme. 
Evidence from WW17, 126, 150-152 serves to illustrate the relationship between weight 
loss and duration of participation. If a 5% loss of weight in any given period is the 
ultimate goal, WW yielded the following data: 
x At three months a loss of 4.7%17 
x At six months a loss of 5%151 and 7.3%126 
x At one year a loss of 5.8%152 
x At two years a loss of 4.6%150 and 3.0%150 
 
It seems reasonable to suggest that, other things being equal, there is a positive 
relationship between weight loss and length of programme participation, with 
optimal results coming between six months and one year. 
 
2.4.4.4 Other considerations 
Adverse events  
Five interventions in four studies ± Atkins,11 Zones,11 WW,11, 150, 152 Ornish11 and 
meal replacement144 ± mentioned adverse events. None of the serious adverse events 
was found in four interventions: Dansinger and colleagues11 study, i.e. WW, Atkins, 
Zone and Ornish; WW investigated by Heshka and colleagues150 as well as Jebb and 
colleagues152 studies reported no adverse events found.  
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For adverse events associated with meal replacement, Anderson and colleagues144 
UHSRUWHGSDUWLFLSDQWV¶DGYHUVHHvents were higher than 50% in both groups, and were 
related to dietary problems and constipation. Participants in the control group 
(56.3%) had less adverse events than those in MR-FV group (59.1%). Nevertheless, 
any adverse events that occurred in the remaining study were not reported. This may 
be a reflection of minor adverse events, which are not related to either dropout rate or 
effective weight loss.  
 
Dropout rate 
The lowest dropout rate was from Nutrisystem147 (2.9%) followed by JC (4.7%,154 
8.6%153) and a telephone-based154 (6.7%) programme. On the other hand, the dropout 
rates exceeded 50% for some interventions such as LL119 (59%), General Practice17 
(54%), WW11 (53%) and Zone11 (50%). The dropout rates in the remaining 
interventions11, 17, 113, 117, 124, 126, 144, 146, 148, 150-152, 155, 157 were similar to those in control 
groups113, 119, 124, 126, 144, 146, 148, 150-152, 155, 157 ranging between 11% and 49%.  
 
Interestingly, it would appear that standard treatment had a low dropout rate 
compared to CWLPs. For instance, the dropout rate in Diabetes support and 
education (DSE: control)147 was 0%, with an accompanying reported weight loss of 
0.4%. Usual care in the study by Rock and colleagues had a low dropout rate of 
5.7%153 and 8.8%154 respectively, whilst none of the controls had dropout rates 
higher than 50% ± see Table 2.14 and Table 2.15.  
 
Although 85% of all studies reported some level of dropout rate, the dropout rate was 
not related to the effective weight loss. For example Nutrisystem147 (7.1%), which 
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showed the lowest dropout rate (2.9%), had a lower percentage weight loss than meal 
replacement144 (13.9%) which reported an 18% dropout rate. In contrast, the 12.3% 
of weight change in LL119 was accompanied by an attrition rate of three-fifths (59%). 
It appears that the interventions mainly had relatively lower dropout rates of between 
11%-49%, which may be related to the provision and receipt of weekly support ± see 
Table 2.14 and Table 2.15.  
 
2.4.4.5 Publication bias 
Easterbrook et al.159 classified 100 as the cut off point between smaller and larger 
sample sizes. Outcomes for publication bias will be reported only as percentage 
differences.  
 
Eleven (55%) of the randomised studies involved sample sizes of at least 101 
participants. Nine17, 124, 126, 148, 150-152, 154, 155, 157 (82%) studies reported significant 
outcomes, whilst two11, 117 (18%) studies reported non-significant outcomes. For 
studies with a sample of less than 100, eight113, 119, 144-147, 153, 156 (89%) studies yielded 
statistically significant differences in outcomes across groups whilst one149 (11%) 
study showed non-significant outcomes. Over four-fifths of all studies presented 
statistically significant differences, which were interpreted as representing no 
publication bias ± see Table 2.17.  
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Table 2.17 Characteristics of 20 studies classified by statistical significance 
Characteristics of sample size  
Outcomes with statistical significance  Total  
Significant Not significant  
< 100 8  1  9  
 9  2  11  
 
2.5 Discussion 
2.5.1 Main findings 
This review identified 20 studies which considered the effectiveness of CWLPs on 
weight or BMI change in overweight and obese adults. The majority of the studies 
were conducted in the US. Over four-fifths of all studies included both men and 
women participants. Over two-thirds of all studies involved participants aged 
between 40 and 50 years with a mean BMI of 30-34.9 kg/m2 at baseline (obesity 
class I). The interventions mainly lasted longer than three months. Four-fifths of the 
studies included the delivery of diet and exercise programmes. The remaining 
interventions were diet or meal replacement.  
 
Provision of support for the diet and exercise groups also featured as a key 
intervention component. Several support initiatives were found in diet and exercise 
groups. Most support was provided by health care professionals, including dieticians, 
physician/doctors, therapists, pharmacists, nurses or food advisors (nutritionists). 
Support was also provided by non-health care professionals such as a group 
supporter, trained worker or facilitator. 
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The majority of primary outcome measures related to weight loss or weight change. 
Less than one-fifth of the studies measured both weight and BMI as primary outcome 
indicators. Seventeen studies demonstrated a statistically significant difference 
between CWLP and a control group. Twelve studies successfully achieved weight 
loss of at least 5% of the initial body weight, whilst eight did not achieve this 
successful reduction in this primary outcome. Only one fifth of the studies reported 
adverse events. The majority of studies reported dropout rated ranging of between 
11% and 49%. 
 
Overall, the majority of studies contained a low risk of bias (n = 17, 81%) whilst 
14% (n = 3) were unclear and 5% registered high risk of bias.  
 
2.5.1.1 General discussion 
Based on the findings from 20 studies, this systematic review provides information 
about CWLPs weight loss interventions, particularly those based on diet (total 
kcal/day), exercise and support. Over half of all studies meaningfully targeted weight 
loss of at least 5% of the baseline body weight. From this finding, it would seem that 
calorie restriction is more effective in body weight reduction than the macronutrient 
composition of the diet. 
 
Overall, judgements about weight loss interventions across studies can be made by 
considering the elements of interventions provided and the duration of the 
programme. The duration of studies ranged from 2 months to 24 months. Participants 
who took part in the CWLPs for up to three months lost weight ranging from 2.1 to 
12.7 kg, whilst those who attended over three months lost weight ranging from 0.8 to 
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13.9 kg. There appears to be little difference in the overall amount of weight loss 
across different lengths of programmes. For instance, the percentage change in 
weight of participants in short term meal replacement programmes (10.4%-13.7%)146 
is not substantially different from longer term meal replacement programmes 
(13.9%).144 
 
The studies were difficult to directly compare as the interventions varied 
considerably, which made concluding which weight loss programme pattern is the 
most effective more complex. However, this review compared the effectiveness of 
three categories based on key elements provided in the interventions: diet (total 
kcal/day), exercise and support, as well as taking into account other outcomes such 
as adverse events and the dropout rate. The percentage of weight change was 
considered in terms of significant differences and meaningfully amounts of weight 
loss as defined in the NICE guideline.15  
 
The differences in diet, exercise and support in the programmes potentially affected 
the weight loss. The most effective CWLP, for a short term treatment, involved meal 
replacement, when compared with diet programmes and diet and exercise 
programmes. This intervention involved HMR shakes as diet (energy intake 1,200 
kcal/day), exercise (energy expenditure 2,000 kcal/week) and weekly health care 
provider support although the dropout rate of HMR was 15%-18%.144, 146 However 
this claim needs to be considered with caution as it was only based on two studies in 
the US. Despite this, the important elements of this intervention can be taken forward 
to other programmes such as specifying calorie intake, exercise amounts and 
providing weekly support. 
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A VLCD alone was more effective than diet and exercise groups in terms of 
percentage change in weight. This programme can be appropriate for participants 
who have BMI  30 kg/m2 and struggle to exercise due to their size. However, the 
dropout rates in diet alone groups were higher than 50%. This may be because the 
participants had difficulty keeping to such a very low-calorie daily diet. 
 
Although the percentage change in weight of participants in the diet and exercise 
group (2.4% to 7.1% for a short-term treatment, 1.5% to 8.9% for long-term 
treatment) was lower than with meal replacement (10.4% to 13.7% for a short-term 
treatment, 13.9% with long-term treatment), the structure of interventions is similar 
to meal replacement. Both groups were provided with daily exercise targets and 
weekly support.  
 
Another intervention in diet and exercise group, Nutrisystem147 yielded a 7.1% 
weight loss for a short-term treatment and had the lowest dropout rate (2.9%). This 
intervention showeGSDUWLFLSDQWV¶PHDQDJHWREHROGHUWKDQ\HDUVZKLFKPD\EH
related to older participants being more able or motivated to commit to remaining in 
the trial for longer. This study was for obese patients with type 2 diabetes with a BMI 
30-50 kg/m2. Their health condition may also have been a motivating factor for 
remaining in the programme. This programme had different levels of calorie 
constraint for men (1,550 kcal/day) and women (1,250 kcal/day), so this suited each 
gender. Although this intervention produced a lower weight loss compared with meal 
replacement, it may be more appropriate for obese patients with BMI 30-50 kg/m2 
than a meal replacement programme as, although there is a higher calorie intake and 
a lower weight loss, there was a very low dropout rate. Support in this programme 
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was led by health care professionals, similar to other diet and exercise groups and the 
meal replacement model.  
 
The main points to take into account when considering the effectiveness of CWLPs 
for a long term treatment were in diet and exercise groups, and consisted of calorie 
level (energy intake 1,200-2,300 kcal/day), exercise (weekly) and several types of 
support. JC154 was considered to be the most effective weight loss programme; 
however, this intervention did not report about its generalisability. This study was 
conducted in the US as the programme is only offered there. Given the effectiveness 
of the programme it is likely to be taken up in other countries. Similarly, VTrim148 
was as effective as JC when taking into account calorie level per day, exercise, 
support and no reports of adverse events. This intervention was also conducted in the 
US and although this intervention was more economical in terms of saving costs of 
transport and staff costs, not all potential participants may want an Internet-based 
programme or have access to the resources needed.  
 
Standard treatment had a low dropout rate compared to CWLPs, perhaps due to the 
less restrictive diet and lack of demands about exercise. This review found that 
participants may find it difficult to stick to a very low-calorie daily diet in a CWLP ± 
thus levels of support in such programmes may need to be increased.  
 
Requirements to maintain a balanced diet (Zone: 40% carbohydrate, 30% fat, 30% 
protein) through good healthy eating without calorie restriction allows easier 
compliance but this results in weight loss at a somewhat slower rate than with 
CWLPs employing a low-calorie diet such as WW (1,200-1,600 kcal/day), RC, JC 
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(1,200-2,300 kcal/day), eDiets (1,200-1,300 kcal/day) or Nutrisystem. High 
carbohydrate intake programmes such as LEARN (55%-60% carbohydrate, 10% fat) 
are appropriate for obese people with comorbid health risks, but are unsuitable for a 
lifelong diet because this can lead to dietary deficiency and also may be difficult to 
adhere to. 
 
2.5.1.2 Other issues and methodological concerns 
The concept of this review was to focus on randomised trials. The study 
identification was arranged by taking into account the different multicomponent 
interventions. Although it was difficult to compare a variety of CWLPs, this review 
was able to compare the effectiveness of the various settings across studies, based on 
the main elements of the programmes namely, diet, exercise and support. Settings did 
not appear to be a key element that affected the achievement of weight loss, so the 
findings could be generalised to other settings.17, 150-152  
 
Recruiting people to participate in the interventions was mostly done via media 
advertisements. Seven studies reported the use of incentives to assist with 
recruitment17, 117, 126, 150, 151, 153, 154, 157 such as that reported by Heshka and 
colleagues150, 151 where they gave participants a $9 weekly attendance reward. The 
dropout rate was 16% at 26 weeks, one and two years with 5%, 4.6% and 3.1% 
weight loss, respectively. This suggests that there may be a positive relationship 
between incentives and the likelihood of dropping out. 
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Achieving weight-loss goals may depend on whether participants in the CWLPs had 
previously attempted weight loss and the duration of the period of their being 
overweight or obese. Unfortunately, none of the included studies reported these 
characteristics and thus the effectiveness of the programmes, in the light of this issue, 
is unknown. In addition, it is possible that the roles of health care providers may 
change. Practices in different countries vary, even within the countries themselves. 
This review was unable to provide sufficient information on the process of training 
providers, a deficit also noted by Loveman and colleagues.124  
 
In terms of methodological rigour, over half of the studies were assessed to be at a 
low risk of bias. However very few were blinded studies as well as the previous 
systematic review had a few studies for blinding of the assessor.160 Realistically, it 
was very hard to blind people who participated in the weight loss programmes 
because they will tend to know what they are eating and how much exercise they 
take. Similarly, the previous systematic review of weight loss interventions reported 
adequate concealment of allocation in only a few studies.160 There appeared to be 
little selective reporting of outcomes from the studies or of inadequate randomisation 
procedures.  
 
This review showed mainly the number of interventions with statistical significance. 
Nevertheless, Easterbrook et al.159 suggested that small sample size should be used 
with great caution.  
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2.5.2 Strengths, limitations and generalisability 
2.5.2.1 Strengths 
This is the first systematic review to determine the effectiveness of CWLPs in 
helping overweight and obese adults worldwide. The main strength of this study lies 
in its contribution to providing insight into CWLPs and what they offer to 
overweight or obese populations, by focusing attention on drawing out the relevant 
literature about CWLPs, which are essentially directed towards achieving weight 
loss.  
 
The studies included in the review were obtained by following the principles for 
conducting a systematic review. The methods were set out in a research protocol, 
which defined the research question, a comprehensive search of databases, inclusion 
and exclusion criteria, the data extraction process, quality assessment and data 
synthesis. The review team undertook their task using the original articles published. 
The research protocol was informed by comments and advice from the review team. 
The main reviewer (SS) reviewed all articles which were rechecked by a second 
reviewer (HB). The review team also commented on the review report. All articles 
were critically appraised and reported in a consistent and transparent manner. 
Therefore, this review was inclusive in terms of efficacy in CWLPs provided they 
warranted inclusion in this review. Studies included in this review were commonly 
judged to have a low risk of bias.  
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2.5.2.2 Limitations 
Several limitations of this review were stated. The selection of English language 
articles published may have introduced bias. Additionally, there are an increasing 
numbers of studies with positive results that are published in English language 
journals, which indicates the global spread and acceptance of English language 
articles. The non-English language studies have been commonly published in local 
language journals, without the funds for translating their findings into English and 
hence, the quality of these studies is unknown.128  
 
This review was also limited studies to those which were published between 1980 
and 2011. The reason was that the prevalence of the conditions of overweight and 
obesity began to be a health issue from the mid-1980s onwards.  
 
Another drawback of this review was not including the grey literature and conference 
proceedings, because of the inaccurate or incomplete articles in the electronic 
bibliographic databases. 
 
If the studies reviewed have shown the secondary or other outcomes, that evidence 
was not extracted. This was because this review only reflected the scope of weight or 
BMI change in overweight and obese adults. Thus, the sustainability of other 
intervention effects was not always known. 
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A narrative review approach was used to synthesise the included studies. Although 
20 studies were included in the review of effectiveness of CWLPs, differences in the 
interventions such as programme type and duration rendered them inappropriate for 
meta-analysis.  
 
There were several different weight loss interventions and data were pooled across 
studies in each of three category conditions based on the intervention components. 
Also, this review was informed by consideration of the three essential elements 
which were i) calorie restriction, ii) exercise and iii) support to indicate which 
CWLPs were superior in achieving weight loss. This was synthesised by following 
the primary intervention of weight management for three categories of overweight, 
obesity class I and obesity class II. Therefore, evidence of the effectiveness of 
CWLPs would be used to support any recommendations to the NHS in order to 
somewhat reduce health care expenditure, particularly funds employed to counter the 
effects of being overweight or obese.  
 
2.5.2.3 Generalisability 
Although the authors of included studies reported generalisability, only a few studies 
could be generalised. In this review, generalisability was applicable for popular diets 
such as WW, SW, RC, Atkins, Zone and Ornish.  
 
Generalisability was considered in terms of study design, study population, 
particularly for overweight or obese participants, and methods to deliver 
interventions. To enhance generalisability in terms of methods, maximising the 
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sample size and using broad inclusion criteria are needed. Special training of support 
providers is also needed and should be reported in papers.  
 
When considering CWLP in the UK, RC126 was considered to be the most effective 
weight loss approach for long-term treatment; however, this intervention did not 
report generalisability. Intervention in this study consisted of a low-calorie exchange 
diet (high carbohydrate, protein or fat among three meals), with the option of 
exercise and support (e.g. role modelling; group, telephone, website and individual 
support with weekly contact). RC is only offered for UK overweight or obese adults, 
so other countries that would like to use this programme should develop the 
programme based on the main elements of RC and should consider which element 
may not suit their citi]HQV¶OLIHVW\OHV 
 
Globally, although WW is reported to be the largest worldwide CWLP that includes 
all three potential weight-loss elements: restriction of calorie level per day, exercise 
and support, this programme had a wide range of dropout rates, from as low as 16% 
to as high as 72%. This intervention is able to be generalised to other groups of 
participants, because in this review, WW is multicentred. This programme is known 
for being able to produce positive weight change during the long-term treatment.  
 
2.5.3 Comparison with existing systematic reviews 
The current systematic review is compared with existing systematic reviews between 
CWLPs and non-commercial weight loss programmes (NCWLPs).  
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2.5.3.1 Comparison with commercial weight loss programmes 
Tsai and colleagues116 emphasised only the effectiveness of commercial weight loss 
programmes and focused on WW and HMRs (Meal Replacement). Comparisons 
with Tsai and colleagues116 study will be described in terms of quality of study, the 
potential elements, effectiveness of programmes and national perspectives. 
 
This present review extracted data by following CONSORT statement of randomised 
trials of non-pharmacological treatment and assessed the quality of studies by using 
the risk of bias; however both reviews did no statistical analysis because of the 
limited comparability of interventions and the quality of data. Using valid and 
reliable tools contributed to the strength of this current review. Although data 
extraction in Tsai and colleagues116 study had no quality assessment,116 the two 
systematic reviews are similarly focused on changes in weight. The key elements of 
CWLP in the present review are presented in terms of diet (total calorie level per 
day), exercise (daily or optional) and support to potentially enhance the effective 
weight loss. Tsai and colleagues116 focused on two types of CWLPs.116  
 
The similarities of WW and HMRs programmes, noted in both reviews, are low 
calorie diet, exercise and support using behaviour weight control methods and 
weekly group and social support. However, there is a difference in terms of weight 
change. Weight loss of WW in the present study ranged from 3% at 12 months to 
7.3% at six months, whilst these data in Tsai and colleagues116 study were 5.3% at 26 
weeks and 7.5% at 12 weeks.11, 17, 117, 126, 145, 150-152, 156 Although the maximum change 
is similar in its effectiveness, the length of treatment is different, as the most 
effective time for weight loss is between 12 and 24 weeks. It is accepted that WW is 
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able to achieve the weight loss goal of at least 5% of the initial body weight at 12 
weeks.  
 
For HMRs or meal replacement programmes, this present study found 13.7% and 
13.9% weight loss at three and six months, whilst Tsai and colleagues116 study found 
losses of between 14.1% and 15.3% at 12 weeks. There is a slightly different weight 
loss because the dropout rate144, 146 of the study in the current review may cause a 
lower range of weight loss.  
 
Regarding national perspectives, WW is the only CWLP whose effectiveness has 
been shown in a large and multicentred RCT in the US.116 In the UK, WW is also 
popular CWLP and shows sufficient evidence to be able to generalise for obese 
adults in the UK.11, 17, 126, 145, 150-152, 156 Therefore, this WW programme is an 
important option for the UK population, with all three elements of diet, exercise, 
support from the group (successful members).  
 
In the UK, similar programmes using very low or low calorie diet are LL119 and 
RC.17, 126 LL and RC programmes also consist of diet, exercise and support through 
group, telephone and Internet. Although LL is focused on diet and optional exercise, 
weight loss in this programme is greater than WW, in combination with diet and 
exercise. This may be as a result of the very low calorie restriction in the LL 
programme, which allows only 550 kcal/day for energy intake; the greater the calorie 
restriction in any one day, the greater weight loss at a particular time point. 
Therefore, in both the US and UK studies LL produced a greater weight loss than 
WW.  
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It is clear from this review that CWLPs are effective in helping overweight and obese 
adults to lose weight. Although studies varied in the type of programmes in terms of 
diet; exercise; and support including lifestyle modification, not all interventions 
achieved a weight loss of at least 5% of initial body weight. 
 
In conclusion, after reviewing all included studies, the main body of this review 
found that the evidence from WW and JC in the US, or LL and RC in the UK, 
confirmed these particular CWLPs can be recommended to assist people in losing 
weight, as can meal replacement programmes. CWLPs are provided for participants 
who are willing to pay for the programme and their resultant health benefits. 
Furthermore, it would be of interest to guide health care providers not only to assist 
their patients with weight control but also to advise patients as to which commercial 
programme may be the most appropriate programme for them, based on available 
evidence. 
 
2.5.3.2 Comparison to non-commercial weight loss programmes  
There are five systematic reviews of non-commercial weight loss programmes 
(NCWLPs). Loveman and colleagues161 and Franz and colleague143 systematically 
reviewed the effectiveness of weight loss management for the long-term treatment of 
obesity whilst Avenell and colleagues162 and Heymsfield and colleagues163 reviewed 
the long-term benefits of weight reducing diets in adults. Lastly, Gordon and 
colleagues18 focussed on community pharmacy-based weight management services. 
Findings from the current review will be compared with the five systematic reviews 
of NCWLPs in terms of quality of study, successful elements, effectiveness of 
programmes and national perspectives. 
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With reference to their quality, two reviews143, 163 included meta-analysis, however, 
one review163 used Jadad criteria for assessing quality. Gordon and colleagues18 
assessed studies using a checklist for the Review Body for Interventional Procedures, 
whilst Avenell and colleagues162 used their own assessment instrument. Loveman 
and colleagues161 used risk of bias, as did this present review. Therefore, all reviews, 
except Avenell and colleagues,162 had used previously developed statements to assess 
the quality of the studies. 
 
Loveman and colleagues161 only reported the effective weight loss at a 3-year follow-
up. To make a comparison with this review time points need to coincide, which in 
the current review was not be able to do so. 
 
For RWKHU V\VWHPDWLF UHYLHZV SDUWLFLSDQWV¶ PHDQ ZHLJKW ORVV LQ WKHSUHVHQW UHYLHZ
was greater than Franz and colleague143 study. The reason was that their findings 
were a mixture of NCWLP and CWLP. Additionally, their reported mean weight loss 
was 5% via a diet, whilst mean weight loss in this current review was 7.1% for a 
diet-based intervention. Diet-based groups in the present review registered greater 
weight losses than was noted in the study of Franz and colleague143 but were similar 
to a study done by Heymsfield and colleagues163 (7.8%). The reason for the 
similarity in the findings between this current study and Heymsfield and 
colleagues163 study may be calorie restriction in diet programmes. Therefore, 
consuming a diet incorporating calorie intake restrictions was associated with greater 
weight loss. 
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Avenell and colleagues162 found that low fat diets produced significant weight loss 
up to three years (-3.55 kg). In this review, mean weight loss in fat restriction was 
similar to Dansinger and colleague study (-3.3 kg)11 but slightly less than from 
Gardner and colleague (-2.6 kg).117 The reason for the similarity in the findings of 
three studies may be that there was no specific energy restriction goal in the fat 
restriction programmes. Therefore, consuming a diet with fat restriction, in 
combination with an energy restriction goal, was associated with greater weight loss. 
 
Another setting in the community pharmacy-based weight management clinic 
recently showed mean weight loss ranged from 1.1 to 4.1 kg for 12 months.18 In this 
present review, mean weight loss was similar to General Practice (-1.4 kg) but 
slightly less than from Pharmacy (-2.1 kg)17 for 12 weeks. Participants who attended 
in pharmacy in this current review had greater mean weight loss than those in 
Gordon and colleagues18 study. This may be related to easier access setting.  
 
Taking into account national perspectives, three studies (Loveman and colleagues,161 
Avenell and colleagues162 and Gordon and colleagues18) were conducted in the UK 
whilst two remaining reviews143, 163 were conducted in the US. The effective weight 
loss of reported in the two US studies was similar to the weight loss reported in the 
current review, probably due to two thirds of the studies in the current review having 
been conducted in the US. Therefore, more studies are needed in the UK to 
determine whether or not the findings from the US can be applied in the UK.  
 
In addition, the NCWLPs have the advantage that they do not involve the payment of 
fees, although the findings from the systematic reviews suggest they are less 
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effective in achieving weight loss than CWLPs. The current review has demonstrated 
that CWLPs can be a good choice for health care providers to advise overweight or 
obese adults to take up, in order to help them to lose weight. Calorie restriction, 
exercise and support are the key elements of most weight loss programmes. 
Therefore, the current systematic review can help policy makers to set up the 
programmes, which consist of structured interventions (diet and exercise) and 
various forms of support. Such programmes should be able to demonstrate that they 
can meet the NICE guidance for weight loss of at least 5% of the initial body weight 
at three months.  
 
CWLPs appeared to be more effective at producing weight loss than NCWLPs. 
Overweight or obese people, who are willing to pay for attending these programmes, 
need to consider whether or not their health benefits of such programmes are superior 
to NCWLPs.  
 
2.5.4 Implications 
Restriction of calorie intake levels per day, exercise and support are potential factors 
related, to a greater or lesser extent to the achievement of effective weight loss. This 
helps health care providers to exclusively consider the most effective support for 
those individuals either wishing or needing to lose weight.  
 
The potential elements in the current review may help policy makers to draw the big 
picture of weight loss strategy. NHS would focus on the restriction of calorie level 
per day (energy intake), exercise (energy expenditure) and support methods to 
energetically assist overweight or obese adults to try losing weight. Additionally, 
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obesity is related to comorbidity health risks and therefore the greater should be the 
increase in both physical and psychological health benefits.  
 
The dropout rate in the current review is between 11% and 49%. To decrease the 
dropout rate, the CWLPs need to provide information on diet and exercise by health 
care providers or counsellors as well as providing weekly client contacts. Participants 
should keep daily records of their diet and exercise and have weekly counselling via 
telephone or Internet. This would, or at least should, encourage overweight or obese 
adults to achieve weight loss.  
 
This review showed the effectiveness of CWLPs that provide a pattern of three key 
elements (diet, exercise and support) which are the elements recommended by NICE 
in their obesity guidelines. The first key element in achieving weight loss is diet 
where calorie restriction was found to be essential, as opposed to concentrating on 
the structure of that diet. The second element for successful weight loss is exercise, 
where a structured programme of exercise is needed which clearly defines the 
required amounts and types of exercise are defined is needed. The last element is 
support, where at least weekly contact provided best results. However, adverse 
events and dropout rates also need to be considered when selecting an appropriate 
weight loss intervention. Adverse events may reflect a high dropout rate, which is 
somewhat related to the less effective programme.  
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2.5.5 Recommendations for further study 
The studies in this systematic review lacked evidence of their cost effectiveness and 
sufficient detail about the support provided. Future studies should consider cost 
effectiveness of the programme from the viewpoint of the consumer. Future studies 
should also describe in more detail the support provided so this can be analysed in 
order to select key elements that could be used in the design of future programmes. 
Although there were some studies of Internet-based weight loss programmes, more 
research in this area is needed to determine whether or not such programmes are 
effective.  
 
2.6 Summary 
The three elements of diet, exercise and support commonly underpin the 
effectiveness of CWLPs, and these programmes can assist overweight and obese 
adults to lose weight. Most of the evidence in this current review is from US. 
Therefore, further research is needed in order to investigate the effectiveness of 
CWLPs in the UK setting.  
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Chapter 3 
Pilot study for a retrospective evaluation of 
pharmacist-led weight management clinics 
 
This chapter presents the pilot study which tested the proposed data collection 
method for the main study, as well as testing the prepared database. The quality of 
the data held in stores was assessed and the data that were used to estimate the 
sample size needed for the main study will be provided. 
 
3.1 Aim and objectives 
This pilot study aimed to test the data collection method and data quality for the 
evaluation of a pharmacist-led weight management clinic. The objectives were to 
determine:  
1) If it would be possible to measure the effectiveness of Boots Pharmacy 
Weight Loss Programme (BPWLP).  
2) Whether or not clients who participated in this programme achieved their 
target of at least 5% weight reduction of their initial body weight at six 
months.  
3) The sample size calculation for the main study. 
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3.2 Methods  
3.2.1 Study design  
The pilot study was conducted in two Boots pharmacies. Both pharmacies were 
contacted by Boots staff from Boots Head Office to ask if they would be willing to 
participate in the research. One of two stores was the first store where the Boots 
Pharmacy Weight Loss Programme (BPWLP) was launched in 2005. Ethical 
approval for the pilot study was obtained from Division of Social Research in 
Medicines and Health, School of Pharmacy, University of Nottingham ± see 
Appendix 6. 
 
The criteria for selecting Customer Record Forms (CRFs) were clients who had been 
assessed as being suitable for the programme and who had received at least one 
supply of orlistat.  
 
3.2.2 Study population and sample size 
The population of this study represents people who were prepared to pay for a weight 
management programme. A total of 558 CRFs were held at the two pharmacies for 
clients who participated in the BPWLP. Sixty CRFs were systematically selected 
from each Boots pharmacy to give a total of 120 records ± see Figure 3.1. The 
systematic selection of every nth client¶V paper records at pharmacies was the data 
gathering method chosen to provide the correct sample size ± a one-in-four sample at 
the first pharmacy and a one-in-six sample at the second. This data were entered into 
the prepared Access database. The reason for sampling 60 CRFs at each store was 
guide by a recommendation for pilot studies, that the minimum number should be 30 
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subjects164 and to provide sufficient data for the testing planned. A sample of 120 
was chosen as the attrition rate from the service was unknown and a sufficient 
number of clients were needed for analysis at three and six months follow-up points. 
 
 
 
Figure 3.1 Flow chart of data collection for a pilot study 
 
The Access database was designed and informed by following the Customer Record 
Form (CRF). There were four components to the BPWLP: Customer record form; 
repeat supply record; consultation checklist; and weight loss chart and cXVWRPHU¶V
consultation notes (Appendix 7). All record forms were hand written by the 
pharmacists; however, there was one section for the customer to complete 
FXVWRPHU¶VDQGGRFWRU¶VGHWDLOVDQGPHGLFLQHVXVH.  
 
A prepared Microsoft Office Access database 2007 was generated to store customer 
records taken from the confidential forms. The database included most items from 
the record forms. Data not collected were any client identifiers such as name, address 
and telephone number. At entry to the service, partial date of birth (only year) and 
postcode (the first part and number from the second e.g. NG7 2) were collected. It 
Eligible clients selected from 2 stores
60 clients collected from each store
Systematic sampling
120 clients at Baseline 
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was therefore not possible to identify individual clients from the data collected ± see 
Figure 3.2 to Figure 3.5.  
 
The pilot study was conducted to test the quality of data. Four store-held forms are 
used for each client. Only three of the four store-held forms were needed for the 
main study. The consultation checklist (Figure 3.5) was not used because this form is 
used by the pharmacist to confirm whether or not the procedures of the programme 
have been followed.  
 
All clients who attended an initial assessment for the BPWLP had their details 
recorded on a CRF. Pharmacists used this form in checking whether or not clients 
were suitable for the programme. Therefore, not all clients with a completed CRF 
were granted entry to the programme and received a supply of orlistat. For this 
evaluation, only clients who received at least one supply of orlistat were included.  
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Figure 3.2 Customer Record Form 
 
Figure 3.3 Repeat supply record 
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Figure 3.4 Weight loss programme consultation notes 
 
Figure 3.5 Consultation checklist 
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3.2.3 Data collection 
This pilot study was observational and depended on existing records that might be 
incomplete. Data collection by the main researcher, based on the 120 records at the 
two stores, took a total of seven days. Key variables collected at baseline, and 
baseline and follow up are shown in Table 3.1.  
 
Table 3.1 Key variables collected for baseline and follow up (monthly or three monthly) 
Baseline Baseline and Follow up (monthly or three monthly) 
- Demographics 
- Height (m or ft & inches) 
- History information 
- Inclusion and exclusion criteria 
- Blood pressure (BP) 
- Blood glucose (BG) 
- Weight (kg or St & lbs)  
- Body mass index (kg/m2) 
- Advice given and supply of orlistat  
- Side effects experienced 
- Dates of visits  
- Outcome of the consultation  
 
All available data were entered directly from store-held forms into a prepared 
database, Figure 3.2 to Figure 3.5. Stores held the forms in an accessible manner so 
that different forms for each client could be identified.  
 
3.2.4 Data quality 
Data were checked for the completion rates for all parts of the forms. The quality of 
data recorded was rated as µacceptable¶ where items were recorded in at least 90% of 
the forms. Where a visit date had been recorded it was assumed that there had been a 
consultation on that date and therefore the related data should have been present. 
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3.2.5 Analyses 
Data were entered into a prepared Microsoft Office Access database 2007 and 
transferred to IBM SPSS (Statistical Package for the Social Sciences) V19.0 for 
analysis. At baseline, continuous variables were expressed as mean r SD and 
categorical variables as frequency counts and percentages. Cross tabulations (F2) 
were used to explore differences in the characteristics of clients and to investigate 
differences across groups in the length of treatment, weight loss (kg) and changes in 
obesity status classified by BMI. Paired t-tests were performed to compare changes 
LQFOLHQWV¶ZHLJKWDQG%0,at three months and six months. A p-value of < 0.05 was 
considered to be statistically significant. 
 
3.2.5.1 Testing normal distribution 
The reason for using a paired t-test was that both parameters of weight and BMI were 
normally distributed as tested by Kolmogorov-Smirnov, and two other common 
procedures, which were graphical methods (histogram, a curve pattern in the 
corresponding Q-Q plot and detrended normal Q-Q plots) and numeric methods 
(skewness and kurtosis indices).  
 
3.2.5.2 Sample size calculation for the main study 
Data from this pilot study was used to estimate the minimum sample size calculation 
for the larger study of the effectiveness of the weight loss service using mean weight 
loss (r SD).  
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3.3 Results 
3.3.1 Number of cases per day 
Similar numbers of cases were able to be collected during the day in each store ± a 
mean of 18 and 20 per day in the two stores.  
 
3.3.2 Completion rates 
Completion rates for data recorded in the customer record forms (CRFs) varied from 
90% to 100%; almost 65% of variables had a 100% completion rate ± see Table 3.2. 
The key variables of importance to this study were well completed, particularly at 
baseline. Blood glucose was less well completed at baseline with 93% of clients 
having this measure recorded. Dates of visit and weight at the 3-month visit were 
also less well recorded, with 92% of clients having a record for both.  
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Table 3.2 Quality of data recording in store by variables 
Variables Records with complete number % 
Gender 
Age  
Height (metres) 
120  
119 
120 
100 
99.2 
100 
Weight (kg)   
Baseline 
3 months 
6 months 
120  
110  
46  
100 
91.7 
100 
BMI (kg/m2) 120 100 
Date of visits   
Baseline 
3 months 
6 months 
120  
110 
46  
100 
91.7 
100 
BP recorded 
  Systolic blood pressure (SBP) 
  Diastolic blood pressure (DBP) 
Random blood glucose recorded 
Minimum weight loss required at 3 months (kg) 
 
118  
118  
112  
119 
 
98.3 
98.3 
93.3 
99.2 
Other variables at the initial visit   
Postcode 
Target weight: Weight loss required at 3 months (kg/lbs) 
119 
119 
99.2 
99.2 
History information   
'RFWRU¶VGHWDLOV 
Any medicines currently used 
120 
119 
100 
99.2 
Inclusion criteria   
BMI equal or greater than 30 kg/m2 
BMI equal or greater than 28 30 kg/m2 with one co-
morbid health risk 
120 
120 
100 
100 
Meet the inclusion criteria 119 99.2 
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Table 3.2 (continued) 
Variables Records with complete number % 
Eligible for the BPWLP: Exclusion criteria: 8 itemsa 117  97.5 
Advice given: 6 itemsb 
Orlistat supply: 9 itemsc 
120  
120  
100 
100 
Other variables at subsequent visits   
Side effects experienced  
BP > 140/90 mmHg: Systolic and diastolic 
BG > 5.6 mmol/L 
120  
8  
- 
100 
6.7 
- 
a
 8 items = 1. Pregnant, 2. Breast-feeding, 3. Insulin-dependent diabetes, 4. Any present liver; gall bladder or 
jaundice, 5. Surgery for weight loss, 6. Gastrointestinal malabsorption problems, 7. Sensitivity to orlistat and 8. 
Any concomitant medication such as amiodarone, acarbose or ciclosporin 
b
 6 items = 1. Agree to use orlistat, 2. Aware that orlistat can produce side-effects, 3. Agree to read the orlistat 
Patient Information Leaflet (PIL), 4. Inform about discontinuing orlistat after 12 weeks is inadequate, 5. Aware of 
the free Electronic-Motivation, Advice and Pro-active (EMAP) website support service and 6. Inform about 
selling orlistat for their use 
c
 9 items = 1. Outcome of consultation, 2. Your steps to successful weight loss leaflet, 3. PatienW¶VJXLGH
Orlistat 120 mg capsules (84 capsules/pack), 5. Final check by pharmacist, 6. Quantity, 7. Batch, 8. Expiry and 9. 
Comments (Yes/No) 
 
3.3.3 Demographics 
Records for 120 clients, who were suitable for the BPWLP and who had received at 
least one supply of orlistat, were selected. Follow-up data were available for clients 
attending the programme for up to 20 months.  
 
Most clients were women (91%) aged 40-59 years. Almost three quarters of clients 
were taking prescribed or purchased medicines for other conditions and most had not 
used the programme previously ± see Table 3.3.  
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Clients¶ mean weight at baseline was 93 kg and mean BMI was 35 kg/m2. Mean 
baseline blood pressure and blood glucose were within the normal ranges. Clients 
were required to give their minimum weight loss goal (4.7 r 0.9 kg) for the first three 
months. 
 
Over 80% of clients had a BMI greater than 30 kg/m2 at baseline and opted to pay for 
three months of orlistat supply (rather than the more expensive pay monthly option). 
Less than half of clients (n = 51, 42.5%) continued on the programme longer than 
three months ± see Table 3.3. 
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Table 3.3 Client demographics at baseline (n = 120) 
Characteristics Number of clients or Mean r SD  % or range 
&OLHQW¶VGHWDLOV 
Gender 
  Female 
  Male 
 
 
109  
11 
 
 
90.8 
9.2 
Age at entry to programme, years (n = 119)* 
  18-29 
  30-39 
  40-49 
  50-59 
  60 and older 
 
11 
13 
35 
42 
18  
 
9.2 
11.0 
29.4 
35.3 
15.1 
Currently taking any medicines prescribed or purchased 
  Yes 
  No 
 
87  
33 
 
72.5 
27.5 
Number of medicines prescribed or purchased 
  No medicine 
  1 medicine 
  2 medicines 
  3 medicines 
  4 or more medicines  
 
33 
32 
17 
19 
19  
 
27.5 
26.7 
14.2 
15.8 
15.8 
Previous BPWLP 
- No 
- Yes 
- Did not report 
 
62  
8  
50  
 
51.7 
6.7 
41.7 
&OLHQW¶VELRPHWULFV 
Height, metres  
Weight, kg  
Baseline BMI, kg/m2 
 
1.63 r 0.8 
92.9 r 16.9  
34.8 r 5.1  
 
1.42-1.84 
60.0-151.8 
28.3-57.9 
Blood pressure (range), mmHg (n = 118)* 
  - Systolic blood pressure  
  - Diastolic blood pressure  
 
130.8 r 16.0  
85.6 r 11.0  
 
95-178 
62-113 
*This groupings do not total 120 due to missing data. 
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Table 3.3 (continued) 
Characteristics Number of clients or Mean r SD  % or range 
&OLHQW¶s biometrics 
Blood glucose (range), mmol/L (n = 112)* 
 
5.6 r 1.8 (3.1-18.9) 
 
2.6-18.5 
Minimum weight loss required at 3 months, kg  
(n = 119)* 
4.7 r 0.9 2.7-7.7 
Other details   
3KDUPDFLVW¶VFKHFNOLVWIRULQFOXVLRQFULWHULD   
Inclusion criteria** 
  BMI  kg/m2 
  %0,kg/m2 with at least one co-morbid health risk 
 
100 
20 
 
83.0 
17.0 
Oristat supply*** 
  3-month option 
  1-month option 
 
102  
18 
 
85.0 
15.0 
The length of treatment in months (range) 
- Up to 2 months 
- 3 months 
- 4-6 months 
- More than 6 months 
4.5 r 3.5  
33 
36 
24 
27 
1-20 
27.5 
30.0 
20.0 
22.5 
*This groupings do not total 120 due to missing data. 
**This BMI is the inclusion criteria for participating in this programme. 
***3-month option is a supply of 3x84 orlistat 120 mg capsules. 1-month option is a supply of 84 orlistat 120 mg 
capsules 
 
3.3.4 Study outcomes 
3.3.4.1 Testing normal distribution 
Graphical interpretation and the values of skewness and kurtosis could help to assess 
normality. Although both skewness and kurtosis are zero in a normal distribution, 
their values were 0.78 and 0.77 in weight and 1.4 and 3.0 in BMI, respectively; the 
farther away from zero, the more non-normal the distribution. Although the 
distribution of weight was moderately skewed, and the BMI data was highly skewed, 
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it could be acceptable for normal distribution by testing formal normality ± see 
Appendix 8 and Table 3.4. 
 
Testing normality with significant value from the results of the Kolmogorov-
Smirnov statistic indicated a p-value greater than 0.05, which defines as a normal 
distribution. The p-value of weight and BMI data set was larger than 0.05. Therefore, 
both mean weight and mean BMI at baseline were normally distributed.  
 
Table 3.4 Tests of normality for both weight and BMI 
Tests of normality Weight (kg) BMI (kg/m2) 
Skewness* 0.78 1.4 
Kurtosis** 0.77 3.0 
Kolmogorov-Smirnov (Sig.)*** 0.22 0.11 
*The skewness value provides the asymmetrical distribution either positive (skew to the right) or negative (skew 
to the left) skewed.165, 166 If the distribution is normal, skewness value is zero or between -2 and +2. 
**Kurtosis provides the peakedness of the distribution. If the distribution is normal, kurtosis value is 3 (exactly 
0).165 
***p-value < 0.05 considered statistically significant. 
 
3.3.4.2 &OLHQWV¶ZHLJKWDQG%0, 
Most clients lost up to 3 kg in the first month and at three months had lost more 
weight; 69% met the criteria at month 3 ± see Table 3.5. Using a paired t-test to 
compare mean weight and mean BMI ± see Table 3.6, there were statistically 
significant differences from baseline at both three and six months (p < 0.001). About 
four-fifths (78%) of clients remaining in the programme achieved their weight loss at 
three months. 
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Table 3.5 Weight change over time for clients attending BPWLP (n = 120) 
 Change from baseline 
Month 1  
(n = 116) 
Month 3  
(n = 111) 
Month 6  
(n = 46) 
Mean weight change (kg) r SD 2.7 r 1.9 4.9 r 2.4 8.0 r 3.7 
Number of clients (%) in each weight change 
category  
   
- Gain 
- No change 
7 (6.0) 
1 (0.9) 
1 (0.9) 
- 
2 (4.3) 
- 
Loss of 
  0.1-0.9 kg 
  1-2.9 kg 
  3-4.9 kg 
  5-7.9 kg 
  8-10.9 kg 
  11-13.9 kg 
 
10 (8.6) 
47 (40.5) 
35 (30.2) 
16 (13.8) 
- 
- 
 
3 (2.7) 
20 (18.0) 
33 (29.7) 
44 (39.6) 
8 (7.2) 
2 (1.8) 
 
- 
2 (4.3) 
2 (4.3) 
17 (37.0) 
12 (26.1) 
11 (23.9) 
 
Table 3.6 Weight and BMI change at 3-month and 6-month visits compared with baseline  
 Time   
 Baseline (n = 116) 3-month (n = 111) 6-month (n = 46) 
Weight (kg)    
Mean weight (r SD) 
Mean weight change from baseline 
(r SD) 
93.0 r 16.8 
- 
88.6 r 16.5 
4.9 r 2.4 
85.1 r 13.8 
7.9 r 3.7 
Comparison with baseline (Paired 
t-test) 
- t = 22.2, p < 0.001 t = 15.6, p < 0.001 
BMI (kg/m2)    
Mean BMI (kg/m2) r SD 
Mean change in BMI from baseline 
(r SD) 
34.8 r 5.1 
- 
33.1 r 5.1 
1.8 r 1.0 
31.9 r 4.2 
3.0 r 1.5 
Comparison with baseline (Paired 
t-test) 
- t = 18.4, p < 0.001 t = 13.9, p < 0.001 
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Differences in baseline characteristics were compared for those who remained in the 
programme less than three months (n = 69) with those remaining for three months or 
more (n = 51).  
 
There were no significant differences in the baseline characteristics of clients who 
remained in the programme for up to and more than three months in terms of gender 
(F2 = 0.18, p = 0.67), age (F2 = 1.21, p = 0.89), geographical area (F2 = 0.69, p = 
0.71), previous experience of BPWLP (F2 = 1.59, p = 0.45), number of other 
medicines taken (F2 = 1.90, p = 0.93) and BMI (F2 = 2.42, p = 0.49) ± see Table 3.7.  
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Table 3.7 Baseline characteristics of clients who remained in the programme less than 3 
months and at least 3 months (n = 120)  
Characteristics 
No of clients in the programme (%) 
F2, p-value* Up to 3 months 
n = 69 
> 3 months 
n = 51 
Sex 
- Female 
- Male 
 
62 (89.8) 
7 (10.2) 
 
47 (92.2) 
4 (7.8) 
 
0.18, 0.67 
Age (years), n = 119** 
- 18-29 
- 30-39 
- 40-49 
- 50-59 
- 60-69 
- 70+ 
 
8 (11.6) 
8 (11.6) 
21 (30.4) 
22 (31.9) 
9 (13.0) 
1 (1.4) 
 
3 (6.0) 
5 (10.0) 
14 (28.0) 
20 (40.0) 
7 (14.0) 
1 (2.0) 
 
1.21, 0.89 
Geographical area, n = 119** 
- No record found 
- Deprived area 
- Affluent area 
 
2 (2.9) 
11 (16.2) 
55 (80.9) 
 
2 (3.9) 
11 (21.6) 
38 (74.5) 
 
0.69, 0.71 
Previous experience of BPWLP 
- No 
- Yes 
- Question not on the form 
 
33 (47.2) 
6 (8.7) 
30 (43.5) 
 
29 (56.9) 
2 (3.9) 
20 (39.2) 
 
1.59, 0.45 
Number of other medicines taken    
- No medicine 
- 1 medicine 
- 2 medicines 
- 3 medicines 
- 4 or more medicines 
20 (29.0) 
19 (27.5) 
8 (11.6) 
12 (17.4) 
10 (14.5) 
13 (25.5) 
13 (25.5) 
9 (17.6) 
7 (13.7) 
9 (17.6) 
1.90, 0.93 
*p-value < 0.05 considered statistically significant. 
**This groupings do not total 120 due to missing data. Geographical area was categorised, based on FOLHQWV¶partial 
postcode, into three groups: affluent and deprived areas, and no record found. 
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Table 3.7 (continued)  
Characteristics 
No of clients in the programme (%) 
F2, p-value* Up to 3 months 
n = 69 
> 3 months 
n = 51 
BMI (kg/m2) 
- 28.0-29.9 
- 30.0-34.9 
- 35.0-39.9 
-  
 
10 (14.5) 
32 (46.4) 
18 (26.1) 
9 (13.0) 
 
10 (19.6) 
16 (31.4) 
19 (37.3) 
6 (11.8) 
 
2.42, 0.49 
Blood pressure (mmHg), n = 118** 67 (100.0) 51 (100.0) - 
Blood glucose (mmol/L), n = 112** 64 (100.0) 48 (100.0) - 
*p-value < 0.05 considered statistically significant. 
**This groupings do not total 120 due to missing data. 
 
3.3.4.3 &OLHQWV¶KHDOWKULVNV 
More than three quarters of clients had no co-morbid health risks. The most frequent 
co-morbid health risks were high blood pressure, osteoarthritis and high cholesterol ± 
see Table 3.8. 
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Table 3.8 Clients with BMI < 30 kg/m2 and their co-morbid health risks (n = 20) 
28 kg/m2 d BMI < 30 kg/m2 with one co-morbid health risk Number  %  
Number of co-morbid health risk 
  No co-morbid 
  One co-morbid 
  Two co-morbid 
 
100 
10 
10 
 
83.4 
8.3 
8.3 
Co-morbid health risk*   
High blood pressure (HBP)  
  Osteoarthritis of a weight-bearing joint (e.g. knee, spine or hip)  
Raised cholesterol 
  Any respiratory disease (e.g. asthma) 
Non insulin dependent diabetes (NIDDM) 
Heart disease 
  Others e.g. back or knee pain or knee joint problems  
9 
5 
4 
3 
1 
1 
11 
7.5 
4.2 
3.3 
2.5 
0.8 
0.8 
9.2 
*Many clients had more than one co-morbid health risk which came from the selected list in CRFs. 
 
3.3.4.4 &OLHQWV¶SDUWLFLSDWLRQLQWKH%3:/3 
Using the dates recorded in clients¶ records, 97% (n = 116/120) returned for their 
follow-up visit at one month, 93% (n = 111/120) at three months and 38% (n = 
46/120) returned for six month follow-up visits ± see Appendix 9 and Table 3.9.  
 
Table 3.9 Number and percent of clients who attended and did not attend in the programme 
follow-up visits (n = 120) 
Particular time at follow-up visits Month 1 (%) Month 3 (%) Month 6 (%) 
Attended 
Continued  
Left programme 
116 (97) 
115 (96) 
1 (1) 
111 (93) 
98 (82) 
9 (11) 
46 (38) 
27 (22) 
14 (16) 
Did not attend  4 (3) 4 (7) 5 (62) 
 
  
Chapter 3 Pilot study 
 
164 
 
During the follow-up visits, most clients were supplied with orlistat 97% (n = 116), 
78% (n = 94) and 34% (n = 41) at month one, three and six, respectively ± see 
Appendix 9. 
 
3.3.4.5 &OLHQWV¶FRQVXOWDWLRQQRWHV 
The consultation notes in BPWLP were classified into three themes: positive, neutral 
(absence of problems) and problem notes. The positive notes included comments 
such as (very) happy/pleased/motivated, achieved/met target, brilliant/well, 
good/ok/fine or encouraged. The neutral, or absence of problems, notes included no 
change in medical condition/medication change, no side-effects, no problem, no 
treatment effects and no contraindication. Problem notes included comments relating 
to disappointment in rate or quantity of weight loss (e.g. slow loss, not 
achieved/happy) or reports of side-effects (e.g. constipation, diarrhoea). 
 
Most clients had positive notes (n = 99, 82.5%) and neutral notes (n = 79, 65.8%) in 
their consultation notes. Around one third (n = 42, 35%) had problem notes in their 
consultation records, with only three clients having no notes. Many clients had a 
mixture of comments in their notes with 16% having all three types (positive, neutral 
and negative) of comments in their records ± see Table 3.10.  
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Table 3.10 Consultation notes recorded (n = 120)  
Consultation notes Number of clients*  %  
Positive and neutral notes 
Positive and problem notes 
Neutral and problem notes 
46 
15 
4 
28.3 
12.5 
3.3 
Positive notes 
Neutral or absence of problems 
Problem notes 
No comment in notes 
19 
10 
4 
3 
15.8 
8.3 
3.3 
2.5  
All positive, neutral and problem notes 19 15.8 
*Many clients had more than one comment in their records. 
 
Regarding the problem notes, any report of side-effects related to orlistat was found 
in the notes for eight clients (6.8%). Half of these side-effects were reported as 
constipation and half were diarrhoea. 
 
3.4 Discussion 
3.4.1 Main findings 
The objective of this pilot study was to test the data collection method and data 
quality for a wider evaluation of a pharmacist-led weight management programme. 
In terms of the method for collecting data, around 20 cases per day were able to be 
recorded. This number was used to determine the minimum number of clients that a 
store should have, in order to be selected for the main study. The number 20, in 
relationship to cases per day, was arbitrarily defined to make the data collection 
process more time efficient.  
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Completion rates for key variables were generally very good with the majority being 
over 95% but some were less well recorded. Notably, blood pressure and blood 
glucose at follow-up visits were rarely recorded, with only 7% of clients having a 
blood glucose measurement other than at baseline, because recording the variables of 
blood pressure and blood glucose was not a mandatory component of the 
programme. Therefore, it will not be possible to determine the effects of the 
SURJUDPPHRQFOLHQWV¶EORRGSUHVVXUHDQGEORRGJOXFRVHLQWKHPDLQVWXG\ 
 
The basic planned analyses were tested with the pilot study to ensure that the data 
gathered would be of sufficient quality and availability to perform the analyses. 
 
The primary objective of the main study was initially planned to determine the 
effectiveness of BPWLP, whether or not clients who participated in this programme 
achieved a weight reduction at six months. However, the pilot study has shown that 
less than one-third of clients remained in the programme at six months. As a 
consequence, the timing of the primary end point of the study needed to be 
reconsidered and this low number of clients means it may be difficult to make any 
conclusions about longer term effects of the programme.  
 
The mean reduction in weight for completers at three and six months was 4.9 kg and 
7.9 kg, whilst mean BMI at those time points was 33.0 kg/m2 and 31.7 kg/m2, 
respectively. Mean weight loss at three months could be used to help calculate the 
sample size for a larger study of the effectiveness of the pharmacist-led weight 
management service. 
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In addition, compared to a community-based weight loss programme of the same 
duration, at three months167 mean weight losses were approximately 3 kg, whereas 
this CWLP at three and six months had mean weight losses ranging from 4 kg to 7 
kg. These data are similar to when compared with the studies of Graham et al.168 and 
Van Gaal et al.169 however, at six months, this pilot study showed greater reduction 
in weight (5.0 kg) than both studies.168, 169 On the other hand, to compare with Kaya 
et al.75 study at three months, this pilot study showed a smaller mean weight loss and 
BMI decrease than Kaya et al.75 who reported a mean weight loss of 9.3 kg and mean 
BMI reduction of 3.6 kg/m2.  
 
3.4.2 General discussion 
The majority of clients in the programme were females aged between 40 and 59 
years. All clients met the inclusion criteria for the programme. Most clients remained 
in the programme for up to three months. The researcher had initially anticipated that 
six months might be a suitable primary outcome measure but in the light of the pilot 
data this needs to be reconsidered. Also due to low numbers of clients it may be 
difficult to make any conclusions about longer term effects of the programme. A 
previous study has examined efficacy and tolerability of orlistat for 6-month 
treatment period in 124 obese men and women with mean weight loss 9.8%.169  
 
This pilot study evaluated the effectiveness of the pharmacist-led weight 
management clinic at Boots Pharmacy. About three quarters (78%) of clients 
remaining in the programme achieved meaningful weight loss at three months ( 5% 
of initial body weight) as a part of the pharmacist-led weight management 
programme. This pilot study showed a greater a proportion of participants achieving 
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this meaningful weight loss than a previous study where 32% achieved at least 5% 
weight loss after 12 weeks.170 
 
The mean reduction in weight for clients who completed follow-up at three and six 
months was 4.9 r 2.4 kg and 7.9 r 3.7 kg UHVSHFWLYHO\$GGLWLRQDOO\FOLHQWV¶%0,
diminished to 33.0 r 5.0 kg/m2 and 31.7 r 4.2 kg/m2 during the same period of 
treatment, respectively. Similarly, mean BMI in another study was ranging from 30 
kg/m2 to 34.9 kg/m2 in a category of obesity class I.167 Furthermore, clients mostly 
stayed in the programme for up to three months. 
 
Clients who were attending the BPWLP had low obesity-related health risks with 
only one quarter of the total clients reporting having these. In this pilot study, the 
most common co-morbid health risks were high blood pressure, osteoarthritis and 
high cholesterol. The previous literatures showed slight differences in the most 
frequent co-morbid health risks associated with obesity, which were coronary heart 
disease, type 2 diabetes mellitus and high blood pressure.29 However, co-morbid 
health risks in this study were inferred from the client checklist, which was 
completed based upon questions from the pharmacist, and had a little detail. Other 
reasons for fewer co-morbid health risks may be the nature of the Boots programme, 
and clients may have been healthier than those in some of the other studies cited. 
TKHUHIRUH LQIRUPDWLRQ FRQFHUQLQJ FOLHQWV¶ FR-morbid health risks could only be 
based upon what was included on the forms.  
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)RUFOLHQWV¶SDUWLFLSDWLRQLQWKH%3:/3, less than half of the clients returned for their 
follow-up visit at six months. As a result, the primary outcome for the main study 
will change from weight loss at six months to weight loss at three months.  
 
The evaluation of consultation notes showed 6.8% of clients reported side-effects 
from the service. This rate of side-effects differs from that found in other studies, 
where the levels of those experiencing side-effects were 48% and 67%.75, 168 The 
consultation notes only contain what pharmacists chose to record and therefore it is 
not known whether these reflect the true level of occurrence of side-effects. 
However, pharmacists also had an electronic record for their clients if any clients 
ever came in for anything else. Therefore, the record of side-effects on the CRFs was 
the low percentage. 
 
3.4.3 Strengths  
The Boots Pharmacy Weight Loss Programme is a commercial weight loss 
programme led by pharmacists using orlistat in combination with a restricted diet and 
exercise.  
 
A prepared database was supportive for collecting data from store held forms. It was 
accessible to directly collect CRFs for each client. Clients were selected by 
systematic random sampling because this sampling method led to a further spread of 
the sample across the form population.171  
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This pilot study has enabled the researcher to assess the quality of the data. 
Regarding results, completion rates for all parts of the forms were generally very 
good with the majority being over 90%, which was within the expected range. 
 
The pilot study ensured that there was sufficient quality and available information for 
testing and performing the analyses. This confirmed that it is possible to measure the 
effectiveness of Boots Pharmacy Weight Loss Programme (BPWLP) for clients who 
attended this programme and achieved the target of at least 5% weight reduction of 
their initial body weight at three months. As a result, this pilot study has provided 
estimates for the main study sample size calculation, using mean weight loss (kg) 
and standard deviation (SD). 
 
3.4.4 Limitations 
The limitations of this pilot study were primarily before and after study design. Only 
one group of clients who attended was willing to pay for the BPWLP; therefore, this 
would limit the study design. Another limitation was the major loss to follow-up. The 
dropout rate will affect the evaluation of the effectiveness of this particular 
commercial weight loss programme. Lastly, there was the potential bias in using 
unblinded recording of information. This would be affected by organisational 
constraints; therefore, data for the main study will be selected from multiple types of 
Boots pharmacies.  
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3.4.5 Refinements for the main study 
As a result of this pilot study a number of refinements will be made to the main 
study. In particular the researcher will be obliged to reconsider the time frame for the 
primary outcome and also the fact that the researcher will not be able to investigate 
changes in blood pressure or blood glucose during the programme, due to a lack of 
follow-up data. 
 
3.5 Summary 
The pilot study showed the feasibility of evaluating the effectiveness of a 
pharmacist-led weight management clinic. The data recording was generally of a 
very high quality with completion rates in the data records for the key variables 
being higher than 90%. The lower than anticipated rates of participation in the 
programme beyond three months means that the primary outcome will need to 
change from weight loss at six months to three months and that consequently it will 
not be possible to investigate the longer term effects of the programme. 
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Chapter 4 
Retrospective evaluation of a pharmacist-led weight 
management clinic 
 
This chapter describes a retrospective evaluation of a pharmacist-led weight 
management clinic conducted in Boots pharmacies. This record review of the Boots 
Pharmacy Weight Loss Programme (BPWLP) investigated the effectiveness of the 
service in assisting clients to lose weight.  
 
4.1 Aim and objectives 
The aim of this study was to evaluate the effectiveness of a pharmacist-led weight 
management clinic in achieving weight loss for obese clients through the prescription 
of orlistat, in combination with diet, exercise and advice.  
 
The primary outcome of the study was to achieve a change in body weight of at least 
5% of the initial body weight at three months. 
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The objectives of the study were to:  
x Describe the characteristics of clients who participated in the weight loss 
programme in terms of: 
o The length of time clients remained in the programme  
o The rate of unwanted effects based on the consultation notes 
o Reasons for drop-out from the programme 
x Determine the effect of orlistat 120 mg on body weight and BMI at three 
months for clients participating in the programme 
x 'HWHUPLQH DQ\ DVVRFLDWLRQV EHWZHHQ FOLHQWV¶ ELRPHWULF GDWD DW WKH LQLWLDO
visit and:  
o Gender: female and male 
o Age: younger than 50 years and 50 years and older 
o Time period in the programme: up to three months and more 
than three months 
x Determine characteristics associated with:  
o Weight reduction at three months  
o Clients who achieved at least 5% weight loss from their initial 
weight 
 
4.2 Methods 
4.2.1 Study design 
Data were collected using Customer Record Forms (CRFs) and customer 
consultation notes from a programme run by a commercial weight management 
clinic. A retrospective record analysis was performed.  
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An agreement about the study was made between the University of Nottingham, 
Boots UK Limited and SS (PhD research student) ± see Appendix 10. This 
agreement was drafted by Boots UK (Dr Tracey Thornley and Julie Hanmer, 
Industrial Supervisors), the University (Cheryl Ruse, Contracts Officer) and by the 
academic supervisors (HB and AA). The agreement described the project¶V aim, the 
primary outcomes, the included records for data collection and data analysis. SS was 
not permitted to directly access the CRFs held in Boots pharmacies. In order to meet 
the requirements of the Data Protection Act of 1998,172 detailVRIFOLHQWV¶QDPHVDQG
addresses were not recorded. The clients were assigned a unique study number so 
that the individual part of their store records could be linked whilst ensuring data 
confidentiality. 
 
4.2.2 Study population 
In 2011, the BPWLP was available in 205 Boots pharmacies in England and Wales, 
of which 22 are located in the East Midlands area. For convenience, pharmacies in 
the East Midlands were selected as potential study sites to save time and money in 
data collection. Boots Head Office provided data about the number of clients who 
had used the services between January 2006 and January 2009.  
 
Stores included in the study had a minimum of 20 clients who had participated in the 
programme; therefore 20 of the 22 stores were suitable for inclusion in the study. 
The pharmacies were grouped into high street pharmacies ± large stores and other 
pharmacies which included small stores, health centres and edge of town pharmacies. 
Five pharmacies in each group were then randomly selected using SPSS. 
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Each of the pharmacies was contacted by a member of staff at Boots head office to 
ask if they were willing to participate in the study. If a pharmacy declined to 
participate in the study, a further random sample from the same type of pharmacies 
was taken in order to select another pharmacy as a replacement. At the first contact, 
five large high street and three other pharmacies agreed to participate. Therefore, two 
other pharmacies were randomly selected from the remaining stores, and they agreed 
to participate in the study ± see Figure 4.1. 
 
 
 
Figure 4.1 Summary of steps for collecting data 
 
20 Boots pharmacies in the East Midlands area where 
more than 20 clients had participated in the programme
10 large high street pharmacies
Data collected for all clients starting the programme 
between 1 January 2006 and 31 January 2009 
Random sampling
10 other pharmacies
5 large high street pharmacies 5 other pharmaciesFirst contact
3 pharmacies agreed + randomly 
selected 2 more pharmacies 
All large pharmacies agreed
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Data collectors were recruited from undergraduate and postgraduate students from 
the University of Nottingham who were employed part time at Boots. They visited 
the pharmacies and photographed the records of all the clients who had started the 
programme between 1 January 2006 and 31 January 2009. To ensure confidentiality, 
post-it notes were used to cover personal details of clients (name, address and partial 
date of birth) for the photographs, revealing only partial postcode (the first part of the 
postcode) and year of birth.  
 
The inclusion criteria for clients in the study were:  
x that they had received at least one supply of orlistat 
x that their initial visit was over two years before the data collection date, that 
is, prior to 31 January 2009 (to allow for them to complete the maximum two 
years in the programme) 
 
7KHLQFOXVLRQFULWHULDIRUFOLHQWV¶ERG\mass index (BMI) in the BPWLP were: 
x Equal to or greater than 30 kg/m2 
x Equal to or greater than 28 kg/m2 with at least one risk factor such as: 
o Non insulin dependent diabetes 
o Raised cholesterol 
o Stress incontinence 
o Any heart disease 
o Hiatus Hernia 
o Awaiting surgery 
o High blood pressure 
o Pituitary disease 
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o Gallstones 
o Gastro-Oesophageal Reflux disease (GORD) 
o Any respiratory disease (e.g. asthma, COPD, sleep apnoea) 
o Osteoarthritis of a weight-bearing joint (e.g. knee, spine or hip)  
 
The exclusion criteria for clients in the BPWLP were:  
x Being pregnant or breast-feeding  
x Having the following health conditions:  
o Insulin-dependent diabetes 
o Liver disease 
o Gall bladder or bile duct problems which result in Cholestasis 
(jaundice) 
o Surgery for weight loss  
o Gastrointestinal malabsorption problems  
o Sensitivity to orlistat  
o Taking the following medicines: amiodarone, acarbose or ciclosporin 
 
In this study the internationally recognised classification for BMI3 was used. A BMI 
that is elevated to 30 kg/m2 or more is defined as obese; overweight was classified as 
having a BMI of 25.0-29.9 kg/m2. Obesity class I included clients with a BMI of 
30.0-34.9 kg/m2, class II was defined as a BMI of 35.0-39.9 kg/m2, and class III was 
defined as a BMI of 40 kg/m2 or greater.3, 24  
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4.2.3 Sample size calculation 
The sample size of CRFs was determined based on 1) the need for sufficient numbers 
from each cluster size (pharmacy) and 2) power calculations to detect differences 
between baseline (before) and follow-up (after) within the Boots Pharmacy Weight 
Loss Programme.  
 
Data from the pilot study was used to determine the minimum required sample size. 
The pilot study found there had been a mean weight loss of 4.9 kg (SD = r2.4) for 
the 120 clients at three months.  
 
Rather than taking a sample from each pharmacy, a random selection of pharmacies 
was chosen. The sampled population was drawn from 10 Boots pharmacies. It was 
assumed that clients within a selected pharmacy may be more similar than clients 
from different stores, due in part to similar socioeconomic characteristics, for 
example.  
 
Differences in body weight (kg) were being compared at baseline (before the start of 
the programme) and at three months (after being in the programme for three months), 
thus there was only one group of clients. A one-sample test was needed, which 
would challenge the null hypothesis that the mean of individual differences in body 
weight was zero: that is programme had no effect on body weight. If the 
effectiveness of this programme was the same as the pilot result, a mean difference 
of -4.9 kg in body weight would be seen. A sample size calculator173 was used to 
determine the number of clients needed, using a power of 95% two-sided and alpha = 
Chapter 4 Retrospective evaluation 
 
179 
 
0.05.  
 
This study considered weight changes of at least 5% of the initial weight at three 
months as the primary endpoint, and the length of time clients remained in the weight 
loss programme, the rate of unwanted effects and change in BMI as secondary 
endpoints.  
 
It was calculated at 95% power (at the two-side error 5.0% level) to detect a 
difference of 4.9 kg in body weight, 256 clients would be needed as the initial 
number. To compensate for expected client drop-out before three months (an 8% of 
drop-out rate was indicated in the pilot study), 384 clients were selected as the 
minimum number of clients¶UHFRUGVWKDWQHHGHG to be collected.  
 
4.2.4 Data collection 
Data were collected for all clients who participated in the programme from January 
2006 to January 2009. The data collected from the three different store held forms 
were (Appendix 7): 
x Demographics e.g. gender, year of birth, the first four digits of postcode 
x Biometric data: weight (kg), height (cm), body mass index (kg/m2), blood 
pressure, blood glucose 
x History information FXVWRPHU¶V GHWDLOV, GRFWRU¶V GHWDLOV DQ\ PHGLFLQHV
taken, previous weight loss attempts 
x Detail of whether or not clients met programme inclusion and exclusion 
criteria 
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x Records of advice given and supply of orlistat by the pharmacist 
x Side effects reported to the pharmacist 
x Dates of visits to the programme  
x $GGLWLRQDOQRWHVRISKDUPDFLVWV¶FRQVXOWDWLRQV 
 
All records were hand written, clients completed their personal details, and the 
pharmacist completed the rest of CRF. Photographs of the forms were downloaded to 
a computer with password protection. Data collectors (Appendix 10) checked the 
photos at the pharmacies to ensure they were readable and if not retook them prior to 
leaving the store. Unfortunately, a few records were still unreadable because of the 
handwriting. If the photographs were unclear, at least two pharmacists, who were 
independent, were asked to read the handwriting; if the checkers agreed that they had 
been able to interpret the handwriting, the data were included but where there was no 
agreement about what had been written the data were treated as missing data. Data 
were subsequently entered into a prepared Microsoft Office Access database 2007 
database.  
 
For the FOLHQWV¶ initial BPWLP visit, the pharmacist recorded data about the client 
including gender, age, weight (kg or lbs), height (metres or feet and inches), body 
mass index (kg/m2), blood pressure, blood glucose, history information e.g. any 
previous weight loss (WL) attempts; details of their general practitioner and any 
medicines taken, programme inclusion and exclusion criteria, supply of orlistat, dates 
RI YLVLWV WR WKH SURJUDPPH DQG RXWFRPH RI SKDUPDFLVWV¶ FRQVXOWDWLRQ LQFOXGLng 
minimum weight loss required at three months.  
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Boots head office provided information about straight-line distances from the 
SKDUPDF\WRWKHFOLHQW¶VKRPHthat were transformed from the partial postcodes. 
 
4.2.5 Data analysis 
Data were entered into a prepared Microsoft Office Access 2007 database and 
transferred to SPSS version 19.0 for analysis. Data were analysed both descriptively 
and inferentially. The dHPRJUDSKLF GDWD DQDO\VLV LQFOXGHG FOLHQWV¶ EDVHOLQH GDWD DW
entry to the programme which consisted of frequency counts, percentages, mean and 
VWDQGDUGGHYLDWLRQV 6'&OLHQWV¶ DJHZDVGHWHUPLQHGE\ VXEWUDFWLQJ WKHLU \HDURI
birth from the year of entry to the programme. 
 
A chi-square test (F2) was used to investigate differences in baseline data relating to 
gender, age and BMI for clients who participated in the programme for less than 
three months with those who participated for three months or more. 
 
The Wilcoxon Signed Rank Test was used for continuous data in terms of comparing 
weight and BMI at baseline and at three months because of non-normal distribution ± 
see testing normal distribution, page 199. The Mann-Whitney U test was used to 
compare the categorical variables within the two groups (such as gender, age, time 
period of being in the programme, and characteristics of dropout group with 
remaining group) and the continuous variables (such as weight and BMI). The 
Kruskal-Wallis test was used to compare differences across groups of blood pressure 
and previous weight loss attempt, classified by weight. A two-tailed p-value < 0.05 
was considered statistically significant.165 
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In addition, sensitivity analysis was performed only on the weight changes using a 
last-observation-carried-IRUZDUG /2&) DQDO\VLV WKDW LQFOXGHG DOO FOLHQWV¶ UHFRUGV
where missing data were imputed by carrying forward the last measured observation. 
 
4.3 Results 
A total of 658 records were collected from the 10 pharmacies. Five hundred and fifty 
seven records were included in the study, and 101 records excluded. Records were 
excluded where they were not within the study time frame of 1st January 2006 and 
31st January 2009 (n = 66) or no orlistat was supplied at the initial visit (n = 35) ± see 
Table 4.1. 
 
Table 4.1 Total of the included and excluded records 
Records 
Total records  
n % 
Collected 
Included 
658  
557  
100.0 
84.6 
Excluded  
Not in time frame (before 1 January 2006 or after 31 January 2009) 
No orlistat supply at the initial visit 
  No reasons given for non-supply 
  Met the inclusion criteria but decided not to attend Boots programme 
  Met the inclusion criteria but clients declined to receive advice about orlistat 
101  
66  
35  
19  
11  
5  
15.4 
10.0 
5.4 
2.9 
1.7 
0.8 
 
4.3.1 Reasons why orlistat was not supplied  
It was found that 11 clients met the programme inclusion criteria but did not 
participate in the Boots programme. Reasons recorded for this were: the client 
decided not to participate and decided to try a different programme or continued to 
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try to lose weight on their own.  
 
Other reasons why orlistat was not supplied were related to clLHQWV¶Kealth problems 
such as allergy, arthritis and high blood pressure; factors that did not necessarily 
exclude clients from the programme but led to the clients choosing not to participate 
due to these health issues ± see Table 4.2.  
 
Table 4.2 Characteristics of clients excluded due to not receiving orlistat (n = 35)  
Characteristics Number of clients or Mean r SD % or range 
Gender 
  Female 
  Male 
 
30  
5  
 
85.7 
14.3 
Age at entry to programme (years, n = 19)* 
  18-29 
  30-39 
  40-49 
  50-59 
  60 and older 
 
3  
2  
4  
8  
2  
 
15.8 
10.6 
21.0 
42.0 
10.6 
Height (metre, n = 27)* 
Baseline weight (kg, n = 27)* 
BMI (kg/m2) 
  Baseline* (n = 29) 
  Inclusion criteria** (n = 34) 
    %0, 
    %0,ZLWKRQHFR-morbid health risk 
1.6 r 0.1  
88.1 r 12.3  
 
33.4 r 4.4  
 
25  
9  
1.5-1.76 
71.2-120.2 
 
28-47.1 
 
73.5 
26.5 
Reasons for not participating in the programme 
  Unknown 
  Met the inclusion criteria but decided not to attend Boots 
programme 
 
19 
11 
 
54.3 
31.4 
  Met the inclusion criteria but no advice of orlistat to clients  5  14.3 
*This grouping does not total 35 due to missing data. **This BMI is for inclusion criteria for participating in this 
programme. 
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4.3.2 Completeness of customer record forms 
Completion rates for baseline data in the customer record forms (CRFs) varied from 
94% to 100%, with only six variables not being 100% completed ± see Table 4.3. 
Random blood glucose (RBG) was less well completed at baseline with 94% of 
clients having this measure recorded. The completeness of records for both 
pharmacists reporting the clients value as following the inclusion criteria (or stating 
it was normal) in a check box or reporting biometric values was 98% for blood 
pressure and 94% for blood glucose. ± see Appendix 11. Variables of blood pressure 
and blood glucose were not compulsory whilst other variables recorded during the 
FOLHQW¶V LQLWLDO YLVLW VXFK DV KLVWRUy information, inclusion and exclusion criteria, 
RUOLVWDWVXSSO\DQGWKHRXWFRPHRISKDUPDFLVWV¶FRQVXOWDWLRQs, were fully completed. 
 
Table 4.3 Completeness of data set at baseline (n = 557) 
Variables* Data set with complete information (%) 
Gender 
Age  
Height (metres) 
Weight (kg) 
BMI  
Date of visits 
BP recorded 
  Systolic BP (SBP) 
  Diastolic BP (DBP) 
Random BG recorded 
Minimum weight loss required at 3 months (kg) 
554  
557  
556  
556  
557  
557  
 
545  
545  
524  
553  
99.5 
100 
99.8 
99.8 
100 
100 
 
97.8 
97.8 
94 
99.3 
*Other variables were 100% completed. 
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4.3.3 Completeness of data at follow-up visits 
Data noted at each follow-up visit included date of visit, orlistat supply, either weight 
and/or BMI and any consultation notes. A total of 1,141 follow-up visits were 
recorded for the 557 clients. Over two-thirds of visits had a record of orlistat supply 
(n = 797, 70%) and four-fifths had either weight or BMI recorded (n = 942, 83%). 
Consultation notes were optional, and 740 (65%) of visits had a comment from the 
pharmacist. Variables recording orlistat supply and consultation notes were not 
expected to be 100%. It was expected that either weight or BMI would be recorded. 
Both pharmacists and clients knew results from the printout of weight from the 
electronic scales. Clients needed to weigh themselves on every single visit which 
LQYROYHG D SKDUPDFLVWV¶ FRQVXOWDWLRQ ,I IRU ZKDWHYHU UHDVRQ WKLV GLG QRW KDSSHQ
clients were asked to weigh themselves before having their next visit. Pharmacists 
could then record how much clients had lost or gained since their previous visit.  
 
4.3.4 Data checking and cleaning 
A 10% random sample of clients¶ data was checked for data entry errors. Fifty-five 
client records were checked and one error was discovered. This error was 19 kg 
being entered as the minimum weight loss target at three months (5%) kg/lbs. After 
rechecking, it was amended by converting from pound (lbs) to kg = 7 kg.  
 
Data cleaning was shown in Table 4.4 below. 
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Table 4.4 Data cleaning  
Variables Label and values* No others values 
found 
Client number The range of client number was from 1 to 557. 9 
Store number All values of store numbers were checked from Boots 
document. 
9 
Gender All values were 1 for male and 2 for female. There were three 
missing values which 
were 999. 
Age (years) 
In programme  
 
 
<HDURIFOLHQWV¶SDUWLFLSDWLRQZDVVXEWUDFWHGE\\HDURI
FOLHQWV¶ELUWK 
 
9 
In group All values of age group were on the range from 1 to 5  
1 = 18-29 years 
2 = 30-39 years 
3 = 40-49 years 
4 = 50-59 years 
5 = 60 years and older 
9 
Postcode  All actual values were partial postcodes. There were first three 
or four digits of 
postcodes recorded. 
&OLHQWV¶GHWDLOV All values of all client detail variables were 0 for no and 
1 for yes whether:  
Aged between 18 and 82 years  
Registered with a GP (doctor) 
Willing for Boots to contact doctors and referred clients 
for future treatment if necessary 
Agreed to a BP test and to a finger-prick blood sample 
for in store measurement of BP 
Agreed to proceed with treatment if appropriate and 
accepted any advice on diet, exercise and lifestyle 
changes from the Boots pharmacist 
9 
Information 
received 
All values of any direction of information received about 
BPWLP were multi-selection list as 0 for no and 1 for 
yes following: 
TV/radio, Magazine/newspaper, Boots leaflet, 
Recommendation from a friend, Internet, Other 
One client did not 
answer for any type 
of information 
received so that 999 
were entered. 
'RFWRU¶VGHWDLOV All valXHVRIDOOGRFWRU¶VGHWDLOYDULDEOHVZHUHIRU
absent and 1 for present. 
9 
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Table 4.4 (continued) 
Variables Label and values No others values 
found 
Any medicines 
prescribed by 
doctors or 
purchased over 
the counter  
All values of all medicines taken variables were 0 for 
absent and 1 for present. 
If any medicines were taken, how many they were on the 
range from 0 to 4 
0 = No medicines 
1 = 1 medicine 
2 = 2 medicines 
3 = 3 medicines 
4 = 4 or more medicines 
9 
Previous weight 
loss attempts 
All values of all previous weight loss attempts were 0 for 
absent and 1 for present. 
If clients had history of any previous weight loss 
attempts, what they were on the range from 0 to 8. 
0 = No attempts 
1 = Only diets 
2 = Only exercise 
3 = Only slimming pills 
4 = Both diets and exercise 
5 = Either diets or exercise and slimming pills 
6 = All attempts of diets, exercise and slimming pills 
7 = Other attempts e.g. BPWLP, herbal medicines, other 
programmes 
8 = Multi-attempts e.g. Any of diets, exercise, slimming 
pills or others 
9 
'HWDLOVRIFOLHQWV¶
previous weight loss 
attempts were 
completely explained 
in either results or 
discussions.  
Inclusion criteria All values of all four inclusion criteria were 0 for no and 
1 for yes whether: 
&OLHQWV¶%0,ZDV 30 kg/m2 
&OLHQWV¶%0,ZDVkg/m2 with one-co-morbid health 
risk 
Clients met the inclusion criteria for the BPWLP 
Clients were eligible for the BPWLP 
$OOYDOXHRI%0,kg/m2 with one-co-morbid health 
risk were multi-selection list as 0 for no and 1 for yes 
following: 
9 
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Table 4.4 (continued) 
Variables Label and values No others values 
found 
Inclusion criteria 
(continued) 
Non insulin dependent diabetes, Raised cholesterol, 
Stress incontinence, Any heart disease, Hiatus Hernia, 
Awaiting surgery, High BP, Pituitary disease, Gallstones, 
Gastro-Oesophageal Reflux disease (GORD), Any 
respiratory disease (e.g. asthma, COPD, sleep apnoea), 
Osteoarthritis of a weight-bearing joint (e.g. knee, spine, 
hip), Other 
9 
Exclusion 
criteria 
All values of all eight exclusion criteria were 0 for no and 
1 for yes whether: 
Clients were pregnant, breast-feeding, insulin-dependent 
diabetes, any present liver; gall bladder or bile duct 
problems, surgery for weight loss, gastrointestinal 
malabsorption problems, sensitivity to orlistat, taking any 
concomitant medication (amiodarone, acarbose, 
ciclosporin) 
9 
Orlistat advice to 
clients 
All values of all orlistat advice were 0 for no and 1 for 
yes whether: 
Clients agreed to use orlistat only whilst following the 
BPWLP with diet and exercise recommendation 
Clients were aware orlistat can produce side effects in the 
digestive system 
Clients agreed to read patient information leaflet (PIL) 
and followed the instructions before taking orlistat 
Clients were informed about orlistat will be discontinued 
if their weight loss was less than 5% of the initial weight 
after 12 weeks 
Clients were informed about orlistat is use for weight loss 
9 
Outcome of 
consultation 
All values of outcome of consultation were: 
1 = Client is suitable for entry and has decided to buy 
treatment from Boots. 
2 = Client is suitable but has decided to go to their 
doctor. 
3 = Client is suitable but has decided not to buy treatment 
from Boots. 
9 
Doctor referral Boots pharmacist explained to their clients that if 
diabetes or high BP may not aware of their condition, 
there were no obvious signs or symptoms, the affected 
individual client may feel well and completely normal. If 
DSKDUPDFLVWIRXQGFOLHQW¶V%3RU%3ZDVRXWVLGHWKH
expected range or any other significant concerns, client 
will be advised to consult their doctor. 
,IFOLHQW¶V%3!PP+JRU%G mmol/L, 
pharmacist will consider No, Yes or Refer 
9 
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 Table 4.4 (continued) 
Variables Label and values No others values 
found 
Doctor referral 
(continued) 
All values were: 0 for no, 1 for yes, 2 for refer, 3 for yes 
and refer 
9 
&OLHQW¶V
biometrics on 
entry to the 
programme 
Height (metres/feet and inches) 
Weight (kg/lbs) 
BMI (kg/m2) 
Minimum weight loss required at 3 months (5%) kg/lbs 
Final target weight (kg/lbs) 
Systolic/Diastolic BP (mmHg) 
Random BG (mmol/L) 
At least two actual 
values of height, 
weight or BMI 
recorded were able to 
be calculated. 
&OLHQW¶VFRQVHQW 
3KDUPDFLVW¶V
signature 
All values were:  
0 for signature absence, 1 for signature presence 
Actual date to know what year clients participated in the 
programme  
9 
Orlistat supply All values were:  
1 = 1-month supply of 84 orlistat 120 mg capsules 
2 = One of 3-month supply of orlistat 120 mg capsules 
9 
Checklist A checklist for the dispensed pack which included 1) 
\RXUVWHSWRVXFFHVVIXOZHLJKWORVVOHDIOHWSDWLHQWV¶
guide, 3) orlistat 120 mg capsules and 4) final check by 
pharmacist.  
 All values of checklist were 0 for no, 1 for yes 
9 
Date of visit 
Weight 
(kg/mlbs) 
BMI 
Consultation 
notes 
All actual values were weight (kg/lbs) and/or BMI. 
All values of date of visit were 0 for not attending and 1 
for attending 
All values of consultation notes were: 
0 = No comments 
1 = Problem note 
2 = Neutral note 
3 = Positive note 
4 = All problem, neutral and positive notes 
5 = Problem and neutral notes (1+2) 
6 = Problem and positive notes (1+3) 
7 = Neutral and positive notes (2+3) 
9 
Details of side-effects 
note were completed 
by counting episode 
of side-effects   
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Table 4.4 (continued)   
Variables Label and values No others values 
found 
Side-effects All values of side-effects were: 
1 = Constipation 
2 = Diarrhoea 
3 = Headache  
4 = Stomach ache 
5 = Slight suffering of side-effects  
6 = Loose stools 
7 = Gastrointestinal system, dry mouth and disturbed 
sleep 
9 
*All variables were checked for missing data. If it was found, values were 999. 
 
4.3.5 Characteristics of clients  
4.3.5.1 Clientsಬ demographics 
Most clients were female (n = 514, 93%), were aged 40-59 years (n = 285, 51%) and 
were currently using medicines either prescribed by their doctor or purchased over 
the counter (n = 340, 61%). Mean weight was 92.8 kg and BMI at baseline was 34.5 
kg/m2, whilst baseline mean systolic and diastolic blood pressure and random blood 
glucose were 127 mmHg, 85 mmHg and 5.6 mmol/L, respectively ± see Table 4.5. 
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Table 4.5 Client characteristics at baseline (n = 557)  
Characteristics Number of clients or Mean r SD  % or range 
&OLHQW¶VGHWDLOV 
Gender* 
  Female 
  Male 
 
 
514  
40  
 
 
93.0 
7.0 
Age at entry to programme, years 
  18-29 
  30-39 
  40-49 
  50-59 
  60 and older 
 
54  
125  
139  
146  
93 
 
9.7 
22.4 
25.0 
26.2 
16.7 
Currently taking any medicines prescribed or purchased 
  Yes 
  No 
 
343  
214 
 
61.6 
38.4 
Number of medicines prescribed or purchased 
  No medicine 
  1 medicine 
  2 medicines 
  3 medicines 
  4 or more medicines  
 
214  
132  
80  
55  
76  
 
38.4 
23.7 
14.4 
9.9 
13.6 
&OLHQW¶VELRPHWULFV 
Height, metres (n = 556)* 
Weight, kg (n = 556)* 
Baseline BMI (kg/m2) 
 
1.6 r 0.7  
92.8 r 15.6  
34.5 r 4.9  
 
1.45-1.91 
59.4-158.7 
28-55.1 
BP, mmHg (n = 545)* 
  Systolic BP 
  Diastolic BP 
 
127.4 r 18.1  
85.3 r 11.3  
 
92-198 
55-127 
Random BG, mmol/L (n = 524)* 5.6 r 1.7  2.6-18.5 
Minimum weight loss required at 3 months, kg  
(n = 553)* 
4.6 r 0.8 3-7.9 
*This grouping does not total 557 due to missing data.  
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Table 4.5 (continued)  
Characteristics Number of clients or Mean r SD  % or range 
3KDUPDFLVW¶V checklist for inclusion and exclusion criteria   
Inclusion criteria** 
  %0, kg/m2 
  %0,kg/m2 with at least one co-morbid health risk 
 
483  
74  
 
86.7 
13.3 
Orlistat supply*** 
  3-month option 
  1-month option 
 
477  
80 
 
85.6 
14.4 
**This BMI is for inclusion criteria for participating in this programme. 
***3-month option is a supply of 3x84 orlistat 120 mg capsules. 1-month option is a supply of 84 orlistat 120 mg 
capsules 
 
4.3.5.2 &OLHQWV¶GHWDLOV 
The inclusion criteria for a record of clients¶GHWDLOV were that they should be aged 
between 18 and 82 years, and that all were willing for Boots to contact their doctor or 
refer them for future treatment if necessary. They also all agreed to the measurement 
of their blood pressure and to provide a finger-prick blood sample for in-store 
measurement of blood glucose. All agreed to proceed with treatment if appropriate 
and accept any advice on diet, exercise and lifestyle changes that might be offered 
from the Boots pharmacist. Clients received information about BPWLP through a 
variety of methods, most having found out about the programme from a Boots leaflet 
in one of their pharmacies (60%) ± see Table 4.6. 
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Table 4.6 Sources of information about BPWLP (n = 557) 
Information source Number of clients*  %**  
Television/radio 
Magazine/newspaper 
Boots leaflet (in store) 
Recommendation from a friend 
Internet 
Other 
23 
50 
337 
88 
49 
44 
4.1 
9.0 
60.6 
15.8 
8.8 
7.9 
*Many clients received more than one type of BPWLP information. 
**One client did not select an information source. 
 
4.3.6 Other variables measured at the initial visit 
4.3.6.1 BMI and health risks 
Over one-fifth of clients (n = 74) had a BMI 28 kg/m2 or more, with at least one co-
morbid health risk; the remainder having a BMI of 30 kg/m2 or more. Over two-
thirds (n = 51) of those with a BMI between 28 and 30 kg/m2 had only one co-
morbid health risk. The most frequent co-morbid health risks were osteoarthritis of a 
weight-bearing joint (n = 18, 27%), followed by high BP (n = 14, 21%) and gastro-
oesophageal reflux disease, GORD (n = 14, 21%) ± see Table 4.7. 
 
  
Chapter 4 Retrospective evaluation 
 
194 
 
Table 4.7 Clients with BMI < 30 kg/m2 and their co-morbid health risks (n = 74) 
28 kg/m2 d BMI < 30 kg/m2 with one co-morbid health risk Number  %  
Number of co-morbid health risks 
  One co-morbid 
  Two co-morbid 
  Three co-morbid 
  Four co-morbid 
 
51 
16 
5 
2 
 
68.9 
21.6 
6.8 
2.7 
Co-morbid health risk* 
Osteoarthritis of a weight-bearing joint (e.g. knee, spine or hip)  
  High BP (HBP) 
Gastro-Oesophageal Reflux disease (GORD) 
Raised cholesterol 
  Stress incontinence 
  Any respiratory disease (e.g. asthma, COPD, sleep apnoea) 
  Awaiting surgery 
  Non insulin dependent diabetes (NIDDM) 
  Hiatus Hernia 
  Others e.g. back or hip/knee joint problems, knee pain, breathlessness, 
osteoporosis, thyroid condition, glucose intolerance 
 
18 
14 
14 
12 
11 
8 
3 
1 
1 
20 
 
27.0 
21.0 
21.0 
18.0 
16.4 
12.0 
4.5 
1.5 
1.5 
30.0 
*Many clients had more than one co-morbid health risk. 
 
4.3.6.2 Previous weight loss attempts 
Nearly two-thirds (n = 361) of clients¶ reported previous weight loss attempts 
involving both diet and exercise. About an eighth reported multiple previous 
attempts (n = 70) and diet only attempts (n = 62). Examples of multiple attempts 
involved diets, exercise, slimming pills (e.g. Reductil, Xenical, Adios), herbal 
medicines or other programmes ± see Table 4.8.  
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Table 4.8 ClieQWV¶SUHYLRXVZHLJKWORVVDWWHPSWVEHIRUHparticipating BPWLP (n = 557)  
Previous weight loss attempts Number  %  
Both diet and exercise  
Multiple attempts  
Diet only  
No weight loss attempts 
Exercise only 
Slimming pills in addition to diet or exercise 
Slimming pills only 
361 
70 
62 
33 
19 
9 
3 
64.8 
12.6 
11.1 
6.0 
3.4 
1.6 
0.5 
 
4.3.6.3 Medicines prescribed or purchased over the counter  
Two-fifths of clients used medicines designed to deal with obesity-related health 
risks (n = 231) such as drugs used in heart failure, hypertension and 
hypercholesterolemia. One-fifth (n = 117) took medicines to treat other conditions, 
which included hormone replacement therapy (HRT), antibiotics, non-steroidal anti-
inflammatory drugs (NSAIDs) or pain killers, antihistamine, anti-anxiety, anti-
epileptic, anti-coagulant or anti-vertigo ± see Table 4.9. The remaining two-fifths 
were not using any prescribed or over the counter medicines.  
 
The medicines prescribed or purchased OTC were recorded by clients ± see 
Appendix 12, Table A12.1. For those 74 clients who had a BMI of 28-29.9 kg/m2 the 
pharmacist recorded co-morbid conditions as reported by the clients ± see Table 4.7. 
A comparison for these 74 clients between their reported conditions and the 
medicines recorded showed a few discrepancies. Two clients reported taking 
metformin, but only one client reported diabetes ± however the second client taking 
metformin reported having polycystic ovary disease. Details of the medicines 
recorded by clients with a BMI of 28-29.9 kg/m2 are reported in Appendix 12, Table 
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A12.2.  
 
Table 4.9 &OLHQWV¶medicines prescribed or purchased over the counter (n = 557)  
Medicines prescribed or purchased over the counter Number*  %  
Medicines for obesity-related health risks 231 41.5 
Only medicines for health risk 
Both medicines for health risk and other medicines 
Vitamin supplement, medicines for health risk and other medicines 
Vitamin supplement and medicines for health risk 
144 
71 
11 
5 
25.9 
12.7 
2.0 
0.9 
No medicine 214 38.4 
Other medicines 177 21.0 
Only other medicines 
Both medicines for health risk and other medicines 
Vitamin supplement, medicines for health risk and other medicines 
Vitamin supplement and others 
86 
71 
11 
9 
10.2 
8.4 
1.3 
1.1 
Vitamins 42 7.6 
*Many clients had more than one medicine, prescribed or OTC. 
 
4.3.6.4 Straight-line distance and drive time 
This straight-line distance174, 175 was a proxy for drive time from the FOLHQWV¶KRPHWR
the Boots pharmacy. 7KH PHDQ GLVWDQFH EHWZHHQ %RRWV SKDUPDFLHV DQG FOLHQWV¶
homes was 6.5 km and driving time was 11.8 minutes. A drive time is important as 
straight-line distance may not accurately reflect the time taken for a person to travel 
from home to the pharmacy.175 Time in travelling to the pharmacy is likely to better 
reflect whether or not a client is willing to make the effort to attend a particular 
pharmacy for a service ± see Table 4.10. 
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Table 4.10 Straight-line distance and drive time to Boots pharmacies (n = 547)  
Straight-line distance and drive time to Boots pharmacies Mean r SD (range) 
Straight-line distance (km) 
Drive time (minutes) 
6.5 r 6.4 (0.3-61.5) 
11.8 r 7.5 (0.89-64.62) 
 
4.3.7 Consultation notes  
The consultation notes in BPWLP consisted of three themes: positive, neutral 
(absence of problems) and problem notes ± see Table 4.11. The positive notes 
included comments such as happy/pleased, achieved, brilliant/well or good/ok/fine. 
The neutral or absence of problems notes included no change in medication, no side 
or adverse effects, no problems and no contraindications. Problem notes included 
coPPHQWVUHODWLQJWR WKHFOLHQW¶VGLVDSSRLQWPHQWLQZeight loss, such as not having 
achieved a specific target, being unhappy or the reporting of side-effects such as 
constipation, diarrhoea, headache or stomach ache. 
 
It was found that over one-third of clients (n = 231) had no comments in their 
consultation notes. About one-tenth (n = 49) of the consultation notes in BPWLP 
contained FRPPHQWVUHODWLQJWRFOLHQWV¶SUREOHPVZKLOVWOHVVWKDQRQH-tenth included 
a neutral comment (n = 42), and 10% had positive comments (n = 52). Additionally, 
some notes had combinations of comments involving positive, neutral and problem 
notes relating to the weight loss programme (n = 67) ± see Table 4.11.  
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Table 4.11 Consultation notes recorded for 557 clients 
Consultation notes Number  %  
No comment 
Problem notes only 
Neutral or absence of problems only 
Positive notes only 
231 
114 
86 
59 
41.5 
20.5 
15.4 
10.6 
Positive and problem notes 
Positive and neutral notes  
Neutral and problem notes 
25 
18 
15 
4.5 
3.2 
2.7 
All positive, neutral and problem notes 9 1.6 
 
For 75 (14%) of the 557 clients, a side-effect related to orlistat was reported. Most of 
those reported side-effects were gastrointestinal disturbances with 40% reporting 
loose stools and over 25% diarrhoea ± see Table 4.12.  
 
Table 4.12 Side-effects recorded by pharmacists as possibly or probably related to orlistat 
treatment (n = 75) 
Episode of side-effects Number of clients  %  
Gastrointestinal system 
Loose stools* 
Diarrhoea** 
Slight suffering of side-effects  
Constipation 
Stomach ache 
 
30 
17 
14 
3 
2 
 
40.0 
22.6 
18.7 
4.0 
2.7 
Others 
Gastrointestinal system, dry mouth and disturbed sleep 
Diarrhoea, stomach pain, nausea, vomit or dizziness 
Headache 
 
4 
3 
2 
 
5.3 
4.0 
2.7 
*Included fatty/oily stool, liquid/soft stools 
**Uncontrolled oily discharge included faecal incontinence, flatus with discharge and oily spotting. 
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4.3.8 Participation in the BPWLP 
4.3.8.1 Dropout 
Using the dates recordHGLQFOLHQWV¶UHFRUGVQ UHWXUQHGIRUWKHLUIROORZ-
up visit at one month, and 38% (n = 214) returned for the 3-month follow-up visit. 
During the follow-up visits, most of these clients were supplied with a further 
treatment of orlistat: 95% (n = 444/468) at one month and 55% (n = 115/207) at three 
months ± see Appendix 13.  
 
Most clients continued in the programme for at least one follow-up with 85 (15.3%) 
not returning for any follow-up. One-third of the 468 clients who attended the 
programme at one month opted not to continue ± see Table 4.13.  
 
Table 4.13 Number and percent of clients who attended and did not attend in the programme 
follow-up visits (n = 557) 
Particular time at follow-up visits Month 1 (%) Month 3 (%) 
Attended 
Continued  
Left programme 
468 (84) 
271 (48.6) 
197 (35.4) 
207 (37) 
98 (17.6) 
109 (19.4) 
Did not attend 
Expected to continue programme later 
Left programme 
89 (16) 
4 (0.7) 
85 (15.3) 
68 (12) 
68 (12) 
- 
 
Reasons for leaving the programme were recorded for most clients, and these 
included achieving desired weight loss, personal circumstances and dissatisfaction 
with side-effects. Almost half of the clients who left the programme after three 
months had achieved the desired weight loss ± see Table 4.14. 
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Table 4.14 &OLHQWV¶UHDVRQVIRUOHDYLQJWKHSURJUDPPHDW- and 3-month  
&OLHQWV¶UHDVRQV 
Number of clients 
leaving the programme at 
1 month (n = 197) 
Number of clients 
leaving the programme 
at 3 months (n = 109) 
n  %  n  %  
Returned at particular time point and left  
No reason recorded 
Achieved the desired weight loss 
Personal reasons e.g. continued on own, 
holidays or moved 
 
72 
30 
25 
 
36.6 
15.2 
12.7 
 
16 
47 
13 
 
14.6 
43.0 
12.0 
Dissatisfied with side effects  
Health-related problems 
Did not achieve the desired weight loss 
Refund 
Gained weight  
Behaviour reasons e.g. lack of motivation 
Others e.g. not happy, disappointed 
25 
21 
10 
8 
5 
1 
- 
12.7 
10.7 
5.0 
4.1 
2.5 
0.5 
- 
9 
4 
15 
- 
3 
1 
1 
8.2 
3.7 
13.8 
- 
2.7 
1.0 
1.0 
Total 197 100.0 109 100.0 
 
4.3.8.2 Comparison of characteristics between clients who remained in the 
programme for less than three months and those who remained for 
three months or more 
There was a statistically significant difference between the ages of those continuing 
in the programme for at least three months and those who left earlier (F2 = 10.22, p = 
0.001). Younger clients were less likely to remain in the programme for three months 
than those aged 50 years and over ± see Table 4.15. In contrast, there were no 
significant differences in the gender (F2 = 0.47, p = 0.49) and BMI (F2 = 1.52, p = 
0.68) of clients, relative to length of time in the programme.  
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Table 4.15 Differences between characteristics of clients who stayed less than 3 months and 
at least 3 months 
Characteristics 
Dropout before 
3 months (n = 
391) 
Stayed at 3 
months and over 
(n = 166) Total (%) F2  p-
value* 
n %  n %  
Gender (n = 554)        
Female 
  Male 
359 
30 
92.3 
7.7 
155 
10 
93.9 
6.1 
514 (92.8) 
40 (7.2) 
0.47 0.49 
Age, years (n = 557)        
18-49 
50 and older 
241 
150 
61.6 
38.4 
78 
88 
47.0 
53.0 
319 (57.3) 
238 (42.7) 
10.22 0.001 
BMI (kg/m2)        
28.0-29.9 
30.0-34.9 
35.0-39.9 
 
50 
201 
98 
42 
12.8 
51.4 
25.1 
10.7 
24 
77 
48 
17 
14.5 
46.4 
28.9 
10.2 
74 (13.3) 
278 (49.9) 
146 (26.2) 
59 (10.6) 
1.52 0.68 
*p-value < 0.05 considered statistically significant. 
 
4.3.9 Effects of orlistat 120 mg on body weight and BMI at three 
months 
This section includes testing for a normal distribution, changes in weight and BMI at 
three months. 
 
4.3.9.1 Testing for a normal distribution 
Wilcoxon Signed Rank test (W) was used to test changes in weight and BMI before 
and after participating in the programme. The reason for this choice was that both 
parameters were non-parametrically distributed. This test was designed for use with 
the repeated measures on two different occasions.165 Using the same method to test 
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for normality, as in Chapter 3 (page 155), three procedures were employed: graphical 
methods (histogram, a curve pattern in the corresponding Q-Q plot and detrended 
normal Q-Q plots), numeric methods (skewness and kurtosis indices) and a formal 
normality test (the Kolmogorov-Smirnov test).  
 
Although both skewness and kurtosis are zero in a normal distribution, their values in 
this study were 0.97 and 1.41 in weight and 1.55 and 3.24 in BMI, respectively. The 
further away from zero, the more non-normal the distribution; the non-normal 
distribution was analysed using non-parametric statistics ± see Appendix 14. Results 
of the Kolmogorov-Smirnov test showed significant value smaller than 0.05 which 
indicates a non-normal distribution. The p-values of weight and BMI data were both 
less than 0.05; therefore, both mean weight and mean BMI at baseline were not 
normally distributed ± see Table 4.16. 
 
Table 4.16 Tests of normality for both weight and BMI 
Tests of normality Weight (kg) BMI (kg/m2) 
Skewness 0.97 1.55 
Kurtosis 1.41 3.24 
Kolmogorov-Smirnov* 0.000 0.000 
*Significant value < 0.05 
 
Testing normality for the variables of age, length of treatment, blood pressure and 
blood glucose at baseline were conducted as above. Graphical interpretation and the 
values of skewness and kurtosis were used to assess normality. There was only 
skewness and kurtosis of age shown by the parameters nearest to zero, which were 
0.12 and -0.58, respectively. The remaining data for the four characteristics of age, 
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length of treatment, blood pressure and blood glucose were skewed ± see Appendix 
14. Results of the Kolmogorov-Smirnov statistic showed that significant values of 
length of treatment, systolic and diastolic blood pressure and random blood glucose 
were smaller than 0.05 which defines the results as constituting a non-normal 
distribution. Therefore, only age was normally distributed ± see Table 4.17. 
 
Table 4.17 Tests of normality for five characteristics data 
Tests of normality Age (years) 
Length of 
treatment 
(years) 
BP (mmHg) Random BG 
(mmol/L) Systolic BP Diastolic BP 
Skewness 0.12 0.73 0.73 0.45 2.81 
Kurtosis -0.58 0.55 0.55 0.38 14.71 
Kolmogorov-Smirnov* 0.81 0.000 0.004 0.020 0.000 
*Significant value < 0.05 
 
4.3.9.2 Weight change 
There was a statistically significant reduction in median weight at three months (z = -
11.4, p < 0.001). The median value on weight change decreased from baseline (Md = 
90.7) to three months (Md = 85.3) ± see Table 4.18.  
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Table 4.18 Changes in cOLHQWV¶ZHLJKWDWEDVHOLQHDQGPRQWKVfor completers only 
Weight (kg) 
Time 
Baseline (n = 556)* Month 3 (n = 166) 
Median 90.7 85.3 
Percentiles 
  25th  
  75th  
Z-value** 
p-value*** 
 
81.2 
100.9 
- 
- 
 
76.5 
94.8 
-11.4 
< 0.001 
*One client had no height and weight recorded. 
**Z-value = The number of standard errors to test statistic Wilcoxon Signed Rank test (W) to approximate the 
distribution. 
***p-value < 0.05 considered statistically significant. 
 
At three months, two-thirds of clients (n = 110/166, 66%) had lost between 3.00 kg 
and 7.99 kg. Meanwhile, five percent of clients gained weight at three months ± see 
Table 4.19. 
 
Table 4.19 Weight changes at three-months for completers only 
Weight change (kg) 
&OLHQWV¶ZHLJKWFKDQJHVat 3 months (n = 166) 
n % 
Gain 
No change 
9 
1 
5.4 
0.6 
Loss 
  0.01-0.99 
  1.00-2.99 
  3.00-4.99 
  5.00-7.99 
  8.00-10.99 
  11.00-13.99 
   14.00 
 
4  
18  
46  
64  
19  
4 
1 
 
2.4 
10.8 
27.8 
38.6 
11.4 
2.4 
0.6 
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Sixty-two percent of completers (n = 103) met the three-month weight loss target of 
at least 5% of their initial body weight at three months ± see Table 4.20.  
 
Table 4.20 Percentage of weight change at three months for completers only compared with 
baseline 
Percentage of weight change 
Month 3 (n = 166) 
n % 
Decrease from baseline weight 
  0-4.9% 
  5-9.9% 
   10% 
 
54 
92 
11 
 
32.6 
55.4 
6.6 
Increase from baseline weight 
  0-4.9% 
  5-9.9% 
  10% 
 
7 
1 
1 
 
4.2 
0.6 
0.6 
 
Weight change at three months was divided into three groups: 1) successful ± lost at 
least 5% of the initial weight 2) maintainers or improvers ± lost < 5% of the initial 
weight and 3) the unsuccessful group (or gainers) gained weight at three months. A 
weight loss of around 5-10% for a period of three months is enough to see an 
improvement in health.15 Due to the small numbers in the unsuccessful group, the 
successful group was compared with the maintainers or improvers ± see Table 4.21. 
 
There was no difference in the proportion of women being successful on the 
programme, compared with maintainers or improvers ± see Table 4.21; z = -0.06, p = 
0.95. At three months, although completed clients who were successful (84.5 kg) had 
lower median weight than those who were maintainers or improvers (87.2 kg), the 
Chapter 4 Retrospective evaluation 
 
206 
 
median BMI in the successful group (32.1 kg/m2) was higher than those in the 
maintainers or improvers group (31.6 kg/m2).  
 
Table 4.21 Baseline characteristics of completed clients classified according to their success 
with the percentage at 3 months 
Baseline characteristics  
(n = 557) 
Successful  
/RVWRILQLWLDO
body weight, n = 103) 
Maintainers or 
improvers  
(Lost 0-4.9% of initial 
body weight, n = 54) 
Z-
valuea 
p-
valueb 
Gender: Male/Femalec (%) 
40/514 (7.0/93.0) 
 
9/93 (8.7/90.3) 
 
6/48 (11.1/88.9) 
-0.41 0.05 
Age (range), years 
47 (18-82) 
 
51 (18-74) 
 
49 (27-74) 
-0.18 0.86 
BMI (range), kg/m2 
34.5 (28-55.1) 
 
32.1 (25.6-50.2) 
 
31.6 (25.6-53.5) 
-1.00 0.32 
Weight (range), kg 
92.8 (59.4-158.7) 
 
84.5 (61.7-145.1) 
 
87.2 (56.7-131.5) 
-0.06 0.95 
Weight change (range), kg 
- 
 
6.4 (3.6-16.8) 
 
3.1 (0.0-5.4) 
-9.61 <0.001 
aZ-value = The number of standard errors to test statistic Mann-Whitney U test (U) to approximate the 
distribution. 
bp-value < 0.05 considered statistically significant. 
cThis grouping does not total 157 due to missing data. 
 
4.3.9.3 BMI change 
There was a statistically significant reduction in BMI at three months (z = -12.2, p < 
0.001). The median value of BMI level decreased from 33.4 kg/m2 at baseline to 31.6 
kg/m2 at three months, Md = 1.8, 5.7% - see Table 4.22. 
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Table 4.22 Change in FOLHQWV¶BMI at baseline and 3 months for completers only 
BMI (kg/m2) 
Time 
Baseline (n = 557) Month 3 (n = 166) 
Median 33.4 31.6 
Percentiles 
  25th  
  75th  
Z-value* 
p-value** 
 
31.1 
36.7 
- 
- 
 
29.1 
35.1 
-12.2 
< 0.001 
*Z-value = The number of standard errors to test statistic Wilcoxon Signed Rank test (W) to approximate the 
distribution. 
**p-value < 0.05 considered statistically significant. 
 
Most clients had BMI level of 30.0-34.9 kg/m2 at baseline (n = 278, 50%) and month 
three (n = 63, 38%) ± see Table 4.23. The percentage of clients who had a BMI level 
of 30 kg/m2 or greater was 87% at baseline and 63% at three months. 
 
Table 4.23 Changes in FOLHQWV¶BMI at baseline and 3 months for completers only 
BMI (kg/m2) 
&OLHQWV¶%0,FKDQJHVat 3 months  
Baseline, n = 557 % Month 3, n = 166 % 
25.0-27.9 
28.0-29.9 
30.0-34.9 
35.0-39.9 
 
- 
74 
278 
146 
59 
- 
13.3 
49.9 
26.2 
10.6 
19 
43 
63 
30 
11 
11.4 
25.9 
38.0 
18.1 
6.6 
 
For clients who remained in the programme at three months, 34 (21%) clients 
decreased their BMI level from obesity class I to overweight (25.0-29.9 kg/m2). 
Twenty-two (13%) clients decreased their BMI level from obesity class II to obesity 
class I whilst 16 (10%) of clients decreased a BMI level from overweight with one-
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comorbidity (28.0-29.9 kg/m2) to 25.0-27.9 kg/m2. For 82 (49%) clients there was no 
change in BMI classification ± see Table 4.24. 
 
Table 4.24 Changes of BMI level at three months for completers only (n = 166) 
BMI (kg/m2) 
1XPEHURIFOLHQWV¶%0,FKDQJHV 
Month 3 % 
No change 
Change from overweight with one-comorbidity to 25.0-27.9 
82 
16 
49.4 
9.6 
Decreased from 
  Obese class I to overweight 
  Obese class II to overweight 
  Obese class II to obese class I 
  Obese class III to obese class II 
 
34 
1 
22 
7 
 
20.5 
0.6 
13.3 
4.2 
Increased from 
  Obese class I to obese class II  
  Obese class II obese class III 
 
3 
1 
 
1.8 
0.6 
 
4.3.10 Comparison of baseline biometric data by age, gender and 
length of time in the programme  
A comparison of baseline biometric data was done to find if there were differences. 
 
4.3.10.1 Length of time in the programme  
The median baseline diastolic blood pressure of clients who participated in the 
programme for up to three months (Md = 84.0, n = 445) was lower than the baseline 
median of clients who participated in the programme for more than three months (Md 
= 87.5, n = 100), z = -2.11, p < 0.03 ± see Table 4.25. No other baseline biometric 
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data showed statistically significant differences related to length of time in the 
programme.  
 
Table 4.25 'LIIHUHQFHVRIFOLHQWV¶ZHLJKW%0,%3DQG%*by the time period of being in 
the programme 
Baseline measures 
Up to 3 months  
(n = 452) 
More than 3 months 
(n = 105) Z-value* p-value** 
Median N Median N 
Weight (kg) *** 
BMI (kg/m2)  
SBP (mmHg) *** 
DBP (mmHg) *** 
BG (mmol/L) *** 
90.7 
33.4 
124.0 
84.0 
5.3 
451 
452 
445 
445 
429 
89.8 
33.2 
127.0 
87.5 
5.3 
105 
105 
100 
100 
95 
-1.01 
-0.64 
-1.43 
-2.11 
-0.50 
0.31 
0.52 
0.15 
0.03 
0.61 
*Z-value = The number of standard errors to test statistic Mann-Whitney U test to approximate the distribution. 
**p-value < 0.05 considered statistically significant. 
***This grouping does not total 557 due to missing data. 
 
There were no significant differences in the proportion of clients who participated in 
WKHSURJUDPPHXSWRWKHWKUHHPRQWKV¶SRLQWIURPWKRVHZKRSDUWLFLSDWHGIRUPRUH
than three months by gender (F2 = 1.11, p = 0.29) or age (F2 = 6.93, p = 0.14) ± see 
Table 4.26.  
 
There were no significant differences in the proportion of clients who participated in 
the programme up to three months with those who participated for more than three 
months, in terms of medicines prescribed or purchased (F2 = 1.99, p = 0.16), 
previous weight loss attempts (F2 = 0.94, p = 0.63), blood pressure (F2 = 3.15, p = 
0.21), blood glucose (F2 = 0.12, p = 0.73), health risk (F2 = 0.09, p = 0.76), straight-
line distance (F2 = 1.49, p = 0.22) and drive time (F2 = 0.40, p = 0.53), respectively. 
Chapter 4 Retrospective evaluation 
 
210 
 
Interestingly, clients with baseline blood pressure greater than or equal to 140/85 
mmHg represented a higher proportion of clients remaining in the programme than 
those with baseline blood pressure lower than or equal to 140/85 mmHg (F2 = 3.15, p 
= 0.21) ± see Table 4.26. 
 
Table 4.26 'LIIHUHQFHVDPRQJFOLHQWV¶FKDUDFWHULVWLFV by the time period of being in the 
programme  
Characteristics 
Up to 3 months More than 3 
months  Total (%) F2  p-
value* 
n %  n %  
Gender (n = 554) 
Female  
 
415 
 
92.2 
 
99 
 
95.2 
 
514 
(92.8) 
1.11 
 
0.29 
Male 35 7.8 5 4.8 40 (7.2)   
Age, years (n = 557) 
18-29 
30-39 
 
49 
104 
 
10.8 
23.0 
 
5 
21 
 
4.8 
20.0 
 
54 (9.7) 
125 
(22.4) 
6.93 
 
0.14 
40-49 109 24.2 31 29.5 140 
(25.1) 
  
50-59 120 26.5 25 23.8 145 
(26.0) 
  
60 and older 70 15.5 23 21.9 93 (16.7)   
Medicines prescribed or 
purchased OTC (n = 557) 
     1.99 
 
0.16 
No medicines 180 39.8 34 32.4 214 
(38.4) 
  
At least one medicine 272 60.2 71 67.6 343 
(61.6) 
  
*p-value < 0.05 considered statistically significant. 
 
 
Chapter 4 Retrospective evaluation 
 
211 
 
Table 4.26 (continued) 
Characteristics 
Up to 3 months More than 3 
months  Total F2  p-
value* 
n %  n %  
Previous weight loss attempts 
Both diet and exercise 
 
292 
 
64.6 
 
69 
 
65.7 
 
361 (64.8) 
0.94 0.63 
Other attempts 135 29.9 28 26.7 163 (29.3)   
No attempts 25 5.5 8 7.6 33 (5.9)   
BP level recorded, mmHg    
(n = 545) 
     3.15 
 
0.21 
d 129/84  
130/85 - 139/89 
 
196 
95 
154 
44.0 
21.3 
34.7 
37 
19 
44 
37.0 
19.0 
44.0 
233 (42.8) 
114 (20.9) 
198 (36.3) 
  
BG level recorded, mmol/L  
(n = 524) 
     0.12 0.73 
< 5.6  
 
249 
180 
58.0 
42.0 
57 
38 
60.0 
40.0 
306 (58.4) 
218 (41.6) 
  
Health risks 
No cormorbid risks 
At least one cormorbid risk 
 
391 
61 
 
86.5 
13.5 
 
92 
13 
 
87.6 
12.4 
 
483 (86.7) 
74 (13.3) 
0.09 0.76 
Straight-line distance to 
pharmacy, km (n = 153)  
     0.12 2.38 
< 10 360 81.4 80 76.2 440 (79.0)   
 82 18.6 25 23.8 107 (21.0)   
Drive time to pharmacy 
(minutes) 
     0.40 0.53 
< 15 329 74.4 75 71.4 404 (72.5)   
 113 25.6 30 28.6 143 (27.5)   
*p-value < 0.05 considered statistically significant. 
 
  
Chapter 4 Retrospective evaluation 
 
212 
 
4.3.11 Characteristics of clients associated with weight reduction at 
three months  
The association between baseline characteristics and weight reduction are described 
in this section. 
 
Women were more likely to be successful in losing at least 5% from baseline body 
weight at three months, compared with men (F2 = 4.34, p = 0.04). No other baseline 
characteristics were found to be associated with being successful in losing weight (at 
least 5% at three months) ± see Table 4.27. 
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Table 4.27 Baseline characteristic associated with weight reduction at three months (n = 157)  
Characteristics 
Successful 
(n = 103) 
Maintainer/Improver 
 (n = 54) Total (%) F2  p-
value* 
n %  n %  
Gender (n = 156) 
Female 
 
99 
 
97.1 
 
48 
 
88.9 
 
147 
(94.2) 
4.34 
 
0.04 
Male 3 2.9 6 11.1 9 (5.8)   
Age, years (n = 155)      1.06 
 
0.30 
18-49 
50 and older 
45 
57 
44.1 
55.9 
28 
25 
52.8 
47.2 
73 (47.1) 
82 (52.9) 
  
Medicines prescribed or 
purchased OTC 
     0.83 0.31 
No medicines 
At least one medicine 
36 
67 
35.0 
65.0 
15 
39 
27.8 
72.2 
51 (32.5) 
106 
(67.5) 
  
Previous weight loss 
attempts 
     1.56 
 
0.46 
Both diet and exercise 70 68.0 33 61.1 103 
(65.6) 
  
Other attempts 
No attempts 
25 
8 
24.3 
7.7 
18 
3 
33.3 
5.6 
43 (27.4) 
11 (7.0) 
  
BP level recorded, mmHg 
(n = 151) 
     2.70 
 
0.26 
d 129/84  
130/85 - 139/89 
 
41 
16 
42 
41.4 
16.2 
42.4 
17 
14 
21 
32.7 
26.9 
40.4 
58 (38.4) 
30 (19.9) 
63 (41.7) 
  
BG level recorded, mmol/L 
(n = 146) 
     0.09 0.76 
< 5.6  
 
52 
41 
55.9 
44.1 
31 
22 
58.5 
41.5 
83 (56.8) 
63 (43.2) 
  
*p-value < 0.05 considered statistically significant. 
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Table 4.27 (continued)        
Characteristics 
Successful 
(n = 103) 
Maintainer/Improver 
 (n = 54) Total (%) F2  p-
value* 
n %  n %  
Health risks 
No comorbid risks 
 
93 
 
90.3 
 
44 
 
81.5 
 
137 
(87.3) 
0.47 0.12 
At least one comorbid risk 10 9.7 10 18.5 20 (12.7)   
Straight-line distance to 
pharmacy, km (n = 153)  
     2.38 
 
0.12 
< 10  84 84.0 39 73.6 123 
(80.4) 
  
 16 16.0 14 26.4 30 (19.6)   
Drive time to pharmacy, 
minutes (n = 153) 
     1.38 
 
0.24 
< 15 75 75.0 35 66.0 110 
(71.9) 
  
 25 25.0 18 34.0 43 (28.1)   
*p-value < 0.05 considered statistically significant. 
 
4.3.12 Characteristics of clients who achieved at least 5% weight loss  
There were significantly different characteristics of clients who achieved at least 5% 
weight loss at three months. Women (Md = 6.4) were more likely to achieve weight 
loss compared with men (Md = 5.0, z = -2.08, p = 0.04). Clients with no comorbid 
risks (Md = 6.4) were more likely to achieve weight loss compared with those with at 
least one comorbid risk (Md = 5.5, z = -2.42, p = 0.01). The remaining characteristics 
were not found to be associated with clients who achieved at least 5% weight loss ± 
see Table 4.28. 
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Table 4.28 Baseline characteristic associated with clients who achieved at least 5% of weight 
loss (n = 103) 
Characteristics Weight change (%) Z-value*  p-value** 
Gender (n = 102)  -2.08 0.04 
Female (99) 
Male (3) 
6.4 
5.0 
  
Age, years (n = 103)  -0.25 0.81 
18-49 (45) 
50 and older (58) 
6.4 
6.4 
  
Medicines prescribed or purchased OTC (n = 103) -0.58 0.81 
No medicines (36) 
At least one medicine (67) 
6.4 
6.4 
  
Previous weight loss attempts*** (n = 103)  4.18 0.81 
Both diet and exercise (70) 
Other attempts (25) 
No attempts (8) 
6.4 
6.3 
6.5 
  
BP level recorded, mmHg*** (n = 99)  1.59 0.45 
d 129/84 (41) 
130/85 - 139/89 (16) 
(42) 
5.9 
6.8 
6.4 
  
BG level recorded, mmol/L (n = 93)  -0.40 0.97 
< 5.6 (52) 
(41) 
6.4 
6.4 
  
Health risks (n = 103)  -2.42 0.01 
No comorbid risks (86) 
At least one comorbid risk (17) 
6.4 
5.5 
  
*Z-value = The number of standard errors to test statistic Mann-Whitney U test to approximate the distribution. 
**p-value < 0.05 considered statistically significant. 
***F2 = Value to evaluate differences in mean ranks across the groups of previous weight loss attempts and BP 
level using Kruskal-Wallis test. 
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Table 4.28 (continued) 
Characteristics Weight change (%) Z-value*  p-value** 
Straight-line distance to pharmacy, km (n = 101)  -1.44 0.15 
< 10 (65) 
 (35) 
6.4 
6.1 
  
Drive time to pharmacy, minutes (n = 101)  -0.33 0.74 
< 15 (75) 
 15 (26) 
6.4 
6.4 
  
Total 6.4   
*Z-value = The number of standard errors to test statistic Mann-Whitney U test to approximate the distribution. 
**p-value < 0.05 considered statistically significant. 
 
4.3.13 Sensitivity analysis 
4.3.13.1 Weight change 
A repeated measures Wilcoxson Signed Rank Test, using LOCF (Last-observation-
carried-forward analysis), revealed a significant difference for median reduction in 
initial weight (z = -16.4, p < 0.001); at three months the median value of weight 
change (Md = 88.0) ± see Table 4.29. 
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Table 4.29 &KDQJHVLQFOLHQWV¶ZHLJKWDWEDVHOLQHDQGPRQWKVIRU/2&) (n = 556a) 
Weight (kg) 
Time 
Baseline  Month 3  
Median 90.7 88.0 
Percentiles 
  25th  
  75th  
Z-valueb 
p-valuec 
 
81.2 
100.9 
- 
- 
 
79.7 
98.3 
-16.4 
< 0.001 
aOne client had no height and weight recorded. 
bZ-value = The number of standard errors to test statistic Wilcoxon Signed Rank test (W) to approximate the 
distribution. 
cp-value < 0.05 considered statistically significant. 
 
Identical analysis was conducted using the LOCF. More than two-fifths of clients 
being investigated (n = 232, 42%) had lost between 1.00 kg and 4.99 kg in weight, 
whereas 19% of clients had lost more than 5 kg ± see Table 4.30. 
 
Table 4.30 Weight changes at three-months for LOCF 
Weight change (kg) 
&OLHQWV¶ZHLJKWFKDQJHVat 3 months (n = 556) 
n % 
Gain 
No change 
39 
143 
7.0 
25.7 
Loss 
  0.01-0.99 
  1.00-2.99 
  3.00-4.99 
  5.00-7.99 
  8.00-10.99 
  11.00-13.99 
   14.00 
 
38 
122 
110 
75 
23 
5 
1 
 
6.8 
21.9 
19.8 
13.5 
4.2 
0.9 
0.2 
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Using the LOCF analysis, only one-third (n = 131, 33.6%) met the three-month 
weight loss target of at least 5% of their initial body weight ± see Table 4.31.  
 
Table 4.31 Percentage of weight change at three months for LOCF comparing with baseline 
Percentage of weight change 
Month 3 (n = 556) 
n % 
No change 143 25.7 
Decrease from baseline weight 
  0-4.9% 
  5-9.9% 
   10% 
 
243 
120 
11 
 
43.7 
21.6 
2.0 
Increase from baseline weight 
  0-4.9% 
  5-9.9% 
  10% 
 
33 
4 
2 
 
5.9 
0.7 
0.4 
 
There was no difference in the proportion of women being successful on the 
programme compared with maintainers or improvers ± see Table 4.32; z = -0.26, p = 
0.05. At three months, LOCF clients who were successful (85.3 kg, 31.8 kg/m2) had 
lower median weight and BMI than those who were maintainers or improvers (88.0 
kg, 32.1 kg/m2).  
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Table 4.32 Baseline characteristics of LOCF clients classified according to their success with 
the percentage at 3 months 
Baseline characteristics  
(n = 557) 
Successful  
/RVWRILQLWLDO
body weight, n = 131) 
Maintainers or 
improvers  
(Lost 0-4.9% of initial 
body weight, n = 243) 
Z-
valuea 
p-
valueb 
Gender: Male/Femalec (%) 
40/514 (7.0/93.0) 
 
7/123 (5.4/94.6) 
 
6/48 (9.5/90.5) 
-0.26 0.05 
Age (range), years 
47 (18-82) 
 
50 (18-74) 
 
45 (21-82) 
-2.4 0.16 
BMI (range), kg/m2 
34.5 (28-55.1) 
 
31.8 (25.6-50.2) 
 
32.1 (25.6-54.0) 
-1.40 1.61 
Weight (range), kg 
92.8 (59.4-158.7) 
 
85.3 (61.7-145.1) 
 
88.0 (56.7-152.4) 
-1.12 0.26 
Weight change (range), kg 
- 
 
6.4 (3.6-16.8) 
 
2.3 (0.01-6.40) 
-15.27 <0.001 
aZ-value = The number of standard errors to test statistic Mann-Whitney U test (U) to approximate the 
distribution. 
bp-value < 0.05 considered statistically significant. 
cThis grouping does not total 157 due to missing data. 
 
4.3.13.2 BMI change 
A repeated measures Wilcoxson Signed Rank Test, using LOCF, revealed a 
significant difference for median reduction in BMI (z = -12.8, p < 0.001); the median 
value of weight change at three months was 31.6 kg/m2 ± see Table 4.33. 
 
 
 
 
 
 
Chapter 4 Retrospective evaluation 
 
220 
 
Table 4.33 &KDQJHLQFOLHQWV¶%0,DWEDVHOLQHDQGPRQWKVIRU/2&) (n = 557)  
BMI (kg/m2) 
Time 
Baseline (n = 557) Month 3 (n = 166) 
Median 33.4 31.6 
Percentiles 
  25th  
  75th  
Z-value* 
p-value** 
 
31.1 
36.7 
- 
- 
 
29.1 
34.9 
-12.8 
< 0.001 
*Z-value = The number of standard errors to test statistic Wilcoxon Signed Rank test (W) to approximate the 
distribution. 
**p-value < 0.05 considered statistically significant. 
 
All clients had BMI levels of 30.0-34.9 kg/m2 at baseline (n = 278, 50%) and month 
three (n = 250, 44.9%) ± see Table 4.34. The percentage of clients who had a BMI 
level of 30 kg/m2 or greater was 87% at baseline and 96.6% at three months. 
 
Table 4.34 Changes LQFOLHQWV¶%0,DWEDVHOLQHDQGPRQWKVIRU/2&) (n = 557) 
BMI (kg/m2) 
&OLHQWV¶%0,FKDQJHVat 3 months  
Baseline % Month 3 % 
25.0-27.9 
28.0-29.9 
30.0-34.9 
35.0-39.9 
 
- 
74 
278 
146 
59 
- 
13.3 
49.9 
26.2 
10.6 
19 
107 
250 
130 
51 
3.4 
19.2 
44.9 
23.3 
9.2 
 
Using LOCF analysis at three months, 57 (10.2%) clients decreased their BMI level 
from obese class I to overweight (25.0-29.9 kg/m2). Thirty-six (6.5%) clients 
decreased their BMI level from obese class II to obese class I, whilst 28 (5%) clients 
decreased their BMI level from overweight with one-comorbidity (28.0-29.9 kg/m2) 
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to 25.0-27.9 kg/m2. With 416 (74.7%) clients there was no change in BMI 
classification ± see Table 4.35. 
 
Table 4.35 Changes of BMI level at three months for LOCF (n = 557) 
BMI (kg/m2) 
1XPEHURIFOLHQWV¶%0,FKDQJHV 
Month 3 % 
No change 
Change from overweight with one-comorbidity to 25.0-27.9 
416  
28  
74.7 
5.0 
Decreased from 
  Obese class I to overweight 
  Obese class II to overweight 
  Obese class II to obese class I 
  Obese class III to obese class II 
 
57 
1 
36 
12 
 
10.2 
0.2 
6.5 
2.2 
Increased from 
  Obese class I to obese class II  
  Obese class II obese class III 
 
3 
2 
 
0.4 
0.3 
 
4.3.13.3 Characteristics of clients associated with weight reduction at three 
months  
There were no significant differences in the proportion of LOCF clients who were 
successful and maintainer or improver by gender (F2 = 1.94, p = 0.16) or age (F2 = 
2.52, p = 0.052) ± see Table 4.36.  
 
In addition, there were no significant differences in the proportion of LOCF clients 
who were successful and were maintainers or improvers in terms of medicines 
prescribed or purchased (F2 = 0.12, p = 0.73), previous weight loss attempts (F2 = 
1.00, p = 0.61), blood pressure (F2 = 5.07, p = 0.08), blood glucose (F2 = 0.03, p = 
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0.87), health risk (F2 = 2.07, p = 0.15), straight-line distance (F2 = 0.01, p = 0.93) and 
drive time (F2 = 0.75, p = 0.39), respectively ± see Table 4.36. 
 
Table 4.36 Baseline characteristics of LOCF clients associated with weight reduction at three 
months (n = 374)  
Characteristics 
Successful 
(n = 131) 
Maintainer/Improver 
 (n = 243) Total (%) p-
value* F2 
n %  n %  
Gender (n = 372) 
Female 
 
123 
 
94.6 
 
219 
 
90.5 
 
342 
(91.9) 
0.16 1.94 
Male 7 5.4 23 9.5 30 (8.1)   
Age, years       0. 052 2.52 
18-49 61 44.6 146 60.1 207 
(55.3) 
  
50 and older 70 53.4 97 39.9 167 
(44.7) 
  
Medicines prescribed or 
purchased OTC 
     0.73 0.12 
  No medicines 44 33.6 86 35.4 130 
(34.8) 
  
  At least one medicine 87 66.4 157 64.6 244 
(65.2) 
  
Previous weight loss 
attempts 
     0.61 1.00 
Both diet and exercise 90 68.7 161 66.3 251 
(67.1) 
  
Other attempts 33 25.2 71 29.2 104 
(27.8) 
  
No attempts 8 6.1 11 4.5 19 (5.1)   
*p-value < 0.05 considered statistically significant. 
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Table 4.36 (continued)        
Characteristics 
Successful 
(n = 131) 
Maintainer/Improver 
 (n = 243) Total (%) p-
value* F2 
n %  n %  
BP level recorded, mmHg (n 
= 365) 
     0.08 5.07 
d 129/84  50 39.7 101 42.3 151 
(41.4) 
  
130/85 - 139/89 
 
19 
57 
15.1 
45.2 
55 
83 
23 
34.7 
74 (20.3) 
140 
(38.4) 
  
BG level recorded, mmol/L 
(n = 358) 
     0.87 0.03 
< 5.6  69 57.5 139 58.4 208 
(58.1) 
  
 51 42.5 99 41.6 150 
(41.9) 
  
Health risks 
No comorbid risks 
 
118  
 
90.1 
 
206 
 
84.8 
 
324 
(86.6) 
0.15 2.07 
At least one comorbid risk 13 9.9 37 15.2 50 (13.4)   
Straight-line distance to 
pharmacy, km (n = 269)  
     0.93 0.01 
< 10  100 77.5 187 77.9 287 
(77.8) 
  
 29 22.5 53 22.1 82 (22.2)   
Drive time to pharmacy, 
minutes (n = 269) 
     0.39 0.75 
< 15 88 68.2 174 72.5 262 
(71.0) 
  
 41 31.8 66 61.7 107 
(29.0) 
  
*p-value < 0.05 considered statistically significant. 
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4.4 Discussion 
4.4.1 Main findings 
4.4.1.1 Characteristics of clients 
The objective of this study was to retrospectively evaluate weight loss resulting from 
the use of orlistat, in combination with diet and exercise, on obese clients who 
participated in a pharmacist-led weight management clinic for three months. This 
study evaluated the effectiveness of pharmacist-led weight management clinics, 
located in Boots stores in the East Midlands. Pharmacies were randomly selected 
using cluster sampling. A total of 557 customer records from 10 stores met the 
VWXG\¶VLQFOXVLRQFULWHULD 
 
The majority of clients in the programme were female, aged from 40 to 59 years. 
Mean weight and BMI at baseline were 92.8 kg and 34.5 kg/m2, respectively. Mean 
blood pressure and random blood glucose (RBG) levels were within normal ranges.  
 
Most clients found out about the BPWLP from an in-store leaflet ± other sources of 
information about the programme were recommendations from friends, information 
in magazines or newspapers, the Internet and television or radio. Many of the clients 
had made previous weight loss attempts, primarily through both diet and exercise.  
 
4.4.1.2 Changes in weight and BMI at three months 
For those remaining in the programme, there were statistically significant differences 
in weight and BMI at three months, compared with their baseline data. Two-thirds 
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(62%) of clients who attended the programme at three months achieved at least a 5% 
reduction in body weight from their baseline measurement. However, around half of 
clients did not change their BMI category.  
 
The sensitivity analysis showed one-third (33.6%) of clients who attended the 
programme at three months achieved at least a 5% reduction in body weight from 
their baselines, whereas around three quarters did not change their BMI category.  
 
4.4.1.3 Predictors of remaining in the programme to three months and of 
achieving at least 5% weight loss  
Women were more likely to have remained in the programme for at least three 
months than men (F2 = 1.11, p = 0.29). It was notable that those who remained in the 
programme for at least three months had higher diastolic blood pressure compared 
with those who left the programme earlier (z = -2.11, p < 0.03).  
 
The proportion of women who fell into the successful groups was not different from 
those in the maintainers or improvers groups. For a sensitivity analysis, this 
confirmed that there was statistically significant difference of weight loss between 
baseline and month 3. 
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4.4.2 Strengths and limitations 
4.4.2.1 Strengths 
The present study has provided valuable up-to-date evidence of a community 
pharmacy-based weight management intervention.  
 
This study has examined the feasibility and efficacy of a weight loss programme in a 
community pharmacy setting. The supply of orlistat via a PGD, in combination with 
diet and exercise, was offered in the pharmacist-led weight management clinics 
located in Boots pharmacies.  
 
The BPWLP was provided with and implemented by community pharmacists who 
were properly trained and were therefore able to offer competent professional advice 
WRWKHSURJUDPPH¶VFOLHQWV.  
 
4.4.2.2 Limitations 
There were several limitations to this study. Although it was based on a µbefore and 
after¶ GHVLJQ, which involved a high proportion of dropouts, analysis showed the 
BPWLP was effective in assisting clients to lose weight.  
 
There was a high dropout rate from this programme. The reasons why clients either 
did, or did not manage to achieve their weight loss targets were not recorded. 
However, there are many possible reasons behind success or failure, including level 
of motivation to achieve the desired weight loss, both positive and negative personal 
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circumstances and dissatisfaction with side-effects. Therefore, methods to improve 
client retention on weight loss programmes require further study.  
 
Another limitation is that clients who were included in the programme were content 
to pay for the service and were determined as suitable for the BPWLP. The findings 
therefore cannot be generalised to non-commercial weight loss programmes.  
 
$QRWKHU OLPLWDWLRQ LV WKDW WKLV VWXG\ KDV UHOLHG IRU LWV GDWD H[FOXVLYHO\ RQ FOLHQWV¶
records of their personal details and pharmacists records, which were taken as part of 
the recruitment to the programme and were not intended to be used for research 
purposes. The impact of any poorly recorded data is unknown; however, there was a 
low rate of missing data, with most records being well completed by the pharmacists. 
 
Other limitations relate to the potential bias from data based on the provision of 
services by a single commercial weight loss programme provider (Boots) and using 
data from only one geographical area ± the East Midlands. The current-retrospective 
study had no comparison group either with another commercial weight loss 
programme or with a minimal intervention or control group. Without such a 
comparator, this study was subject to confounding: that is any weight loss results 
cannot be validly attributed to the programme.  
 
As this study was a retrospective record review ideally data relating to all clients who 
had use the service between 2006 and 2011 (total population n = 20,195) at Boots 
pharmacies would have been included in the study. However the records where in the 
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form of paper records held at each store and only the number of clients using the 
service each month were reported centrally within Boots. Due to time and financial 
considerations it was not feasible to collect data for all clients who used the BPWLP. 
Therefore, a sample size calculation was needed to find an appropriate number of 
clients to include in the sample for research.  
 
If we had used the total population of clients (20,195) for the study and assuming the 
results would be the same, just over 6,000 clients (30%) would remain in the 
programme for at least three months and more than 3,600 clients (18%) would 
achieve a weight loss of at least 5% of the initial weight.  
 
Regarding objectives, long-term results (more than three months) and weight 
maintenance were not examined in this study. As regards clients remaining in the 
programme, there was a relatively low number of clients who did so, including some 
clients who remained in the programme at six months. The results of this study may 
not represent the obese male groups, due to low rates of participation by males in the 
weight management programme. Reasons for these low rates of participation are 
unknown.  
 
Lastly, the programme specification did not require follow-up measurements of 
blood pressure and blood glucose. Therefore, it is not possible to determine the 
impact of any weight loss on these biometric measures.  
 
Chapter 4 Retrospective evaluation 
 
229 
 
4.4.3 Comparison with the previous studies 
4.4.3.1 Characteristics of clients 
At the baseline visit, the majority of clients in the programme were female and aged 
40 to 59 years. This is similar to other studies where more women than men 
participated in weight management programmes.176, 177 Average ages reported in 
such studies range from 42 to 56 years. Findings in the current study are similar to 
other commercial weight loss programmes; Shuger et al.155 IRXQGSDUWLFLSDQWV¶PHDQ
weight and BMI at baseline were 92.8 kg and 34.5 kg/m2; these figures are lower 
than data cited in other previous studies.176, 178  
 
The majority of adverse effects from other studies where orlistat was supplied were 
oily discharge,179 diarrhoea,75 faecal incontinence and flatulence,178 respectively.169, 
180
 In the study of Kaya et al.75 gastrointestinal adverse effects (48%) were observed 
during a short follow-up period of 12 weeks. Fourteen percent of clients in the 
present study reported an episode of side-effects, mainly gastrointestinal events. 
Most adverse events were loose stools, diarrhoea, constipation, stomach ache or 
headache. This proportion of clients reporting adverse events is lower than that 
reported in other studies.176, 178 
 
The treatment guidelines for obesity recommend maintaining a healthy weight by 
EDODQFLQJ µFDORULHV LQ¶ DQG µFDORULHV RXW¶ DQd eating a healthy diet. If people are 
managing to lose weight with lifestyle modification by improving their diets and 
exercise behaviours, they should not be considered for pharmacological treatment.180 
Both healthy eating and regular exercise are recommended for the treatment of 
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overweight and obese adults with a BMI < 40 kg/m2.69 In this current study and other 
studies,181 most participants had made previous attempts to lose weight mostly 
through a combination of diet and exercise.  
 
Clients in this current study had a higher drop-out rate than the rates in previous 
published studies of CWLPs. In Finley et al.,182 32% of clients were no longer active 
in the programme at six weeks and 53% had dropped out by 12 weeks, compared 
with an approximately 70% dropout in the present study at three months. In the 
current study, half of the clients dropped out at one month which was higher than 
another study where 37% of participants had left by four weeks.183 One reason for 
leaving the programme was achieving the desired weight loss (n = 77, 25%). 
However, due to the programme specification those who did not achieve a 5% 
weight loss (n = 25, 8%) at three months were not able to continue. Published data on 
retention in a CWLP has found that reasons for leaving the programme included cost, 
scheduling conflicts/travel, tiring of the food, unrelated health issues, meeting weight 
loss goals and/or having stopped losing weight.182  
 
Clients who remained at three months and over more likely to be older compared 
with those who left the programme before three months (F2 = 1.06, p = 0.30). 
Similarly, a systematic review by Moroshko et al.184 demonstrated that younger 
patients had a higher attrition rate than older patients.  
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4.4.3.2 Changes in weight and BMI at three months 
This study evaluated effectiveness of the pharmacist-led weight management clinic 
on weight loss at Boots UK. According to the NICE recommendations, patients who 
failed to achieve the 12-week weight loss criteria should be discontinued from 
orlistat.15 Previous studies have shown that in patients with a weight loss of at least 
5% during the first 12 weeks of orlistat treatment, around half had lost significantly 
more weight after two years.170 In the present analysis, the initial target of weight 
loss at three months was a reduction in body weight of at least 5% of the baseline 
figure. Approximately two-thirds of clients remaining in the programme (n = 103, 
62%) achieved meaningful weight loss at three months. Meaningful weight loss was 
defined as weight loss that met the target of at least 5% of the initial weight. 
Nevertheless, at three months, Kaya et al.75 found that mean weight loss was 10% of 
the initial body weight, whilst the present study found percent weight loss was 6.4% 
of the FOLHQWV¶ initial body weight. It would seem that clients in both studies were 
using different combinations of orlistat supply, diet, exercise and advice.  
 
Heshka et al.150 reported BMI decreased more in a structured commercial weight loss 
programme than in a self-help group at one year. However, there is evidence75 about 
short-term (12 weeks) weight changes in obese patients, where decreases in BMI 
(mean -3.64 r 0.97 kg/m2) were recorded in a randomised trial. In comparison, 
FOLHQWV¶median BMI in the present study was reduced by 1.8 kg/m2 at three months 
(p < 0.001).  
 
Chapter 4 Retrospective evaluation 
 
232 
 
4.4.3.3 Factors associated with length of time in the programme  
Gender 
Women were more likely to participate in the BPWLP and also to be successful in 
losing body weight baseline at three months compared with men (F2 = 4.34, p = 0.04) 
who achieved at least 5% weight loss at three months. Likewise, the previous studies 
showed overall, both men and women achieved significant weight loss.168, 170  
 
Achieving at least 5% weight loss 
Clients with no comorbid risks were more likely to achieve at least 5% weight loss (z 
= -2.42, p = 0.01). Likewise, Finer et al.176 claimed that obese patients using orlistat, 
who achieve and maintain 5-10% weight loss, have decrease in blood pressure and 
blood glucose levels. Although blood pressure and blood glucose in this study were 
PHDVXUHG E\ SKDUPDFLVWV GXULQJ WKH FOLHQW¶V LQLWLDO YLVLW WR WKH ZHLJKW ORVV FOLQLF
pharmacists should also consider measuring blood pressure and blood glucose prior 
to clients leaving the programme, in order to compare pre- and post-levels for blood 
pressure and blood glucose. This would be useful to measure blood pressure and 
blood glucose. This information may be extra motivation for further weight loss if 
clients notice the beneficial effects on blood pressure and blood glucose.  
 
4.5 Implications 
This study would suggest that CWLP can be a successful programme for overweight 
or obese people who wish to lose weight. This programme can be provided in a 
pharmacy because this setting is easily accessed by clients. Not only can pharmacists 
take a more active high-profile role in weight loss management but they can also 
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inform clients about the health benefits of CWLPs.  
 
A pharmacy-led weight management clinic with PGD supply should provide 
information on orlistat use, diet and exercise and weekly support to clients by 
following NICE guidance.15 This may need to be tested in a NHS environment to 
determine whether or not this approach would positively target weight loss and could 
help to reduce the high dropout rate from such weight loss programmes. 
 
Orlistat is currently available as a pharmacy medicine and is therefore easier to 
access than prescription only alternatives. To motivate people to pay for such a 
programme, providing full and detailed information by pharmacists is essential. 
Counselling and general advice from pharmacists can maximise clients¶ participating 
in the programme and understanding of how to successfully lose weight.  
 
4.6 Recommendations for further study 
The first recommendation is a RCT and economic evaluation of CWLPs. Secondly, 
research into reducing FOLHQWV¶dropout rates is recommended. Lastly, a comparison 
study is recommended for a prospective evaluation of clients who are supplied 
orlistat as a pharmacy medicine compared to those who are supplied orlistat as a part 
of the BPWLP. This would help to provide more data of CWLPs for further study. 
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4.7 Summary 
The BPWLP involves the supply of orlistat 120 mg used in combination with diet 
and exercise. The evaluation showed that a community pharmacist-led weight 
management clinic was able to achieve weight loss at three months. Additionally, 
62% of clients who remained in the programme lost a clinically meaningful amount 
of weight at three months; at least 5% of their baseline body weight.  
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Chapter 5 
$VXUYH\HYDOXDWLQJFOLHQWV¶YLHZRI%RRWV3KDUPDF\
Weight Loss Programme  
 
This chapter describes the process of developing and validating a questionnaire used 
to investigate clients¶ YLHZ RI WKH %RRWV 3KDUPDF\ :HLJKW /RVs Programme 
(BPWLP). The questionnaire was developed WRGHWHUPLQHFOLHQWV¶H[SHULHQFHVRIWKH
BPWLP. It was designed to complement the evaluation of the BPWLP as described 
in Chapter 3 and Chapter 4. However, the questionnaire was not administered due to 
the low number of on-going clients in the programme.  
 
5.1 Aim and objectives 
The aim of this study was to develop a questionnaire for clients who participated in a 
pharmacist-led weight management clinic.  
 
The objectives of the study were to:  
x Develop the questionnaire  
x Test the validity of the questionnaire 
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5.2 Methods 
The questionnaire was developed with reference to the literature and discussions with 
supervisors and Boots staff, both from Head Office and the pharmacists providing 
the service ± see Figure 5.1. It had been intended to administer the questionnaire to 
clients attending the BPWLP; however the launch of an over-the-counter version of 
orlistat (20 April 2009)185 meant that the numbers of clients attending the patient 
group direction (PGD) service declined to the extent that distributing the 
questionnaire was not viable.  
 
 
 
Figure 5.1 Process of developing and testing questionnaire 
 
Review of relevant literature and discussions 
with research team and Boots staff
Final draft of questionnaire ready for 
piloting with clients: Post-questionnaire
Tested the questionnaire with 
subject matter experts
A rough questionnaire draft: Pre-questionnaire
Developed and designed the questionnaire
Check questionnaire form
Initial draft of the questionnaire
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5.2.1 Literature review  
The literature was searched for studies about evaluating health services which 
focused on weight management services, client views of weight management 
services,186 measuring clientV¶ views and factors associated with their experiences. 
Such information guided the development of the questionnaire. 
 
5.2.2 Questionnaire design 
5.2.2.1 Questionnaire content  
The pilot customer questionnaire (CQ) for the BPWLP consisted of five sections 
briefly described below. The full questionnaire is in Appendix 15. 
 
Section 1: Experiences of the Boots Pharmacy Weight Loss Programme  
Eight questions related to FOLHQWV¶ personal views about the programme and amount 
of time spent in the programme, their weight at entry to the programme and target 
weight loss at three months.  
 
Section 2: Experiences of medicine  
There were 11 questions about the medicine (orlistat 120 mg). The questions 
HYDOXDWHG WKH FOLHQWV¶ XQGHUVWDQGLQJ RI WKH medicine including how to take it, side 
effects experienced and other concerns.  
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Section 3: Experiences of weight loss service 
Eighteen closed-questions included three questions about the facilities related to the 
service, and fifteen questions were about services received.  
 
Section 4: Experiences of other weight loss programmes and activities187  
In this section, clients are asked four closed-questions and give examples of the 
HDVLHVW DQG PRVW VXFFHVVIXO PHWKRGV FOLHQWV¶ KDYH XVHG LQ SUHYLRXV ZHLJKW ORVV
attempts, diets and physical activities that respondents have tried. 
 
Section 5: Demographics 
This section involves nine questions asking about the following demographic 
characteristics.  
x Gender: male/female188, 189 
x Age group: 18-29, 30-39, 40-49, 50-59, 60-69, 70 years and older190 
x Ethnic origin34, 191 
x Legal marital status32-34, 192, 193 
x Education32, 33 
x Current work status189 
x Family annual income32, 33 
x Height and current weight  
x Health status190, 194, 195 
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Questions were mainly closed-questions with categorical answers employing a 5-
point Likert scale (range 5-strongly agree to 1-strongly disagree) as well as an option 
of not applicable (NA). 
 
5.2.2.2 Testing the questionnaire 
The questionnaire171, 196 was tested for face validity and the sequence of questions:  
x Face validity is the subjective assessment of the relevance of the 
questionnaire, including determining whether the questionnaire appeared to 
be relevant, reasonable, unambiguous, clear, well sequenced and well laid 
out. The questionnaire also assessed whether the content of the questionnaire 
comprehensively measures the scope of the characteristics of the weight loss 
service, VXFK DV WKH UROH RI WKH SKDUPDFLVW XVLQJ WKH PHGLFLQH DQG FOLHQWV¶
experiences.171 
x The sequence of questions was also assessed to check there was a logical path 
through the questions to make the questionnaire easier for clients to complete 
and to easily feel the same format questions appeared together.197 
 
The reason for testing the questionnaire196 was to improve the quality of data 
collected and minimise non-sampling errors. Items were developed following a 
review of the literature and pilot study findings (Chapter 3) in order to ensure face 
validity. The face validity and sequence of questions was further discussed with two 
supervisors (a pharmacist and a general practitioner) and Boots staff, namely 
pharmacists who were providing the service in-store and head office staff.  
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Testing for face validity, also known as expert review, is not only a formal and 
systematic scrutiny of a questionnaire and very economical but it also identifies 
potential problems of question areas, layout and question wording.198 Expert 
reviewers were asked to comment on the questionnaire design in terms of relevance, 
reason, clarity, layout, sequence of questions and content comprehensiveness by 
using a Validity Evaluation form ± see Appendix 16.  
 
Seventeen pharmacists were asked to comment on the questionnaires (five who 
worked for Boots and 12 who did not). Comments on the questionnaire were 
reviewed and the questionnaire was then revised.  
 
5.3 Results 
A total of 11 out of 17 experts commented on the questionnaire; three pharmacists 
who worked for Boots and eight who did not. Of those eight who were not employed 
by Boots, four worked in academia and four were community pharmacists. All 
pharmacists reviewed all questions to judge whether content was comprehensible and 
visual layout was good. They also completed a short questionnaire about their overall 
views of the questionnaire. About 10 of expert reviewers reported that the content 
was reasonable, and each of nine reviewers agreed that the questionnaire was 
relevant, had a good sequence of questions and was comprehensive ± see Table 5.1.  
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Table 5.1 Experts view of the questionnaire (n = 11) 
Comprehension from Weight Loss Programme Questionnaire Yes  No  Not sure  
Questions appear to be:    
1. Relevant 9  1  1  
2. Reasonable 10  1  - 
3. Unambiguous 5  - 6  
4. Clear 5  1 5  
5. Good layout 8  - 3  
6. Sequence of questions 9  - 2  
7. Content comprehensive 9  1  1  
Total 55  4  18  
 
Details of comments received from the pharmacists were summarised in Table 5.2. 
Responses to Section 1 and Section 3 suggested the questions were mostly 
considered relevant and clear; however, some questions needed to be reworded. 
Similarly, Section 4 was reworded to contain non-technical words to ensure 
respondents would understand. In contrast, Section 2 was restructured and redundant 
or repeated questions were removed. Overall the feedback comments suggested the 
sections were mostly relevant, had a logical good sequence and good layout. 
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Table 5.2 3KDUPDFLVWV¶FRPPHQWVRQWKHTXHVWLRQQDLUH 
Section 3KDUPDFLVWV¶FRPPHQWVn = 11) 
Section 1: Experiences of the Boots 
Pharmacy Weight Loss Programme 
(BPWLP) and Section 3: Experiences of 
other weight loss programmes and activities 
Rewrite or reword some questions to make them 
clearer 
Overall, both sections were relevant and clear. 
Section 2: Experiences of the medicine 
(orlistat) and services received 
This section is quite long, unstructured and contained 
repeated questions. It is needed to be split into another 
section.  
Section 4: About you Replace some technical words with normal words that 
general or lay people can easily understand. 
Others Give an example how to fill out weight and height so 
respondents recognised the format. 
Examples of comments received: pretty good, quite 
comprehensive, fine, very clear with appropriateness, 
easy-to-answer questions, reasonable, unambiguous, in 
a sequence of questions and a good layout. 
 
Following the pharmacists¶ assessment of the questionnaire a number of changes 
were made. Five questions were deleted, Section 2 was re-organised and the 
questions relating to facilities were moved to a separate section. A number of other 
changes were also made to improve the clarity of the questionnaire ± see Table 5.3. 
The initial questionnaire and finalised questionnaire are shown in Appendix 15. 
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Table 5.3 Differences in the questionnaires before and after expert review  
The previous questionnaire The reviewed questionnaire 
Section 1: There were 10 questions.  Section 1: There were 8 questions, Q*7 and Q10 were 
deleted. 
Section 2: There were two parts in section 2: 
part 1 with 12 statements and part 2 with 19 
statements.  
 
  
Section 2: 
- Comments were quite long, unstructured and 
repeated questions so that it has been separated up into 
another section  
- One statement was deleted, and the sequence of 
statements was arranged and now there are 11 
statements. 
- Deleted Q3 and added a space for clients to comment 
about the advantages of this service 
 Section 3: 
- Divided into 2 sub-headings that are: 
1. About facilities, 3 questions and  
2. About serviced received, 13 questions 
Section 3: There were 5 questions. Section 4: Deleted Q5, arranged the layout and added a 
question about programme recommendation (Q4) 
Section 4: There were 11 questions. Section 5:  
- Deleted Q10 so there are 10 questions 
- Arranged the band of household income and words in 
Q4, Q6 and Q10 
Other changes: Number had been written in 
box of weight and height only 
 
Other changes:  
- Questionnaire booklet: Had cover page with 
instruction, date of sending out and names of research 
team 
- Given an example on how to write weight and height 
in the box given so that respondents can follow easily 
*Q = Question 
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5.4 Discussion 
5.4.1 Main findings 
The self-complete questionnaire was developed by reviewing the literature concerned 
ZLWK HYDOXDWLQJ KHDOWK VHUYLFHV LQ WKH 8. DQG FOLHQWV¶ YLHZV WRZDUGV ZHLJKW
management services. This was followed by discussions within the research team 
and with Boots staff, both in store and at head office between May and December 
2010. More than 70% of pharmacists reported that the questionnaire was relevant, 
rational, sequential, comprehensive and had a good layout.  
 
The questionnaire was planned to be distributed to clients who were participating in 
the Boots Pharmacy Weight Loss Programme as a pilot study. However, the total 
number of clients participating in the BPWLP decreased from 2,847 customers per 
year in March 2010199 to 427 clients per year in March 2011.200  
 
The pilot questionnaire was approved by Boots and the agreement for the study was 
in place in April 2011. Using the annual BPWLP reports, the total number of clients 
across the country who attended the programme between March 2008 and March 
2011 was 20,195.199-201 The number of clients who started the programme during 
each financial year and remaining in the programme by March were 64%, 28% and 
4% in 2009,201 2010199 and 2011,200 respectively. The total number of clients 
remaining in the programme by March 2011 was 427 and of those 65 had a planned 
follow-up after March 2011 across 13 stores.200 Therefore, it was decided that the 
plan to request that pharmacist handed the questionnaire to clients attending the 
programme was not viable as there were so few clients across the stores. The 
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questionnaire could have been piloted with these 65 clients; however given the 
reduced attendance at the programme it was felt that a wider survey that was 
representative of clients attending the programme would not be possible. In order to 
carry out the pilot study, many of potential participants for the wider survey would 
need to be used limiting the size of the main survey. 
 
Other methods of distributing the questionnaire, such as a retrospective survey, were 
considered but it was felt that it would not be possible to achieve a reasonable sample 
size for analysis. A retrospective postal survey to previous clients was not possible 
due to lack of access to clients contact details ± when they attended the service, they 
did not sign up to further contact from Boots or for research. Additionally, a 
retrospective survey would mean that potentially several months would have passed 
since the clients attended the programme and therefore such a survey would be likely 
to have problems with recall bias. Recall bias occurs where respondents remember 
only partial details of an experience ± the longer clients have been out of the 
programme, the greater likelihood they would not recall their experiences of the 
programme correctly.202 The main reason why clients were no longer attending the 
BPWLP is likely to have been the launch of OTC orlistat 60 mg in 2009.185  
 
Another alternative to replace the questionnaire survey was interviewing current 
clients; however there were several disadvantages of such interviews, including:  
x 7KH SRWHQWLDO ODQJXDJH EDUULHU EHFDXVH (QJOLVK LV QRW WKH UHVHDUFKHU¶V ILUVW
language; and hence listening and responding appropriately would be harder 
than for a native English speaker. Also the researcher might miss some of the 
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more subtle parts of the conversation which would affect both the interviews 
and interpretations of the transcribed interviews. 
x High travelling expenses as the 65 clients were located across England, 
Wales and Scotland. 
x Recruitment to the interviews would have relied on store pharmacists asking 
clients to participate. This would be an additional task to add in to 
consultation and therefore recruitment rates were likely to be low to 
pharmacists forgetting to ask for permission as this would not be a priority for 
them in the consultation.  
x Clients attended the programme at one or three monthly intervals and 
therefore recruitment would need to take place over several months.  
 
5.4.2 Strengths and limitations 
5.4.1.1 Strengths 
7KHFXVWRPHUTXHVWLRQQDLUHSURYLGHGDJHQHUDOPHDVXUHRIFOLHQWV¶YLHZVThe main 
strength of this questionnaire lies in that it was developed with reference to the 
literature and discussions with supervisors and Boots staff, both from Head Office 
and pharmacists providing the service. Moreover, testing the questionnaire used face 
validity judgements from Boots pharmacists and non-Boots pharmacists. Testing for 
face validity was assessed the relevant questionnaire in terms of the related content, 
clarity and format. Additionally, the sequence of questions was checked in order to 
establish whether or not it was easier for clients to complete and to feel more at ease 
with the same format questions. 
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5.4.1.2 Limitations 
The customer questionnaire was limited to, and only intended to be used with, clients 
of the BPWLP, and only three Boots pharmacists commented on the questionnaire.  
 
5.5 Summary  
$TXHVWLRQQDLUHZDVGHYHORSHGDQG WHVWHG WRHYDOXDWHFOLHQWV¶YLHZDERXW%3:/3
The questionnaire was tested for face validity and sequence of questions by experts. 
The testing resulted in a number of amendments to the questionnaire. Regrettably, 
this survey was not carried out due to insufficient numbers of clients participating in 
the programme, rendering the sample size insufficient. However, it is anticipated that 
the questionnaire would be useful for use with clients on any other weight loss 
programmes provided by Boots.  
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Chapter 6 
Discussion 
 
The thesis describes two studies: 1) a systematic review of the literature relating to 
CWLPs and 2) an evaluation of a commercial weight loss programme. This chapter 
summarises the findings from each study about the effectiveness of CWLPs on 
weight loss and discusses the practical implications in terms of health care 
professional support, policy and strengths and limitations of the study. Finally there 
are recommendations for future study. 
 
6.1 Key findings  
There is little evidence from the UK about the effectiveness of CWLPs; in particular 
whether this type of programme could help overweight and obese people to lose 
weight. Characteristics of overweight and obese people who participated in CWLPs 
were mainly women and aged between 40 and 51 years with a mean BMI between 30 
kg/m2 and 34.5 kg/m2 at baseline (obesity class I). 
 
The systematic review found three important elements of effective CWLPs: calorie 
restriction, exercise and support. For a 12-week treatment,119, 147 participants in the 
CWLPs achieved a mean weight loss within the range of 3.3 kg (3.6%)17 to 12.7 kg 
(13.7%),146 whilst those in the BPWLP lost 5.8 kg (6.4%). It was found that a 
meaningful weight loss, which is weight loss of at least 5% of the initial weight, 
could only be achieved with restriction in total calorie level intake per day and daily 
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exercise. Meanwhile, support in weight loss interventions in the review were mainly 
led by health care professionals, such as dieticians, physicians or pharmacists.  
 
The BPWLP involved a private PGD to supply orlistat, together with diet and 
exercise advice. This programme found 62% of clients who remained in the 
programme at three months achieved at least a 5% reduction from their initial weight 
± this meets the NICE guidance on management of overweight and obese adults.15  
 
The findings are further discussed below in four topic areas: calorie restriction, 
exercise, support and medicine. 
 
6.1.1 Calorie restriction 
Clients who were put on a very low-calorie diet (<800 kcal/day) can lose 9.5% and 
12.3% of the initial body weight up to and for more than three months 
respectively.119 This type of diet has a high ability to initiate rapid weight loss so that 
it is appropriate IRUREHVHDGXOWVZLWK%0,kg/m2. This is perhaps the preferred 
methods, if the clients can tolerate this. However, when this programme is prescribed 
for obese adults with comorbid health risks, they should be placed under medical 
supervision. This is because a very low-calorie diet can create a negative water 
balance in participants. Therefore, it is necessary for the health care providers to 
closely administer this diet for a reasonable length of time, which is approximately 
12 to 16 weeks.114   
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Another type of calorie restriction is to put clients on a low-calorie diet (800-1,200 
kcal/day). The systematic review shows that a combination of meal replacement 
(HMR), calorie restriction of 1,200 kcal/day, exercise up to 2,000 kcal/week and 
weekly support by a health care provider can produce a weight loss of 13.7%146 and 
13.9%144 of the baseline body weight for up to or more than three months, 
respectively.  
 
Considering calorie restriction with energy intake 1,200 kcal/day, the two effective 
weight loss programmes in the review were JC154 (8.9%) and VTrim148 (8.9%). 
Participants in the programmes had restricted diets, with JC providing their own pre-
packaged meals and in VTrim by reducing energy intake by daily exercise of up to 
1,000 kcal/day. However, the BPWLP did not specify calorie intake but simply 
advised clients to adopt a low-fat diet as a part of their everyday habit.99  
 
6.1.2 Exercise 
The systematic review suggests that effective CWLPs should specify a target amount 
of calories to be burned, such as through daily exercise, of up to 1,000 kcal/day.148 
However, older clients may require different types of exercise due to limitations 
imposed by their age and health conditions.147 For instance, younger overweight or 
obese adults can exercise up to 1,000 kcal per day whilst older overweight or obese 
adults can adhere to a daily exercise routine by walking 30-60 minutes only.147 
 
  
Chapter 6 Discussion 
 
251 
 
In the BPWLP, clients were advised to take exercise as a part of their routine in their 
daily life.99 However, this programme does not require exercise to be a chore. Clients 
can find activities suitable to them to burn their calories. Also, this can be done in 
any location convenient to clients. 
 
6.1.3 Support 
Support is another element in weight loss interventions, which is mainly provided by 
health care professionals17, 113, 117, 119, 126, 144-147, 153-155, 157 (such as dieticians or 
physicians) and included counselling, giving advice, encouraging and motivating 
overweight or obese clients to lose weight. For example, overweight or obese adults 
who have a very low-calorie diet (<600 kcal/day) need health care providers 
advice119 because this diet can create a negative water balance in clients so that this 
diet needs to be closely administer for a reasonable length of time (12-16 weeks).114 
 
Counselling for BPWLP clients is provided by pharmacists during the monthly visit, 
which includes comprehensive support and advice on healthy eating and physical 
activity.  
 
6.1.4 Medicine 
Pharmacotherapy is the second-line treatment for obesity.16 The study presented in 
this thesis conducted an assessment of the effectiveness of a pharmacist-led weight 
management clinic in the UK, which focused on the use of orlistat 120 mg, in 
combination with advice on diet and exercise. The key findings show that mean 
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weight loss through a BPWLP was 6.4% of the initial body weight, whilst mean 
weight loss noted in the systematic review ranged from 3.6% to 13.7% of the initial 
body weight for a 12-week treatment. The mean weight loss in the BPWLP was the 
same range that achieved by participants in another orlistat study, which reported a 
weight loss between 6-10%.75  
 
6.2 General discussion 
There are two categories of weight loss intervention reviewed in this study: primary 
and secondary. Primary weight loss intervention consists of three potential elements: 
calorie restrictive diet, exercise and behavioural or psychological support by health 
care professionals. However, if clients failed to achieve their weight loss goal of at 
least 5% of their initial weight, a secondary intervention could be used; an anti-
obesity medicine.  
 
In comparing this systematic review of CWLPs, the previous review of pharmacy-
based weight loss programmes18 and the BPWLP, two key areas are discussed ± 
amount of weight lost and dropout rates. In the BPWLP, mean weight loss was -5.8 
kg whilst mean weight change in the systematic review of CWLPs showed a range 
from -3.3 to -12.7 kg at 12 weeks. A study that focused on retention in a weight loss 
programme182 reported a weight change of -7.5 kg (8.3%) at 13 weeks, which was in 
the range of the current review but greater than the BPWLP. Gordon et al.18 in their 
systematic review of community pharmacy-based weight management programmes 
included only NCWLPs and found a mean weight change from -4.9 to -5.6 kg at 
either three or six months. A more recent RCT in the UK included a non-commercial 
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pharmacy arm where they found a mean weight loss of -2.1 kg at 12 weeks.17 
Therefore, mean weight loss for clients who attended the BPWLP was similar to that 
found in the literature for weight loss in short-term.  
 
The systematic review showed that successful weight loss interventions for short- 
and long-term treatment had dropout rates ranging from 0% to 54% and 11% to 49%, 
respectively. The dropout rate in the BPWLP (70%) at 12 weeks was higher than the 
dropout rate in the current review and the study by Finley et al.182 (58%) at 13 weeks.  
Gordon and colleagues study18 of non-commercial pharmacy-based programmes 
found dropout rates between 31% and 52% over periods of 6-24 months. It is perhaps 
surprising that when clients spend their own money on a weight loss programme that 
they do not remain in the programme longer. Possible reasons for the higher dropout 
rate may be that each visit in a CWLP costs money, that when clients achieve their 
desire weight loss, they do not feel they need to return for another visit or they are 
dissatisfied with the programme and its effect on their weight loss and therefore do 
not return.  
 
There are several reasons for attrition, deduced from the findings, including difficulty 
of keeping to a very low-calorie daily diet, meeting weight loss goals or failure to 
lose weight. Nevertheless, there are many possible reasons behind success or failure, 
including levels of motivation to achieve the desired weight loss, both positive and 
negative personal circumstances and dissatisfaction with side-effects. To reduce the 
dropout rate, support from health care providers should be encouraging, aimed at 
motivating clients to stay in the programmes longer, particularly is related to the 
accompanying positive health benefits.  
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The number of adverse events reported in the CWLPs and BPWLP was lower than in 
other studies.176, 178 Only Anderson and colleagues144 study reported adverse events 
in terms of dietary problems and constipation. For the BPWLP, this programme 
found adverse events were mainly related to gastrointestinal issues. The most 
common adverse events were loose stools, diarrhoea, constipation, stomach ache or 
headache. In CWLPs, therefore, the fewer number of adverse events reported, the 
more likely it is that people will pay for attending the programme. 
 
6.3 Practical implications 
6.3.1 Weight loss programmes supported by health care 
professionals 
The systematic review shows that CWLPs can be effective in achieving weight loss. 
Health care professionals need to be aware that commercial programmes are 
effective and which of these are offered in the local area to better advise their clients 
about losing weight and the help available to support overweight and obese people. 
 
Health care professionals can help overweight or obese people to lose weight by 
counselling their clients. They support their clients in terms of diet and exercise 
advice. This study indicated that weight loss interventions which contain health care 
SURIHVVLRQDOV¶VXSSRUWDUHPRUHOLNHO\WRDFKLHYHFOLQLFDOO\VLJQLILFDQWZHLJKWORVVHV
However, Jolly and colleagues17 study showed that CWLPs arms such as WW 
(4.7%), SW (3.8%) and RC (4.5%) had greater weight loss than NCWLPs arms of 
GP (1.5%) and pharmacy (2.3%). Therefore, it is reasonable to suggest that relevant 
health care professionals in the CWLPs, such as physicians/general practitioners 
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(GPs) and pharmacists, can enhance weight loss in overweight or obese people who 
attend the programme. 
 
A number of CWLPs have been shown to be effective in terms of weight lost.117, 119, 
124, 126, 144, 146-148, 151-155
 However, it is not known how these programmes compared 
with each other in term of effectiveness as it is not possible to be sure that the control 
arms are sufficiently similar. A range of weight loss strategies will allow clients to 
select a programme which they feel is possible for them to adhere to over several 
months or years.  
 
The systematic review found that effective CWLPs included a number of elements ± 
daily calorie restriction, daily exercise and support (in the reviews this was mainly 
led by physicians or GPs). These elements match the first line strategy for obesity 
treatment in the NICE guideline, as did the target of 5% weight loss over three 
months being seen as a suitable amount which would benefit health.15 Second line 
obesity treatment recommended by NICE combines the first line treatment with anti-
obesity medicine, as in the BPWLP. 
 
6.3.1.1 General practitioners  
In this study, health care providers who are part of the support structure in the CWLP 
are sometimes physicians or GPs, demonstrating, they can play a role in obesity 
treatment by doing some or all of the following:93 
x Be aware of and active in identifying patients:69 
o Who are visibly overweight or obese. 
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o With health risks or conditions affecting weight loss, such as 
cardiovascular disease, diabetes, hypertension or joint disorder. 
o Where patients want to lose weight. 
o Where previous weight loss attempts have not been successful. 
x Talk with patients about health problems; inform them about health benefits 
and other reasons for losing weight. For example, physicians in one study11 
administered diet-specific advice to each intervention. Physicians revealed 
the important information, provided the rationale and positively reinforced 
dietary changes to maximise adherence to the weight loss programme.  
x Increase motivation by clarifying with patients:69 
o What their realistic and achievable weight loss goals are. 
o How to modify their lifestyle to integrate regular physical activity for 
enhancing cardiovascular health and individual weight status. For 
example, participants in meal replacement programmes144, 146 were 
encouraged to record the number of meal replacements and the 
calories burned in physical activity. 
o The likely health benefits resulting from their weight loss.  
o Advise on the comparable cost of CWLPs. 
x Advise by providing: 
o Relevant counselling about weight loss and its outcomes alongside 
information and resources for patients to access.203 
o Lifestyle prescriptions such as portion control consultation. For 
example, dieticians can help patients to devise suitable menus for 
specific diets such as a low-carbohydrate/high-protein diet (LCHP)119 
as an alternative to doctors prescribing medication. 
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o Self help materials. For example, diet assignments, exercise 
strategies114 and information about barriers and facilitators of weight 
change. Additionally, details of factors associated with greater or 
lesser weight change and components of interventions associated with 
the effective health-related behaviour change161 and also the difficulty 
of weight loss.69 
x Develop appropriate weighWORVVLQWHUYHQWLRQVEDVHGRQSDWLHQWV¶ZLOOLQJQHVV
to change, such as: 
o Asking patients to keep a food and exercise diary, and reviewing this 
when they attend the programme and tailoring their advice based on 
the diary. 
o Learning about the principles of obesity management including 
behavioural change techniques and promotion of increase exercise 
levels.204  
x Ensure that patients understand the benefits of taking medications to control 
health conditions. For instance, clients in the BPWLP who were taking 
medicines prescribed by their doctors should record all generic names of 
medicines taken. The reason is that all medicines taken should not affect 
weight gain. 
x Prescribing and referral: 
o Prescribing pharmacotherapy where appropriate. 
o Referring to dieticians, exercise physiologists or psychologists if 
needed. GPs support in the weight loss programmes may not 
necessarily enhance patients¶ attendance to the CWLPs. This evidence 
was found in the GP programme17 with the high dropout rate (54%). 
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+RZHYHU*3VVKRXOGIRFXVSULPDULO\RQFOLHQWV¶SV\FKRORJLFDOQHHGV, 
because obesity is also a social issue. For instance, physicians should 
work with dieticians11, 17, 126, 145, 150-152, 156 as a team to encourage 
SDUWLFLSDQWV WR FKDQJH FOLHQWV¶ EHKDYLRXU LQ D SRVLWLYH GLUHFWLRQ E\
giving advice and attention to such issues as healthy eating, increasing 
daily activity, promoting healthy lifestyle and providing written 
educational materials if the clients are on the CWLPs.  
 
Therefore, GPs¶ involvement may build confidence and trust with the clients, which 
may improve their weight change over time. 
 
6.3.1.2 Pharmacists 
This study reported the successful implementation of a weight management clinic led 
by community pharmacists. Pharmacists in the BPWLP provided orlistat, guidelines 
for calorie restriction and exercise, and monthly counselling. Therefore, these 
multiple roles may be recommended for future services offered by community 
pharmacists. However, this role can be expanded in order to maximise the 
effectiveness of BPWLP and minimise the attrition rate. 
 
3KDUPDFLVWVLQWKH%3:/3FDQHQKDQFHFOLHQWV¶UHGXFWLRQLQZHLJKWDQG reduce the 
dropout rate by:  
x Providing safe supply of orlistat:  
o Warning about adverse effects and drug interactions.  
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o Identifying and monitoring appropriate individuals to use weight-loss 
medicines to maximise safety and efficacy. 
x 5HFRUGLQJFOLHQWV¶FRPPHQWVDQGDGYHUVHHYHQWVLQWKHconsultation notes at 
monthly and three monthly visits.  
x Appropriate counselling in terms of WKH FOLHQW¶V healthy eating, increasing 
daily exercise and medicines use.  
x At follow-up visits where clients have co-morbid health risks from their 
chronic disease, pharmacists should review orlistat treatment in the light of 
any changes in their medications (prescribed or purchased OTC) and general 
health.168  
x The procedures for BPWLP did not require recording of co-morbid 
conditions in clients whose BMI  30 kg/m2. ,ISKDUPDFLVWV¶DGYLFHLVWREH
tailored to individual clients needs, understanding the complete picture of 
clients health is needed. However, pharmacists should only have records on 
what is needed to provide their services and some may feel weight 
PDQDJHPHQW VHUYLFH FDQ EH SURYLGHG ZLWKRXW SKDUPDFLVWV¶ NQRZOHGJH RI
FOLHQWV¶FR-morbid conditions.  
x Providing information for clients in terms of making referrals if necessary, 
for example having high blood pressure or excessive blood glucose levels. 
Clients VKRXOGFRQVXOWZLWKWKHLUGRFWRUVDQGGLVSOD\GRFWRU¶VFRQILUPDWLRQWR
pharmacists as to whether or not clients are able to continue or discontinue 
the programme.  
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x Communicating with clients about the health advantages of losing weight and 
collaborating with other health care professionals.  
x 0RWLYDWLQJFOLHQWV¶changes for their lifestyle to improve and maintain weight 
loss. 
x Providing advice and pro-active support by telephone contact to improve the 
success of weight loss and maintenance efforts. 
x 5HPLQGLQJFOLHQWV¶ZHLJKWWDUJHWV± at least 5% weight loss at 12 weeks. 
 
Although the BPWLP was withdrawn in September 2012, this programme supported 
overweight or obese clients to lose weight by providing a combination of orlistat 120 
mg supply with advice and support about diet and physical activity. However, there 
is still insufficient evidence in terms of weight management interventions in the 
community pharmacy setting, to offer unequivocal support to the CWLPs. Despite 
this being a setting which could be an ideal venue for weight loss programmes due to 
the convenience of access and long opening hours. This could be an ideal public 
health service for pharmacies to provide as part of their contribution to tackling 
health problems in their local authority area. 
 
Pharmacists could improve weight loss and reduce the dropout rates in CWLPs such 
as MR or conventional reduce-calorie diet (RCD)205 programme by:206, 207  
x Learning all the necessary skills to facilitate weight loss interventions, such 
as taking the relevant measurements (weight, BMI and waist circumference) 
and motivational interviewing. 
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x Understanding the wider aspectVRIFOLHQWV¶ZHight loss goals:  
o How to approach and support clients to improve their weight loss; 
providing information on diet, exercise, lifestyle and current habits; 
advising them in terms of energy intake and energy expenditure; and 
facilitating diet programmes, for example, VLCD, LCD or meal 
replacement. 
o Learning to be comfortable in the conversations with overweight and 
obese people. 
o Understanding and being empathetic about FOLHQWV¶ difficulties with 
losing weight. 
o Providing weight loss services in their community pharmacy. 
x Being clear about their role as health care professionals rather than retailers 
or shopkeepers. Orlistat 60 mg (Alli®) is available for OTC supply in the 
pharmacy, but must be supervised by a registered pharmacist.85, 110 This OTC 
weight loss product is effective when used in combination with a reduced-
calorie, low-fat diet and exercise programme. However like other medicines, 
anti-obesity medicines are not just a product and should only be sold after a 
consultation with the clients and with appropriate advice.  
x Collaborating with other health care professionals in terms of:  
o Integrating into the primary care team and developing good 
relationships. 
o Coordinating with multi-disciplinary teams, such as GPs and 
dieticians in order to offer better weight management services. 
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x Being proactive in developing their professional role: 
o Help clients to feel more confident by taking the time needed in 
consultations. 
o Be trustworthy, skilful and knowledgeable in the weight management 
services they provide. For example, Wollner and colleagues study208 
showed effective weight loss could be achieved in their convenience 
care clinic which was based in pharmacies. They also showed that this 
CWLP could increase market share in a pharmacy setting with the 
additional benefit of monitoring co-morbidities associated with 
obesity. 
 
With the increasing numbers of overweight and obese UK adults, effective weight 
loss interventions are needed that are designed to be easier for clients to manage. 
Drug treatment is a suitable second step for obese people who are unable to lose 
weight by using a combination of diet, exercise and lifestyle modification. As a 
member of the health care professional team, pharmacists should encourage people 
to control their weight and to maintain a healthy weight in everyday life. This 
includes providing weight management services for overweight and obese people.  
 
6.3.2 Policy 
This study suggests that CWLPs are effective in helping overweight and obese 
people to achieve their weight loss goals and to become healthier. Public health 
policy should reflect the place of CWLPs as well as health services in developing 
and implementing weight loss interventions. Public health authorities should offer a 
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range of options for dietary restriction, appropriate exercise regimens and support 
from both professionals and self-help groups in providing affordable and accessible 
weight loss programmes so that individuals can choose the programme they feel is 
most likely to be successful. Such weight loss strategy should include action at local 
and national levels if it is to achieve a significant reduction in population health risks 
related to obesity.  
 
The review found three key elements (calorie restriction, exercise and support) in the 
CWLPs that were essential factors in weight loss. For those who are not successful in 
their initial attempts to lose weight a further option in obesity treatment is anti-
obesity medicine, which should be offered where appropriate as a second line 
treatment. Therefore, the NHS should ensure that such elements are included in 
public weight loss programmes.  
 
The CWLPs could help UK JRYHUQPHQW¶V SODQV for tackling obesity in terms of 
building the evidence base about the effectiveness of CWLPs in order to promote the 
spread of good practice and full use of evidence.209 The commercial programme can 
deal with overweight or obese problems among people who are willing and able to 
pay for the programme.   
 
This study proposes three crucial components of the CWLPs for the policy makers to 
attend to: calorie restriction, exercise and support. This component should be 
combined in a structured programme and typical element would be: 
1. Promotion of healthy food intake with guideline daily amounts (GDA) by the 
creation of healthy food environments related to food and nutrition policy in 
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obesity treatment210 such as a portion controlled diet plans (calorie controlled 
for all foods in women with 1,250 kcal/day and men with 1,550 kcal/day),147 
carbohydrate or fat restriction,11, 117 macronutrient balance (40% 
carbohydrate, 30% fat, 30% protein),11, 117 The LEARN Manual for Weight 
Management (55-60% carbohydrate, 10% fat)117 and balanced diets.17 
2. Choose the suitable options for obese people such as:  
a. A very low-calorie diet (<600 kcal/day) intake, which does not 
specify requirement for exercise. However, medical supervision is 
needed. 
b. A low-calorie diet (800-1,200 kcal/day) with daily exercise, which 
requires weekly support from health care professionals. 
c. For clients who meet the NICE guideline for receiving anti-obesity 
medicines, they should receive such medicine with non-
pharmacotherapy for obesity treatment, as above, and should be 
supported by members of a health care professional team, such as 
dieticians, physicians and pharmacists.  
3. Specify the appropriate exercise to target amount of calories to be burned and 
attempt to encourage exercise as an activity of everyday life. For example, 
local authorities could set exercise standards and guideline to create 
environments that promote exercise such as walking,147 running and 
jogging,211 cycling210 and swimming.211 
4. Provide counselling to overweight or obese people about their eating habits 
and personal habits by210  
a. Monitoring their weight and health risks associated with obesity.  
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b. Communicating up-to-date information about healthy eating and 
exercise. 
c. Motivating patients to adopt healthy lifestyles with consistent 
information. 
5. A multidisciplinary team comprising qualified counsellors and health care 
professionals such as registered dieticians, doctors and pharmacists should  
a. Be involved to help patients achieve their weight loss goals.11, 17  
b. Develop clinical governance processes for the care of overweight and 
obese people.  
c. Support obesity research by any organisations, public or private sector 
carrying out high quality research.210 
 
6.3.3 Strengths and limitations of the study 
6.3.3.1 Strengths 
The systematic review has identified the important components of weight loss 
programmes that enable the achievement of meaningful weight loss. The evidence 
from the systematic review and the retrospective study suggests the need for 
researchers to think similarly about options in obesity treatment. This is the first 
systematic review of literature from across the world rather than being restricted to 
particular countries. This provides valuable up-to-date evidence of the CWLPs.  
 
Moreover, a pharmacist-led weight management intervention primarily evaluates 
through a combination of orlistat supply and advice in the UK. This study not only 
has examined the efficacy of CWLPs in a variety of settings such as primary and 
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secondary care settings, including community settings but also has been supported 
the programmes by health care and non-health care providers to offer competent 
professional DGYLFHWRWKHSURJUDPPH¶VFOLHQWV. Therefore, the evidence in this study 
shows a good combination of a first and a second line treatment in obesity. The 
systematic review of CWLPs demonstrates the effectiveness of the first line 
treatment whilst the retrospective study of BPWLP shows the effectiveness of the 
second line treatment in obesity.  
 
6.3.3.2 Limitations 
There are several limitations to the work presented in this thesis. Firstly, this study 
only investigated the effectiveness of the CWLPs. Therefore, the population in this 
study is confined to overweight and obese adults who are willing and able to pay in 
order to attend their weight loss programmes. As a result, overweight or obese people 
who cannot afford to join a private health care service have been excluded from this 
study; this study¶VILQGLQJVcannot therefore be generalised to NCWLPs. 
 
Secondly, this study is based on a secondary analysis of the published literature 
between 1980 and 2011, combined with data from the records of the BPWLP. The 
results were only from studies that conformed to the inclusion criteria related to the 
CWLPs, such as a structured programme and organisation delivering intervention for 
profit organisation.  
 
Thirdly, by the time the questionnaire was approved, there were insufficient numbers 
of clients participating in the BPWLP so that the planned research initiative based on 
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the customer questionnaire was not carried out. The questionnaire was designed to 
HYDOXDWH FOLHQWV¶ YLHZs of the BPWLP in terms of experiences of programme, 
medicine, and other weight loss programmes and activities. Therefore, the 
questionnaire is limited in that it is designed for a specific group of clients.  
 
Lastly, this study focuses solely on weight loss outcome in overweight and obese 
adults. Therefore, other outcomes such as weight maintenance, factors related to 
obesity and cost-HIIHFWLYHQHVVDUHXQNQRZQ,QSDUWLFXODU%3:/3¶VFOLHQWVUHSRUWHG
factors related to comorbid health risks, which was a requirement for clients to report 
their comorbid health risks on the customer record forms, whilst pharmacists 
recorded side effects, which may be less reported on the consultation notes. Also, the 
level of accuracy of the records made by the pharmacists during the consultation is 
not known. 
 
6.4 Recommendations for further study 
Further study is warranted in order to gain knowledge relating to retention rates and 
to focus on the factors which contribute to long-term treatment and weight 
maintenance of participants. It is also suggested that a direct comparison be made 
between commercial and non-commercial weight loss programmes in terms of cost-
effectiveness. This can be achieved by conducting a RCT. The advantage of using a 
RCT is that it can reduce bias by minimising allocation and balancing both known 
and unknown confounding factors.212 Moreover, more support from providers should 
be recommended. This may help to reduce the dropout rate during the trials, which is 
one factor which is related to judging the effectiveness of CWLPs.  
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A questionnaire survey can also be undertaken with overweight or obese people who 
attend the CWLPs. 7KLVPD\KHOSWRH[SORUHWKHSDWLHQWV¶H[SHULHQFHRIWKH&:/3V
weight loss service, use of diet; exercise; support and/or medicine, and demographics 
of respondents. This will shed light on patient satisfaction, facilitators and barriers to 
losing weight. 
 
In addition, this study did not investigate the effectiveness of unstructured CWLPs 
such as OTC weight loss products and orlistat 60 mg. Further research would be 
needed to evaluate these services and their clinical outcomes. It would be interesting 
to assess by comparing other CWLPs and/or pharmacy medicine with usual or 
standard care in order to ensure whether such weight loss programmes are more or 
less effective in helping overweight and obese people to achieve meaningful weight 
loss, at least 5% of their initial weight. 
 
6.5 Summary 
This thesis has evaluated the effectiveness of CWLPs by systematically reviewing 
literature and determining the effectiveness of the BPWLP in order to propose which 
elements are most effective in CWLPs. Three elements, those of calorie restriction, 
exercise and support are currently insufficient evidence for CWLPs in the UK to 
VXSSRUW FOLHQWV¶ GHFLVLRQV LQ FKRRVLQJ ZKich CWLP is appropriate for them. 
Therefore, more research is needed to strengthen this evidence base for CWLPs. 
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Appendix 1 Boots PGD for the supply of orlistat 
 
Table A1.1 Patient Group Direction (PGD) for the supply of orlistat 
Name of authorising body Boots IMA 
PGD comes into effect 01-09-2008 
PGD expires 31-08-2010 
Supply and legal classification Orlistat will be supplied as 120 mg hard capsules in blister packs 
containing 84 capsules. 
Legal classification POM 
The capsule is presented as turquoise cap and turquoise body 
EHDULQJWKHLPSULQWRI³52&+(;(1,&$/´ 
Class of health professional who 
supply orlistat 
Royal Pharmaceutical Society of Great Britain (RPSGB) 
registered pharmacists who are authorised to provide the Boots 
Pharmacy Weight Loss Programme (BPWLP) and who have 
received training and been authorised to supply orlistat under this 
PGD. 
Supply outside the terms of the 
summary of product 
characteristics (SPC) 
Orlistat may not be supplied outside the terms of the SPC. 
Clinical situation for which 
medicine is to be used 
Orlistat is indicated in conjunction with a nutritionally balanced, 
mildly hypocaloric diet for the treatment of the following groups 
of patients: 
- 3DWLHQWVZKRDUHREHVH%0,kg/m2), are actively 
participating in a weight management programme and have 
demonstrated motivation to change dietary behaviour.  
- 3DWLHQWVZKRDUHRYHUZHLJKW%0,kg/m2 but < 30 kg/m2), 
with at least one associated risk factor/co-morbidity (such as 
cholesterol > 5.2 mmol/L, high blood pressure, any heart disease, 
non insulin-dependent diabetes mellitus, chronic respiratory 
disease including asthma and chronic obstructive pulmonary 
disease (COPD), arthritis of a weight bearing joint such as 
hip/knee/ankle, gastro-oesophageal reflux disease, hiatus hernia, 
gall stones, stress incontinence, those on a waiting list for 
surgery, pituitary disease or any other condition where loss of 
weight would be medically beneficial). 
Treatment with orlistat will be discontinued after 12 weeks if 
patients have been unable to lose at least 5% of the body weight 
as measured at the start of drug therapy. 
Treatment may be continued for up to 24 months or until the 
patient reaches the target weight corresponding to a BMI of 20-
25 kg/m2, as agreed between the patient and pharmacist. 
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Table A1.1 (continued)  
Criteria for inclusion Patients must be registered with a GP and be willing to accept 
treatment from a pharmacist. 
- All patients will have their height, weight, BP and random 
blood sugar measured in the pharmacy.  
- %0,kg/m2 but < 30 kg/m2 with at least one associated risk 
factor/ co-morbidity as described above 
- %0,kg/m2 with or without associated risk factors 
- Age 18-82 years, inclusive 
- Informed verbal consent to treatment and adherence to 
appropriate dietary intake 
- Consent to inform GP of relevant clinical detail including 
treatment with orlistat under the PGD 
Criteria for exclusion - BMI < 28 kg/m2  
- Age under 18 years and 83 years or older 
- Refusal of consent 
- Known hypersensitivity to orlistat  
- Current cholestasis 
- Breast feeding or pregnancy 
- Concurrent administration of ciclosporin, acarbose, amiodarone, 
sibutramine or other weight loss agents and insulin 
- Chronic malabsorption syndrome 
- Weight management surgery 
- Insulin dependent diabetes mellitus 
Patients not eligible for treatment under this direction will be 
given weight management advice and recommended to consult 
their GP for further assessment, where appropriate. 
Criteria for referral Patients should be referred to their GP: 
- When patient is considered eligible for orlistat therapy under a 
weight loss programme, but supply through pharmacy is 
excluded by the PGD. 
This might include any of the conditions referred to as exclusion 
criteria above and also: 
- Previously unrecognised co-morbidities: 
BP > 140/90 mmHg 
Random blood glucose exceeding 5.6 mmol/L 
- Uncontrolled symptoms of other illnesses that are a cause for 
concern  e.g. mental health, orthopaedic problems 
Dosage and method of 
administration 
The recommended dose of orlistat is one 120 mg capsule which 
should be taken with water immediately before, during or up to 
one hour after each main meal (2-3 times daily). If a meal is 
missed or contained no fat, the dose of orlistat should be omitted. 
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Table A1.1 (continued)  
Period of administration This will be determined by the pharmacist but will normally 
follow the following guidelines: 
- Treatment with orlistat will be discontinued:  
After 12 weeks if patients have been unable to lose at least 5% of 
the body weight as measured at the start of drug therapy 
If patients fail to achieve adequate to continuing weight 
reduction. Most patients will be an average of 0.5 to 1 lb weight 
loss per week. 
- Treatment with orlistat may be continued up to 24 months or 
until the target weight is reached corresponding to a BMI of 20-
25 kg/m2, as agreed between the patient and pharmacist. 
Drug interactions The concomitant administration of orlistat is not recommended 
with the following: 1) Acarbose, 2) Anorectic drugs, 3) 
Amiodarone, 4) Ciclosporin 
Administration in patients taking warfarin or other anticoagulants 
requires International Normalised Ratio (INR) values to be 
monitored. Therefore these patients should be referred to the GP 
for INR monitoring. 
Whilst there is not an interaction with oral contraceptives, orlistat 
may indirectly reduce the availability of oral contraceptives and 
lead to unexpected pregnancies in some individual cases. An 
additional contraceptive method is recommended in case of 
severe diarrhoea. 
Side effects The most frequent adverse reactions to orlistat are largely 
gastrointestinal in nature: 
- Oily spotting from rectum 
- Flatus with discharge 
- Faecal urgency 
- Fatty/oily stool 
- Oily evacuation 
- Increased defecation 
- Faecal incontinence 
The patient information leaflet will include detail of adverse 
events associated with orlistat, and the patient is asked to read 
this. 
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Table A1.1 (continued)  
Advice to patient The advice to patients will include specific product advice, in 
addition to general advice relating to physical activity and diet: 
- Orlistat must be taken with recommended healthy balanced diet 
containing less than 30% energy (calories) from fat. 
- 1 x 120 mg capsule orlistat should be taken immediately before, 
during or up to one hour after each main meal (2-3 times daily).  
- If a meal is missed or contained no fat, the dose of orlistat 
should be omitted. 
- The capsule should be stored in a cool place. 
Recommend that the patient read the appropriate enclosed 
information leaflet which should be given to the patient at the 
time of supply. This gives details of how to take orlistat and how 
to modify dietary intake appropriately.  
Follow-up Follow-up appointments should be made at the end of month 1, 3, 
6, 12, 18 and 24. 
BMI should be assessed at each follow-up appointment. 
Adverse outcomes Patients must be advised to follow a healthy balanced dietary 
intake containing less than 30% of energy (calories) from fat 
while taking orlistat. 
If the caloric intake exceeds 30% of energy (calories) from fat, 
patients may experience gastrointestinal side effects such as: 
- Oily spotting from rectum 
- Flatus with discharge 
- Faecal urgency 
- Fatty/oily stool 
- Oily evacuation 
- Increased defecation 
- Faecal incontinence 
Patients should be advised about the time of dispensing orlistat 
and a balanced diet with appropriate fat intake. These treatment 
effects can be managed and are less to occur. Any event of this 
mature suggests that the dietary intake has been inappropriate and 
may reflect hidden fat in the diet. This possibility can be alerted 
to the patient. 
Patients should be able to modify their dietary intake 
appropriately to avoid these treatment effects. 
Pharmacists will make a record of suspected adverse reactions to 
orlistat which will be reported to the Medicines and Healthcare 
products Regulatory Agency (MHRA) using the Yellow Card 
scheme. 
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Table A1.1 (continued)  
Facilities and supplies Orlistat should be stored in a cool place. 
Orlistat, when issued, is to be labelled with the date of dispensing 
DQGWKHSDWLHQW¶VQDPHDFFRUGLQJWRSKDUPDF\SURFHGXUHVRQWKH
patient medication record system. A mechanism will be put in 
place to ensure that the patient record acknowledges the supply of 
orlistat under PGD. 
Management and monitoring Patients need to be registered with the authorised pharmacy 
where treatment is provided for supply of medicines under a 
private PGD. The pharmacist will record and retain patient details 
including name, address, date of birth (DOB), sex, telephone 
number and the GP name and contact details. 
At each follow-up consultation, the pharmacist will review 
adherence to the dosage regimen, the development of any side 
effects, any changes to concomitant diseases or medicines and 
confirm that there is adequate to continuing weight loss. 
Informed consent Patient information relating to the supply of orlistat under PGD 
will be kept confidential. Individual information regarding the 
SDWLHQW¶VFDUHZLOOEHVKDUHGZLWKWKHSDWLHQW¶V*3$QRQ\PLVHG
information, collected for the purpose of clinical audit may be 
shared with other bodies such as regulatory agencies of the 
orlistat marketing authorisation holder, with the written consent 
of the patient. 
Details of record keeping for 
audit purposes 
The pharmacist must keep a record for each consultation, in 
accordance with care standards guidelines. This record will be 
timed and dated and signed by the pharmacist with their 
designation. Records will be securely retained in accordance with 
minimum care standard guidelines. 
Characteristics of staff authorised 
to take responsibility for supply 
and administration 
Member of the RPSGB and a practising community pharmacist 
Have undergone training an weight management and the PGD, 
including the self-directed learning package on administration or 
orlistat, and received authorisation to provide this service by the 
IMA 
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Appendix 2 Search strategies for database and terms 
Table A2.1 Search strategies for database and terms for Medline, EMBASE, PsycInfo, 
HMIC and IPA 
Database  Search strategies Results 
Medline 
EMBASE 
PsycInfo 
HMIC 
IPA 
Population 
1. overweight.tw.  
2. obes$.tw. 
3. exp morbid obesity/ or obesity.mp. 
4. or/1-3 
Medline: 165046 
EMBASE: 234636 
PsycInfo: 20924 
HMIC: 3179 
IPA: 2819 
 Intervention/Comparison 
5. commercial$.tw. 
6. (commercial adj7 program$).tw. 
7. (weight adj5 program$).tw. 
8. (weight adj5 product$).tw. 
9. diet$.tw. 
10. supplement$.tw. 
11. meal replacement.tw. 
12. exercise.tw. 
13. physical activ$.tw. 
14. antiobesity agent$.tw. 
15. pharmacotherapy.tw. 
16. drug therapy.tw. 
17. physician$.tw. 
18. pharmac$.tw. 
19. usual care.tw. 
20. standard care.tw. 
21. proprietary.tw. 
22. or/5-21 
Medline: 1329856 
EMBASE: 1713175 
PsycInfo: 188737 
HMIC: 23789 
IPA: 173839 
 Outcomes 
23. weight loss.tw. 
24. weight control.tw. 
25. weight reduction.tw. 
26. weight management.tw. 
27. weight change$.tw. 
28. body mass index.tw. 
29. or/22-28 
Medline: 118564 
EMBASE: 153680 
PsycInfo: 16742 
HMIC: 1574 
IPA: 2994 
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Table A2.1 (continued) 
Database Search strategies Results 
Medline 
EMBASE 
PsycInfo 
HMIC 
IPA 
Studies 
30. randomi$ control$ trial.tw. 
31. controlled clinical trial.tw. 
32. clinical trial$.tw. 
33. random$.tw. 
34. control.tw. 
35. time series.tw. 
36. controlled before and after.tw. 
37. uncontrolled before and after.tw. 
38. cohort$.tw. 
39. or/30-38 
Medline: 2101710 
EMBASE: 2576506 
PsycInfo: 391247 
HMIC: 26889 
IPA: 91913 
 40. 4 and 22 and 29 and 39 
41. limit 38 to  
Medline: (english language and humans and yr="1980 - 2011" 
and "all adult (19 plus years)")  
EMBASE: (humans and english language and yr="1980 - 
2011" and (adult <18 to 64 years> or aged <65+ years))  
PsycInfo: (human and english language and adulthood <18+ 
years> and yr="1980 - 2011")  
HMIC: yr="1980 - 2011"  
IPA: (english language and human and yr="1980 - 2011")  
42. remove duplicates from 41 
Medline: 4442 
EMBASE: 4594 
PsycInfo: 999 
HMIC: 193 
IPA: 206 
Results 
 
Medline: 4442 
EMBASE: 4594 
PsycInfo: 999  
HMIC: 193 
IPA: 206 
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Table A2.2 Search strategies for database and terms for CENTRAL and CINAHL 
Database Search strategies Results 
CENTRAL Population: (Obesity OR Obesity, Morbid) OR Overweight 5834 
 Intervention/Comparison: (commercial* or weight loss program* or weight 
loss product*) OR (Diet OR Dietary Supplements OR meal replacement) 
OR (Exercise OR physical activ* OR Anti-Obesity Agents OR Drug 
Therapy OR Physicians OR Pharmacists OR Pharmacy OR Pharmacies) 
OR (usual care or standard care) OR proprietary 
138923 
 Outcomes: (Body Weight Changes OR Weight Loss OR Body Mass Index) 
OR weight control OR weight reduction OR weight management OR 
weight change*  
25143 
 Studies: randomi* control* trial OR controlled clinical trial OR clinical 
trial* OR random* OR control OR time series OR controlled before and 
after OR uncontrolled before and after OR Cohort Studies 
438373 
 AND combines all components 
From 1980 to 2011 
2531 
2492 
CINAHL Population: Obesity or obes* or Overweight 18746 
 Intervention/Comparison: (commercial* or weight loss program* or weight 
ORVVSURGXFWRU0+³'LHW´250+³'LHWLWLDQV´25³GLHWRU0+
³'LHWDU\6XSSOHPHQWV´250+³'LHWDU\6XSSOHPHQWDWLRQ´25
³VXSSOHPHQW´RU³PHDOUHSODFHPHQW´RU0+³([HUFLVH25³H[HUFLVH´RU
0+³3K\VLFDO$FWLYLW\´25³SK\VLFDODFWLY´RU0+³$QWLREHVLW\
$JHQWV´25³DQWLREHVLW\DJHQW´RU0+³'UXJ7KHUDS\´25
³SKDUPDFRWKHUDS\´RU0+³3K\VLFLDQV´25³SK\VLFLDQ´RU0+
³3KDUPDFLVWV´25³SKDUPDF´RUXVXDOFDUH25VWDQGDUGFDUHRU
³SURSULHWDU´ 
498513 
 Outcomes: 0+³%RG\0DVV,QGH[´25 ³ERG\PDVVLQGH[´RUZHLJKW
loss or weight control or weight reduction or weight management or weight 
change*  
39639 
 6WXGLHV0+³RandomisHG&RQWUROOHG7ULDOV´250+³&OLQLFDO7ULDOV´
25³UDQGRPLFRQWUROWULDO´RUFRQWUROOHGFOLQLFDOWULDORUUDQGRPRU 
FRQWURORU0+³7LPH6HULHV´25³WLPHVHULHV´RUFRQWUROOHGEHIRUHDQd 
after or uncontrolled before and after or cohort* 
616633 
 AND combines all components 
Published Date from: 19800101-20111231; English language; Age Groups: 
Adult: 19-44 years, Middle Aged: 45-64 years, Aged: 65+ years 
1658 
909 
Results 
 
CENTRAL: 2492 
CINAHL: 909 
 
  
Appendices 
 
293 
 
Table A2.3 Search strategies for database and terms for Scopus and WOS 
Database Search strategies Results 
Scopus (obes* OR mobid* obesity OR overweight) AND ((commercial* OR 
weight loss program* OR weight loss product*) OR (diet* OR 
supplement* OR meal replacement) OR (exercise OR physical activ*) OR 
(antiobesity agents OR drug therapy OR pharmacotherapy OR physician* 
OR pharmac*) OR (usual care OR standard care) OR (proprietary)) AND 
(body mass index OR weight loss OR weight control OR weight reduction 
OR weight management OR weight change*) AND (randomi* control* 
trial OR controlled clinical trial OR clinical trial* OR random* OR control 
OR time series OR controlled before and after OR uncontrolled before and 
after OR cohort*) AND (/LPLWWR/DQJXDJH³(QJOLVK´$1'-2011)) 
2376 
WOS Population: obes* OR mobid* obesity OR overweight 76546 
 Intervention/Comparison: (commercial* OR weight loss program* OR 
weight loss product*) OR (diet* OR supplement* OR meal replacement) 
OR (exercise OR physical activ*) OR (antiobesity agents OR drug therapy 
OR pharmacotherapy OR physician* OR pharmac*) OR (usual care OR 
standard care) OR proprietar* 
582026 
 Outcomes: body mass index OR weight loss OR weight control OR weight 
reduction OR weight management OR weight change*  
30025 
 Studies: randomi* control* trial OR controlled clinical trial OR clinical 
trial* OR random* OR control OR time series OR controlled before and 
after OR uncontrolled before and after OR cohort* 
934417 
 AND combines all components, Timespan = 1980-2011 145 
Results 
 
Scopus: 2376 
WOS: 145 
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Appendix 3 Data extraction form for full articles 
 
 
 
 
 
 
 
 
 
 
  
Article identification:  5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year:  Country:  
Objectives  
Methods  
Participants Inclusion criteria:  
 Exclusion criteria:  
 Settings and/or locations:  
 Duration:  
 Recruitment methods :  
 Sample size:  
Study design Randomization-sequence generation:  
 Allocation concealment:  
 Implementation:  
 Blinding:  
 Statistical methods:  
Intervention  
Comparison/ 
Control 
 
Outcomes Primary and secondary outcome measures 
Results  
Participant flow  
Baseline data Demographics:  
Number analyzed Summary data for each intervention group (ITT and/or completers) 
Outcomes and 
estimation 
 
Adverse events  
Discussions  
Interpretation Introduction 
 Methods 
 Assessing outcomes:  
Provider: 
 Statistical methods:  
 Results 
 Discussion 
Generalisability  
Other evidence General comments 
Funding   
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Appendix 4 Judging risk of bias 
 
Criteria for the risk of bias were identified to assist making judgements about the 
papers. There are seven domains in this assessment tool which include 1) sequence 
generation, 2) allocation concealment, 3) blinding of participants and personnel, 4) 
blinding of outcome assessors, 5) incomplete outcome, 6) selective outcome 
reporting and 7) other sources of bias.  
 
Reviewers judged for the risk of bias and indicated the each criterion as bHLQJµORZ
ULVN¶µKLJKULVNRUµXQFOHDUULVN¶. The criteria for judging risk of bias were described 
in Table A4.1 below. 
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Table A4.1 Criteria for judging risk of bias 
Low risk of bias: Described High risk of bias: Described Unclear risk of bias: Described 
Sequence generation: Judging for    
A random number of table 
A computer random number 
generator 
Coin tossing 
Shuffling cards or envelopes 
Throwing dice 
Drawing of lots 
Minimisation: Implemented without 
a random element and considered to 
be equivalent to being random 
Sequence generated by odd or even date of 
birth, by some rule based on date or day of 
admission or by some rule based on 
hospital or clinic record number 
Allocated by judgement of the clinician, 
by preference of the participant or by 
availability of the intervention 
Allocation based on results of a laboratory 
test or a series of tests 
Insufficient 
detail in the 
sequence 
generation 
process to judge 
either yes or no 
Allocation concealment: Judging for   
Participants were enrolled to conceal 
allocation as:  
Central allocation includes 
telephone, web-based and pharmacy-
controlled randomisation 
Sequentially numbered drug 
containers or opaque sealed 
envelopes 
Participants were enrolled to conceal 
allocation and introduced selection bias 
based on using:  
An open random allocation schedule e.g. a 
list of random numbers 
Assignment envelopes used with 
inappropriate safeguards e.g. unsealed 
envelopes, non-opaque or not sequentially 
numbered 
Alternation or rotation 
Date of birth 
Case record number 
Other unconcealed procedure 
Insufficient 
detail in 
allocation 
concealment 
process to judge 
either yes or no 
No description 
of concealment 
methods 
Unclear 
whether 
envelopes were 
sequentially 
numbered, 
opaque or 
sealed 
Blinding of participants, personnel and outcome assessors: Judging for 
No blinding, but reviewers judge that 
outcomes were unlikely to be 
influenced by lack of blinding 
3DUWLFLSDQWV¶DQGNH\VWXG\
SHUVRQQHO¶VEOLQGLQJZDVFHUWLILHG
that blinding is unlikely to be broken. 
If participants and key study 
personnel were not blinded, but 
outcome assessors were blinded, 
non-blinding of others were unlikely 
introduced bias. 
No blinding or incomplete blinding, and 
outcomes were likely to be influenced by 
lack of blinding 
3DUWLFLSDQWV¶DQGNH\VWXG\SHUVRQQHO¶V
blinding was certified that blinding was 
likely to be broken. 
If participants and key study personnel 
were not blinded, non-blinding of others 
were unlikely introduced bias. 
Insufficient 
detail to judge 
either yes or no 
No description 
of outcomes 
  
Appendices 
 
297 
 
Table A4.1 (continued) 
Low risk of bias: Described High risk of bias: Described Unclear risk of bias: Described 
Incomplete outcome data: Judging for  
No missing outcome data 
Reasons for missing outcome data 
were not related to true outcome 
Missing outcome data balance in 
numbers across intervention groups 
with similar reasons for missing data 
across groups 
Missing data was used appropriate 
methods. 
For continuous outcome data, 
difference in mean or standard 
deviation among missing outcomes 
was not clinically sufficient relevant 
bias in observed effect size. 
Reasons for missing outcome data were 
related to true outcome with either 
imbalance numbers or reasons for missing 
data across intervention groups 
Missing data was used inappropriate 
methods. 
For continuous outcome data, difference in 
mean or standard deviation among missing 
outcomes was clinically sufficient relevant 
bias in observed effect size. 
Insufficient 
detail in 
reporting 
attrition rate to 
judge either yes 
or no 
No description 
of number of 
randomisation, 
reasons of 
missing data or 
outcomes 
Selective outcome reporting: Judging for  
The study protocol was available. 
Primary and secondary outcomes 
were interested and reported in the 
pre-specified way. 
If the study protocol was not 
available but clear to publish studies 
that included all expected outcomes, 
those were pre-specified. 
None of all primary outcomes were 
reported. 
One or more primary outcomes were 
reported using measurements, and analysis 
methods or subsets of the data were not 
pre-specified. 
One or more reported primary outcomes 
were not pre-specified e.g. an unexpected 
adverse effect. 
The study report excluded results for a key 
outcome that would be expected to report 
in the study. 
Insufficient 
detail to judge 
either yes or no 
Other bias: Judging for   
Appeared to be free of other sources 
of bias 
 
Either one of: 
Had a potential source of bias related to 
the specific study design  
Stopped early due to some data-dependent 
process 
Had extreme baseline imbalance 
Claimed to be fraudulent 
Had some other problems 
Insufficient 
detail to assess 
whether or not 
an important 
risk of bias 
exists  
Insufficient 
rationale or 
evidence to 
identify 
problems that 
introduced bias  
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Table A4.2 Form for rechecking risk of bias by a second reviewer  
Bias 
$XWKRU¶VMXGJHPHQW 
Low risk  Unclear risk  High risk  
Random sequence generation (selection bias)    
Allocation concealment (selection bias)    
Blinding of participants and personnel (performance 
bias) 
   
Blinding of outcome assessment (detection bias)    
Incomplete outcome data (attrition bias)    
Selective reporting (reporting bias)    
Other bias 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Appendix 5 Data from included studies 
Studies are listed alphabetically. 
Anderson 2011144  
Article identification: 1/2011 5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Anderson 2011 Country: US 
Objectives Compared effects of a standardised behavioural intervention using meal replacements 
(MRs), fruits and vegetables (MR-FV) and increased physical activity with a usual-care 
intervention on body weight change 
Methods  
Participants Inclusion criteria: Subjects aged 20-65 years with BMI between 30 and 39.9 kg/m2 and 
being good health. 
 Exclusion criteria: Pregnant, unable to read and write in English, allergy to MRs 
ingredients, participated in other clinical studies, lost or gained > 5 lb during the previous 3 
months, used weight-loss medications or supplements and anticoagulants or 
R[FDUED]HSLQHGLDJQRVHGDVGLDEHWHVPHOOLWXVRUKDGDIDVWLQJSODVPDJOXFRVHYDOXH
mg/dL 
 Settings and/or locations: University medical centre 
 Duration: 24 weeks  
 Recruitment methods: The study advertised by newspapers, radio, bulletin board 
announcements or word of mouth. 
Interested subjects were screened by telephone asking questions by the study coordinator.  
The orientation was described by the senior author and study coordinator.  
The screening visit and randomisation were performed by a study physician. 
 Sample size: 45 participants randomised  
Study design Randomisation-sequence generation: Randomised controlled trial used random numbers in 
blocks of 10 subjects. 5 of every 10 subjects were selected to each group. 
 Allocation concealment: 23 participants were randomly assigned to MR-FV group. 22 
participants were randomly assigned to the control group.  
No further report 
 Implementation: 2 lead physicians (2 investigators) randomly assigned participants to 2 
study groups. 
 Blinding: Blinded 2 lead physicians (2 investigators) 
 Statistical methods: The primary outcome was presented by the percentage weight change 
from baseline to 24 weeks in the trial.  
80% power was used for sample size calculation. Participants were analysed as completers, 
available cases and ITT. Baseline values used mean r SD whilst follow-up values used 
mean r SE.  
Comparison between groups used 2-sample independent t tests with 2-sided significance at 
p d 0.05. Data analysis used SAS V9.1. 
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Anderson 2011 (continued)  
Methods  
Intervention Healthy solutions option: Meal replacements, fruits and vegetables (MR-FV) provided a 
low-energy diet as details below. Participants:  
- Attended weekly weight-loss classes for 16 weeks and weekly maintenance classes for 8 
weeks 
- 90-PLQXWH³FRUH´ZHLJKW-loss classes for the first 12 weeks 
- 90-PLQXWH³RQJRLQJ´ZHLJKW-loss classes for 4 weeks 
- 60-PLQXWH³PDLQWHQDQFH´FODVVHVIRUWKHUHPDLQLQJZHHNV 
- Consumed 3 HMR shakes, 2 HMR entrées and 5 servings of fruits or vegetable daily  
- Were given a weekly progress chart, kept record the numbers of MRs; fruits and 
vegetables consumed daily and recorded the calories burned in exercise 
Weight maintenance classes: 
- Consumed 2 MRs daily and continued 5 servings of fruits and vegetables daily 
- Kept record daily all MR and food intake 
- $FKLHYHGH[HUFLVHJRDOVH[SDQGP-ZHHNRUNFDO 
- Made midweek phone calls to report their nutrition intake and physical activity 
Comparison/ 
Control 
Usual-care weight-loss counselling from an experienced or a registered dietician 
Participants counselled at baseline, 8 weeks and 16 weeks about: 
- At the initial session, participants discussed about their weight loss target and any current 
health conditions related to obesity. 
- Next, counselled with a dietician about how to maintain a nutritionally balanced, energy-
restricted diet that provided 30% of energy from fat, 50% from carbohydrate and 20% 
from protein 
- Received multivitamin tablets to take one daily 
Outcomes Primary outcome measures: Weight change at 24 weeks 
Secondary outcome measures: Side effects, behavioural patterns and risk factors at 8 and 
16 weeks 
Results  
Participant flow 48 individuals screened. 3 persons failed screening. 45 participants randomised. 
23 participants were randomly assigned to MR-FV group. 22 participants were randomly 
assigned to the control group.  
ITT: 38 enrolled to the treatment (22) and control (16) group. 
Baseline data Table 1: Baseline characteristics of participants, mean (r SD) 
  Control group, n = 16 MR-FV group, n = 22 
 Female, n (%) 12 (75.0) 17 (77.3) 
 Age, years 45.4 (10.2) 50.5 (7.3) 
 Weight, kg [mean (r SE)] 99.2 (3.3) 99.7 (3.2) 
 BMI, kg/m2 34.9 (2.7) 35.8 (3.2) 
 3DUWLFLSDQWV¶FKDUDFWHULVWLFVLQERWKJURXSVZHUHVLPLODU+RZHver, there were 76% of female 
with mean aged 48 years and had mean BMI 35 kg/m2 and mean weight 99 kg, approximately. 
Number 
analyzed 
ITT: 22 participants in the intervention group, 16 participants in the control group 
Completers: 31 participants completed the last observation carried forward.  
18 participants in the intervention group, 13 participants in the control group 
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Anderson 2011 (continued) 
Results  
Outcomes and estimation 
Table 2: Changes in weight from baseline, mean (r SE) 
 Control group MR-FVa group 
p-valueb 
ITT a, n = 16 Completers, n 
= 13 ITT
a
, n = 22 Completers, n 
= 18 
Weight change, % 
8 weeks 
16 weeks 
24 weeks  
 
-1.3 (0.9) 
-0.7 (1.1) 
-0.7 (1.1) 
 
-1.4 (0.7) 
-0.7 (1.1) 
-0.6 (1.2) 
 
-8.5 (0.6) 
-12.5 (0.9) 
-13.9 (1.1) 
 
-8.9 (0.6) 
-13.8 (0.7) 
-15.4 (1.0) 
 
<0.0001 
<0.0001 
<0.0001 
aMR-FV = meal replacement, fruit and vegetables, bp-value < 0.05 considered statistically significant 
$WZHHNVIRU,77DQDO\VLVREHVHSDUWLFLSDQWV¶PHDQZHLJKWORVVLQ05-FV group (13.9 kg, 13.9%) was 
greater than those in the control group (0.7 kg, 0.7%) as well as completers analysis, their mean weight loss in 
MR-FV group (15.4 kg, 15.4%) was greater than those in the control group (0.7 kg, 0.7%).  
$VDUHVXOWREHVHSDUWLFLSDQWV¶ZHLJKWGHFUHDVHGRYHUof the initial weight, 13.9% in ITT and 15.4% in 
completer analysis.  
There were statistically significant differences between groups for both ITT and completer analysis (p < 0.0001).  
Secondary outcome At 16-week weight loss period, WC (p < 0.01), glucose (p = 0.02) and LDL-C (p < 0.05) 
were significantly greater decrease in MR-FV group. 
Adherence was self-reported record and found that there was good (85%-90%) to 
H[FHOOHQW!LQSDUWLFLSDQWV¶DGKHUHQFH 
Results also presented weight maintenance and behavioural assessments but not extracted 
here. Only adherence was presented. 
Adverse events 3DUWLFLSDQWV¶DGYHUVHHIIHFWVZHUHKLJKHUWKDQLQERWKJURXSV3DUWLFLSDQWVLQ&JURXS
(56.3%) were less adverse events than those in MR-FV group (59.1%). 
Discussions  
Interpretation Introduction 
- Reviewed the prevalence of overweight in the globe and also in the US  
- Reviewed the relevant studies about the effect of commercial weight loss programmes  
- Described the matter of this study: Limited studies of RCTs for commercial weight loss 
programme used meal replacement products in the community pharmacy  
- Focused on a behavioural/nutritional intervention programme by physician counselling 
expenditure of obesity affected costs in the US  
- Explained the primary and secondary objectives 
 Methods 
Randomised controlled trial: Randomisation-sequence was generated by blocking of 10 
subjects and selected 5 of every 10 subjects to each group. Numbers of subjects were 
reported as allocation concealment and shown numbers excluded and completed as the 
participant flow. Implementing randomisation and blinding by 2 lead physicians 
(investigators) 
Comparison of 2 treatment groups: MR-FV group provided a low-energy diet with weight 
loss products whilst control group with usual-care weight-loss counselling from an 
experienced or a registered dietician. At baseline, no statistically significant differences. 
Provider: Physician, a registered dietician 
Assessing outcomes: Measured weight in triplicate on an electronic scale (Detecto, Model 
6800, Webb City, MO) with subjects wearing the light cloth without shoes. This should be 
valid in terms of measuring weight. 
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Anderson 2011 (continued)  
Discussions  
Interpretation 
(continued) 
Statistical methods: Reported power calculation, value presented, tests used, p-value and 
programme used. 
Power calculation was 80% to detect a 4.5% difference in mean weight loss between 
groups and complete at least 16 subjects each group by assuming a SD of 5% and 1-tailed 
of significance at the 0.05 level. 
Power calculation could help this study for: 1) Scanning whether or not participants 
randomised were enough to see an effect and 2) preparing for sufficient participants if they 
declined to participate during the study. 
At 24 weeks of weight loss period, values presented only the available cases. 
 Results 
- Participant flow presented including number of screening, randomisation, exclusion, 
allocation, and ITT and completers analysis 
- Reported values as mean weight with SD or SE 
- Both diets reported statistically significant differences using 2-sample independent t-tests 
(p < 0.05). 
 - MR-FV group was presented weight loss at 24 weeks with ITT and completers analysis. 
However, the primary data analysis was ITT so that the percentage of obese partLFLSDQWV¶
weight loss decreased about 13.9% of their initial weight.  
 Discussion 
 The authors discussed about the mildly or moderately obese people who participated in the 
MR-FV programme (12.5% of the initial weight, ITT and 13.8% completers) were 
similarly effective weight loss to other studies, particularly Medifast (12.3% at 16 weeks, 
completers). Unlikely, other commercial weight loss programme evidences such as Weight 
Watchers, Jenny Craig, Medifast, Nurtisystem,etc. were hardly compared outcomes 
because of difference in comparator trials such as type and duration of programme.  
The authors also referred to commercial weight loss programmes with food choices 
affected greater weight loss as well as commercial programmes combination with the 
behavioural modification. Therefore, subjects who participated in HMR programme could 
have over 10% weight loss of their initial weight at 16 weeks. 
Generalisability Did not report 
Other evidence General comments 
This study compared to other weight loss programmes claimed that it was impossible to be 
the most effective commercial weight loss programmes.  
No comments on genralisability and factors related weight loss were risk factors, adverse 
events and behavioural adherence. 
Also, limitations were conducting at a single site and a small number of subjects. The 
control group subjects were having fewer visits and interactions with clinical staff. 
Regarding small sample size, the impact of MR use, fruit and vegetable consumption and 
exercise on weight loss have not been evaluated. 
For further research, the study will be needed to examine the comparative effectiveness of 
the 3 major components: MR use, fruit and vegetable consumption, and exercise and can 
be effectively provided by physicians. 
Funding  - 
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Dansinger 200511 
Article identification: 1/2005 5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Dansinger 2005 Country: US 
Objectives Determined the effectiveness of 4 popular diets (Atkins, Zone, Weight Watchers and 
Ornish) on weight loss and cardiac risk factor reduction 
Methods  
Participants Inclusion criteria: Overweight or obese participants  
- Aged 22-72 years with BMI 27-42 kg/m2 
- Had at least 1 of the metabolic cardia risk factors: Hypertension (6%3'%3
PP+JIDVWLQJK\SHUJO\FHPLD%*PJG/RUPPRO/G\VOLSLGHPLD7&
PJG/RUPPRO//'/FKROHVWHUROPJG/RUPPRO/+'/
cholesterol (d 40 mg/dL or d PPRO/WULJO\FHULGHVPJG/RUmmol/L) 
- Used oral medications to treat hypertension, diabetes or dyslipidemia 
 Exclusion criteria: Overweight or obese participants had 
- Unstable chronic illness, insulin therapy, urinary microalbumin > 2 times normal, serum 
FUHDWLQLQHPJG/23.8 Pmol/L) 
- Clinically significant abnormalities of liver or thyroid test results, weight loss 
medication, pregnancy 
 Settings and/or locations: Academic medical centre in Boston, Massachusetts 
 Duration: 1 year  
 Recruitment methods : Recruited participants via newspaper advertisements and television 
publicity (local news) in the Greater Boston area 
Race and sex criteria were designed for the recruitment strategy. 
 Sample size: 160 participants randomised 
Study design Randomisation-sequence generation: A single-centre randomised trial 
A computer generated the randomised Latin-square sequence 
10 participants were assigned to 1 of 4 class rosters. Each diet was conducted to each of 
the class times only once in order to minimise the potential confounding between class 
time and diet type. A new set of diet classes was run every 3-4 months for 4 cycles. 40 
participants each in Atkins, Zone, Weight Watchers (WW) and Ornish 
 Allocation concealment: No description 
 Implementation: Dietician and physician 
 Blinding: Participants were blinded by the study statistician.  
Study nurses and laboratory personnel who evaluated outcomes were blinded.  
 Statistical methods: Sample size calculation used 80% power.  
Using t tests was to compare the mean absolute change from baseline to 1 year.  
Using ANOVA was to evaluate differences of baseline variables among diet groups, and 
independent t tests were used to compare baseline variables among participants. Absolute 
changes at 2, 6 and 12 months were normal distribution for weight loss and used 1-sample 
t test whilst non-normal distribution used Wilcoxon rank sum test.  
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Dansinger 2005 (continued)  
Methods  
Study design Data analysis used SPSS V10.1 with 2-sided significant at p d 0.05. 
All interventions All participants received supplements (non-prescription multivitamin daily), exercise (at 
least 1 hour per week) and external support (commercial support services). 
Intervention 1 Atkins diet (Carbohydrate restriction):  
Carbohydrate daily < 20 g with gradual increase up to 50 g per day 
Intervention 2 Zone diet (Macronutrient balance):  
40-30-30 balance of carbohydrate, fat and protein in percentage calories  
Intervention 3 Weight Watchers diet (Calorie restriction):  
Keep total daily points in a range of current weight. Each point was 50 calories. Most 
participants intended 24-32 points per day. 
Intervention 4 Ornish diet (Fat restriction): A vegetarian diet contained 10% of fat calorie 
Outcomes Primary outcome measures: Weight loss at baseline, 2, 6 and 12 months 
Other outcome measures: 1) Cardiac risk factors: Waist size, BP, serum total cholesterol, 
HDL-C, triglycerides, glucose, insulin, high density C-reactive protein and creatinine 
levels, and 2) self-selected dietary adherence  rates per self-report 
Results  
Participant flow 1010 overweight or obese adults telephone inquiries. 763 adults excluded. 
247 participants screened individually. 87 participants excluded.  
160 participants randomised. 40 participants each assigned to Atkins, Zone, Weight 
Watchers and Ornish 
Baseline data  
7DEOH3DUWLFLSDQWV¶FKDUDFWHULVWLFVDWEDVHOLQHQ HDFKPHDQr SD) 
 Atkins  Zone  WW Ornish All diets, n = 160 
Age, year 47 (12) 51 (9) 49 (10) 49 (12) 49 (11) 
Women, n (%) 21 (53) 20 (50) 23 (58) 17 (43) 81 (51) 
Weight, kg 100 (14) 99 (18) 97 (14) 103 (15) 100 (15) 
BMI, kg/m2 35 (3.5) 34 (4.5) 35 (3.8) 35 (3.9) 35 (3.9) 
Notes: There were no significant differences in all diet groups because of p-value > 0.05. 
3DUWLFLSDQWV¶FKDUDFWHULVWLFVZHUHQRWVLJQLILFDQWGLIIerences among all diet groups. There were 51% of women 
with mean aged 49 years and had mean BMI 35 kg/m2 and mean weight 100 kg, approximately. 
Number analyzed ITT: 40 participants each assigned to Atkins, Zone, Weight Watchers and Ornish 
Completers: 21 participants in Atkins, 26 participants in Zone, 26 participants in Weight 
Watchers and 20 participants in Ornish  
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Dansinger 2005 (continued)  
Outcomes and estimation 
Table 2: Weight change from baseline to 2, 6 and 12 months in analysis with baseline values carried forward in 
the case of missing data*, n = 40 each, mean (r SD) 
 Atkins  Zone  WW Ornish p-value across diets 
Weight, kg      
2 months -3.6 (3.3)** -3.8 (3.6)** -3.5 (3.8)** -3.6 
(3.4)** 
0.89 
6 months -3.2 (4.9)** -3.4 (5.7)** -3.5 (5.6)** -3.6 
(6.7)** 
0.76 
12 months -2.1 (4.8)** -3.2 (6.0)** -3.0 (4.9)** -3.3 
(7.3)** 
0.40 
BMI, kg/m2      
2 months -1.3 (1.1)** -1.3 (1.2)** -1.2 (1.3)** -1.2 
(1.1)** 
0.83 
6 months -1.1 (1.7)** -0.9 (2.4)** -1.2 (2.0)** -1.2 
(2.3)** 
0.65 
12 months -0.7 (1.6)** -1.1 (2.0)** -1.1 (1.7)** -1.4 
(2.5)*** 
0.36 
*Atkins participants: 31 at 2 months (mo), 22 at 6 mo and 21 at 12 mo, Zone participants: 33 at 2 mo, 26 at 6 mo 
and 26 at 12 mo, Weight Watchers participants: 33at 2 mo, 30 at 6 mo and 26 at 12 mo, Ornish participants: 29 at 
2 mo, 21 at 6 mo and 20 at 12 mo. **Significant at p < 0.01 for difference from baseline within groups 
***
 Significant at p < 0.05 for difference from baseline within groups  
$W\HDURYHUZHLJKWRUREHVHSDUWLFLSDQWV¶PHDQZHLJKWOoss in Atkins diet (2.1 kg, 2.1%), Zone diet (3.2 kg, 
3.2%), Weight Watchers diet (3.0 kg, 3.0%), Ornish diet (3.3 kg, 3.2%) were statistically significant difference 
within groups (p < 0.01). However, there was no statistically significant difference between groups (p = 0.40). 
Table 3: Weight change from baseline to 2, 6 and 12 mos in analysis with missing data excludeda, mean (r SD) 
 Atkins  Zone  WW Ornish p-valueb within grs 
Weight, kg      
2 months -4.7 (2.9) -4.6 (3.4) -4.2 (3.8) -5.0 
(3.0) 
< 0.01  
6 months -5.8 (5.3) -5.2 (6.4) -4.7 (6.1) -6.7 
(8.0) 
< 0.01  
12 months -3.9 (6.0) -4.9 (6.9) -4.6 (5.4) -6.6 
(9.3) 
< 0.01  
BMI, kg/m2      
2 months -1.6 (1.0) -1.6 (1.2) -1.5 (1.3) -1.7 
(1.0) 
< 0.01  
6 months -2.0 (1.9) -1.7 (2.2) -1.7 (2.1) -2.4 
(2.7) 
< 0.01  
12 months -1.4 (2.1) -1.6 (2.3) -1.7 (1.9) -2.3 
(3.2) 
< 0.01  
aAtkins participants: 31 at 2 months (mo), 22 at 6 mo and 21 at 12 mo, Zone participants: 33 at 2 mo, 26 at 6 mo 
and 26 at 12 mo, Weight Watchers participants: 33at 2 mo, 30 at 6 mo and 26 at 12 mo, Ornish participants: 29 at 
2 mo, 21 at 6 mo and 20 at 12 mo. bSignificant at p < 0.01 for difference from baseline within groups  
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Dansinger 2005 (continued)   
Results  
Secondary outcome At 1 year, LDL/HDL-C ratio was significant reduction approximately 10% (all p < 0.05) 
whereas SBP, DBP and glucose were not significant difference.  
Results also presented dietary adherence and changes in exercise but not extracted here. 
Outcomes and 
estimation 
At 1 year with missing data excluded, overZHLJKWRUREHVHSDUWLFLSDQWV¶PHDQZHLJKWORVV
in Atkins diet (3.9 kg, 3.9%), Zone diet (4.9 kg, 4.9%), Weight Watchers diet (4.6 kg, 
4.6%), Ornish diet (6.6 kg, 6.4%) were statistically significant difference within groups   
(p < 0.01).  
Adverse events Not be able to identify diet related adverse effects 
Discussions  
Interpretation Introduction 
- Reviewed the widespread of obesity that made more patients and clinicians were 
interested in using popular diets for weight loss  
- Reviewed the 4 popular diets that were Atkins, Ornish, WW and Zone diets about the 
diet differences  
- Described the matter of this study: Limited studies regarding the relative benefits, risks, 
effectiveness and sustainability of popular diets   
- Explained aim of this study  
 Methods 
A single-centre randomised trial: A computer generated the randomised Latin-square 
sequence. Overweight or obese participants were allocated to 1 of 4 class rosters. Dietician 
and statistician implemented randomisation. There was double blind because participants, 
study statistician, study nurses and laboratory personnel were blinded. 
 Comparison of 4 diets: Atkins diet (Carbohydrate restriction), Zone diet (Macronutrient 
balance), Weight Watchers diet (Calorie restriction) and Ornish diet (Fat restriction) were 
different restriction of calorie. At baseline, no statistically significant differences.  
 Provider: Dietician, physician 
 Assessing measures: Measured weight by using a single calibrated scale (Detecto, Webb 
City, MO) of participants wearing light clothing and no shoes. Although there was no 
report of measuring height, weight values should be valid. 
 Statistical methods: Reported power calculation (80%) to detect a weight change of 2% 
from baseline and 3% between diets.  
Power calculation could help this study for: 1) Scanning whether or not participants 
randomised were enough to see an effect, 2) not wasting time on an underpowered study 
and 3) preparing for sufficient participants if they declined to participate during the study. 
Reported analysis of baseline carried forward with and without missing data and 
completers (greater results), p-value, tests used and programme analysed, however, 
confidence intervals were unavailable. 
 Results 
- Reported participant flow, numbers excluded and analysed by ITT or completers and 
reasons of declining for follow-up 
- Reported values in mean weight with SD 
- All 4 diets reported statistically significant differences (p d 0.05). 
- At 1 year for completers, all diets could significantly decrease participanWV¶ZHLJKWORVV 
  
Appendices 
 
307 
 
Dansinger 2005 (continued)   
Discussions  
Interpretation 
(continued) 
Discussion 
This study was reported that a variety of popular diets could reduce weight, however, there 
was the minority of participants who were highly dietary adherence. Although there was 
high adherence level, there was not with diet type. Nevertheless, at 1 year of weight loss, 
the highest reduction was Ornish. Regarding to weight loss, the higher overweight or 
obese adults related to cardiac risks, the more increase dietary adherence rates needed.  
7KHDXWKRUV¶UHFRPPHQGDWLRQWRLPSURYHDGKHUHQFHZDVPDWFKLQJLQGLYLGXDOVZLWKWKHLU
food preferences, lifestyles and cardiovascular profiles. However, this study was double 
blind so that participants could not select their diet programmes. It would affect adherence.  
Moreover, this study supported carbohydrate and saturated fat restriction because this 
could be effective to cardiovascular disease. Three types of diets were discussed:  
1. Low carbohydrate increased HDL but decreased TG, glucose, the key predictor of 
weight loss and cardiac risk factors reduction.  
2. Similarly, low carbohydrate/high-fat diets increased HDL, however, it was insufficient 
evidence of the relevant dietary intervention trials.  
3. Likewise, high saturated fat increased HDL but decreased LDL/HDL-C that would not 
benefit to lipid profiles.  
Reasonably, it could be demonstrated that any diet type decrease weight and cardiac risk 
factors but was not potentially recommended because either carbohydrate or fat restriction 
depended on individual profiles as lifestyle, health and medical conditions and food 
preferences.  
Generalisability Applicable because discontinuous participants were similar to other groups, had higher 
evidence of weight loss than weight gain and attained the meaningful weight loss 
Other evidence General comments 
There were several limitations which were 1) Lack of a long-term support system (low 
adherence), 2) Each diet was not identified as a best diet (popular diets), 3) A larger 
sample size may be required and 4) Adverse effects were not reported. 
Further study: Needed to study the cardiovascular and other health effects of dietary 
alternatives 
Funding  The General Research Centre via the National Centre for Research Resources of the 
National Institutes of Health (NIH) 
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Djuric 2002145 
Article identification: 1/2002 5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Djuric 2002 Country: US 
Objectives Investigated the effects of combining weight-loss counselling with the Weight Watchers 
plan on weight loss for obese women with breast cancer 
Methods  
Participants Inclusion criteria: Women aged 18-70 years, breast cancer stage 1 and 2 with diagnosed  
within 4 years, completed chemotherapy or radiation therapy at least 3 months 
 Exclusion criteria: Did not report 
 Settings and/or locations: Single-centre 
 Duration: 12 months 
 5HFUXLWPHQWPHWKRGV5HFUXLWHGE\PDLOLQJWRSDUWLFLSDQWVRI³5DFHIRUWKH&XUH´SUHVV
releases and brochures at breast clinics 
 Sample size: 48 participants randomised. 
Study design Randomisation-sequence generation: Randomised pilot study (Prospective trial) 
48 participants randomised and assigned to 1 of 4 groups: Control, Weight Watchers 
(WW), individualised counselling or a combination of WW and individualised counselling 
No further description 
 Allocation concealment: No description 
 Implementation: Did not report 
 Blinding: Did not report 
 Statistical methods: Means of each group were compDUHGE\SDLUHGRU6WXGHQW¶VWWHVWRU
ANOVA with a Scheffe post hoc test for significance between groups.  
F2 tests were used to compare the proportions.  
Data analysis used SPSS V10.1 with significant at p d 0.05. 
Intervention 1 Weight Watchers arm: Attended weekly WW meeting without dietary or exercise 
instruction 
Intervention 2 Individualised arm: Dietician scheduled weekly for the first 3 months, biweekly at month 
3 to 6 and monthly thereafter. Contacted by telephone 
One-on-one counselling provided diet and exercise by a registered dietician. 
Weight loss goal: 10% decreased out of the initial baseline weight over 6 months 
The dietary goal: Used the American Dietetic Association Exchange List diet plan 
Energy intake: Decreased 500 to 1000 kcal/d. Target fat intake: 20% to 25% of energy 
from fat. Fruit and vegetable intake: At least 5 serving/d. Protein intake: Up to 20% of 
energy. 
&RXQVHOOLQJDSSURDFKXVHGWKHWKHRUHWLFDOIUDPHZRUNRI%DQGXUD¶VVRFLDOFRJQLWLYH
theory. 
Subjects encouraged addressing their thoughts and beliefs about themselves and their 
weight, regarding self-image and self-acceptance. 
Intervention 3 Comprehensive arm: Received the individualised counselling and attended weekly WW. 
Omitted monthly meeting because of adding the dietician-led monthly group. The weekly 
WW programme has dietary and cancer-prevention guidelines plus details of the dietary-
exchange goals.  
Participants could assign for their personal diet plan by learning the points system of WW, 
which takes into account energy; fat and fibres contents of foods including the food-group 
exchanges. Also requested to daily keep exercise and dietary logs. 
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Methods  
Comparison/ 
Control 
&RQWURODUP6XEMHFWVUHFHLYHGWKHQDWLRQDO&DQFHU,QVWLWXWH¶V³$FWLRQ*XLde to Healthy 
(DWLQJ´DQGWKH³)RRG*XLGH3\UDPLG´SDPSKOHWV 
No other dietary or exercise instructions or help 
Met dietician at baseline, 3, 6 and 12 months 
Outcomes Primary outcome measures: Mean weight loss at 3, 6 and 12 months 
Results  
Participant flow 48 participants randomised. 9 excluded. At 12 months, 39 participants remained. 
12 participants in control, 8 participants in WW, 9 participants in individualised 
counselling and 10 participants in combination of WW and individualised counselling 
Baseline data 3DUWLFLSDQWV¶Gemographics: 2EHVHZRPHQ¶DJHUDQJHGIURPWR\HDUVZLWKZHLJKW
95.4 kg and BMI 35.5 kg/m2 at the study entry.  
Number analyzed ITT: 12 participants each in control, WW, individualised counselling, and combination of 
WW and individualised counselling 
Completers at 12 months: 12 participants in control, 8 participants in WW, 9 participants 
in individualised counselling and 10 participants in combination of WW and 
individualised counselling 
Outcomes and 
estimation 
At 12 months, mean weight loss was 0.85 r 6.0 kg in control group, -2.6 r 5.9 kg in WW 
and -8.0 r 5.5 kg in the individualised group. 
Obese participants in comprehensive groups were higher weight loss than other groups at 
3 (7.4 kg), 6 (9.3 kg) and 12 (9.4 r 8.6 kg) months whilst those in control, WW and 
individualised counselling groups approximately lost weight range from 1 kg to 4 kg at 3 
months and range from 1 kg to 8 kg at 6 and 12 months, respectively. 
As a consequence, there was statistically significant difference from control group at 3, 6 
and 12 months (p < 0.05). 
Other outcomes Other results also presented group attendance, telephone counselling, dietary intake and 
exercise but not extracted here. 
Adverse events Did not report 
Discussions  
Interpretation Introduction 
- Reviewed the weight loss methods in the previous studies and factors related to obesity 
such as survivors from breast cancer, group counselling approach and demographic 
characteristics e.g. race, health risk factors.  
- Described the matter of this study: No studies used individualised counselling methods 
combination with weight loss programme  
- Explained the aim of this study  
 Methods 
Randomised pilot study (Prospective trial): Randomisation-sequence generated and 
assigned 48 participants to 1 of 4 groups: Control, Weight Watchers (WW), individualised 
counselling or a combination of WW and individualised counselling. Implementation and 
blinding were not applicable. The reasons were that investigators and participants need to 
know what weight loss structures are and how to advise in details for each arm. This 
would affect to how participants complied to weight loss programme as well. 
Comparison of 4 arms: control, Control, WW, individualised counselling and 
comprehensive arms 
Assessing outcomes: Measured weight in clothing with no shoes using a professional 
beam scale (model 402KLS, Health-o-Meter, IL). Although there was not informed height 
measurement, weight values could be acceptable. 
Provider: A registered dietician 
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Djuric 2002 (continued)  
Discussions  
Interpretation 
(continued) 
Methods (continued) 
Statistical methods: Reported p-value, tests used and programme analysis, however, no 
report of power calculation and confidence intervals. Therefore, this study may not be 
enough participants randomised to see an effect and insufficient participants if they 
declined to participate during the study. 
 Results 
- No report of participant flow but explained in details of numbers excluded, remained for 
ITT and completers analysis  
- Reported values in mean weight with SD and also presented as a graph 
- All diets reported statistically significant differences at p d 0.05. At baseline, results of 
SDUWLFLSDQWV¶FKDUDFWHULVWLFVSUHVHQWHGDVDZKROHVDPSOHVL]HEHFDXVHRIDVPDOOQXPEHURI
each group. 
- Obese participants in comprehensive groups were highest weight loss than other groups 
at 3 (7.4 kg), 6 (9.3 kg) and 12 (9.4 kg) months and statistically significant difference from 
control group at 3, 6 and 12 months (p < 0.05). 
 Discussion 
The authors discussed about the major target of interventions with breast cancer survivors 
and what factors related to participants. This study gave examples of factors related such 
as exercise, dietary changes and quality and weight loss approaches e.g. group support, 
individuals. Based on other evidences, comparing to the counselling methods, this study 
found that the individualised and comprehensive arms were similar to the behavioural 
modification used in the Lifestyle, Exercise, Attitudes, Relationships and Nutrition 
(LEARN) programme.  
Moreover, weight loss counselling in this study was individual contacts by telephone to 
increase fruit and vegetable consumption and decrease fat intake in participants. It was 
suggested that participants were successful weight loss by using this counselling method. 
Compared with e-mails contact, this method also showed the effective weight loss, 
however, it is only any participant who can access the Internet. Thus, telephone contact 
was more convenient in the similar success of weight loss. 
Generalisability Did not report 
Other evidence General comments 
This study concluded that the comprehensive arm was the most successful weight loss. It 
was not only integrated between WW and individualised counselling but also consisted of 
diet, exercise, social support. Therefore, one approach with the combination of 
individualised counselling and the commercial WW programme was the most effective 
weight loss. 
Further study: The comprehensive arm with the combination of individualised counselling 
and the commercial WW programme should be applicable in the larger studies and also 
useful in people who suffered from other medical complications of obesity. 
Funding  NIH, The Weight Watchers Group, Inc. and The Ford Motor Company Fund 
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Donnelly 2007146 
Article identification: 1/2007 5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Donnelly 2007 Country: US 
Objectives Compared the efficacy between a phone and a traditional face-to-face clinic approach to 
achieve 10% weight loss and weight maintenance 
Methods  
Participants Inclusion criteria: Men and women participants aged 25-68 years with BMI 33.2 r 3.8 
kg/m2, were healthy from a written medical history, stable weight and BP medications. 
 Exclusion criteria: Participants used tobacco products, had metabolic disease and 
medications after metabolism. 
 Settings and/or locations: Weight management clinic 
 Duration: 12 weeks 
 Recruitment methods: A detailed letter 
 Sample size: 96 participants (24 men, 72 women) 
Study design Randomisation-sequence generation: No description. Randomised controlled trial 
 Allocation concealment: Did not report 
 Implementation: Did not report 
 Blinding: Did not report 
 Statistical methods: Used Kruskal-Wallis test to compare all 3 groups at 12 weeks 
(weight-loss duration). Weight and BMI were summarised in median (range). 
Intervention 1 Phone group: Weight management clinic weekly 
- Conducted 60 minutes  
- Participated via a group conference call with health educators 
- Received the behaviourally based clinic on lifestyle change, physical activity and 
nutrition and MR by post  
- Self-reported on weight 
Intervention 2 Clinic group: Weight management clinic weekly 
- Conducted 60 minutes 
- Attended a traditional face-to-face clinic with health educators 
- Received the behaviourally based clinic on lifestyle change, physical activity and 
nutrition and MR at the clinic site  
- Reported their weight on a scale at the clinic site 
Intervention 1 and 
2 
Weight loss diet: Total calories for the day are 1250 kcal comprised of 5 MR (3 shakes, 2 
entrees), 7 total fruits and vegetables. 
 Physical activity: Targeted at least 2000 kcal/week by using a progressive protocol of both 
structured exercise and lifestyle PA 
The first 4 weeks: Started with a daily 15-min session and add about 10 more minute/day 
each week for the next 3 weeks 
Control Did not report details of the programme 
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Donnelly 2007 (continued)  
Methods  
Outcomes Primary outcome measures: Weight loss and weight maintenance but not extracted here 
including secondary outcome measures such as attendance, meal replacements (MRs), 
fruits/vegetables (F/V) and physical activity (PA). 
Results  
Participant flow Did not report 
Baseline data  
7DEOH3DUWLFLSDQWV¶characteristics at baseline, median (range) 
 Phone, n = 25 Clinic, n = 27 Control, n = 22 
Age, years 53 (42) 52 (29) 46 (29)* 
Male/Female 9/16 10/17 4/18 
Weight, kg 102.5 (51.2) 95.6 (66.6) 88.2 (54.9) 
BMI, kg/m2 34.6 (14.8) 32.8 (14.3) 31.5 (12.6) 
*Significantly different from phone and clinic groups at p < 0.05 
3DUWLFLSDQWV¶FKDUDFWHULVWLFVLQDOOJURXSVZHUHVLPLODULQWHUPVRIPDMRULW\RIZRPHQZLWKDJHG\HDUVDQG
mean weight 95 kg and BMI 33 kg/m2, approximately. 
Number analyzed ITT: 25 participants in phone group, 27 participants in clinic group and 22 participants in 
control group 
Outcomes and estimation 
Table 2: Weight change in median and percentage at 12 weeks 
 Phone, n = 25 Clinic, n = 27 Control, n = 22 
Weight, kg    
Baseline 102.5 (51.2) 95.6 (66.6) 88.2 (54.9) 
Week 12 10.6 (16.6)* 12.7 (19.9)*, a 0.25 (5.6) 
Weight , %    
< 10 10 6 - 
10-14.9 10 10 - 
15-19.9 5 11 - 
 - - - 
*Significantly different from control groups at p < 0.05 
aSignificantly different between phone and clinic groups at p < 0.05 
At 12 weeks, the median of clinic group was the greatest weight loss with 82.9 kg (13.7%, n = 21) whilst the 
phone group lost weight of 91.9 kg (10.4%, n = 15), and control group lost 88.0 kg (0.2%). Both phone and clinic 
approaches were statistically significant difference when compared with control group. 
Adverse events Did not report 
Discussions  
Interpretation Introduction 
- Defined obesity and the association such as life expectancy and health risk factors. 
However, there was not shown the percentage of US adults who were obese. The article 
reported roughly in terms of ratio of obese people and US population.  
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Donnelly 2007 (continued)   
Discussions  
Interpretation 
(continued) 
Introduction (continued) 
- Reviewed reasons of not researching Internet but interested in phone approach and also 
the advantages of phone approach in the weight loss programme.  
- Described the matter of this study: The previous research studied telephone counselling 
compared with a mail intervention or standard care for 6 months. However, this study was 
doing the phone intervention compared with clinic counselling for 3 months. Did not 
report that no studies have been done before; however, explained the aim and primary 
outcome of this study 
 Methods 
Randomised controlled trial. Allocation concealment, implementation and blinding were 
not applicable.  
Comparison of 3 weight loss deliveries: Phone vs clinic approach and control group. No 
report of what control group looked like. Sample of weight loss diet was shown in a list of 
breakfast, mid-morning snack, lunch, afternoon snack, dinner and late-night snack. At 
baseline, there were only statiVWLFDOO\VLJQLILFDQWGLIIHUHQFHVLQSDUWLFLSDQWV¶DJHV 
 Assessing outcomes: Measured weight in a standard hospital gown by a calibrated digital 
scale, r 0.1 kg accurately. Weight values should be valid even though there was not 
informed height measurement. 
Provider: Physician, health educator 
 Statistical methods: Reported only tests used to compare all 3 groups at the particular time 
point, however, power calculation, significant level, programme used and confidence 
intervals were unavailable. Data analysis used nonparametric test to compare weight 
change of sample size in each group and presented values as median (range) from SPSS.  
This study has no power calculation so that it may not be enough participants randomised 
to see an effect and insufficient participants if they declined to participate during the study. 
 Results 
- No report of participant flow but reported values in median weight with range 
- All approach groups reported statistically significant differences (p < 0.05). 
- At 12 weeks, weight loss in the clinic and phone groups was statistically significant 
difference from baseline whilst both phone and clinic approaches were statistically 
significant difference when compared with control group. 
 Discussion 
The authors firstly discussed about the study type, intervention groups and primary 
outcomes of this study. Weight loss at 12 weeks was presented in median and shown that 
there was significantly different between phone and clinic approaches. Moreover, weight 
loss achieved over 10% weight loss from baseline. This met the National Heart, Lung, and 
Blood Institute (NHLBI) guidelines. The reason of 10% weight loss of the initial weight 
was that the recommendation of NHLBI in order to improve chronic disease.  
Secondly, comparing to other previous studies, findings were not different from those at 
the similar approach.  
Lastly, limitations were mainly female, and self-reported could be under or over 
estimation (e.g. height). 
Generalisability Did not report 
Other evidence General comments 
Comparison between a phone approach and the traditional weight management clinic was 
similar success at 10% weight loss of the initial weight at baseline. Further study: Focused 
on cost analysis 
Funding  Health Management Resources 
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Foster 2009147 
Article identification: 1/2009 5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Foster 2009 Country: US 
Objectives Assessed the effects of a commercially available weight loss programme on weight and 
glycemic control among obese patients with type 2 diabetes 
Methods  
Participants Inclusion criteria: Obese patients with type 2 diabetes with BMI 30-50 kg/m2, aged 21-75 
years, screened HbA1c DOORZHGWRXVH0HWIRUPLQ7KLD]ROLGLQHGLRQHV6XOIRQ\OXUHDV 
 Exclusion criteria: Obese patients had serious medical illness such as uncontrolled 
K\SHUWHQVLRQPP+JWRRNOLSLG-lowering medications or medications affected 
body weight, pregnant or lactating and used diabetes treatment e.g. insulin. 
 Settings and/or locations: Temple University 
 Duration: 3 months for weight loss 
 Recruitment methods: Recruited via newspaper advertisements, flyers and physician 
referrals from August 2007 to December 2008 
 Sample size: 69 patients randomised 
Study design Randomisation-sequence generation: Randomised study. Used random-number generator 
to a prepackaged, portion-controlled diet plan (PCD) or a diabetes support and education 
(DSE) programme 
 Allocation concealment: Insufficient information 
 Implementation: Statistician generated the randomisation sequence and allocation 
concealment. The research coordinator enrolled participants and randomly assigned them 
to either group. 
 Blinding: Did not report 
 Statistical methods: Differences between groups at baseline used independent samples t 
tests or Wilcoxon rank-sum tests for continuous variables and F2 for categorical variables. 
ITT analysis used at 3 months. Values of changes were performed as mean r SD or 
percentage. 
Intervention A commercially available weight loss programme: A prepackaged, portion-controlled diet 
plan (PCD) consisted of NutriSystem® DTM PCD 3 months 
- Women consumed approximately 1250 calories/d: Instructed to consume 3 meals and 1 
snack per day from NutriSystem® DTM PCD, added conventional foods 
- Men consumed approximately 1550 calories/d: With adding other sources, NutriSystem® 
DTM PCD meals and snacks 
- Participants received behavioural treatment in groups of 8-12 people, led by health care 
professional: Weekly from week 1-12, biweekly from week 13-24. Topics included self-
monitoring, stimulus control, goal setting and relapse management. 
- Principal walking: Beginning at week 4, the PCD group participated in 4 sessions of 20 
minutes each and progressing by week 24 to 5 sessions of 40 minutes each.  
Comparison/ 
Control 
A diabetes support and education (DSE) programme 
- Participants attended 3 group sessions of 8-12 people in week 1, 5, 9. 
- After 12 weeks, participants began weekly comprehensive group behavioural treatment 
and NutriSystem® DTM PCD in week 1-12. 
- Principal walking: Beginning at week 16, the DSE group participated in 4 sessions of 20 
minutes each and progressing by week 24 to 4 sessions of 40 minutes each. 
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Foster 2009 (continued)  
Methods  
Outcomes Primary outcome measures: Weight and BMI changes  
Secondary outcome measures: WC, BP, HbA1C (glycemic control), glucose, triglycerides, 
TC and quality of life also presented but not extracted here. 
Results  
Participant flow Did not report 
Baseline data  
7DEOH3DUWLFLSDQWV¶characteristics at baseline 
Measures, mean or n (r SD or %) PCD, n = 35 DSE, n = 34 
Age, years  52.1 (7.7) 52.8 (11.2) 
Weight, kg 111.5 (19.3) 110.9 (23.5) 
BMI, kg/m2 39.1 (5.5) 38.9 (6.9) 
Gender, n (%) 
Male 
Female 
 
9 (25.7) 
26 (74.3) 
 
11 (32.2) 
23 (67.7) 
3DWLHQWV¶FKDUDFWHULVWLFVLQERWKJURXSVPRVWO\ZHUHIHPDOHDQGDJHGDERXW\HDUVZLWKPHDQZHLJKWNJ
and BMI 39 kg/m2, approximately. 
Number analyzed ITT: 69 patients (49 females, 20 males), 35 patients in PCD and 34 patients in DSE 
Completers: 34 patients each in PCD and DSE groups 
Outcomes and estimation 
Table 2: Primary outcomes measured at baseline and month 3, completed patients = 68 
Measures, mean or n (r SD or %) PCD, n = 34 DSE, n = 34 p-value 
Weight, kg 
Baseline 
3 months 
Adjusted change (range) 
 
111.5 (19.3) 
103.9 (17.6) 
-8.2 (9.5 to -6.7) 
 
110.9 (23.5) 
110.4 (23.0) 
-0.6 (-2.0 to 0.8) 
 
 
 
< 0.0001* 
BMI, kg/m2 
Baseline 
3 months 
Adjusted change (range) 
 
39.1 (5.5) 
36.6 (5.4) 
-2.6 (-3.3 to -1.9) 
 
38.9 (6.9) 
38.5 (6.8) 
-0.4 (-1.1 to 0.3) 
 
 
 
< 0.0001* 
*Significant at p < 0.05    
Outcomes and 
estimation 
$WPRQWKVFRPSOHWHGSDWLHQWV¶PHDQZHLJKWORVVNJLQ3&'JURXSZDV
greater than those in DSE group (0.6 kg, 0.4%) as well as mean BMI (2.6 kg/m2, 6.6%) in 
PCD group was greater than those in DSE group (0.4 kg/m2, 1.0%). Weight loss and BMI 
decrease of both groups at baseline and 3 months were statistically significant difference  
(p < 0.0001). 
 Patients who participated in a commercially available weight loss programme using a 
prepackaged, portion-controlled diet plan (PCD) effectively lost weight. 
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Foster 2009 (continued)   
Results  
Adverse events Did not report 
Discussions  
Interpretation Introduction 
- Reviewed the increase of obesity and development of diabetes in adults  
- Described the matter of this study: Few studies about the effects of commercial weight 
loss programme among obese patients with type II diabetes, and explained the purpose of 
this study  
 Methods 
Randomised study: Generated sequence of randomisation by random-number generator to 
a prepackaged, portion-controlled diet plan (PCD) or a diabetes support and education 
(DSE) programme. Allocated 69 patients (49 females, 20 males) to PCD (35 patients) and 
DSE (34 patients). Implemented by statistician  
Blinding was not applicable. 
 Assessing outcomes: Measured weight by calibrated scaled (Detecto, Webb City, MO) 
with wearing light cloth and without shoes and height by a stadiometer (Harpenden, 
Holtain Limited, Crosswell, UK). Both were measured twice and presented by the average 
of the 2 readings at baseline. Should be valid and reliable 
Providers: Physician, facilitators from ALED and HEED 
 Statistical methods: Although there was no report of the percentage of power calculation, 
significant level and programme used for analysis, the study presented the tests used. 
Consequently, SPSS was used, and significant level was p < 0.001 and 0.0001 as shown in 
results. 
 Results 
- No participant flow presented but reported values in mean weight with SD or frequency 
(%). Both diets reported statistically significant differences (p < 0.001 and 0.0001). 
 
- At 3 months, the percentage of weight change in PCD group (7.1 r 4%) was greater than 
weight change in DSE groups (0.4 r 2.3%). Weight loss of both groups was statistically 
significant difference between baseline and 3 months (p < 0.0001). 
 Discussion 
The authors discussed about comparing weight loss between PCD and DSE programme. 
At baseline, no significant differences between 2 groups. They commented about 
partiFLSDQWV¶FKDUDFWHULVWLFVDWEDVHOLQH3DUWLFXODUO\7KHLUUDFHZDV that over half were 
African American who lost less weight than White, likewise other studies.  
,QIDFWQRQHHGWRFRPPHQWRQSDUWLFLSDQWV¶FKDUDFWHULVWLFVEHFDXVHWKLVVWXG\GLGQRW
focus on demographic factors but health risk factors. Thus, it was found that the higher 
weight loss, the more reduction in HbA1c, WC, BP, triglycerides and quality of life. 
Nevertheless, findings were clinically and statistically significant difference of PCD group 
(8.2 kg, 7.1%).  
Recommendation for further study: Evaluating the effectiveness of this weight loss 
approach in a clinical setting and a longer time period. 
Limitations: Short period of the study, inability to disconnect the contact between 
professional and the PCD group 
Generalisability Did not report 
Other evidence General comments 
Reported height and weight should be accuracy because of measuring by a calibrated tool 
and repeating measure. This study suggested that obese patients with type 2 diabetes had 
profit from the weight loss programme. 
Funding  NutriSystem® DTM 
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Gardner 2007117 
Article identification: 2/2007 5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Gardner 2007 Country: US 
Objectives Determined the effects of 4-weight loss diets from low to high carbohydrate intake on 
weight loss and the related health risk factors among overweight and obese pre-
menopausal women  
Methods  
Participants Inclusion criteria: Premenopausal women aged 25-50 years with BMI 27-40 kg/m2, had 
stable weight in the last 2 months and stable medications for at least 3 months.  
 Exclusion criteria: Women had hypertension, type 1 or 2 diabetes mellitus, heart, renal or 
liver disease, cancer or active neoplasm, hyperthyroidism, alcohol intake at least 3 
drinks/day, medications affect weight or energy expenditure, pregnancy, lactation, no 
menstrual period in the previous 12 months or plan to be pregnant in the next year. 
 Settings and/or locations: Local community in the US 
 Duration: 12 months from February 2003 to October 2005 
 Recruitment methods: From the local community via media advertisements 
 Sample size: 311 participants randomised 
Study design Randomisation-sequence generation: Randomised trial 
Randomisation in blocks of 24: 6 participants per treatment group 
1479 individual screened. 311 randomised. 
 Allocation concealment: 77 Atkins group, 79 Zone group, 79 LEARN group, 76 Ornish 
group 
 Implementation: The group assignment from an opaque envelope was chosen by a blinded 
research technician. 
 Blinding: A research technician was blinded for participant selection.  
Clinic and laboratory staff members were blinded to treatment.  
 Statistical methods: 2.7 kg (6 lb or 3% out of 180 lb approximately) was clinically chosen 
for the minimal significance among group differences in weight change. SD was 6.3 kg of 
weight change based on the previous study.  
80% power was selected to detect a 2.7 kg difference for 12 months. 
ANOVA was used to analyse the differences of weight changes among 4 diets at month 
12. If significant, all pairwise comparisons were tested by using the Tukey studentised 
range adjustment. 
Statistical test was 2-tailed using a significant at p < 0.05. 
Intervention  Participants for each diet group:  
- Needed to attend 1-hour classes led by a registered dietician once per week for 8 weeks 
- Were given the incentive payments of $25, $50 and $75 to complete the 2-, 6- and 12-
month data collection 
Intervention 1 Atkins: Participants received  
- 'LHWERRNRI³'U$WNLQV¶QHZ'LHW5HYROXWLRQ´ 
- 20 g/day or less of carbohydrate for induction 2-3 months 
- JGD\RUOHVVRIFDUERK\GUDWHIRUWKHVXEVHTXHQW³RQJRLQJZHLJKWORVV´SKDVH 
The programme was no specific energy restriction goals. 
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Gardner 2007 (continued)  
Methods  
Intervention 2 =RQH3DUWLFLSDQWVUHFHLYHGGLHWERRNRI³(QWHUWKH=RQH´ 
The programme was a 40%-30%-30% distribution of carbohydrate, protein and fat, 
respectively and also specific energy restriction goals. 
Intervention 3 2UQLVK3DUWLFLSDQWVUHFHLYHGGLHWERRNRI³(DW0RUH:HLJKW/HVVE\2UQLVK´ 
The programme emphasized on 10% maximum of energy from fat including exercise, 
nutritional supplements and behavioural modification strategies and also no specific 
energy restriction goals. 
Intervention 4 /($513DUWLFLSDQWVUHFHLYHGGLHWERRNRI³7KH/($510DQXDOIRU:HLJKW
0DQDJHPHQW´ 
A 16-week programme consisted of 55%-60% energy from carbohydrate and < 10% 
energy from saturated fat, caloric restriction, increased physical activity and behaviour 
modification strategies including specific energy restriction goals. 
Outcomes Primary outcome measures: Weight loss 
Secondary outcome measures: Lipid profile (low- and high-density lipoprotein, non-high-
density lipoprotein, cholesterol and triglycerides levels) 
Percentage of body fat, waist-hip ratio, fasting insulin and glucose levels, BP 
Results  
Participant flow 1479 screened: 698 ineligible or not interested, 470 declined to participate or other reasons 
 311 randomised:  
 77 Atkins group: 68 completed, 9 withdrew 
 79 Zone group: 61 completed, 18 withdrew 
 79 LEARN group: 61 completed, 18 withdrew 
 76 Ornish group: 59 completed, 17 withdrew 
Baseline data  
7DEOH3DUWLFLSDQWV¶FKDUDFWHULVWLFVDWEDVHOLQHPHDQr SD) 
 Atkins,  
n = 77 
Zone,  
n = 79 
LEARN,  
n = 79 
Ornish,  
n = 76 
All diets,  
n = 311 
Age, years 42 (5) 40 (6) 40 (7) 42 (6) 41 (6) 
Weight, kg 86 (13) 84 (12) 85 (14) 86 (10) 85 (12) 
BMI, kg/m2 32 (4) 31 (3) 31 (4) 32 (3) 32 (4) 
3DUWLFLSDQWV¶FKDUDFWHULVWics in all diet groups aged 41 years with mean weight 85 kg and BMI 32 kg/m2. 
Number analyzed ITT: 77 Atkins group, 79 Zone group, 79 LEARN group, 76 Ornish group 
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Gardner 2007 (continued)  
Results  
Outcomes and estimation 
Table 2: Mean weight and BMI changes from baseline at 12 months, mean (r SD or 95% CI) 
 Atkins, n = 77 Zone, n = 79 LEARN, n = 79 Ornish, n = 76 p-value 
Weight, kg -4.7  
(-6.3 to -3.1) * 
-1.6  
(-2.8 to -0.4) 
-2.2  
(-3.6 to -0.8) 
-2.6 
 (-3.8 to -1.3) 
< 0.05* 
BMI, kg/m2 -1.65 (2.54) -0.53 (2.00) -0.92 (2.00) -0.77 (2.14) 0.01** 
*Significant at p < 0.05. ** Significant at p < 0.01 
At 12 months, Atkins group (81.3 kg, 5.5%) was significantly greater weight loss than others whilst LEARN 
(82.8 kg, 2.6%), Ornish (83.4 kg, 1.9%) and Zone (82.4 kg, 1.9%) groups lost weight, respectively.  
There was statistically significant difference between Atkins and Zone diets (p < 0.05). However, there were no 
statistically significant differences among Zone, LEARN and Ornish.  
Secondary outcome At 12-month changes, HDL-C, triglycerides, SBP and DBP were significant difference at 
p = 0.002, 0.01, < 0.01 and 0.009, respectively. Only Atkins group was the most 
improvement. 
Results also presented dietary intake and energy expenditure but not extracted here. 
Adverse events Did not report 
Discussions  
Interpretation Introduction 
- Reviewed the health cost, health consequence and health benefits of weight loss by 
National Dietary Weight Loss Guidelines  
- Described the matter of this study: Had the limited evidence of the effectiveness of other 
diets, however, no reasons of study population selected premenopausal women   
- Referred to 4 diets selected in this study which were Atkins (A, very low carbohydrate), 
Traditional (T, LEARN: Life-style, Exercise, Attitudes, Relationships and Nutrition), 
Ornish (O, very high carbohydrate) and Zone (Z, low carbohydrate). 
- Explained 2 objectives of this study  
 Methods 
Randomised trial: Randomisation sequence was generated as blocks of 24. 6 participants 
per treatment group. 311 participants were randomised and allocated 77 to Atkins group, 
79 to Zone group, 79 to LEARN group and 76 to Ornish group. A blinded research 
technician chose the group assignment from an opaque envelope. Clinic and laboratory 
staff members were blinded to treatment. 
Blinding was only investigator side that meant single blind. Participants were not blinded 
because they might need to know what programme structures were.  
Comparison of 4 diet groups: Atkins (A, very low carbohydrate), Zone (Z, low 
carbohydrate), LEARN (T, Life-style, Exercise, Attitudes, Relationships and Nutrition) 
and Ornish (O, very high carbohydrate).  
Assessing outcomes: Measured weight to the nearest 0.1 kg on a calibrated clinical scale 
and height to the nearest ml using a standard wall-mounted stadiometer. Both weight and 
height values should be valid. 
Provider: A registered dietician 
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Gardner 2007 (continued)  
Discussions  
Interpretation 
(continued) 
Statistical methods: Reported power calculation (80%) to detect a 2.7-kg difference for 12 
months of weight change between 4 treatment groups, at least 75 participants per group.  
Power calculation could help this study for: 1) Saving time and money, 2) Scanning 
whether or not participants randomised were enough to see an effect, 3) not wasting time 
on an underpowered study and 4) preparing for sufficient participants if they declined to 
participate during the study. Also, reported significant level, values presented and tests 
used but not programme used. This study used SPSS for data analysis as default from tests 
used.  
 Results 
- Reported flow of participants with reasons of ineligibility or not interesting, declining to 
participate or others and withdrawals and also ITT (primary) and completers analysis and 
values in mean weight with SD 
- All 4 diet groups reported statistically significant differences at p < 0.05, however, there 
was no report of significant difference among groups at baseline. At 12 months, 
SDUWLFLSDQWV¶PHDQZHLJKWORVVZDVNJ&,-6.3 to -3.1) in Atkins group, 1.6 kg (-
2.8 to -0.4) in Zone, 2.2 kg (-3.6 to -0.8) in LEARN and 2.6 kg (-3.8 to -1.3) in Ornish. 
There were no statistically significant differences among Zone, LEARN and Ornish. 
However, there was statistically significant difference between Atkins and Zone diets (p < 
0.05). 
 Discussion 
The authors commented on women who participated in the diet group by having very low 
to very high carbohydrate content and discussed the findings.  
They firstly discussed about concerns on diets that affected blood lipid level and 
cardiovascular risk. Atkins group was more effective than others because participants in 
other groups received fat up to 10% in LEARN and Ornish and up to 30% in Zone. As a 
result, those in other groups less complied. This would affect the primary and secondary 
outcomes such as LDL-C levels. However, this study did not provide percentages of 
dietary programme adherence. If so, Atkins would be greater adherence than others. 
Moreover, Atkins highly decreased TG, SBP and DBP so that this would be associated 
with cardiovascular risk factors and body weight decrease. Moreover, there were other 
concerns such as only overweight premenopausal women aged 20-50 years for the initial 
inclusion criteria of participants and differences in statistical power. 
Secondly, this study was compared to 2 previous studies of Dansinger and Krauss. Both 
ZHUHVLPLODUWRWKLVVWXG\LQDYDULHW\RIIDFWRUV%DVHGRQ'DQVLQJHU¶VHYLGHQFHWKHUH
were similar in many design features such as numbers and types of treatment groups and 
WKHVDPHSHULRGRIWKHVWXG\+RZHYHUWKHUHZDVGLIIHUHQWUHSRUWIURP'DQVLQJHU¶VVXFK
as no significant difference among diet groups but only adherence level. This study only 
reported significant difference between groups at 12 months.  
7KLUGO\FRPSDULQJWR.UDXVV¶VVWXG\LWZDVPDLQO\GLVFXVVHGDERXWGLHWVXVHG)RU
example, the different carbohydrate content was compared to fat or protein diets.  
Lastly, the authors addressed more ideas on greater success in a long-term weight loss 
programme that depended on increasing energy expenditure, social and environmental 
supports.  
There were strengths of this study which were a lager sample size, a long-term treatment 
and the different diet content in each group. Nevertheless, there were also limitations on 
only premenopausal women, no considering on menstrual cycle timing, no stability on 
weight loss trajectories at 12 months and lack of a valid and comparable assessment of 
individual adherence. 
Generalisability Generalisation to other populations is possibility with caution. 
Other evidence General comments 
There were more other limitations but not associated with weight loss. Further study: 
Focus more on health benefits, clinical practice or policy. Physicians are recommended to 
be counselled to reassure using diets. 
Funding  National Institutes of Health  
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Gold 2007148 
Article identification: 3/2007 5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Gold 2007 Country: US 
Objectives Investigated the effectiveness of a structured behavioural weight loss website (VTrim) vs a 
commercial weight loss website (eDiets.com) 
Methods  
Participants Inclusion criteria: Overweight or obese subjects aged 18 years and older with BMI 25-39.9 
kg/m2 and regular access to a computer. 
 Exclusion criteria: Subjects planned to move or get pregnant within the next 12 months, 
had history of major medical or psychiatric problems, smoked or been a non-smoker < 1 
year, took medication affected weight, and were unable to participate the exercise 
programme weekly meetings. 
 Settings and/or locations: Website weight loss programme 
 Duration: 12 months  
 Recruitment methods: Recruited via advertisement in a local Burlington, VT, newspaper. 
Also, a technology checked before randomisation, including recruitment by sending and 
receiving lines of text in a chat programme and submitting entries in an electronic food 
journal 
 Sample size: 185 participants randomised.  
Study design Randomisation-sequence generation: Randomised controlled trial, face-to-face 
intervention. Conducted from February 2003 to March 2005 
All subjects were measured at baseline, 6 and 12 months. No further description 
 Allocation concealment: No description 
595 eligible participants assessed. 185 participants randomised and allocated to 
eDiets.com 62 participants, VTrim 62 participants and arm unrelated to this study 61 
participants. 124 overweight and obese adults (101 women and 23 men) allocated in the 
study. 
 Implementation: Did not report 
 Blinding: Did not report 
 Statistical methods: An independent-samples t test was used to compare baseline data 
between groups for continuous variables as well as F2 for categorical variables. Weight 
change used a baseline-carried-forward (BCF) analysis and completer analysis at 6 and 12 
months. Data analysis used SPSS V11.5. 
Intervention A structured behavioural weight loss website (VTrim): 6-month on-line therapist-led 
weight loss programme and 6-month on-line weight maintenance programme 
6-month weight loss phase: Focused on the modification of eating and exercise habits 
through the use of behavioural strategies and self-management skills, self-reported their 
weight each week, chatted on-line in hour-long weekly, asked to reduce energy intake up 
to 1000 calories/d, instructed to gradually increase energy expenditure and burn minimum 
of 1000 calories/wk, encouraged peer-to-peer interaction and group support 
6-month weight maintenance phase: Provided the same as on-line  but less frequency, bi-
weekly meeting, encouraged journaling everyday and used the support components of the 
website 
Comparison/ 
Control 
Commercial weight loss website (eDiets.com): Participants 
- Participated in a pre-study orientation of the site 
- Determined how to self-guide their use of the weight loss programme 
- Were prescribed a calorie goal based on an estimate of their resting metabolic rate 
- Self-reported weight weekly 
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Gold 2007 (continued)  
Methods  
Comparison/ 
Control 
This programme: 
- Provided a calorie-controlled meal plan tailored to individual preferences 
- Encouraged participants to follow their meal plan (my diet), recipe instructions and 
menu-specific grocery lists 
- Supported exercise (my fitness) to provide progress weekly 
- Monitored by experts and peers in Support central 
Outcomes Primary outcome measures: Weight loss  
Secondary outcome measures: Social support and use of website components but not 
extracted here. 
Results  
Participant flow 595 eligible participants assessed. 410 excluded.  
185 participants randomised and allocated to eDiets.com 62 participants, VTrim 62 
participants and arm unrelated to this study 61 participants. 14 and 22 participants lost to 
follow-up in eDiets.com and VTrim groups, respectively. 
Completers: 48 participants in eDiets.com and 40 participants in VTrim groups 
Table 1: Baseline characteristics of participants in VTrim and eDiets.com groups, n = 62 each 
Variable VTrim, mean (r SD) eDiets.com, mean (r SD) 
Age, years  46.5 (10.7) 48.9 (9.9) 
Weight, kg 92.0 (15.7) 90.2 (14.1) 
BMI, kg/m2 32.3 (3.9) 32.5 (4.2) 
Sex, n (%) 
Female 
Male 
 
48 (77) 
14 (23) 
 
53 (86) 
9 (15) 
3DWLHQWV¶FKDUDFWHULVWLFVLQERWKJURXSVZHUHRIZRPHQZLWKPHDQDJHGDERXW\HDUVPHDQZHLJKWNJ
and mean BMI 32 kg/m2, approximately.  
Number analyzed ITT: 62 participants each in eDiets and VTrim groups  
Completers: 48 participants in eDiets.com and 40 participants in VTrim groups 
Outcomes and 
estimation  
Primary outcome: Weight loss at month 6 with ITT analysis, VTrim lost more weight than 
eDiets.com group (6.8 r 7.8 kg vs 3.3 r 5.8 kg, p = 0.005 or 7.3 r 7.8 % vs 3.6 r 6.1%). 
At month 12 with BCF analysis, VTrim also lost more weight than eDiets.com group (5.1 
r 7.1 kg vs 2.6 r 5.8 kg, p = 0.034 or 5.5 r 7.6% vs 2.8 r 5.5%). As a result, patients in a 
therapist-led structured behavioural weight loss website were greater weight loss than a 
self-help commercial weight loss website. 
Weight loss at month 6 with completers analysis, VTrim lost more weight than eDiets.com 
group (8.3 r 7.9 kg vs 4.1 r 6.2 kg, p = 0.004 or 8.9 r 7.8% vs 4.4 r 6.5%). At month 12, 
VTrim also lost more weight than eDiets.com group (7.8 r 7.5 kg vs 3.4 r 5.8 kg, p = 
0.002 or 8.6 r 7.9% vs 3.7 r 6.0%). As a result, patients in a therapist-led structured 
behavioural weight loss website lost weight 5% or more of their initial body weight. 
Adverse events Did not report 
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Gold 2007 (continued)  
Discussions  
Interpretation Introduction 
- Reviewed the proportion of prevalence of US overweight and obesity, the incidence 
related, health costs on overweight and obesity, the principle of treatment in obesity and 
total number and percentage of US people who can access Internet. 
- Reviewed the relevant studies about the Internet research-based weight loss intervention 
studies and presented findings from the previous studies 
- Reviewed the drawback of the effects of on-line weight loss programmes 
- Described the matter of this study: Little knew about the effectiveness of on-line weight 
loss programme  
- Explained 2 aims of this study, however, in this review study focused only on the 
primary purpose that was compared a behavioural on-line intervention to a commercial 
self-help website on weight loss  
 Methods 
Randomised controlled trial, face-to-face intervention: No report of what type of 
randomisation used. However, allocation numbers were existed by following: 595 eligible 
participants were assessed. 185 participants were randomised and allocated to eDiets.com 
62 participants, VTrim 62 participants and arm unrelated to this study 61 participants. 124 
overweight and obese adults (101 women and 23 men) were allocated in the study.  
Implementation and blinding were not applicable. 
 Assessing outcomes: Measured weight by a beam-balance scale with their street clothes 
and no shoes and height with self-reported at baseline. Weight value should be valid 
whilst height may be under of over estimation. 
Provider: Therapist 
 Statistical methods: No report of power calculation and significant level, however, this 
study presented type of analysis, tests used, programme analysed and 2 analyses which 
were BCF and completers analysis 
There was no power calculation to: 1) Detect the difference between baseline and the end 
of programme, 2) scan whether or not participants randomised were enough to see an 
effect and 3) prepare for sufficient participants if they declined to participate during the 
study. 
 Results 
- No report for significant level in the statistical methods, significant level at p < 0.05 was 
regularly selected as default. 
- Reported flow diagram of the study participants, number of ITT and completers analysis 
and values in mean weight with SD. Both weight loss programmes reported statistically 
significant differences at p < 0.05. 
- At month 6 with completers analysis, VTrim lost more weight than eDiets.com group 
(8.3 r 7.9 kg vs 4.1 r 6.2 kg, p = 0.004). At month 12, VTrim also lost more weight than 
eDiets.com group (7.8 r 7.5 kg vs 3.4 r 5.8 kg, p = 0.002). As a result, patients in a 
therapist-led structured behavioural weight loss website lost weight 5% or more of their 
initial body. 
 Discussion 
The authors summarised on the findings of this study. At the first 6 months, weight change 
of both groups was associated with web usage. However, at the last 6 months, both groups 
gained weight because of decreasing web usage.  
They also discussed by comparing to the 2 previous on-line weight loss studies. However, 
it was uncertain that whether or not the effective weight loss was managed by the quality 
of weight loss programme. As a consequence, the on-line weight loss programme was 
compared to university-based on-line programmes. Findings were similar but not yet 
known about whether or not the on-line programmes with a larger population were 
feasible or economical. Nonetheless, during the time period of this study, this study 
informed that eDiets.com charged $99.00 for a 1-year membership. VTrim would be more 
expensive than eDiets.com.  
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Gold 2007 (continued)  
Discussion  
 Discussion (continued) 
Strengths: 1) Randomised controlled trial with the weight data was the first study of 
investigating a commercial online weight loss programme without relating additional 
professional contact. 
2) Comparing to a traditional face-to-face programme, subjects who involved an online 
structured behaviour weight loss website could achieve their weight loss. 
Subjects who received a structured, therapist-led behavioural online weight loss 
programme significant lost more weight than those who enrolled a self-help commercial 
weight loss programme. The percentage of subjects¶ZHLJKWloss in the structured 
programme mostly doubled achieving a 5% or more weight loss target, 65% vs 37.5%.  
Generalisability Did not report 
Other evidence General comments 
Recommendation for further study: Repeat the study on a larger scale and investigate the 
feasibility of a more structured behavioural programme by incorporating and applying into 
a commercial programme 
An online weight loss website, therapist-led structured behavioural intervention was 
greater weight loss than a self-help commercial online weight loss programme. The reason 
was that commercial weight loss website had enormous potential public health impact. 
Funding  US Department of Agriculture Health Act Funds 
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Green 2005149 
Article identification: 2/2005 5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Green 2005 Country: UK, US 
Objectives Investigated whether the working memory impairments characteristics of dieting were 
related to cortico-steroid secretion in the early stages of weight loss 
Methods  
Participants Inclusion criteria: Participants who were healthy, pre-menopausal and overweight women 
with BMI 25-29 kg/m2 aged 20-45 years with normal or corrected to normal, visual acuity 
and English as the first language. 
 Exclusion criteria: Participants with physical or psychiatric health problems, smokers, 
heavy drinkers, taking dietary supplements or oral contraceptive, pregnancy or lactating 
 Settings and/or locations: Birmingham, UK 
 Duration: 8 weeks 
 Recruitment methods: Recruited via newspaper advertisement  
336 potential participants completed the initial telephone and a postal health screening. 
 Sample size: 73 participants randomised  
Study design Randomisation-sequence generation: Randomised controlled trial.  
73 participants randomised. No further description 
 Allocation concealment: Insufficient information 
16 participants in control group, 25 participants in unsupported dieters and 14 participants 
in supported dieters 
 Implementation: Did not report 
 Blinding: Did not report 
 Statistical methods: Analysed data via SPSS V11 by using mean r standard error (SE), 
significant at p < 0.05 
Intervention 1 Supported dieters: Commercial weight loss plan consisted of: calorie restriction, 
nutritionally balanced diet in conjunction with weekly weighing and group support 
sessions but without food provided. 
Intervention 2 Unsupported dieters: Participants were asked to pursue any diet plan selected. The diets 
selected ranged from the nutritionally balanced or calorically restricted diets, low fat diets 
and low carbohydrate diets 
Comparison/ 
Control 
Non-dieting control 
All participants attended weekly weighing sessions. 
Outcomes Outcome measures: Changes in BMI and body weight 
Other outcome measures: Cortisol secretion, neuropsychological assessment and state 
anxiety but not extracted here. 
Results  
Participant flow Did not report 
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Green 2005 (continued) 
Baseline data, outcomes and estimation 
Table 1: Difference of mean BMI and body weight at baseline, week 1, 4 and 8 
 Control group, n = 16 Unsupported dieters, n = 25 Supported dieters, n = 14 
BMI, kg/m2    
Baseline 26.88 (6.52) 28.15 (4.10) 29.27 (6.52) 
Week 1 0.00 (0.14) -0.34 (0.22) -0.37 (0.08) 
Week 4 0.03 (0.20) -0.50 (0.40) -0.59 (0.23) 
Week 8 0.10 (0.35) -0.86 (1.02) -0.97 (0.41) 
Body weight, kg    
Baseline 74.12 (162.95) 75.09 (83.52) 80.42 (94.28) 
Week 1 -0.25 (1.17) -0.79 (1.12) -1.00 (0.54) 
Week 4 -0.13 (1.49) -1.26 (2.82) -1.62 (1.95) 
Week 8 -0.05 (2.84) -2.16 (7.24) -2.65 (3.28) 
Notes: Data presented the baseline measurements and subsequent change from baseline, mean (r SE) 
Table 1: There was no significant difference between baseline and other time within group. On the other hand, 
there was significant difference among groups. 
Both unsupported (2.9%) and supported dieters (3.3%) were higher weight loss than control group (0.07%). 
However, comparing between unsupported and supported dieters was greater weight loss in the unsupported 
dieters. 
Number analyzed ITT: Did not report, 55 participants completed 
Completers: 16 participants in control group, 25 participants in unsupported dieters and 14 
participants in supported dieters 
Adverse events Did not report 
Discussions  
Interpretation Introduction 
- Reviewed the proportion of prevalence of UK overweight and obesity, NHS plan the 
management and prevention of obesity  
- Reviewed the relevant studies about dieting helped weight loss, factors related successful 
weight loss such as age and starting weight, psychosocial status, cognitive function  
- Reviewed the impairment form cognitive function such as diets in unsupervised and 
uncontrolled manner or supervised and supported individuals  
- Hypothesis was that the observed impairment in cognitive function, an elevated stress 
response was occurred during the first stage of unsupported dieting. This hypothesis was 
supported by the previous studies. However, those studies were not clarified whether or 
not these impairments were a function of unsupported or supported dieting. Therefore, the 
matter of this study was compared a function of supervised to unsupervised dieting and 
raised cortico-steroid levels.  
- Explained aim of this study 
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Green 2005 (continued) 
Discussions  
Interpretation 
(continued) 
Methods 
Not applicable for randomisation-sequence generation, allocation concealment, 
implementation, blinding, ITT and sample size or power calculation 
There was no power calculation to: 1) Detect the difference between baseline and the end 
of programme, 2) scan whether or not participants randomised were enough to see an 
effect and 3) prepare for sufficient participants if they declined to participate during the 
study. 
The study was RCT but did not report how to generate and who implemented 
randomisation. However, the study presented 73 participants were randomised. 16 
participants in control group, 25 participants in unsupported dieters and 14 participants in 
supported dieters.  
Comparison of 3 groups: Control, unsupported dieters and supported dieters groups 
 Assessing outcomes: Measured weight in underwear and without shoes by using the foot-
to-foot electronic scale (TBF-350A, Tanita Corp., Tokyo, Japan) and height by using a 
wall mounted stadiometer. Both values should be valid. 
Provider: Dietician 
 Statistical methods: Although statistical analysis was not in the methods section, tests 
used, programme analysed, values presented and significant level were presented in the 
first paragraph of results. Nevertheless, there was no report of power calculation to detect 
differences of sample size each group at the particular time point. 
 Results 
- No report of participant flow, however, reported values in mean weight with SE 
- All 3 groups reported statistically significant differences at p < 0.05. 
- At 8 weeks, supported dieters (3.3%) were greater weight loss than unsupported dieters 
(2.9%). However, the sample size of both dieters was small and short period of the 
treatment. The duration of weight loss should be long-term treatment for the future work. 
 Discussion 
The authors summarised the present study, referred to the previous data of Green about the 
neuropsychological impairments and compared to the similar study about the cortisol 
levels. Reviewer emphasized only on weight loss so that supported dieters were greater 
weight loss than unsupported dieters. Nevertheless, authors discussed about uncertainty of 
the relationship between stress, cortisol, unsupported dieting and cognitive function.  
Authors discussed about confounding variables that was the possibility of confounding 
variables such as depression could affect the differences of the cognitive function. This 
may be for the further research by assessing the influence of confounding variables 
Generalisability Did not report 
Other evidence General comments 
Limitations: Small sample size, short-term treatment  
Further study: Larger sample size and long-term study 
Funding  US Department of Agriculture 
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Haapala 2009124 
Article identification: 2/2009 5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Haapala 2009 Country: Finland 
Objectives Investigated the short- and long-term effectiveness of weight loss in a mobile phone 
weight-loss programme in healthy overweight adults 
Methods  
Participants Inclusion criteria: Overweight healthy adults aged 25-44 years with BMI 25-36 kg/m2, 
accessed to a mobile phone and Internet connection. 
 Exclusion criteria: Participants aged younger than 18 years with BMI < 18 kg/m2, were 
diagnosed as a chronic disease, and had major psychiatric disease and plan or previous 
pregnancy within 6 months 
 Settings and/or locations: University hospital, Kuopio Finland 
 Duration: 1 year from June 2001 to 2002 
 Recruitment methods : Recruited subjects via newspaper advertisement and telephone 
screening 156 eligible via telephone screening 
 Sample size: 125 subjects randomised. 
Study design Randomisation-sequence generation: Randomised controlled study 
The sample size was selected 20% ineligible subjects and 30% attrition rate to detect 
HIIHFWVDWĮ ZLWKSRZHU156 subjects were eligible via telephone screening. 
125 subjects randomised. No further description 
 Allocation concealment: Insufficient information 
62 subjects in experimental group and 63 subjects in control group 
 Implementation: Nurse implemented randomisation and was blinded gender. 
 Blinding: Nurse blinded  
 Statistical methods: Using repeated-measures ANOVA was to test changes in continuous-
dependent variables with normal distribution. ITT analysis used for weight at baseline. 
Values presented as mean r SD.  
Data analysis used SPSS V10.0.5. 
Intervention Mobile phone-operated weight-loss programme, Weight Balance®  
- Instructed a staggered reduction of food intake and daily weight reporting with 
immediate tailored feedback 
- &DOFXODWHGWKHGLHWHU¶VGDLO\HQHUJ\UHTXLUHPHQWDQGSK\VLFDODFWLYLW\ 
- 5HFHLYHGLQIRUPDWLRQRQWKHGLHWHU¶VFXUUHQWZHLJKW 
- &RQVXPHGWKHDPRXQWRIIRRGLQSURSRUWLRQRIVXEMHFW¶VQRUPDOZHLJKW 
- Based on text message so that no phone calls 
- Encouraged reducing food intake but increasing in daily physical activity 
- Website provided a personal password-protected keeping dietary record and tracking 
LQGLYLGXDO¶VZHLJKWORVV 
- Assessed at baseline, 3 (with control), 6, 9 and 12 (with control) month 
- Allowed dieters to target their weight goal with a short- or long-term at every 3-month 
visit 
- Started weight loss at 2 kg/month and could use this programme for weight-loss 
maintenance 
Comparison/ 
Control 
Control: No intervention, but offered the studied weight-loss programme free of charge 
after the 12-month visit. No specific instruction on diet or exercise 
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Haapala 2009 (continued)  
Methods  
Outcomes Primary outcome measures: Weight change  
Secondary outcome measures: User satisfaction  but not extracted here 
Results  
Participant flow 156 subjects were eligible. 31 subjects excluded. 125 subjects randomised.  
62 subjects in experimental group and 63 subjects in control group.  
Experimental group: Completers at 3, 6, 9 and 12 months were 56 (6 excluded), 45 (17 
excluded), 45 (17 excluded) and 45 (17 excluded) subjects, respectively.  
 Control group: 1 subject excluded. At 12 months, completers were 40.  
Table 1: SubjecWV¶FKDUDFWHULVWLFV at baseline 
Demographics, mean or n (r SD or %) Experimental group, n = 62 Control group, n = 62 
Age, years  38.1 (4.7) 38.0 (4.7) 
Weight, kg 87.5 (12.6) 86.4 (12.5) 
BMI, kg/m2 30.6 (2.7) 30.4 (2.8) 
Gender, n (%) 
Male 
Female 
 
13 (21.0) 
49 (79.0) 
 
15 (24.0) 
47 (76.0) 
SuEMHFWV¶FKDUDFWHULVWLFVLQERWKJURXSVZHUHDERXWRIIHPDOHDJHG\HDUVDQGKDGPHDQZHLJKWNJDQG
mean BMI 30 kg/m2, approximately.  
Number analyzed ITT: 62 subjects each in experimental and control groups 
Completers: At 12 months, 42 subjects in experimental group and 40 subjects in control 
group 
Outcomes and estimation 
Table 2: Primary outcomes measured at baseline, month 3 and month 12, mean (r SD) 
Variable Baseline 3 months 12 months 
Body weight, kg* 
EG**, n = 42 
CG***, n = 40 
 
86.6 (12.7) 
85.1 (12.5) 
 
82.0 (12.9) 
- 
 
82.1 (14.1) 
84.0 (13.2) 
Weight loss, %**** 
EG*, n = 42 
CG**, n = 40 
 
- 
- 
 
5.3 (3.5) 
- 
 
5.4 (5.8) 
1.3 (6.5) 
*
 For EG, significant at p = 0.006 level from baseline at each time point.  
**
 EG = Experimental group. *** CG = Control group.  
Outcomes and 
estimation 
$WPRQWKVWKHFRPSOHWHGVXEMHFWV¶PHDQZHLJKWORVVLQH[SHULPHQWDOJURXSNJ
5.4%) was greater than control group (1.1 kg, 1.3%). As a result, weight loss between 
groups at 12 months was statistically significant difference (p = 0.006). Therefore, the 
mobile phone-operated weight-loss programme, Weight Balance® was effective in a 1-year 
study. 
Adverse events Did not report 
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Haapala 2009 (continued)  
Discussions  
Interpretation Introduction 
- Reviewed the innovative and attractive toll for weight loss programme such as Internet, 
email and mobile phone, and also reviewed the relevant studies on the efficacy of Internet-
based weight loss programme compared with traditional programme and also theory 
related that was shown in the flow of contingency model in mobile phone weight loss 
- Described the matter of this study: The mobile phone weight loss programme was a new 
programme and necessary to be reported. Explained the purpose of this study  
 Methods 
Randomised controlled study: The sample size was selected 20% ineligible subjects and 
DWWULWLRQUDWHWRGHWHFWHIIHFWVDWĮ ZLWKSRZHU 
125 subjects were randomised and allocated 62 subjects to experimental group and 63 
subjects to control group. Nurse implemented randomisation and was blinded gender. 
Comparison of 2 weight loss groups: Experiment (mobile phone weight loss) and control 
groups. At baseline, no statistically significant differences. 
 Assessing outcomes: Measured weight and height by nurses but no report of using any 
scale. Both values could be acceptable. 
Provider: Nurse 
 Statistical methods: Reported power calculation, tests used, programme analysed, ITT and 
completers analysis, however, p-value was in results. 
Power calculation could help this study for: 1) Detecting effects to scan whether or not 
participants randomised were enough to see an effect and 2) preparing for sufficient 
participants if they declined to participate during the study. 
 Results 
- Presented participant flow that consisted of numbers of eligible, randomised, excluded 
and completed participants including the percentage of discontinued participants and 
reasons. Reported values in mean weight with SD  
- Both groups reported statistically significant differences at several p-value, however, 
every value was < 0.05. At baseline, there were no significant differences in main 
outcomes. $WPRQWKVLQFRPSOHWHUVDQDO\VLVSDUWLFLSDQWV¶PHDQZHLJKWORVVLQ
experimental group (4.5 kg) was significantly greater than control group (1.1 kg) at p = 
0.006. This new programme, the mobile phone-operated weight-loss programme, was 
effective in a long-term study. 
 Discussion 
The authors summarised findings of the present study, supported this study by the previous 
research and suggested the major factor of using this programme (self-reported) and the 
further research. There were limitations that could be considerable in the future.  
Limitations: 1) May overestimate results of 12 months because of the quarterly weight-ins, 
2) Use individually data report by using a self-administered questionnaire for physical 
activity and dietary habits, 3) Cannot validate measures of energy-dense foods in the 
Finnish population at the time of study. 
In conclusion, weight loss by mobile phone delivery was considerably effective for 
supporting the short- (3 months) and long-term (12 months). Weight loss depended on the 
amount and type of programme used and learning the behavioural and self-efficacy 
changes. The more programme contacted, the more weight loss positive. For long-term 
reduction in weight, the intervention group was equal to or greater than the minimal 
contact programme. The higher text message reported frequently, the greater percentage 
weight lost at 12 months of the initial weight. 
Generalisability Did not report 
Other evidence General comments 
Recommendation for further study: May require the longitudinal studies.  
Funding  GeraCap Invia Ltd, producer of the Weight Balance® 
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Heshka 2000151 
Article identification: 1/2000 5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Heshka 2000 Country: US 
Objectives Compared the effects of a self-help programme and a commercial programme on weight 
loss in overweight and obese men and women 
Methods  
Participants Inclusion criteria: Men and women aged 18-65 years with BMI 27-40 kg/m2 and had 
health problems for eligibility of weight reduction. 
 Exclusion criteria: Men and women with: 
- Fasting glucose level > 140 mg/dL, triglyceride level > 1,000 mg/dL 
- A serum aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, 
lactate dehydrogenase, gamma glutamyltransferase or bilirubin level > twice the upper 
limit of normal level 
- A serum creatinine level > 1.4 mg/dL 
- Using systemic or inhaled corticosteroids or lithium 
- History of alcohol abuse within last year, any significant psychiatric disorder or others 
condition that interfere the weight loss programme 
- Taking a new drug therapy within 30 days and attending the programme 
- Taking prescription medicines for weight loss within 90 days 
 Settings and/or locations: Multicentre (6 clinical research centres) 
 Duration: 26 weeks 
 Recruitment methods: Recruited from the list of former participants in the programme and 
advertised for a long-term nonmedication weight loss study in moderately overweight 
people 
- Interviewed, signed inform consent and underwent screening procedures 
 Sample size: 423 subjects randomised (358 women, 65 men) 
Study design Randomisation-sequence generation: Randomised controlled study by blocking each block 
2-10. Determined blocking by a random number table 
 Allocation concealment: Data-coordinator prepared randomisation envelope and opened 
this to inform the eligible participants to be assigned to the self-help or the commercial 
programme. Randomised 70 subjects per site 
211 subjects in commercial programme, 212 subjects in self-help group 
 Implementation: No description 
 Blinding: Did not report 
 Statistical methods: Used ANOVA or ANCOVA to test hypotheses of greater changes in 
the commercial programme than in the self-help group 
Significant at 0.05 (2-sided), used chi-squared test to compare proportions of both groups, 
reported by mean r SD 
Data analysis used SAS V6.12 and SPSS V8.0 
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Heshka 2000 (continued)  
Methods  
Intervention Commercial programme (Weight Watchers, WW): Subjects had 
- Vouchers cost $9.00 to attend WW sessions 
- Their own choice for any meeting location and time 
- Instruction of participating in a research study 
- A food plan: A nutritionally balanced and moderate diet designed to produce a weight 
loss up to 0.9 kg for a week. 
- An activity plan: Followed current guidelines 
- A behaviour-modification plan: Group and social support 
Comparison/ 
Control 
Self-help programme: Subjects had 
- 20-minute consultations with a dietician at the first session and week 12 visits 
- The printed material orientation for dietary principles and physical activity guidelines on 
weight loss 
- Other resources offering weight loss information such as public library materials, web 
sites on the Internet and telephone number of health promotion organisations  
Outcomes Outcome measures: Weight and BMI changes  
Other outcome measures: WC and body fat were not extracted here. 
Results  
Participant flow Did not report 
Baseline data 7DEOH6XEMHFWV¶FKDUDFWHULVWLFVPHDQr SD) or number (%) 
  Commercial programme, n 
= 211 
Self-help group, n = 212 
 Age, years 45 (10) 44 (10) 
 Weight, kg 94.2 (13.1) 93.1 (14.4) 
 BMI, kg/m2 33.8 (3.4) 33.6 (3.7) 
 ParticipaQWV¶FKDUDFWHULVWLFVLQERWKJURXSVDJHGDERXW\HDUVZLWKPHDQZHLJKW
kg and mean BMI 33.7 kg/m2, approximately.  
Number analyzed ITT with missing data replaced by last observation carried forward (LCF).  
ITT: 211 subjects in commercial programme, 212 subjects in self-help group 
Completers: 174 subjects in commercial programme, 172 subjects in self-help group 
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Heshka 2000 (continued)  
Results  
Outcomes and estimation 
Table 2: Comparison of weight changes (kg) over time, mean (r SD) 
 Commercial programme Self-help group Difference (95% confident 
interval) 
ITT analysis n = 211 n = 212  
Week 0-12 -3.9 (3.7) -1.3 (3.2) 2.6 (1.9-3.3) 
Week 12-26 -0.9 (2.8) -0.1 (2.6) 0.8 (0.3-1.3) 
Week 0-26 -4.8 (5.6) -1.4 (4.7) 3.4 (2.4-4.4) 
Available cases n = 174 n = 172  
Week 0-12 -4.6 (3.4) -1.6 (3.4) 3.0 (2.3-3.7) 
Week 12-26 -1.1 (2.9) -0.2 (2.9) 0.9 (0.3-1.5) 
Week 0-26 -5.7 (5.7) -1.7 (5.0) 4.0 (2.9-5.1) 
$WZHHNVIRU,77DQDO\VLVSDUWLFLSDQWV¶PHDQZHLJKWORVVLQFRPPHUFLDOSURJUDPPHNJ%) was 
greater than self-KHOSJURXSNJDVZHOODVDYDLODEOHFDVHVSDUWLFLSDQWV¶PHDQZHLJKWORVVLQ
commercial programme (5.7 kg, 6.0%) was greater than self-help group (1.7 kg, 1.8%). The differences of weight 
changes between groups were 3.4 for ITT analysis and 4.0 for available cases.   
At 26 weeks, mean BMI in commercial programme decreased to 32.1 kg/m2 (-1.7 r .19 kg/m2) whilst in self-help 
group was 33.1 kg/m2 (-0.5 r 1.6 kg/m2). 
Table 3: Percentage of weight changes by treatment groupa, number (%) 
  Commercial programme, n = 
174 
Self-help group, n = 
172 
Decrease from initial weight    
10% or more  44 (25)* 13 (8) 
5% - 10%  48 (28)* 13 (8) 
0 ± 5%  57 (33)** 82 (48) 
Increase from initial weight    
0 ± 5%  24 (14)* 57 (33) 
5% - 10%  1 (1) 6 (3) 
10% or more  - 1 (1) 
aPercentages do not add to 100 because of rounding error. 
*Significant at p < 0.01, **Significant at p < 0.05 
At 26 weeks, participants in commercial programme who lost weight over 5% of their entry weight were 53% 
whereas those in self-help groups were 16%. There was also statistically significant difference between groups   
(p < 0.01). 
Adverse events Did not report 
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Heshka 2000 (continued)   
Discussions  
Interpretation Introduction 
- Reviewed the adverse effect of traditional weight loss programme, the proportion of US 
adults who participated in the weight loss programme. However, the literature review 
showed concerns about other changes if participants participated in either commercial or 
self-help weight loss programme.  
- Described the matter of this study: The first evaluating of a long-term, multicentre, 
randomised trial in the largest provider of commercial weight loss programme in the US. 
Explained objectives of this study  
 Methods 
Randomised controlled study by blocking each block 2-10. Data-coordinator prepared 
randomisation envelope and opened this to inform the eligible participants to be assigned 
to the self-help or the commercial programme. 423 subjects were randomised. However, 
70 subjects were randomised per site and allocated 211 subjects in commercial programme 
and 212 subjects in self-help group. Determined blocking by a random number table 
Blinding was not applicable. 
Comparison of 2 groups: Commercial and self-help groups. At baseline, no statistically 
significant differences. 
 Assessing outcomes: Measured weight to the nearest 0.1 kg in street clothing with no 
shoes on a calibrated scale. Weight value should be valid. 
Provider: Dietician 
 Statistical methods: No report of power calculation, however, this study reported tests 
used and 2 programmes analysed, significant level, ITT analysis with missing data 
replaced by LOCF and values presented. There was no power calculation to detect a 
difference between baseline and the end of treatment in order to scan whether or not 
participants randomised were enough to see an effect and to prepare for sufficient 
participants if they declined to participate during the study. 
 Results 
- Although there was no report of participant flow, ITT and completers analysis were 
reported. Values in mean weight with SD and 95% CI were reported. Both groups reported 
statistically significant differences at p < 0.05 or 0.01 to strongly significant difference. At 
baseline, there were no statistically significant differences between groups.  
- $WZHHNVIRU,77DQDO\VLVSDUWLFLSDQWV¶PHDQZHLJKWORVVLQFRPPHUFLDOSURJUDPPH
(4.8 kg) was greater than self-help group (1.4 kg) as well as mean BMI in commercial 
programme decreased to 32.1 kg/m2 (-1.7 kg/m2) whilst in self-help group was 33.1 kg/m2 
(-0.5 kg/m2) at p < 0.001. 
 Discussion 
The authors summarised findings of this study mainly focused on commercial weight loss 
results and also referred to WW study. At the same duration of 12 weeks, WW lost weight 
only 2.2 kg with 30% of the original subjects, and another recent study lost 6.1 kg with 
75% of the subjects remained. Comparing to this study, subjects lost weight 4.6 kg by self-
reporting with 80% of the baseline subjects. Authors claimed that results of weight 
changes were similar to other studies in terms of weight loss at 12 weeks. 
For other measures, findings were uncertain. Reviewer only concluded weight change. 
The CWLP had greater weight loss than the self-help group for 26-week weight loss 
programme.  
Generalisability No generalisability because of one particular CWLP with many unique aspects but not 
many commercial programmes 
Other evidence General comments 
Recommendation for further study: Should measure other outcomes such as serum and 
vitamin levels, and any variables associated with cardiovascular disease  
Funding  The Weight Watchers Foundation 
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Heshka 2003150 
Article identification: 1/2003 5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Heshka 2003 Country: US 
Objectives Compared weight loss and health benefits achieved and maintained between self-help 
programme and a structured commercial programme  
Methods  
Participants Inclusion criteria: Men and women aged 18-65 years with BMI 27-40 kg/m2 and were 
persons with health problems. 
 Exclusion criteria: Participants had  
- Fasting glucose > 140 mg/dL/7.8 mmol/L, triglycerides > 1000 mg/dL/11.3 mmol/L, 
liver function test, used systemic and inhaled corticosteroids or lithium 
- A history of alcohol abuse within the past year, psychiatric disorder 
- A new drug therapy within 30 days of randomisation 
- Prescription weight loss within 90 days 
 Settings and/or locations: 6 US clinical centres 
 Duration: 2 years from January 1998 to 2001 
 Recruitment methods: Recruited from the existing clinic records or via advertising a long-
term nonmedication weight loss study 
 Sample size: 423 participants randomised (65 men, 358 women) 
Study design Randomisation-sequence generation: Multicentre randomised controlled trial  
Blocking was used for randomisation by a random number table.  
 Allocation concealment: The envelopes prepared was opened. 484 participants were 
eligible. 423 participants randomised. 211 participants for commercial group, 212 
participants for self-help group. For completers at 2 years, 150 participants for commercial 
group, 159 participants for self-help group. 
 Implementation: Investigators implemented the condition assigned by opening the 
envelopes prepared.  
 Blinding: Double-blind. Participants and investigators at each site were blinded to 2 
groups assigned. 
 Statistical methods: Independent t tests for continuous variables and Fisher exact test for 
categorical variables used to compare differences between groups by following ITT 
analysis (included all randomised participants), a modified ITT analysis (included all 
participants who made at least 1 clinic visit after randomisation) and completers analysis 
(only participants who completed the study). Values reported as mean r SD with statistical 
significance at p < 0.5.  
Data analysis used SAS V8.  
Intervention Structured commercial weight loss programme: Gave vouchers to attend Weight Watchers 
sessions, programme consists of food, activity and behaviour plans 
Food plan: Nutrition balance, Activity plan: Followed NIH guidelines by weekly group 
meetings of an hour's duration, Behaviour plan: Self-reported attendance 
Comparison/ 
Control 
Self-help group: Received 20-minute consultations with dietician at baseline and week 12, 
dietary principles and exercise guidelines for safe weight loss 
Free offered information from public library materials, Web sites and telephone numbers 
of health promotion organisations 
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Heshka 2003 (continued)  
Methods  
Outcomes Primary outcome measures: Weight change 
Secondary outcome measures: BP, TC, HDL-C, triglycerides, insulin, glucose, quality of 
life and adverse events  
Results  
Participant flow 484 participants were eligible. 61 participants excluded.  
423 participants randomised. 211 participants were assigned to commercial group. 212 
participants were assigned to self-help group. 
61 participants lost to follow-up in commercial group. 53 participants lost to follow-up in 
self-help group. 150 participants completed the commercial group. 159 participants 
completed the self-help group. 
198 participants included in modified ITT analysis in commercial group.  
188 participants included in modified ITT analysis in self-help group. 
148 participants included in completers analysis in commercial group. 2 participants 
excluded from the commercial group.  
159 participants included in completers analysis in self-help group. 
7DEOH3DUWLFLSDQWV¶EDVHOLQHFKDUDFWHULVWLFV* 
Variables Commercial group ,n = 211 Self-help group, n = 212 
Age, years 45 (10) 44 (10) 
Women, n (%) 173 (82) 185 (87) 
Weight, kg 94.2 (13.1) 93.1 (14.4) 
BMI, kg/m2 33.8 (3.4) 33.6 (3.7) 
*Values shown are mean (r SD). There were no statistically significant differences between 2 groups. 
3DWLHQWV¶FKDUDFWHULVWLFVLQERWKJURXSVZHUHDERXWRIZRPHQ, aged 44.5 years and had mean weight 93.7 kg 
and BMI 33.7 kg/m2, approximately. 
Number analyzed ITT: 211 participants were assigned to commercial group. 212 participants were assigned 
to self-help group. 
Completers: 150 participants completed the commercial group. 159 participants completed 
the self-help group. 
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Heshka 2003 (continued)  
Results  
Outcomes and estimation 
Table 2: Weight and BMI changes at year 1 and 2 
 Year 1a Year 2b 
 Commercial 
group 
Self-help 
group 
p-value Commercial 
group 
Self-help 
group 
p-value 
Weight*, kg [Mean (r SE)]      
Intention-to-Treat -4.3 (0.4) 1.3 (0.4) <0.001 -2.9 (0.5) -0.2 (0.4) <0.001 
Completers -5.0 (0.5) -1.4 (0.5) <0.001 -3.0 (0.6) -0.1 (0.6) <0.001 
Decreased from initial 
weight, n (%) 
n = 172 n = 170  n = 148 n = 159  
 37 (21) 15 (9) 0.002 24 (16) 9 (6) 0.005 
> 5-< 10 29 (17) 19 (11) 0.15 27 (18) 24 (15) 0.57 
0-5 68 (39) 57 (33) 0.37 42 (28) 46 (29) > 0.99 
BMI*, kg/m2 [Mean (SE)]      
Intention-to-Treat -1.6 (0.2) -0.5 (0.2) <0.001 -1.1 (0.2) -0.2 (0.2) <0.001c 
Completers -1.9 (0.2) -0.6 (0.2) <0.001 -1.2 (0.2) -0.1 (0.2) <0.001c 
ap < 0.01 for hypothesis of similar frequency distribution in the 2 groups. 
bp = 0.002 for hypothesis of similar frequency distribution in the 2 groups. 
c
 Value is significantly different from baseline at p < 0.05. 
*Participants to measure weight and BMI for ITT analysis were 211 in commercial group and 212 in self-help 
group whilst participants for completers analysis were 148 in commercial group and 159 in self-help group. 
At 1 year, WKH,77SDUWLFLSDQWV¶PHDQZHLJKWORVVLQFRPPHUFLDOJURXSNJZDVJUHDWHUWKDQVHOI-help 
group (1.3 kg, 1.4%) as well as BMI in commercial group (1.6 kg/m2) decreased more than self-help group (0.5 
kg/m2). 
)RUWKHFRPSOHWHUVSDUWLFLSDQWV¶PHDn weight loss in commercial group (5.0 kg, 5.3%) was greater than self-help 
group (1.4 kg, 1.5%) as well as BMI in commercial group (1.9 kg/m2) decreased more than self-help group (0.6 
kg/m2). 
Weight loss between groups was statistically significant difference at p < 0.01. 
Of 38% of participants in commercial group lost weight at least 5% of their initial weight whereas only 20% of 
participants in self-help group lost weight at least 5% of their initial weight. 
$W\HDUVWKH,77SDUWLFLSDQWV¶PHDQZHLJKW loss in commercial group (2.9 kg, 3.1%) was greater than self-help 
group (0.2 kg, 0.2%) as well as BMI in commercial group (1.1 kg/m2) decreased more than self-help group (0.2 
kg/m2). 
)RUWKHFRPSOHWHUVSDUWLFLSDQWV¶PHDQZHLJKWORVVLQFRPPHUFLDOJURXS(3.0 kg, 3.2%) was greater than self-help 
group (0.1 kg, 0.1%) as well as BMI in commercial group (1.2 kg/m2) decreased more than self-help group (0.1 
kg/m2). 
Weight loss between groups was statistically significant difference at p < 0.002. 
Outcomes and 
estimation 
Of 34% of participants in commercial group lost weight at least 5% of their initial weight 
whereas 21% of participants in self-help group lost weight at least 5% of their initial 
weight. 
 As a result, a structured commercial programme was more effective than the self-help 
group for participants who participated in the weight loss programme over a 2-year period. 
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Heshka 2003 (continued)   
Results  
Secondary outcome At 2-year changes in WC (p = 0.003), there was significant difference in the commercial 
group whilst changes in BP, lipids, glucose and insulin levels in both groups were not 
significant differences, respectively.  
Results also quality of life but not extracted here. 
Adverse events Reported as no adverse events to withdraw people from the study 
Discussions  
Interpretation Introduction 
- Reviewed the number increasing of US adults who attempted to lose weight and 
described the percentage of adults who participated in the weight loss programme. 
However, the literature review showed that obese participants seldom succeed a normal 
range of BMI. As a result, commercial weight loss programmes were recommended.   
- Described the matter of this study: The previous study showed that the effects of 
commercial weight loss programme on weight loss were seldom evaluating, and there 
were no studies conducted 2-year multicentre randomised trial. 
- Explained objectives of this study  
 Methods 
Multicentre randomised controlled trial: Randomisation-sequence generation used 
blocking from a random number table. 423 participants were randomised and allocated 
211 participants to commercial group and 212 participants to self-help group. Investigators 
implemented the condition assigned by opening the envelopes prepared. This study was 
double-blind because participants and investigators at each site were blinded to 2 groups 
assigned. 
Comparison of 2 groups: Commercial and self-help groups. At baseline, no statistically 
significant differences. 
 Assessing outcomes: No report of measuring weight and height. Hence, both weight and 
height values could be over or under estimation.  
Provider: Dietician 
 Statistical methods: No report of power calculation, however, this study reported tests and 
programme used, significant level, ITT and completers analysis and values presented. 
There was no power calculation to detect a difference between baseline and the end of 
treatment among 3 groups in order to scan whether or not participants randomised were 
enough to see an effect and prepare for sufficient participants if they declined to 
participate during the study. 
 Results 
- Reported participant flow with number of exclusion, randomisation, allocation, follow-
up and lost to follow-up and ITT and completers analysis 
- Also, reported values in mean weight with both SD and SE 
- Both groups reported statistically significant differences at p < 0.01 or 0.001 to strongly 
significant difference. 
- $W\HDUIRU,77DQDO\VLVSDUWLFLSDQWV¶PHDQZHLJKWORVVLQFRPPHUFLDOJURXSr 6.1 
kg) was greater than those in self-help group (1.3 r NJZKLOVWDW\HDUVSDUWLFLSDQWV¶
mean weight loss in commercial group (2.9 r 6.5 kg) was greater than those in self-help 
group (0.2 r 6.5 kg) at p < 0.001. 
 Discussion 
The authors mainly summarised findings of this study.  
The commercial weight loss programme had greater weight loss than the self-help group 
for 2-year programme. Participants attended in the commercial programmes longer than 
the self-help programme. As a consequence, other outcomes such as weight maintenance, 
WC, cardiovascular risk factor and biological parameters have been improved.  
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Heshka 2003 (continued)    
Discussions  
Interpretation 
(continued) 
Discussion (continued) 
Also, they summarised the correlation of changes to additionally analyse factors related, 
however, it was low correlation and not clearly known for weight loss. Thus, further 
research would be recommended. Authors also discussed about statistical methods on 
power calculation to detect differences in weight loss. Moreover, there was no comparing 
to other studies because this study was a long-term study.  
Generalisability No generalisability because of one particular commercial weight loss programme with 
many unique aspects but not many commercial programmes 
Other evidence General comments 
Recommendation for further study: The tendency for successful participants who were 
more likely to lose weight may not have self-selection bias. However, the length of the 
treatment and consequence of number of intervention meetings may affect the success of 
weight loss3DUWLFLSDQWV¶ZLOOLQJDQGPRWLYDWLRQPD\LQIOXHQFHWKHWULDOUHVXOWV 
For overweight and obese adults, a structured commercial weight loss programme 
provided moderate weight loss but it was more effective than brief counselling and self-
help programme. 
Funding  Weight Watchers International 
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Jebb 2011152 
Article identification: 2/2011 5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Jebb 2011 Country: Australia, Germany, UK 
Objectives Compared weight loss in primary care referral to a commercial weight loss programme 
with standard care and examined the association of risk factors  
Methods  
Participants Inclusion criteria: Eligible participants aged at least 18 years, had BMI between 27-35 
kg/m2 who had at least one additional risk factor for obesity-related disease 
Risk factors included:  
Central adiposity (waist circumference > 88 cm in women or >102 cm in men), 
Type 2 diabetes without insulin treatment, family history of diabetes, previous gestational 
diabetes or impaired glucose tolerance or impaired fasting glycaemia, 
Mild to moderate dyslipidaemia (defined by national guidelines) or treatment for 
dyslipidaemia, treatment for hypertension,  
Polycystic ovarian syndrome or infertility without apparent cause other than weight, or 
lower-limb osteoarthritis or abdominal hernia 
 Exclusion criteria: People who lost weight 5 kg or more in the previous 3 months, had 
history of a clinically diagnosed: 
Eating disorder, received treatment with effects on weight or appetite, gastro intestinal 
disorders, previous surgical procedure for weight loss or major surgery in the previous 3 
months,  
Orthopaedic limitations preventing participation in regular physical activity,  
Untreated thyroid disease or more than one change in thyroid treatment in the previous 6 
months, insulin-treated diabetes or diabetes diagnosis in the previous 6 months, glycated 
haemoglobin (HbA1C) of at least 75 mmol/mol (9.0%),  
Pregnancy or lactation and heart problems in the previous 3 months 
Uncontrolled hypertension, new prescription drug for a chronic disorder in the previous 3 
months or change in dose in the previous 1 month,  
History or presence of cancer, with the exception of completely resected basal or 
squamous cell carcinoma if treatment completed 6 months before enrolment, or  
Participating in another clinical trial in the previous 30 days 
 Settings and/or locations: Primary care practices in Germany, Australia and UK 
 Duration: 12 months, September 10, 2007 to November 28, 2008 
 Recruitment methods: A multicentre, randomised controlled trial with a parallel design. 
Participants were recruited from 39, 70 and 6 primary care practices in Germany, Australia 
and UK, respectively 
 Sample size: 772 were eligible participants. 
Study design Randomisation-sequence generation: Stratification. Data manager generated the 
randomisation sequence by using computer generated with Stata. 
 Allocation concealment: Allocated in a 1:1 ratio. 772 participants were remained as 268 
Germany, 268 Australia and 236 UK, entered the trial and completed a baseline 
assessment. 
377 allocated to commercial programme. 395 allocated to standard care. 
 Implementation: No description 
 Blinding: non-blinded 
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Jebb 2011 (continued)  
Methods  
Study design 
(continued) 
Statistical methods: For recruitment in 3 countries, power of analysis was 90% at a 5% 
significance level. 
For the primary outcome, data analysis included all randomised participants with last 
observation carried forward (LOCF). Weight change at 12 months used linear regression 
with fixed effects for continuous normal data, intervention group 9commercial programme 
vs. standard care), country (Australia, Germany and UK). Values presented as mean r SE 
with 95% CI from STATA V11.0. 
Intervention 12 months of free membership to a commercial programme (Weight Watchers) and 
followed-up for other 12 months  
Meeting weekly for 12 months consisted of weigh-in, group discussion, behavioural 
counselling and motivation 
Promoting a hypoenergetic, balanced diet based on healthy-eating principles 
Increasing exercise and group support 
$FFHVVLQJ,QWHUQHWWRPRQLWRUSDUWLFLSDQWV¶IRRGLQWDNHDFWLYLW\DQGZHLJKWFKDQJHWR
participate in community discussion boards, and to access a library of information, recipes 
and meal ideas 
Comparison/ 
Control 
Standard care defined by national treatment guidelines: Receiving weight loss advice from 
a primary care professional 
Outcomes Primary outcome measures: Weight change from baseline to 12 months 
Results  
Participant flow 1010 participants were eligible. 238 participants excluded.  
 772 participants randomised. 377 allocated to commercial programme. 395 allocated to 
standard care. 
Commercial programme: 147 participants withdrew. 230 participants completed at 12 
months. 
Standard care: 181 participants withdrew. 214 participants completed at 12 months.  
Table 1: 3DUWLFLSDQWV¶Fharacteristics at baseline, mean (r SD) 
 Commercial programme, n = 377 Standard care, n = 395 
Sex: Men/Women (%) 47/330 (12/88) 57/338 (14/86) 
Age, years 46.5 (13.5) 48.2 (12.2) 
Weight, kg 86.9 (11.6) 86.5 (11.5) 
BMI, kg/m2 31.5 (2.6) 31.3 (2.6) 
3DUWLFLSDQWV¶FKDUDFWHULVWLFVLQDOOGLHWJURXSVZHUHPRVWO\ZRPHQDJHG\HDUVZLWKPHDQZHLJKW
kg and mean BMI 31.4 kg/m2, approximately.  
Number analyzed ITT: Participants completed the 12-month assessment between baseline and last 
observation carried forward (BOCF and LOCF). 377 participants in the commercial 
programme. 395 participants in standard care. 
At 12 months, 328 (42%) participants from both groups had withdrawn from the trial 
which were 230 in the commercial programme group and 214 in standard care group to be 
included in completers-only analysis, respectively. 
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Jebb 2011 (continued)  
Results  
Outcomes and estimation 
Table 2: Weight changes at 12 months by different analysis, mean (r SE) 
Body weight, kg Commercial programme Standard care 
Adjusted difference 
(95% CI)* p-value 
LOCFa, n = 772 -5.06 (0.31) -2.25 (0.21) -2.77 (-3.50 to -2.03) < 0.0001 
BOCFa, n = 772 -4.06 (0.31) -1.77 (0.19) -2.29 (-2.99 to -1.58)  < 0.0001 
Completers, n = 444 -6.65 (0.43) -3.26 (0.33) -3.16 (-4.23 to -2.11) < 0.0001 
*Adjusted for baseline observation and country 
aLOCF = Last observation carried forward, BOCF = Baseline observation carried forward 
Primary outcome: $WPRQWKVZLWK/2&)SDUWLFLSDQWV¶Zeight change (n = 772) in commercial programme 
was -5.06 kg (5.8%) whilst standard care was -2.25 kg (2.6%). )RU%2&)DQDO\VLVSDUWLFLSDQWV¶Zeight change (n 
= 772) in commercial programme was -4.06 kg (4.7%) whilst standard care was -1.77 kg (2.0%). Lastly, for 
FRPSOHWHUVDQDO\VLVSDUWLFLSDQWV¶Zeight change (n = 444) in commercial programme was -6.65 kg (7.7%) whilst 
standard care was -3.26 kg (3.8%). All groups were statistically significant difference at p-value < 0.0001. 
Adverse events No any severe adverse events 
Discussions  
Interpretation Introduction 
- Reviewed obesity as the worldwide health issue, the proportion of overweight people 
around the world and health risk factors related to obesity US  
- Reviewed the relevant studies of commercial weight loss programme  
- Described the matter of this study: No studies of assessing the effects of commercial 
weight loss programme compared with standard care in a primary health-care setting  
- Explained objectives of this study  
 Methods 
A multicentre, randomised controlled trial with a parallel design: Randomisation-sequence 
was generated by stratification. 772 participants were randomised as 268 in Germany, 268 
in Australia and 236 in the UK. 377 and 395 participants were allocated to commercial 
programme and standard care, respectively. 
Randomisation was implemented by data manager using computer generated with Stata. 
Reported blinding as non-blinded 
Comparison of 2 programmes: Commercial programme and standard care  
Assessing outcomes: In the UK and Australia, measured weight in the light clothes 
without shoes with a Tanita BC-418 segmental body composition analyser (Tanita 
Corporation of America, Arlington Heights, IL, US) 
In Germany, measured weight in GP practices with standard scales. Weight scale was 
different from UK and Australia. To present valid values, it should be calibrated weight by 
repeating and report as the average value. 
Providers: Primary care provider, a facilitator from ALED and HEED. 
 Statistical methods: Reported power calculation to detect a difference in weight change of 
2.6 kg to complete participants in the end of the programme 
Power calculation could help this study for: 1) Scanning whether or not participants 
randomised were enough to see an effect, 2) not wasting time on an underpowered study 
and 3) preparing for sufficient participants if they declined to participate during the study. 
Also, reported p-value, significant level, confidence intervals, tests used and programme 
analysed   
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Jebb 2011 (continued)  
Discussions  
Interpretation 
(continued) 
Results 
- 3UHVHQWHGSDUWLFLSDQWV¶IORZLQFOXGLQJHOLJLEOHH[FOXGHGUDQGRPLVHGDOORFDWHG
withdrew and completed participants. ITT and completers analysis were reported. 
- Reported the percentage of completed participants at 12 months: 230 (61%) in 
commercial programme and 214 (54%) in standard care  
- Reported values in mean weight with SE and 95% CI 
- Both programmes reported statistically significant differences (p < 0.05). 
- $WPRQWKVZLWKDOODQDO\VHVSDUWLFLSDQWV¶Zeight change in commercial programme 
was as twice as those in standard care. Adjusted differences of weight change between 
groups were -2.77 kg with LOCF, -2.29 kg with BOCF and -3.16 kg with completers. 
Values of weight change with completers analysis were highest. The authors could only 
present the most difference of weight change, however, the total number of participants in 
this analysis was 444 (57%) so that ITT analysis was also reported to compare more 
weight change in commercial programme with all analyses.  
 Discussion 
The authors summarised findings which were participants in the commercial programme 
lost 5% or more of the initial weight for 12 months. They also compared this study to 
other similar studies in other countries and discussed about the risk factors related and 
setting with primary care providers.  
Based on other evidences related to standard care, the counterweight programme was 
compared. There was similar to this study. Likely, commercial programme compared with 
Jenny Craig and also found that weight change was alike.  
However, the commercial programme in this study collaborated with primary care 
providers to offer the effective treatment in a primary care setting.  
Another factor to support the effective weight loss in standard care was the variables 
recorded more corresponding than those in commercial programme such as health care 
setting and systems and motivation from peer-support.  
Generalisability Did not report 
Other evidence General comments 
Weight change in the commercial programme was as similar as other community-based 
programme or self-help groups. Although participants participated in a primary care 
weight loss treatment, primary care providers could offer a commercial programme for 
options of the effective treatment. 
Recommendation for further study: Needed to examine long-term weight loss 
maintenance, analysis of cost-effectiveness and only men 
Participants who have been selected by a primary health-care professional were transferred 
from primary care to commercial weight loss programme. They found that commercial 
programme not only provided regular weighing, advice about diet and exercise, motivation 
and group support but also offered a clinically useful early intervention for weight 
management in overweight and obese people at the larger scale. 
Funding  Weight Watchers International 
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Jolly 201117 
Article identification: 3/2011 5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Jolly 2011 Country: UK 
Objectives Assessed the effectiveness of a range of weight loss programmes on weight loss 
Methods  
Participants ,QFOXVLRQFULWHULD(OLJLEOHSDUWLFLSDQWVDJHG\HDUVDQGKDGEHHQUHFRUGHG%0,LQWKHLU
primary care notes in the last 15 months. 
Categories for invitation to weight loss programmes:  
- White Europeans and all ethnic groups apart from South Asians with comorbidities, BMI 
NJP2 RUZLWKRXWFRPRUELGLWLHV%0,NJP2 
- 6RXWK$VLDQVZLWKFRPRUELGLWLHV%0,NJP2 RUZLWKRXWFRPRUELGLWLHV%0,
kg/m2 
 Exclusion criteria: Patients were not able to understand English or pregnant. 
 Settings and/or locations: 17 primary care trust in South Birmingham, England  
 Duration: 12 weeks from January to May 2009 
 Recruitment methods: Eligible participants registered with general practices in South 
Birmingham primary care trust.  
 Sample size: 740 obese or overweight men and women with a comorbid disorder  
Study design Randomisation-sequence generation: 8-arm randomised controlled trial 
Block size of 35 from 10 other practices to one of seven study groups excluding GP in the 
block size of 13. Comparing interventions with a comparator group (Choice of any of the 
six programmes for the final study arm) 
One to one randomisation across groups by blocking sizes. Exceptionally, 2 primary care 
arms were not used blocking and any spaces were limited so that allocation was in a ratio 1 
to 0.7 compared with other groups.  
 Allocation concealment: GP, pharmacy or minimal intervention (comparator) groups were 
allocated by participants at the first sessions.  
100 participants were allocated to each arm. Exceptionally, the general practice and 
pharmacy arms were restricted to 70 participants per arm. 
An independent statistician generated to allocate separating 2 randomisation sequences, to 
ensure blinding and the allocation in opaque, and to consecutively number envelopes. 
 Implementation: General practitioners enrolled participants. 
Nurses assigned participants to interventions and informed them on how to withdraw from 
the trial if they changed their minds. 
A trained practice nurse, health trainer or researcher was blinded to the allocation group 
GLGWKHRQH\HDUDVVHVVPHQWDWWKHSDUWLFLSDQW¶VJHQHUDOSUDFWLFHRUKRPH 
 Blinding: A trained practice nurse, health trainer or researcher blinded. 
 Statistical methods: Used 90% power, significant level at 5% and assume 20% loss to 
follow-up. Thus, at least 70 participants were randomised to each group. 
The 2 kg difference was selected to achieve weight loss at 12 weeks and also 5% weight 
loss was clinically meaningful health benefits. 
Sample size calculation: No adjustment for multiple comparisons  
Used Stata v11.0 and SPSS v17.0 for data analysis 
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Jolly 2011 (continued)  
Methods  
Study design 
(continued) 
Investigating differences between 7-intervention groups and the comparator by measuring 
outcomes on a continuous scale (weight loss) by using least squares linear regression 
Bonferroni correction was used to compare as a pair-wise between intervention and control 
to maintain a 5% type I error across the 7 comparisons. 
Intervention 1 Weight Watchers: One to one support  
Followed by a group talk from the leader with discussion in community venues lasted one 
hour 
Delivered core programme material over five weeks included a food points system (based 
on age, sex, height, weight, and activity), beating hunger, taking more physical activity, 
eating out, and keeping motivated.  
Planned aims for 500 kcal (2.09 MJ) deficit/day, leading to 0.5-1.0 kg weight loss a week 
Encouraged physical activity to gradually build up to 10,000 steps daily 
Changed behaviour included stages of change, food and activity diaries, goal setting and 
evaluation of progress 
Had given rewards for every 3.2 kg (7 lb) lost and for loss of 5% and 10% of body weight 
Intervention 2 Slimming World: Setting weight loss goals by the individual, 90 minutes lasted 
Accessed a website, magazines and one to one telephone support from a consultant or 
other members  
Encouraged members to mainly eat foods with low energy density to achieve satiety, plus 
some extras rich in calcium and fibre with controlled amounts of high energy dense foods 
Supported physical activity with gradual build up to 30 minutes of moderately intense 
activity five days a week 
Group supported 
Rewarded for 3.2 kg (7 lbs) lost and loss of 10% of body weight 
Individual supported, if needed such as self monitoring of food and emotions, visualisation 
techniques and personal eating plans 
Intervention 3 Rosemary Conley: One to one support, 90 minute lasted 
Available supported by email and telephone  
Set goals: either 1-1.5 kg/week with a goal of 6.35 kg (1 stone) loss or 0.5-1 kg/week with 
an initial goal of 3.2 kg (7 lb) 
Optional exercise class for 45 minutes.  
Offered extra exercise sessions for an additional fee.  
Role modelling and group supporting 
Rewarded for slimmers who maintain or lose weight, slimmer of the week, and certificates 
for 3.2 kg and 6.35kg milestones 
Intervention 4 Dietetics led programme: The Size Down Programme - An NHS group based programme 
run in the community 
Supported workers trained by the dietetics service  
Provided 6 weekly 2 hour sessions, with follow-up sessions at 9 and 12 weeks to focus on 
long term changes in patterns of eating behaviour, achieving a balanced diet and increasing 
physical activity in daily life with an interactive style 
Managed behaviour around food and prevention of relapse, the eat well plate, nutritional 
information, planning strategies to deal with lapses into previous dietary behaviours, 
interactive visual aids to show the fat and sugar content of foods and adaptation of recipes 
Based on the cycle of change as a theoretical background 
Discussed about the benefits of physical activity, setting goals and finding activities to fit 
into life which included goal setting, stages of change and self monitoring with a food 
diary 
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Jolly 2011 (continued)  
Methods  
Intervention 5 and 
6 
General practice and pharmacy led: One to one counselling  
Lasted 30 minutes with follow-up sessions of 15-20 minutes 
Solved problems approach which included weight and dieting history 
Explored goals and expectations of patients, the eat well plate, setting goals to reduce 
calorie intake and increase physical activity, planning strategies to deal with challenging 
situations, use of food diaries, and maintaining weight loss 
Weight loss goals were 5-10% of the initial body weight, at a rate of 0.5-1 kg/week over 
three to six months with following by weight maintenance 
Increased physical activity goals to slowly achieve 30 minutes of moderate activity on five 
days a week  
Self monitored with food diaries, hunger scale, waist measurements and physical activity 
Provided resources as homework for discussion in the next session or for personal 
reflection.  
Motivated to reward patients for success 
Intervention 7 Choice of any of the six programmes 
Comparison/ 
Control 
The comparator group (Exercise): Provided 12 vouchers to enabling free entrance to a 
local leisure (fitness) centre where consisted of a swimming pool, fitness suite and other 
sport halls or courts 
Had no appointment and individual advice and support on diet or exercise 
Outcomes Primary outcome measure: Weight loss 
Secondary outcome measure: Weight loss at 1 year and percentage weight loss at 12 weeks 
and 1 year.  
Results also presented effects of choice and sex, physical activity, attendance and costs but 
not extracted here. 
Results  
Participant flow 8810 people received the invitation letters. 7799 did not respond. 740 participants were 
randomised. 271 participated in Lighten Up services as a part of pilot study. 
100 participants each were assigned to Weight Watchers, Slimming World, Rosemary 
Conley, NHS Size Down, Choice and comparator. 
70 participants each were assigned to general practice and pharmacy. 
Baseline data  
7DEOH3DUWLFLSDQWV¶FKDUDFWHULVWLFVPHDQr SD) 
 1a 2b 3c 4d 5e 6f 7g 8h 
Male sex, % 28 35 31 36 33 27 30 25 
Age, years 50.7 
(14.6) 
48.8 
(14.9) 
49.8 
(14.5) 
48.7 
(15.6) 
50.5 
(13.8) 
48.9 
(15.8) 
47.4 
(14.4) 
49.7 
(13.8) 
Weight, kg 93.5 
(14.2) 
94.4 
(13.4) 
93.7 
(13.7) 
95.5 
(17.9) 
92.0 
(14.8) 
92.8 
(13.7) 
91.7 
(12.5) 
93.1 
(15.1) 
BMI, kg/m2 34.0 
(3.9) 
33.8 
(3.8) 
33.4 
(3.5) 
33.8 
(3.9) 
33.1 
(3.5) 
33.4 
(3.5) 
33.4 
(3.5) 
33.9 
(4.4) 
a1 = Weight Watchers, b2 = Slimming World, c3 = Rosemary Conley, d4 = Size down, e5 = General Practice, f6 = 
Pharmacy, g7 = Choice, h8 = Comparator/Exercise 
  
Appendices 
 
347 
 
Jolly 2011 (continued)   
Results  
Baseline data 
(continued) 
3DUWLFLSDQWV¶FKDUDFWHULVWLFVLQDOOJURXSVZHUHPDLQO\IHPDOHDQGDJHG\HDUV
with mean weight 93.3 kg and mean BMI 33.6 kg/m2, approximately.  
Number analyzed ITT: 100 participants of each group for Weight Watchers, Slimming World, Rosemary 
Conley, Size Down, Choice and Comparator 
70 participants of each group for general practice and pharmacy 
Outcomes and estimation 
Table 2: Weight loss (kg) between CWLPs and comparator group at 12 weeks 
kg 1a 2b 3c 4d 5e 6f 7g 8h 
WL 4.4 (3.6-5.3)* 
3.6 (2.7-
4.4)* 
4.2 (3.2-
5.2)* 
2.4 (1.7-
3.1)* 
1.4 (0.4-
2.3)** 
2.1 (1.0-
3.2)* 
3.3 (2.5-
4.1)* 
2.0 (1.2-
2.8)* 
a1 = Weight Watchers, b2 = Slimming World, c3 = Rosemary Conley, d4 = Size down, e5 = General Practice, f6 = 
Pharmacy, g7 = Choice, h8 = Comparator/Exercise, *p d 0.001, **p < 0.05 
WL = Weight loss 
$WZHHNVSDUWLFLSDQWV¶PHDQZHLJKWORVVLQ:HLJKW:DWFKHUVNJZDVJUHDWHUWKDQRWKHUJURXSVDV
Rosemary Conley (4.2 kg, 4.5%), Slimming World (3.6 kg, 3.8%), Choice (3.3 kg, 3.6 %), Size down (2.4 kg, 
2.5%), Pharmacy (2.1 kg, 2.3%), Comparator (2.0 kg, 2.1%) and general practice (1.4 kg, 1.5%), respectively. 
There were statistically significant differences between commercial weight loss programmes and comparator 
group (p d 0.001). 
Table 3: Differences of weight loss (kg and percentage) between CWLPs and comparator group and proportion of 
each CWLP at one year (exercise only) 
CWLPsa 
Mean different 
weight loss in kg 
(95% CI)b 
p-valuec 
Mean different weight 
loss in percentage (95% 
CI) 
p-valuec 
Proportion of achieving 
5% weight loss (95% 
CI) 
WWd -2.4 (-3.6 to -1.2) < 0.001 -2.5 (-3.8 to -1.3) < 0.001 46.0 (36.0 to 56.3) 
SWe -1.5 (-2.7 to -0.4) 0.072 -1.5 (-2.7 to -0.3) 0.106 35.0 (25.7 to 45.2) 
RCf -2.2 (-3.4 to -1.0) 0.001 -2.2 (-3.4 to -1.0) 0.004 42.0 (32.2 to 52.3) 
aCWLPs = Commercial Weight loss Programmes, b95%CI = 95% Confident Interval, cp-value < 0.05 considered 
statistically significant, dWW = Weight Watchers, eSW = Slimming World, fRC = Rosemary Conley 
The differences of mean weight loss between commercial weight loss programmes and comparator groups were 
statistically significant difference in Weight Watchers (2.4 kg, 2.5%, p < 0.001) and Rosemary Conley (2.2 kg, 
2.2%, p < 0.05). Consequently, commercial weight loss programmes were more likely effective than comparators, 
especially Weight Watchers was the most success of weight loss. 
Adverse events Did not report 
Discussions  
Interpretation Introduction 
- Reviewed increasing in the global epidemic obesity worldwide from WHO, the definition 
of obesity by WHO, BMI range, the percentage of obesity and broadly weight loss 
programme participated in England, guideline for primary care physicians and NHS for 
obese patients  
- Reviewed the relevant studies in the US and found that there were good evidences in 
comparing between commercial weight loss and primary care programmes  
- Addressed the study type in the previous research such as the Counterweight programme 
used a cluster randomised trial  
- Described the matter of this study: Lack of evidences in the effectiveness of obesity 
management in primary care and explained objectives of this study  
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Jolly 2011 (continued)   
Discussions  
Interpretation 
(continued) 
Methods 
8-arm randomised controlled trial: Randomisation-sequence was generated by using block 
size of 35 from 10 other practices to one of seven study groups excluding GP in the block 
size of 13. Comparing interventions with a comparator group (Choice of any of the six 
programmes for the final study arm) 
One to one randomisation across groups by blocking sizes. Two primary care arms were 
not used blocking so that allocation was in a ratio 1 to 0.7 compared with other groups. For 
GP, pharmacy or minimal intervention (comparator) groups were allocated by participants 
at the first sessions.  
100 participants were allocated to each arm. There were only the GP and pharmacy arms 
restricted to 70 participants per arm.  
 An independent statistician implemented randomisation sequences and ensured blinding 
and the allocation in opaque and the consecutively number envelopes. 
A trained practice nurse, health trainer or researcher was blinded to the allocation group 
GLGWKHRQH\HDUDVVHVVPHQWDWWKHSDUWLFLSDQW¶VJHQHUDOSUDFWLFHRUKRPH 
A trained practice nurse, health trainer or researcher was blinded. 
Blinding was only investigator side that meant single blind. Participants were not blinded 
because they need to know what programme structures were and how they were consulted.  
Comparison of 8 arms: 1) Weight Watchers, 2) Slimming World, 3) Rosemary Conley, 4) 
Size Down, 5) General practice, 6) Pharmacy, 7) Choice and 8) Exercise/comparator  
 Assessing outcomes: Measured weight without shoes in light clothing, and height was 
measured by using a Seca Leicester portable height. However, some CWLP collected 
height and weight self-reported. Participants could inform their higher height and lower 
weight to a researcher. As a result, average height and weight in such groups would not 
naturally differ from the measuring groups.  
Provider: General practitioner, nurse, food advisor 
 Statistical methods: Reported power calculation, p-value, tests used, programme analysed, 
confidence intervals. There were BOCF, LOCF and completers analysis, however BOCF 
was only primary analysis. 
Power calculation was for: 1) Detecting sample size for the sufficient participants 
randomised to see an effect and 2) preparing for sufficient participants if they declined to 
participate during the study. 
 Results 
- 3UHVHQWHGSDUWLFLSDQWV¶IORZQumber of no response, exclusion and follow-up 
- Reported values in mean weight with both SD and SE including 95% CI 
- All 8 arms reported statistically significant differences within groups. 
- $W\HDUSDUWLFLSDQWV¶PHDQZHLJKWORVVLQ:HLJKW:DWFKHUV.4 kg) was greater than 
Pharmacy (2.1 kg), Comparator (2.0 kg) and general practice (1.4 kg), respectively. There 
were statistically significant differences between Weight Watchers and comparator group 
(2.5 kg, 95% CI: 0.8 to 4.2). 
 Discussion 
The authors summarised the primary outcome of successful weight loss and mentioned 
that Weight Watchers and Rosemary Conley had significantly higher weight loss than 
those in the comparator. They also discussed about details of interventions such as 
physical activity.  
Based on other previous evidences of commercial weight loss programme, the outcome of 
this study was compared to studies of Jebb, Truby and Hardcastle. In contrast, the 
Counterweight Project Team was used to compare with the rest of weight loss 
programmes.  
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Jolly 2011 (continued)   
Discussions  
Interpretation 
(continued) 
Discussion (continued) 
Factors related to lower weight loss in GP or pharmacy were discussed as training 
FRXQVHOORUVJURXSVXSSRUWSDUWLFLSDQWV¶IHHGEDFNDERXWWKHFRQYHQLHQFHRISrogramme or 
VHWWLQJSULPDU\FDUHSUDFWLWLRQHU¶VDELOLW\NQRZOHGJHDQGSUDFWLFHKHDOWKFRQGLWLRQVVXFK
as smoking and behavioural change. 
2WKHULQIOXHQFHVFRXOGEHIURPSDUWLFLSDQWV¶FKDUDFWHULVWLFVVXFKDVJHQGHUPRUHZRPHQ
ethnicity (majority) and socioeconomic deprivation. 
Strengths: Robust evaluation of commercial weight loss services, more diverse of ethnic 
JURXSVDQGSHRSOH¶VZLOOLQJWRDIIRUGWRSDUWLFLSDWHWKHSURJUDPPH 
Limitations: 1) Measuring weight by self-reporting may be overestimate, 2) Low response 
rate to the invitation (11.5%), 3) Only people who had willingness to purchase the 
commercial programmes and 4) Group leaders might practice to have good skills to 
encourage other participants in losing weight. 
Further study: Explore factors influenced Weight Watchers with the highest weight change 
of commercial weight loss programmes 
Generalisability Applicable for CWLP such as Weight Watchers, Slimming World and Rosemary Conley 
Other evidence General comments 
Non-pharmacological weight loss programme using diet and physical activity in the 
programme 
Comparison among commercial weight loss programmes and other weight loss 
programmes in different setting areas has been found that 3 CWLPs were more effective 
than primary care based services. Comparison of weight loss among 3 CWLPs was similar 
in terms of Weight Watchers and Rosemary Conley but less weight loss in Slimming 
World. 
Funding  NHS South Birmingham 
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Luszczynska 2007156 
Article identification: 4/2007 5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Luszczynska 2007 Country: UK, Poland 
Objectives Investigated the effects of the implementation intention prompt (IIP) on weight reduction 
Methods  
Participants Inclusion criteria: Overweight or obese women aged 18-76 years with BMI > 25 kg/m2. 
 Exclusion criteria: Participants had BMI d 25 kg/m2. 
 Settings and/or locations: Warsaw, Poland 
 Duration: 2 months 
 Recruitment methods: Recruited participants from Weight Watchers programme 
 Sample size: 55 participants randomised 
Study design Randomisation-sequence generation: Randomised controlled trial 
Sequence began with the first person with BMI > 25 kg/m2 
No blocking and stratification. Randomised by a random digit generator 
 Allocation concealment: No description. 28 and 27 participants in the control and the IIP 
condition, respectively 
2 and 3 participants from the control and the experimental groups were not available for 
follow-up. Thus, the final samples were 25 each from both groups. 
 Implementation: No description 
 Blinding: Experimenters 
 Statistical methods: Used ANOVA to measure weight, BMI and frequency of planning 
Intervention Weight Watchers with IIP: Participants were 
- Invited to make a plan about their diet and exercise 
- Planned by writing details in 6 food categories such as sweets, fat food, vegetables, 
fruits, meat and whole grain products 
- Provided a plan about how you would react to the risky situations and fill in the form 
- Recorded their exercise plan 
,IDUHVHDUFKHUFKHFNHGDERXWSDUWLFLSDQWV¶SODQDQGIRXQGWKDWLWZDVRFFDVLRQWRGRVR
they should consider and review their plan to completely encourage the regular plan. 
Control The standard Weight Watchers programme provided weekly as:  
- 1-hour group meeting for 7-12 participants focusing on nutrition, exercise, behavioural 
weight control strategies and social support by group members. 
Outcomes Primary outcome measures: Change in weight and BMI 
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Luszczynska 2007 (continued)  
Results  
Participant flow Did not report 
Baseline data, outcomes and estimation 
7DEOH3DUWLFLSDQWV¶ERG\ZHLJKWDQG%0,DWEDVHOLQHDQGPRQWKVPHDQr SD) 
 Control group IIP group 
 Baseline 2 months Baseline 2 months 
Body weight, kg 89.43 (19.41) 87.33 (21.15) 88.61 (21.88) 84.48 (19.48) 
BMI, kg/m2 33.41 (6.48) 32.88 (6.02) 32.98 (6.66) 31.07 (6.25) 
At 2 months, participants in the IIP group (4.2 kg, 4.7%) were greater weight loss than those in control group (2.1 
kg, 2.4%) as well as their BMI in the IIP group (1.91 kg/m2) and the control group (0.53 kg/m2). 
Number analyzed ITT: Did not report 
Adverse events Did not report 
Discussions  
Interpretation Introduction 
- Reviewed overweight and obesity as risk factors for chronic disease, increasing in 
obesity in 4 continentals such as North America; Europe; Asia and Australia since 1980s, 
weight loss approaches such as diet modification; increasing exercise and cognitive 
behaviour change strategies  
- Reviewed the relevant studies about the commercial weight loss programme, especially 
Weight Watchers including benefits from the programme  
- Also, reviewed about theory used in this study, implementation, intentions, planning and 
behaviour change, studies supported this theory  
- Described the matter of this study: Focused on overweight and obese women in Weight 
Watchers  
- Hypothesis was 1) Participants receiving the implementation intention prompt (IIP) 
should lose more weight and achieve a lower BMI than those in the standard Weight 
Watchers for 2 months, 2) Participants receiving the IIP should report more frequent 
action planning and 3) reported frequency of action planning should mediate the effects of 
the IIP on weight and BMI. 
- Explained objectives of this study  
 Methods 
Randomised controlled trial: Randomisation-sequence was begun with the first person 
with BMI > 25 kg/m2. No blocking and stratification 
28 and 27 participants were allocated to the control and the IIP condition, respectively. 
Implemented randomisation by a random digit generator 
Participants (Experimenters) were blinded.  
Comparison of 2 programmes: Control (Standard Weight Watchers) and IIP groups  
 Assessing outcomes: Measured weight by an experimenter to avoid self-reporting bias. 
Weight value should be valid. 
Provider: Only group supporters 
 Statistical methods: No report of level of significant difference, power analysis and 
programmed used. 
There was no power calculation in this study to 1) Detect a difference between baseline 
and the end of treatment with both groups, 2) scan whether or not participants randomised 
were enough to see an effect, 3) not waste time on an underpowered study and 4) prepare 
for sufficient participants if they declined to participate during the study. 
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Luszczynska 2007 (continued)  
Discussions  
Interpretation 
(continued)  
Results 
- 1RUHSRUWRISDUWLFLSDQWV¶IORZDQGHLWKHU,77RUFRPSOHWHUVDQDO\VLV 
- Reported values in mean weight with SD and presented weight change in graph  
- Both programmes reported statistically significant differences at p < 0.05. 
- At 2 months, participants in the IIP group (4.1 kg, 95% CI: 3.19 to 5.07) were greater 
weight loss than those in control group (2.1 kg, 95% CI: 1.11 to 3.09) as well as their BMI 
in the IIP group (1.91 kg/m2) and the control group (0.53 kg/m2). The change in frequent 
action planning mediated the effects of the IIP on weight loss and BMI. 
 Discussion 
The authors summarised the findings and compared to the similar studies such as study of 
Heshka. They also discussed about the percentage of interventions effects in clinical 
outcome and other variables related. 
However, this study was claimed that results supported the previous research in terms of 
IIP and also described how IIP was successful and inexpensive to people who prefer to 
change their behaviour.  
Generalisability Did not report 
Other evidence General comments 
Limitations: Small sample size 
Further study: Assess for  
- Generalisability to other weight loss programmes including community-based 
programmes 
- The record of action plans weekly as well as self-reporting planning and measuring 
lifestyle change  
- Overweight and obese men 
- Larger sample size if possible 
Funding  Warsaw University 
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Rock 2007153 
Article identification: 5/2007 5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Rock 2007 Country: US 
Objectives Tested whether a multifaceted commercial weight loss programme (Jenny Craig, JC) 
promotes greater weight loss in overweight or obese women compared with control 
conditions 
Methods  
Participants Inclusion criteria: Overweight or obese women in San Diego who aged 18 years and older 
with BMI 25-40 kg/m2 were willing and able to participate in clinic visits and maintained 
to contact investigators for 2 years. 
 Exclusion criteria: Participants were  
- Unable to exercise because of severe disability such as severe arthritic conditions 
- Reported a history of presence of a comorbid disease, currently pregnant, breastfeeding 
or plan a pregnancy in the next 2 years 
  Settings and/or locations: San Diego 
 Duration: 12 months 
 Recruitment methods: 276 women screened by telephone as a part of interview 
 Sample size: 70 women randomised 
Study design Randomisation-sequence generation: Randomised trial 
Participants were stratified by BMI 25-YVNJP2 and age d DQG\HDUV
and randomised to 1 of the 2 study groups. 276 women screened. 98 women met the 
inclusion criteria to invite to a clinic visit. 28 women were ineligible whilst 70 women 
were enrolled in the study.  
 Allocation concealment: Insufficient information.  
35 women each were in usual care control group and JC intervention 
 Implementation: Did not report 
 Blinding: Did not report 
 Statistical methods: Baseline data used 2-sample t tests for continuous variables or F2 tests 
for categorical variables and paired t tests for within-group changes for primary analysis. 
2-sample t test was used to compare changes in weight and BMI between both groups at 6 
and 12 months. 
Weight change at least 5% of the initial weight was examined weight loss from baseline to 
6 and 12 months by using SAS V9.1. 
Both groups At baseline, 6 and 12 months visits, all participants were examined their step test. 
Intervention Commercial weight loss programme (JC): Participants received 
- All programme materials including prepackaged prepared foods 
- Description of addressing food, body and mind 
- Weekly one-to-one contact with a consultant with follow-up telephone, e-mail contact 
and website or message board 
The prepackaged prepared foods included:  
- Vegetables, fruit and other additional strategies, provided weekly interactions at a 
community-based facility. 
- The average energy contribution was 820 kcal per day or energy intake 1200-2300 kcal 
per day (35%-RIFOLHQWV¶HQHUJ\ 
Increasing physical activity consisted of goal setting, exercise half an hour on 5 or more 
days/week. 
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Rock 2007 (continued)  
Methods  
Comparison/ 
Control 
Usual care control group 
- Non-prepackaged foods included meals, snacks, vegetables, fruit and dairy products 
- Consultation at baseline and 16 weeks with a research staff dietician 
- Weight loss achieved at least 10% over 6 months 
- Specific meal plans and recommendations to increase exercise were provided to 
individual participants.  
Outcomes Primary outcome measures: Weight loss 
Results  
Participant flow 276 women screened by telephone. 178 were ineligible.  
98 screened at the clinic visit. 28 were ineligible. 70 women randomised. 
35 women each in usual care control group and JC intervention 
At 12 months, 32 participants in intervention group and 33 participants in usual care 
control group 
Baseline data 7DEOH3DUWLFLSDQWV¶FKDUDFWHULVWLFVDWEDVHOLQHQ HDFKDQGPHDQr SD)  
  Intervention group Usual care control group 
 Age, years 42 (11) 40 (12) 
 BMI, kg/m2 34.2 (3.7) 33.8 (3.4) 
 Weight, kg 94.4 (12.2) 89.6 (9.4) 
 3DUWLFLSDQWV¶FKDUDFWHULVWLFVLQERWKJURXSVDJHG\HDUVKDGPHDQ%0,
kg/m2 and mean weight 92 (11.1) kg. 
Number analyzed ITT: 35 participants each in intervention group and usual care control group 
Completers: At 12 months, 32 participants in intervention group and 33 participants in 
usual care control group 
Outcomes and estimation 
Table 2: Weight and BMI changes from baseline to 6 and 12 months by ITT and completers, mean (r SD) 
 Intervention group Usual care control group  
 6 mo, ITT 12 mo, 
ITT 
12 mo, 
completers* 
6 mo, ITT 12 mo, 
ITT 
12 mo, 
completers* 
Weight change, kg** -7.2 (6.7) -6.6 (10.2) -7.3 (10.4) -0.3 (3.9) -0.7 (5.5) -0.7 (5.6) 
% Weight change** -7.8 (7.2) -7.1 (10.8) -7.8 (11.1) -0.3 (4.5) -0.7 (6.0) -0.7 (6.2) 
BMI change, kg/m2** -2.6 (2.5) -2.4 (3.8) -2.6 (3.9) -0.2 (1.5) -0.3 (2.1) -0.3 (2.1) 
*At 12 months, 32 participants in intervention group and 33 participants in usual care control group 
**Significant at p < 0.01 between groups at 6 and 12 months 
At 6 months, mean weight change of participants by ITT (87.2 kg, 7.8%) in the intervention group were greater 
mean weight than those in the usual care control group (89.3 kg, 0.3%) as well as BMI in the intervention group 
(31.6 kg/m2) and the usual care control group (33.6 kg/m2), respectively. 
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Rock 2007 (continued) 
Outcomes and estimation (continued) 
At 12 months, mean weight change of participants by completers (87.1 kg, 7.8%) in the intervention group were 
greater mean weight than those in the usual care control group (88.9 kg, 0.7%) as well as BMI in the intervention 
group (31.6 kg/m2) and the usual care control group (33.5 kg/m2), respectively. 
Adverse events Did not report 
Discussions  
Interpretation Introduction 
- Reviewed the prevalence of obese US adults increased over 20 years, BMI range of 
overweight and obesity and  health risk factors related  
- Reviewed the relevant studies tested weight loss strategies and interventions and the 
previous research of Metz; Jenny Craig programme and Heshka 
- Also, reviewed energy intake and expenditure including energy density to know how 
they manipulate on weight loss 
- Described the matter of this study: No studies of a multifaceted commercial weight loss 
programme tested in a randomised trial  
- Explained 2 aims of this study, however, reviewer emphasized only on the first aim to 
promote weight loss  
 Methods 
Randomised trial: Randomisation sequence was generated by stratification on BMI 25-
29.9 vs. NJP2 and age d DQG\HDUV3DUWLFLSDQWVZHUHUDQGRPO\DOORFDWHGWR
1 of the 2 study groups. 70 women were enrolled in the study. 35 women each were in 
usual care control group and JC intervention. 
Implementation and blinding were not applicable. 
Comparison of 2 diets: Usual care control group and JC intervention. At baseline, no 
statistically significant differences. 
Assessing outcomes: No description of measuring weight. Both weight and height values 
could be bias because of over or under estimation. 
Provider: Dietician 
 Statistical methods: Reported p-value, tests used and programme analysed, however, 
power calculation and confidence intervals were unavailable. 
There was no power calculation could help this study for: 1) Detecting a difference 
between treatment programmes in order to scan whether or not participants randomised 
were enough to see an effect and 2) preparing for sufficient participants if they declined to 
participate during the study. 
 Results 
- 5HSRUWHGSDUWLFLSDQWV¶IORZQXPEer of eligible participants, screening at clinic visit, 
randomisation, allocation, exclusion and completers  
- Also, reported values in mean weight with SD  
- Both diet groups reported statistically significant differences between groups at p < 0.05 
and between groups at 6 and 12 month at p < 0.01.  
At baseline, there was no significant difference between groups. 
 At 6 months, mean weight change of participants by ITT (7.2 kg, 7.8%) in the intervention 
group were greater mean weight than those in the usual care control group (0.3 kg, 0.3%). 
At 12 months, mean weight change of participants by ITT (6.6 kg, 7.1%) in the 
intervention group were greater mean weight than those in the usual care control group 
(0.7 kg, 0.7%). 
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Rock 2007 (continued) 
Discussions 
Interpretation 
(continued) 
Discussion 
The authors summarised findings and referred to rationale of this study that was the 
multifaceted approach never tested in a randomised trial.  
Authors compared to the previous research of Tsai and Wadden that demonstrated the 
similar results. Based on other evidences, they discussed about the prepackaged meals and 
snacks and also compared findings to the current study on weight loss and maintenance. 
Moreover, details on discussion were focused on the main expression of dietary guidance 
in Jenny Craig and changes of many factors associated with obesity.  
The authors discussed comparing between commercial programme and control group and 
lastly concluded by following 2 aims of this study.  
Generalisability Not be able to generalise to all overweight or obese women because the sample only 
agreed to participate in a RCT. 
Other evidence General comments 
Limitations: Small sample size, no power calculation and cost-effectiveness 
If there was power calculation, it would help this study to detect a difference weight loss 
between groups, to scan whether or not enough participants randomised in order to see an 
effect and to prepare for sufficient participants if they declined to participate during the 
study. 
Funding  Jenny Craig, Inc 
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Rock 2010154 
Article identification: 1/2010 5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Rock 2010 Country: US 
Objectives Tested whether a free prepared meal and incentivised structured weight loss programme as 
centre-based or telephone-based intervention promotes greater weight loss and weight loss 
maintenance at 2 years in overweight and obese women compared with usual care 
Methods  
Participants Inclusion criteria: Participants  
- Aged 18 years or older with BMI of 25 to 40 kg/m2  
- Had a minimum of 15 kg over ideal weight as defined by the 1983 Metropolitan Life 
Insurance tables  
- Were willing to participate in any of the 3 study groups over a 2-year period and perform 
a simple step test for assessing cardiopulmonary fitness  
- Had no pregnant, breastfeeding or planning to become pregnant in the next 2 years, 
eating disorders, food allergies or intolerances 
 Exclusion criteria: Women  
- Had BMI > 40 kg/m2 because of extreme obesity relating to more serious comorbid 
conditions 
- Involved another diet intervention  
- Were having a history or presence of a significant psychiatric disorder or any other 
disqualified women  
There were no men because of the minority of enrolees. 
 Settings and/or locations: US institutions at 4 study sites that consisted of 3 universities as 
University of California, Arizona, and Minnesota and one centre of health research, 
Oregon 
 Duration: 24 months 
 Recruitment methods: Recruited participants by using list serves and flyers from the 
research staff at each site  
 Sample size: 446 participants randomised. 
Study design Randomisation-sequence generation: Randomised controlled trial 
No further description 
 Allocation concealment: A 3:3:2 allocation to the centre-based intervention, telephone-
based intervention or usual care used to assign for participants each group. 564 women 
were eligible. 446 participants randomised. Participants were assigned 169 to centre-based 
intervention, 164 to telephone-based intervention and 113 to the usual care group.  
 Implementation: The study statistician generated a randomisation sequence.  
 Blinding: No blinding for counsellors because of providing the programme instruction 
 Statistical methods: At least 80% power calculation was used. ITT and completers analysis 
were presented. Values presented as mean (r SD or 95% CI).  
Data analysis used SAS V9.2 with statistical significance at a 2-sided, p < 0.05. 
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Rock 2010 (continued)   
Methods  
Intervention A free prepared meal and incentivised weight loss programme 
Prepared foods and counsellors were provided by Jenny Craig Inc (California). 
Assigned participants to the centre-based or telephone-based study groups in order to 
receive all programme materials as free-of-charge pre-packaged prepared foods 
Briefed participants weekly one-to-one contacts with an in-person or telephone counsellor 
and follow-up with telephone, e-mail contacts, Web site or message 
Instructed by counsellors to design same as a regular paying client  
Diet component: Low-fat (20%-30% of energy) and reduced energy diet (1200-2000 
kcal/d) including pre-packaged prepared food items that increased amounts of vegetables 
and fruits to reduce the energy density of the diet 
Selected regular foods (e.g. vegetables, fruit, cereal or grain products, low-fat dairy 
products, lean meat or the equivalent and unsaturated fat sources) when preferred and 
encouraged participants to follow a menu plan with pre-packaged foods  
Physical activity: Increased 30 minutes on 5 or more days per week, supported by CDs, 
DVDs and online tools to increase exercise 
Stated their attitudes about weight, food and physical activity including recipes and 
guidance for eating in restaurants 
Comparison/ 
Control 
Usual care: Provided consultation by a research staff dietetics professional, dietary 
material physical activity guidelines to promote weight loss and maintenance at baseline 
and at 6 months  
Achieved a weight loss of 10% over a 6-month period  by aiming energy intake level of 
500 to 1000 kcal/d  
Planned meal based on food groups 
Increased physical activity and strategies and skills e.g. reading food labels, estimating 
serving sizes or eating outside the home  
Followed by monthly check-in via e-mail or telephone lasted one hour 
Discussed in a follow-up counselling session at 6 months  
Outcomes Primary outcome measures: Weight loss, weight loss maintenance 
Results  
Participant flow 564 women were eligible. 118 participants excluded.  
446 participants randomised. 169 participants were assigned to centre-based intervention, 
164 participants were assigned to telephone-based intervention and 113 participants were 
assigned to the usual care group. 
Centre-based intervention: 164 (5 excluded), 159 (10 excluded) and 151 (18 excluded) 
participants at 6, 12 and 24 months, respectively 
Telephone-based intervention: 162 (2 excluded), 157 (7 excluded) and 153 (11 excluded) 
participants at 6, 12 and 24 months, respectively 
Usual care group: 103 (10 excluded), 101 (12 excluded) and 103 (10 excluded) participants 
at 6, 12 and 24 months, respectively 
Primary analysis: 167 participants in centre-based intervention, 164 participants in 
telephone-based intervention and 111 participants in usual care group 
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Rock 2010 (continued)  
Results  
Baseline data Demographic data included age and anthropometric data such as weight and BMI 
Table 1: Demographic characteristics and anthropometric data* of participants at baseline, mean (r SD) 
 Centre-based intervention, 
n = 167 
Telephone-based 
intervention, n = 164 Usual care, n = 111 
Age, year 44 (10) 44 (10) 45 (11) 
Weight, kg 92.2 (90.7 to 93.7) 92.9 (91.1 to 94.7) 91.0 (89.0 to 92.9) 
BMI, kg/m2 33.8 (33.3 to 33.4) 33.8 (33.3 to 34.3) 34.0 (33.4 to 34.6) 
*Baseline values in anthropometric data were shown in mean (95% confidence interval) 
3DUWLFLSDQWV¶FKDUDFWHULVWLFVLQDOOJURXSVDJHGDERXW\HDUVDQGKDGPHDQZHLJKWNJDQGPHDQ%0,
kg/m2, approximately. 
Number analyzed ITT: 167 participants in centre-based intervention, 164 participants in telephone-based 
intervention and 111 participants in usual care group  
Completers: 151 participants in centre-based intervention, 153 participants in telephone-
based intervention and 103 participants in usual care group 
Outcomes and estimation 
Table 2: Weight loss by ITT analysis at 6, 12 and 24 months, mean (95% confidence interval) 
 Intention-to-treat analysis, n = 407 
 6 months 12 months 24 months 
 Centre-based intervention, n = 167 
Weight, kg 83.0 (81.4 to 84.5) 82.1 (81.3 to 84.6) 84.8 (83.0 to 86.5) 
Weight change, kg -9.2 (-9.9 to -8.4) -10.1 (-11.2 to -9.0) -7.4 (-8.7 to -6.1) 
BMI, kg/m2 30.5 (29.9 to 31.0) 30.2 (29.6 to 30.8) 31.2 (30.5 to 31.8) 
 Telephone-based intervention, n = 164 
Weight, kg 84.6 (82.8 to 86.4) 84.4 (82.3 to 86.5) 86.6 (84.4 to 88.9) 
Weight change, kg -8.3 (-9.1 to -7.5) -8.5 (-9.7 to -7.2) -6.2 (-7.6 to -4.9) 
BMI, kg/m2 30.8 (30.3 to 31.4) 30.7 (30.1 to 31.4) 31.5 (30.4 to 32.2) 
 Usual care, n = 111 
Weight, kg 88.1 (86.0 to 90.2) 88.5 (86.3 to 90.8) 89.0 (86.7 to 91.3) 
Weight change, kg -2.9 (-3.8 to -2.0) -2.4 (-3.6 to -1.2) -2.0 (-3.3 to -0.6) 
BMI, kg/m2 32.9 (32.2 to 33.6) 33.2 (32.4 to 33.9) 33.4 (32.5 to 34.2) 
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Rock 2010 (continued)  
Results  
Outcomes and estimation 
$WPRQWKVIRU,77DQDO\VLVSDUWLFLSDQWV¶mean weight loss in the centre-based group (7.4 kg, 7.9%) and in the 
telephone-based group (6.2 kg, 6.8%) were greater than those in the usual care control group (2.0 kg, 2.1%). 
Table 3: Weight loss by completers analysis at 6, 12 and 24 months, mean (95% confidence interval) 
 Completers analysis, n = 442 
 6 months 12 months 24 months 
Centre-based intervention n = 164 n = 159 n = 151 
Weight, kg 82.8 (81.3 to 84.4) 81.5 (79.8 to 83.2) 83.8 (82.0 to 85.7) 
Weight change, kg -9.4 (-10.1 to -8.6) -10.6 (-11.7 to -9.5) -8.2 (-9.5 to -6.8) 
BMI, kg/m2 30.4 (29.9 to 31.0) 30.0 (29.4 to 30.7) 30.8 (30.2 to 31.5) 
Telephone-based 
intervention 
n = 162 n = 157 n = 153 
Weight, kg 84.5 (82.7 to 86.3) 83.8 (81.7 to 85.9) 86.1 (83.8 to 88.4) 
Weight change, kg -8.4 (-9.2 to -7.6) -8.9 (-10.1 to -7.6) -6.7 (-8.2 to -5.2) 
BMI, kg/m2 30.8 (30.2 to 31.4) 30.5 (29.8 to 31.2) 31.3 (30.6 to 32.0) 
Usual care n = 103 n = 101 n = 103 
Weight, kg 87.4 (85.3 to 89.6) 87.7 (85.4 to 90.0) 87.8 (86.3 to 91.1) 
Weight change, kg -3.1 (-4.1 to -2.2) -2.7 (-3.9 to -1.4) -2.1 (-3.6 to -0.7) 
BMI, kg/m2 32.7 (33.2 to 34.7) 32.9 (32.1 to 33.7) 33.0 (32.5 to 34.2) 
$WPRQWKVIRUFRPSOHWHUVDQDO\VLVSDUWLFLSDQWV¶PHDQZHLJKWORVVLQWKHFentre-based group (8.2 kg, 8.9%) 
and in the telephone-based group (6.7 kg, 7.2%) were greater than those in the usual care control group (2.1 kg, 
2.3%). 
Weight loss among 3 groups at 12 months was statistically significant difference (p < 0.05). This study showed 
that the centre-based and telephone-based groups were higher weight loss than the usual care control group. Thus, 
a free prepared meal and incentivised weight loss programme recommended to control weight for over 2-year 
period. 
Adverse events Did not report 
Discussions  
Interpretation Introduction 
- Reviewed the prevalence of overweight and obese US adults, National survey data 
indicated BMI range of overweight and obesity, health risk factors related to obesity and 
recommendation from clinical and public health guideline 
- Described the matter of this study: A few studies of some potential programmes to 
promote weight loss equal or surpass office-based counselling or medical interventions.  
- Explained 2 aims of this study, however, reviewer emphasized only on the first aim to 
promote greater weight loss  
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Rock 2010 (continued)  
Discussions  
Interpretation 
(continued) 
Methods 
Randomised controlled trial: Randomisation sequence was generated by a ratio of 3:3:2 
allocation to the centre-based intervention, telephone-based intervention or usual care used 
to assign for participants each group. 446 participants were randomly allocated 169 to 
centre-based intervention, 164 to telephone-based intervention and 113 to the usual care 
group. Statistician implemented randomisation. No blinding for counsellors because they 
needed to provide the programme instruction.  
Comparison of 3 groups: Usual care, the centre-based intervention and telephone-based 
interventions. At baseline, no statistically significant differences. 
 Assessing outcomes: No description of measuring weight. Both weight and height values 
could be bias because of over or under estimation. 
Provider: Dietician 
 Statistical methods: Reported power calculation, p-value, values presented with 95% CI, 
ITT and completers analysis and programme analysed. No report of tests¶GHWDLOV5RFN¶V
previous study in 2007 reported about using test as 1) Baseline data used 2-sample t tests 
for continuous variables or F2 tests for categorical variables, 2) 2-sample t test was used to 
compare changes in weight and BMI between both groups at 6 and 12 months.  
 Results 
- 5HSRUWHGSDUWLFLSDQWV¶IORZQXPEHURIH[FOXVLRQUDQGRPLVDWLRQDOORFDWLRQ,77DQG
completers, and also presented values in mean weight with 95% CI. All groups reported 
statistically significant differences at p < 0.05. At 12 months for ITT analysis with baseline 
YDOXHVXEVWLWXWLRQSDUWLFLSDQWV¶PHDQZHLJKWORVVLQWKHFentre-based group 7.4 kg, 
(95%CI: 6.1-8.7 kg) or 7.9% (98% CI: 6.5-9.3%) and in the telephone-based group 6.2 kg 
(95% CI: 4.9-7.6 kg) or 6.8% (95% CI: 5.2-8.4%) were greater than those in the usual care 
control group 2.0 kg (95% CI: 0.6-3.3 kg) or 2.1% (95% CI: 0.7-3.5%). 
 Discussion 
The authors summarised overall findings and referred to the previous evidences such as 
clinical practitioners, other weight loss programme in RCT and Look AHEAD (Action for 
Health in Diabetes) programme. They detailed all 3 programmes and compared each 
intervention to other similar programmes.  
The structured commercial weight loss programme with free prepared meals effectively 
promoted weight loss. Many components of this structured commercial programme 
included person-to-person behavioural counselling, low-energy density diet, prepackaged 
foods and increased exercise. Using free foods in prepackaged meals and snacks was a 
dietary pattern in order to reduce the risk for cardiovascular disease and stroke. 
Overweight and obese women achieved their weight loss during participating a free 
prepared meal and incentivised structured weight loss programme. There was greater 
weight loss in the structured weight loss programme over 2 years. 
Generalisability Not be able to generalise to other group of patients because of economic benefits and the 
dropout rate. 
Other evidence General comments 
Limitations: 1) This intervention programme was free of charge whilst patients who 
participated in this structured commercial programme needed to pay for enrolment fees 
and foods supplied. Thus, this is not able to generalise the findings. 2) Patients who 
participated in the intervention programme were more likely to highly motivate than 
others. 3) Unblinding the weight loss programme counsellors may affect patienWV¶
behaviour and effectiveness. And 4) The control group was also intervention so that the 
divergence between control and intervention groups could affect the findings. 
Recommendation for further study: The intervention programme with person-to-person 
behavioural counselling may corporate into medical practice that can include health care 
system and/or employer health promotion initiatives. 
Funding  Jenny Craig Inc. 
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Rolland 2009119 
Article identification: 3/2009 5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Rolland 2009 Country: UK 
Objectives Assessed the effectiveness of a low-carbohydrate/high-protein (LCHP), a commercial very 
low-calorie diet (VLCD) or LighterLife programme (LL), and a 600 kcal-deficient (CDD) 
diet in an obese population 
Methods  
Participants Inclusion criteria: Men and women aged ROGHUWKDQZLWK%0,NJP2 
 Exclusion criteria: Patients with a history of hepatic or renal disease, cancer, pregnant or 
lactating, on antidepressant or anti-obesity medication, eating disorder 
 Settings and/or locations: Specialist Obesity Clinic 
 Duration: 9 months 
 Recruitment methods: Recruited patients by referring to a specialist obesity clinic  
 Sample size: 72 patients randomised 
Study design Randomisation-sequence generation: Randomised controlled clinical trial 
254 patients contacted, 120 obese patients assigned to a 600 kcal-deficient (CDD) diet for 
3 months. 72 patients randomised.  
No further description 
 Allocation concealment: Insufficient information  
34 patients allocated to LL group, and 38 patients allocated to LCHP group. 
 Implementation: Doctors implemented randomisation of patients to either LCHP or LL. 
 Blinding: Did not report 
 Statistical methods: 80% power used for power calculation with 2-VLGHGW\SHHUURUĮ
level). Unpaired t tests were used to compare differences between groups whilst Repeat-
measures ANOVA were used to compare differences within groups. ITT and completers 
analysis were performed after 3 and 9 months in both groups. Values presented as mean r 
SD. Data analysis used SPSS V15.0. 
Intervention 1 9-month a commercial very low-calorie diet (Lighter Life, LL):  
Dietary intervention 
- Screening period: 3 months on the low-fat, reduced-energy diet (LFRE), 600 kcal. 
Dietary advice was reviewed at 2, 4, 8 and 12 weeks. 
Randomisation and diet allocation 
- $GGLWLRQDOPRQWKVRIPDLQWDLQLQJZHLJKWORVV!RISDWLHQWV¶ERG\ZHLJKW
Randomised to either LCHP or LL 
- Low-carbohydrate/high-protein diet (LCHP): 
Restricted to d 40 g carbohydrate/day 
Energy intake ranged from 800-1500 kcal 
Given booklet with information about which foods to eat and which to avoid 
Supplemented with multivitamins and minerals 
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Rolland 2009 (continued)   
Methods  
Intervention 2 
(continued) 
- LL (VLCD): 
Administered soups, shakes and bars to replace conventional food 
Provided a daily average of 550 kcal 
Had 2 stages: 1) weight loss, 2) ongoing weight management. Attended weekly single-sex 
group meetings with 7-12 people at each stage. Delivered by a trained LL counsellor  
Enabled active management of motivation and concordance 
Used group support and counselling to encourage long-term behavioural modification and 
weight management. Group support consisted of a mix of research subjects and self-
referred individuals. 
Remained on the weight loss phase for a minimum of 3 months as required and could be 
given a choice to continue for up to 6 months 
Reintroduced solid foods over a 12-week period 
Offered advice on healthy eating, exercise and continual support 
Came to the trial centres monthly for weighing the first 3 months and every other month 
after screening 
Also supported by telephone and email 
- $GGLWLRQDOPRQWKVRIPDLQWDLQLQJZHLJKWORVV!RISDWLHQWV¶ERG\ZHLJKW 
Overall 
intervention 
Started with a dietary treatment that included a low-fat, reduced-energy diet 
- If patients responded to this approach, they will be continued. 
- If patients failed to lose weight with a dietary treatment, they will be considered the 
alternative approach such as LCHP or prescription medication, reviewed monthly by 
dieticians and quarterly by doctors. 
Outcomes Primary outcome measures: Changes in weight  
Other outcome measures: body composition, waist and hip circumference, cardiovascular 
(CDV) risk but not extracted here 
Results  
Participant flow 254 patients contacted, 120 patients assigned to a 600 kcal-deficient (CDD) diet for 3 
months. 30 patients dropped out. 18 patients achieved 5% weight loss.  
72 patients randomised.  
LL group: 34 patients allocated. 20 patients dropped out. 14 patients completed. 
LCHP group: 38 patients allocated. 18 patients dropped out. 20 patients completed. 
Baseline data Patients¶FKDUDFWHULVWLFV in both LCPH and LL groups aged 42.7 (r 13.1) years and 39.9 (r 
10.4) years with 35 women/3 men and 26 women/8 men, respectively. 
Number analyzed ITT: 34 and 38 patients in LL and LCHP groups, respectively 
Completers: 14 and 20 patients in LL and LCHP groups, respectively 
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Rolland 2009 (continued)   
Results Primary outcome: Weight loss 
Table 1: Weight and BMI measured at baseline, month 3 and month 9, mean (r SD) 
Measurement Included LL, n = 34 and LCHP, n = 38 Completers only in LL, n = 14 and LCHP, n = 20 
 Screening 3 months* 9 months* Screening 9 months Change at 9 
months 
Weight, kg  
LCHP 
 
111.6 (14.1) 
 
108.7 (15.6) 
 
109.6 (16.3) 
 
110.4 (12.2) 
 
109.1 (14.6) 
 
-1.3 (4.5) 
LL 122.6 (19.2) 111.0 (18.4) 107.5 (20.1) 129.6 (23.0) 98.0 (20.3) -31.6 (22.0) 
BMI, kg/m2 
LCHP 
LL 
 
41.6 (4.8) 
46.0 (7.0) 
 
40.6 (5.3) 
41.8 (7.4) 
 
40.9 (5.4) 
40.3 (8.9) 
 
40.8 (4.0) 
47.0 (8.8) 
 
40.3 (4.4) 
35.0 (9.1) 
 
-0.5 (1.7) 
-12.0 (9.7) 
*Significant at p-value < 0.05 
$WPRQWKVSDWLHQWV¶PHDQZHLJKWFKDQJHLQWKH//JURXSNJZHUHJUHDWHUWKDQWKRVHLQ/&+3
group (2.8 kg, 2.5%) as well as BMI in the LL group (4.2 kg/m2) and LCHP group (1.0 kg/m2), respectively. 
At 9 months with includLQJ//DQG/&+3SDWLHQWV¶PHDQZHLJKWFKDQJHLQWKH//JURXSNJZHUH
greater than those in LCHP group (2.0 kg, 1.8%) as well as BMI in the LL group (5.7 kg/m2) and LCHP group 
(0.7 kg/m2), respectively. 
$WPRQWKVZLWKFRPSOHWHUVSDWLHQWV¶ mean weight change in the LL group (31.6 kg, 24.4%) were greater than 
those in LCHP group (1.3 kg, 1.2%) as well as BMI in the LL group (12 kg/m2) and LCHP group (0.5 kg/m2), 
respectively. 
Weight loss between groups at 3 and 9 months was statistically significant difference (p < 0.05). This study 
showed that LL group was higher weight loss than LCHP group. Thus, the LighterLife programme recommended 
to improve weight loss. 
Adverse events Did not report 
Discussions  
Interpretation Introduction 
- Reviewed how importance of the effective weight loss and data from FORESIGHT report 
about obese UK adults, cost of obesity from NHS and policy  
- Reviewed the relevant studies about the effects of a variety of diets on weight loss in 
either short- or long-term and the meta-analysis of the efficacy and safety of a low 
carbohydrate diet 
- Described the matter of this study: Even though there were the previous studies of diets 
on weight loss, it remained uncertain to which diet is more effective to achieve long-term 
weight loss  
- Explained objectives of this study  
 Methods 
Randomised controlled clinical trial: No definite procedure to generate randomisation 
sequence. However, 254 patients were contacted. 120 obese patients assigned to a 600 
kcal-deficient (CDD) diet for 3 months.  
72 patients were randomised. 34 patients were allocated to LL group, and 38 patients were 
allocated to LCHP group. Doctors implemented randomisation of patients to either LCHP 
or LL. Blinding was not applicable. 
Comparison of 2 diets: LL and LCHP groups  
Assessing outcomes: Measured weight by using bioelectrical impedance (Tanita BC-418 
MA; Tanita, Arlington Heights IL, US). Weight values should be valid, however, there was 
no report of measuring height so that this value could be bias because of over or under 
estimation. 
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Rolland 2009 (continued)   
Discussions  
Interpretation 
(continued) 
Methods (continued) 
Provider: Dietician, doctor  
Statistical methods: Reported power calculation, p-value, tests used, ITT and completers 
analysis performed and programme analysed   
Power calculation could help this study for: 1) Scanning whether or not participants 
randomised were enough to see an effect and 2) preparing for sufficient participants if they 
declined to participate during the study. 
 Results 
- 5HSRUWHGSDUWLFLSDQWV¶IORZQXPEHURISDUWLFLSDQWDVVLJQPHQWGURS-out, randomisation 
and completers, and values in mean weight with SD  
- Both diet groups reported statistically significant differences at p < 0.05. 
- $WPRQWKVSDWLHQWV¶PHDQZHLJKt change in the LL group (11.6 r 12.9 kg) were 
significantly greater than those in LCHP group (2.8 r 4.5 kg) as well as at 9 months, 
SDWLHQWV¶PHDQZHLJKWFKDQJHLQWKH//JURXSr 21.1 kg) were greater than those in 
LCHP group (1.9 r 5.0 kg) at p < 0.001. 
 Discussion 
The authors summarised findings and discussed about the present obesity epidemic that 
developed several weight loss strategies. Comparing to other previous studies, findings 
were similar to Yancy study in terms of using high-protein diet on weight loss and Foster 
study to improve other risk factors related to obesity. However, this study found that the 
benefits of LHCP approaches were no longer than 9-month programme on weight loss. 
Also, there was no adverse event on hepatic or renal function that seems to be the same as 
other studies. Moreover, this study analysed weight changes e for the completers in both 
groups.  
Generalisability Did not report 
Other evidence General comments 
Recommendation for further study: Suggested to determine the long-term weight loss 
treatment.  
Limitations: Used simple randomisation to assign patients to their diets and no blinding 
Over 9 months of weight loss treatment, LL (VLCDs) was safe and effective to achieve 
weight loss. 
Funding  LighterLife Ltd. 
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Shuger 2011155 
Article identification: 4/2011 5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Shuger 2011 Country: US 
Objectives Determined the effectiveness of continuous self-monitoring and feedback of SenseWearTM 
Armband (SWA) alone and combination with group weight loss (GWL) to improve 
weight loss and waist circumference reduction over a 9-month period in sedentary 
overweight or obese adults 
Methods  
Participants Inclusion criteria: Both men and women aged 18-64 years who were: 
- Underactive (Participants had no accumulating 150 minutes of moderate-to-vigorous 
SK\VLFDODFWLYLW\WKURXJKRXWWKHZHHNLQERXWVPLQXWHV 
- Overweight or obese had BMI 25-45 kg/m2 
- Able to access to the Internet  
 Exclusion criteria: Participants who: 
- Lost weight > 20 lbs in the last 6 months 
- Elevated BP (160/95 mmHg) 
- Limited physical activity because of sickness 
- Had serious medical conditions or other issues e.g. pregnancy or depression that 
contraindicated or confounded the weight loss intervention 
 Settings and/or locations: The greater Columbia, South Carolina area  
 Duration: 9 months, February 2008-2009 
 Recruitment methods : Used a wide variety of techniques, newspaper, mailers, community 
events, worksite and other e-mail distributions 
 Sample size: Randomised controlled trial. 197 randomised  
Study design Randomisation-sequence generation: Generated by computer.  
 Allocation concealment: Blocking for equal length with fixed numbers of treatment 
allotments in each group was used to balance treatment enrolments over time. Randomly 
assigned to one of the four groups 
50 for standard care, 49 for GWL, 49 for GWL + SWA, 49 for SWA alone 
7DEOH3DUWLFLSDQWV¶GURS-out and completing 
Reasons of loss to follow-up 50 for standard 
care 
49 for GWL 49 for GWL + 
SWA 
49 for SWA 
alone 
Time commitment 11 9 5 5 
No contact 4 3 1 3 
Family conflict 2 3 1 - 
Medical condition 1 1 - 1 
Relocated 1 1 - 1 
Other 5 9 6 7 
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Shuger 2011 (continued) 
Methods  
Study design: Allocation concealment (continued) 
7DEOH3DUWLFLSDQWV¶GURS-out and completing (continued) 
Reasons of loss to follow-up 50 for standard 
care 
49 for GWL 49 for GWL + 
SWA 
49 for SWA 
alone 
Number completed at      
Month 4 30 32 41 37 
Month 9 26 28 37 32 
Total 24 21 12 17 
 Implementation: Did not report 
 Blinding: Did not report 
 Statistical methods: 80% power to detect an effect size of 0.81 (assuming Į ). SD 
was approximately assumed 7.0 for the baseline follow-up differences for 2 outcome 
measures of weight loss and waist circumference reduction. 
Descriptive baseline used mean r SD or %. Data analysis used SAS V9.2 
Intervention  There were two parts of the weight loss manual that were 1) a weight loss workbook with 
14 chapters about healthy eating and active living and 2) a set of forms for participants to 
use to record their daily meal and lifestyle activity intake and physical activity. 
Intervention 1 Group-based behavioural weight loss programme (GWL) 
Participants received: 
- 14 GWL sessions from a facilitator based on Active Living Every Day (ALED) and 
Healthy Eating Every Day (HEED) for the first four months 
- Highly emphasis on weight loss so that a weekly weigh-in was needed 
- Six one-on-one telephone counselling sessions to continue support and improve weight 
loss programme during the last five months. 
Intervention 2 Armband alone group (SWA-alone) 
Participants received: 
- The SenseWearTM platform consisting of the armband, a real-time wrist watch display 
and access to a personalised Weight Management Solutions web account 
- A real-time feedback from the wrist watch on several outcomes (i.e. energy expenditure, 
minutes spent in moderate and vigorous exercise and steps for a day) whilst wearing the 
armband 
- Feedback regarding energy balance after they frequently uploaded their armband to the 
website and recorded daily energy intake and body weight to their web accounts 
- Reminder to wear the armband 16 hours a day, 7 days a week 
Intervention 3 Combined GWL and SWA group (GWL + SWA) 
Participants received all components of the GWL and the SenseWearTM platform. 
Comparison/ 
Control 
Standard care 
Participants received a self-directed weight loss manual. The aim of this manual 
programme was to:  
- Help individuals adopt a healthful eating pattern and  
- Increase their physical activity levels through the use of cognitive and behavioural 
strategies  
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Shuger 2011 (continued)  
Methods  
Outcomes Primary outcome measures: Body weight (kg)  
 Secondary outcome measures: BMI (kg/m2) 
Other outcome measures: PA assessments, participant retention and adherence reported 
but not extracted here 
Results  
Participant flow 787 participants were called for screening interviews. 277 Ineligible or not interested: 
 - 2 not in the age criteria 
- 84 not in the BMI criteria 
- 30 being too active 
- 54 in medical exclusions 
- 10 no internet access 
- 48 in weight loss exclusions 
- 13 for activity limitations 
- 34 declined to participate or other 
 510 individuals were eligible for orientation visit. 272 excluded: 
 - 5 not in the BMI criteria 
- 36 in medical exclusions 
- 20 being CESD (Cholesteryl Ester Storage Disease) 
- 211 declined to participates or other 
 238 individuals were eligible for run-in visits. 14 excluded: 
 - 3 high blood pressure 
- 4 for activity logs 
- 7 declined to participates or other 
 224 individuals were eligible for baseline visit. 27 excluded: 
 - 3 not in the BMI criteria 
- 24 not in the BMI criteria 
Baseline data  
Table 2: 3DUWLFLSDQWV¶characteristics at baseline 
Characteristics Total, n = 
197* 
Standard care, n 
= 50* 
GWL, n = 49* SWA alone, n 
= 49* 
GWL + SWA, n 
= 49* 
Age, years 46.9 (10.8) 47.2 (8.9) 46.8 (12.4) 47.7 (11.6) 45.7 (10.4) 
Female, % 161 (81.7) 42 (84.0) 39 (79.6) 40 (81.6) 40 (81.6) 
Weight, kg 92.8 (18.4) 94.2 (18.2) 93.2 (18.6) 92.0 (21.0) 91.9 (15.7) 
BMI, kg/m2 33.3 (5.2) 33.7 (5.5) 33.1 (4.8) 33.2 (5.4) 33.0 (5.0) 
*mean (r SD) or N (%) 
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Shuger 2011 (continued) 
Results  
3DUWLFLSDQWV¶FKDUDFWHULVWLFVLQDOOGLHWJURXSVZHUHPDLQO\IHPDOHDQGDJHGDERXW 47 years with mean weight 93 
kg and mean BMI 33 kg/m2, approximately. 
Number analyzed ITT from each group included in primary analysis 
Outcomes and estimation 
Table 3: Weight and BMI mean differences over time 
  Standard care, n 
= 50* 
GWL, n = 49* SWA alone, n = 
49* 
GWL + SWA, n 
= 49* 
Weight, kg** BL 102.22 (2.97) 101.84 (2.95) 101.15 (2.95) 100.32 (2.97) 
 M4 101.23 (3.03) 100.74 (2.99) 98.48 (2.97) 96.83 (2.99) 
 M9 101.32 (3.05) 99.98 (3.00) 97.60 (2.99) 93.73 (2.99) 
p-value BL vs. M4 0.32 0.23 0.003 < 0.0001 
 BL vs. M9 0.39 0.05 0.0002 < 0.0001 
BMI, kg/m2** BL 34.52 (0.91) 34.54 (0.90) 34.73 (0.90) 34.39 (0.91) 
 M4 34.12 (0.93) 34.21 (0.92) 33.83 (0.91) 33.13 (0.91) 
 M9 34.16 (0.94) 33.84 (0.92) 33.56 (0.92) 32.11 (0.92) 
p-value BL vs. M4 0.25 0.31 0.003 < 0.0001 
 BL vs. M9 0.32 0.03 0.0005 < 0.0001 
Notes: BL = Baseline, M4 = Month 4, M9 = Month 9, SE = Standard error 
*mean (r SE), **Significantly different from Standard care 
$WPRQWKVSDUWLFLSDQWV¶PHDQZHLJKWORVVLQDOOLQWHUYHQWLRQ groups was statistically significant difference 
from Standard care (0.9 kg, 0.9%), GWL (1.86 kg, 1.83%), SWA alone (3.55 kg, 3.5%) and GWL plus SWA 
(6.60 kg, 6.6%). As a result, participants who participated in GWL plus SWA decreased greater weight loss than 
other groups. Therefore SWA could support group-based behavioural weight loss education to improve people 
weight.  
Adverse events Did not report 
Discussions  
Interpretation Introduction 
- Reviewed the prevalence of obese US adults increased 30% of US population, obesity 
defined as risk factor for health chronic conditions, people attempts to lose weight by 
participating in the clinical and commercial weight loss interventions for a short-term 
treatment and one weight loss approach as self-monitoring  
- Defined a new weight loss intervention and described in details how this works 
- Described the matter of this study: Self-monitoring has not been done in a new weight 
loss intervention  
- Hypothesis: Group weight loss intervention with continuous self-monitoring, a 
SenseWearArmband (SWA), interactive weight loss software and a weight loss manual 
would produce greater weight loss than a similar intervention without SWA and self-
monitoring. 
- Explained the aim of this study  
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Shuger 2011 (continued)  
Discussions  
Interpretation 
(continued) 
Methods 
Randomised controlled trial: Randomisation sequence was generated by computer and 
blocking for equal length with fixed numbers of treatment allotments in each group was 
used to balance treatment enrolments over time.  
197 participants were randomised and assigned to one of the four groups. 50 participants 
were allocated to standard care and 49 participants each were allocated to GWL, GWL + 
SWA and SWA alone, respectively.  
Implementation and blinding were not applicable.  
Comparison of 4 groups: Standard care (control group), group-based behavioural weight 
loss education (GWL), Combined GWL and SWA group (GWL + SWA) and Armband 
alone group (SWA alone).  
 Assessing outcomes: Measured weight by using a calibrated balance-beam scale. Weight 
value should be valid, however there was no report of measuring height so that this value 
could be bias because of over or under estimation. 
Providers: NA, however, there were a facilitator from ALED and HEED. 
 Statistical methods: Reported power calculation, p-value, however, values presented, tests 
used and programme analysed, however, confidence intervals were unavailable. 
Power calculation could help this study for: 1) Scanning whether or not participants 
randomised were enough to see an effect, 2) not wasting time on an underpowered study 
and 3) preparing for sufficient participants if they declined to participate during the study. 
 Results 
- 3UHVHQWHGSDUWLFLSDQWV¶IORZDQGQXPEHURILQHOLJLEOHRUQRWLQWHUHVWHGSDUWLFLSDQWs, 
randomisation, exclusion, run-in visit, allocation and ITT and completers analysis, and 
also reported values reported in mean weight with SE 
- All 4 groups reported statistically significant differences at p d 0.01. 
- $WPRQWKVSDUWLFLSDQWV¶PHDQZHLght loss in all 3 intervention groups was statistically 
significant different from Standard care (0.89 kg, p = 0.39), GWL (1.86 kg, p = 0.05), 
SWA alone (3.55 kg, p = 0.0002) and GWL plus SWA (6.60 kg, p = 0.0001). As a result, 
participants who participated in all 3 interventions decreased greater weight loss than 
standard care.  
 Discussion 
The authors referred to the primary aim of this study, summarised findings and described 
details of SWA approach as a new weight loss strategy and how SWA affected in the 
different time point. Based on other evidences, they discussed about studies and 
systematic review of weight loss self-monitoring. The aspect of this present study was 
compared to other studies in terms of self-monitoring of diet and physical activity with the 
SWA and other self-monitoring approaches. 
The use of self-monitoring was suggested and could predict the successful weight loss in 
technology-assisted weight reduction programmes.  
Strength for the primary outcome was a randomised design.  
Limitations: 1) A large attrition rate, 2) Mostly female, 3) A short intervention and 4) No 
well performance in GWL.  
Generalisability Not generalisabiltiy but acceptable  
Other evidence General comments 
This is a new weight loss intervention by using technolog\WRUHDFKLQGLYLGXDOV¶ZHLJKW
with self-monitoring. 
Further study: A new weight loss intervention can improve health lifestyle change and 
precisely assess free-living energy balance and increase the understanding of the 
contribution of energy intake/expenditure to weight loss 
Funding  BodyMedia, Inc 
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Truby 2006126 
Article identification: 1/2006 RevieZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Truby 2006 Country: UK 
Objectives Compared the effectiveness of 4 commercial weight loss diets available to UK adults 
Methods  
Participants Inclusion criteria: Participants aged 18-65 years with BMI 27-40 kg/m2. 
 Exclusion criteria: Participants had coronary heart disease, type 1 or 2 diabetes, renal, 
OLYHUUHVSLUDWRU\IDLOXUHJRXWREHVLW\ZLWK&XVKLQJ¶VGLVHDVHRUK\SRWK\URLGLVPSUHYLRXV
gastric or weight loss surgery, clinical depression, eating disorders, drug or alcohol misuse, 
malabsorptive state, took lipid lowering or anti-hypertensive drugs, taking any drugs for 
weight loss (orlistat and sibutramine), treated for cancer, pregnant or breastfeeding. 
 Settings and/or locations: Community based sample of healthy overweight and obese 
adults, 5-region centres at Surrey University, Bristol University, Nottingham University, 
Ulster (Caleraine) University and Queen Margaret University College, Edinburgh) 
 Duration: 6 months started date in July 2002 
 Recruitment methods: Recruited participants by a BBC advertising campaign (television 
and other forms of media). Participants were selected from people who lived within 30 
miles of a test centre.  
 Sample size: 293 participants randomised (214 women, 79 men) 
Study design Randomisation-sequence generation: Multicentre randomised unblinded controlled parallel 
dietary intervention. Stratification was used to generate randomisation sequence in each 
test centre by following participants¶ sex.  
 Allocation concealment: A group using random number generation allocated them to 
individual group. 300 people enrolled to baseline screening.  
60 participants each estimated to allocate in 5 groups. At least 44 participants completed in 
each group, approximately. 57 participants in Atkins, 58 participants in Weight Watchers 
(WW), 59 participants in Slim-fast, 58 participants in Rosemary Conley, 61 participants in 
Control  
 Implementation: Investigators implemented randomisation. 
 Blinding: Un-blinded investigators and participants 
 Statistical methods: 80% power was used for sample size calculation with significant at     
p < 0.05. ITT analysis with baseline values carried forward (BCF) used to analyse the 
primary outcome. Using ANOVA was to compare differences between groups as well as 
SRVWKRFSDLUZLVHWHVWLQJZLWK7XNH\¶V+6'KRQHVWO\VLJQLILFDQWO\GLIIHUHQWWHVWHGD
significant effect.  
Also, using t tests for continuous variables and F2 for categorical variables were to 
compare differences between participants over time. 
Intervention 1 'U$WNLQV¶QHZGLHWUHYROXWLRQDVHOIPRQLWRUHGORZFDUERK\GUDWHHDWLQJSODQ
Participants were given a copy of Dr Atkins New Diet Revolution.  
Intervention 2 Weight Watchers (WW) pure points programme (an energy controlled diet with weekly 
group meetings, group-based programme): Participants attended the most convenient class 
that can be reimbursed the cost participated one class per week.  
Intervention 3 Slim-fast plan (a meal replacement approach): Participants could reimburse the 2 meal 
replacements for a day and were provided a copy of the Slim-fast support pack. 
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Truby 2006 (continued)  
Methods  
Intervention 4 5RVHPDU\&RQOH\¶VHDW\RXUVHOIVOLPGLHWDQGILWQHVVDORZIDWGLHWDQGDZHHNO\JURXS
exercise class, group-based programme) 
Comparison/ 
Control 
A delayed treatment control group: Maintained weight by diet and exercise pattern. This 
control group offered participants diets for 6 months at the end of study and also was a free 
of charge programme. 
All groups Participants recorded a 7-day diet and physical activity at baseline, 8 weeks and 24 weeks. 
At week 10, participants were offered a free daily multivitamin. At 12 months, dieting 
behaviour and weight change were recorded. 
Outcomes Primary outcome measures: Weight changes over 6 months, measured at baseline, 2 and 6 
months  
Another main outcome measures: Body fat changes but not extracted here 
Results  
Participant flow 300 participants recruited. 7 participants excluded. 293 participants randomised.  
57 participants in Atkins, 58 participants in WW, 59 participants in Slim-fast, 58 
participants in Rosemary Conley, 61 participants in Control 
Excluded: 17 participants in Atkins, 11 participants in WW, 17 participants in Slim-fast, 
17 participants in Rosemary Conley, 21 participants in Control 
Completers at 24 weeks: 40 participants in Atkins, 47 participants in WW, 42 participants 
in Slim-fast, 41 participants in Rosemary Conley, 40 participants in Control 
Baseline data  
Table 1: Baseline characteristics of participants in the BBC diet trials, mean (r SD) 
Characteristic Atkins, n = 57 
Weight Watchers, n 
= 58 
Slim-fast, n 
= 59 
Rosemary Conley, 
n = 58 
Controls, n = 
61 
Men/Women 15/42 16/42 17/42 16/42 15/46 
Age, years 40.9 (9.7) 39.9 (10.9) 38.9 (10.7) 40.6 (10.3) 40.8 (9.6) 
Weight, kg 90.3 (12.7) 88.8 (13.3) 90.1 (14.1) 89.8 (12.9) 87.9 (13.5) 
BMI, kg/m2 31.9 (2.2) 31.2 (2.7) 32.2 (3.0) 31.6 (2.6) 31.5 (2.9) 
Participants¶FKDUDFWHULVWLFV in all groups were mostly women, aged approximately 40.2 years with mean weight 
89.4 kg and mean BMI 31.7 kg/m2. 
Number analyzed ITT: 57 participants in Atkins, 58 participants in WW, 59 participants in Slim-fast, 58 
participants in Rosemary Conley, 61 participants in Control  
Completers: 40 participants in Atkins, 47 participants in WW, 42 participants in Slim-fast, 
41 participants in Rosemary Conley, 40 participants in Control  
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Truby 2006 (continued)  
Results  
Outcomes and estimation 
Table 2: Intention to treat analysis of main outcomes in participants in the BBC diet trials, mean (r SD) 
Outcome Atkins, n = 57 
Weight Watchers, n 
= 58 
Slim-fast, n 
= 59 
Rosemary Conley, 
n = 58 
Controls, n = 
61 
Weight loss, kg      
0-2 months 5.2 (4.4) 4.7 (3.2) 3.7 (3.5) 4.0 (3.3) 0.4 (1.8) 
2-6 months 1.3 (3.1) 2.2 (3.0) 1.4 (2.8) 2.4 (3.4) -0.9 (1.6) 
0-6 months 6.0 (6.4) 6.6 (5.4) 4.8 (5.6) 6.3 (6.1) -0.6 (2.2) 
Weight loss, %      
0-2 months 5.5 (4.2) 5.1 (3.5) 3.8 (3.4) 4.5 (3.6) 0.4 (2.2) 
2-6 months 1.3 (3.1) 2.4 (3.4) 1.3 (2.9) 2.7 (3.7) -1.2 (1.9) 
0-6 months 6.2 (6.2) 7.3 (6.1) 4.9 (5.5) 7.0 (6.6) -0.6 (2.7) 
Notes: The control group was significantly different from all other groups at p < 0.001. 
'XULQJWKHILUVWPRQWKVSDUWLFLSDQWV¶PHDQZHLJKWFKDQJHLQ$WNLQVGLHWNJZDVJUHDWHUWKDQ::
(4.7 kg, 5.1%), Rosemary Conley (4.0 kg, 4.5%) and Slim-fast (3.7 kg, 3.8%), respectively. However, at 6 
PRQWKVSDUWLFLSDQWV¶PHDQZHLJKWFKDQJHLQ::GLHWNJZDVJUHDWHUWKDQ5RVHPDU\&RQOH\NJ
7.0%), Atkins (6.0 kg, 6.2%) and Slim-fast (4.8 kg, 4.9%), respectively. 
There were not statistically significant differences of mean weight loss over time. Although WW was greater 
weight loss than other diets at month 6, there was no more or less effective than other diets. This study provided 
the effects of commercial weight loss programmes and help people to select which programmes were appropriate 
to their weight loss goal and to the period of being weight loss treatment.  
Adverse events Did not report 
Discussions  
Interpretation Introduction 
- Reviewed the prevalence of obesity in the UK, proportion of overweight adults, cost of 
obesity from NHS, commercial weight loss programme (Weight Watchers) and self-help 
programme (Atkins)  
- Reviewed the relevant studies in the US 
- Described the matter of this study: Limited on evidences of commercial diets  
- Explained the popular commercial weight loss programmes and objectives of this study  
 Methods 
Multicentre randomised unblinded controlled parallel dietary intervention 
Randomisation sequence was generated by stratification in each test centre and following 
participants¶ sex. A group using random number generation allocated them to individual 
group. 300 people enrolled randomly to baseline screening.  
60 participants each were allocated to 5 groups. Investigators implemented randomisation. 
Investigators and participants were un-blinded. 
Comparison of 5 diet groups: Atkins, WW, Slim-fast, Rosemary Conley and Control 
groups. At baseline, no statistically significant differences. 
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Truby 2006 (continued)  
Discussions  
Interpretation 
(continued) 
Methods 
Assessing outcomes: Measured weight in light clothing monthly (would be valid), but no 
report of height value (may be bias because of over or under estimation) 
Provider: Health care professional 
 Statistical methods: Although there was no report of programme analysis used, the tests 
presented in this study were from SPSS. 
Reported power calculation, significant level at p < 0.05, tests used, and ITT analysis with 
baseline values carried forward (BCF)  
Power calculation could help this study for: 1) Scanning whether or not participants 
randomised were enough to see an effect and 2) preparing for sufficient participants if they 
declined to participate during the study. 
 Results 
- 5HSRUWHGSDUWLFLSDQWV¶IORZDQd number of exclusion, randomisation, allocation, 
withdrawal and completers, and also presented values in mean weight with SD  
- All 5 groups reported statistically significant differences at p < 0.05. At baseline, there 
was no significant difference among diet groups.  
At any particular time point, mean weight loss was not significant difference among all 
GLHWJURXSV+RZHYHUDWWKHHQGRIWKHSURJUDPPHSDUWLFLSDQWV¶PHDQZHLJKWFKDQJHLQ
all diet groups was 5.9 kg.  
 Discussion 
The authors summarised this study in terms of clinical benefits such as decreasing in waist 
circumference and BP. The higher weight lost, the more BP and WC reduced. All 4 weight 
loss approaches were similarly effective after 6 months. Based on other evidences, this 
study compared to those and also found that effective weight loss was similar. However, 
more information was needed for health care professionals in order to decide which dietary 
supplements suited patients. Thus, this study could not predict the best approach for each 
person to either lose or maintain weight in the longer term. 
Generalisability Did not report 
Other evidence General comments 
No report of limitations, however, recommendation for further study could be suggested a 
larger number of group members and weight maintenance. 
Commercial weight loss programme could assist the uncomplicated obese adults. Findings 
provided the weight loss goal by dieting and practitioner managing and information on the 
best effect to highly motivate participants for improving weight loss over one year. 
Funding  The BBC 
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Van Wier 2011157 
Article identification: 5/2011 5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Van Wier 2011 Country: Netherlands 
Objectives Determined the effectiveness of a weight-management programme with personal 
counselling by phone or e-mail 
Methods  
Participants ,QFOXVLRQFULWHULD(PSOR\HHVDJHG\HDUVKDG%0,NJP2SDLGHPSOR\PHQW
hours a week, could read and write Dutch and access to the Internet either at work or at 
home. 
 Exclusion criteria: Had pregnant, diagnosis or treatment for disorders that made exercise 
difficult and BMI < 25 kg/m2 
 Settings and/or locations: 7 Dutch service-sector companies 
 Duration: 6 months between January and August 2004 and follow-up at 2 years 
 Recruitment methods: 21,000 employees screened by questionnaire 
 Sample size: 1386 employees randomised 
Study design Randomisation-sequence generation: Randomly assigned the eligible employees to one of 
the three study groups by using blocks of 18. No further description 
At the 2-year follow-up, if participants did not respond the postal questionnaire, they will 
receive a maximum of 5 reminders (post, e-mail and phone). 
The drop-out participants received a once-only letter in order to ask them whether or not 
they would take part in the final weight measurement. They withdrew because of pregnancy 
or dissatisfaction. 
 Allocation concealment: The sequence generated by number and opaque envelopes. Three 
study groups were phone group (n = 462), Internet group (n = 464) and control group (n = 
460). 
 Implementation: By statisticians 
 Blinding: Did not report 
 Statistical methods: Used 2-sided t tests and chi-square tests to compare baseline values in 
groups with complete and incomplete data 
Sample size calculation: Selected 90% power in 2-tailed tests at a significance level of 0.05 
Missing follow-up weight was multiply imputed for the primary analysis of body weight. To 
examine effectiveness, analyses were based on group allocation, regardless of the actual 
intervention received or of adherence to the intervention. 
Intervention Both intervention groups, participants: 
- Received self-help brochures about overweight, healthy diet and exercise  
- Accessed to a lifestyle intervention programme, the principles of behaviour modification 
consisted of 10 modules that provided information on nutrition and exercise, behaviour 
modification strategies (e.g. self-monitoring, goal-setting) 
- At the end of each module, participants were contacted by their personal counsellor. There 
were counselling team included 2 dieticians and 2 physical activity scientists for a maximum 
of 6 months. 
 The phone group, participants received the programme in the workbook form. 
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Van Wier 2011 (continued)  
Intervention 
(continued) 
The Internet group, participants:  
- Accessed the programme through an interactive Website 
- Had no prescription of diet or physical activity 
- Supported to set their own behavioural goals 
Control Participants only received self-help brochures about overweight, healthy diet and physical 
activity. 
Outcomes Primary outcome measures: Body weight change  
Regarding to body weight, 3 outcomes were: 1) weight change at follow-up, 2) likeliness of 
achieving a decrease of at least 5% of initial weight and 3) weight change from 6 months to 
2 years. 
Results  
Participant flow 4619 participants were eligible on screening questionnaire. 2004 participants excluded. 2615 
were invited to participate. 1161 had no or late response. 
 1454 participants had appointment at baseline measurement. 57 participants did not show-
up. 1397 were eligible to assess at baseline measurement. 11 excluded with reasons: 9 BMI 
< 25kg/m2, 1 pregnant and 1 withdrawal. 
 1386 participants randomised. 462 participants in phone group, 464 participants in Internet 
group and 460 participants in control group. 
 Phone group: 199 participants excluded. 263 participants completed.  
Internet group: 201 participants excluded. 263 participants completed.  
Control group: 194 participants excluded. 266 participants completed.  
Baseline data  
Table 1: Baseline characteristics by intervention group 
 Phone, n = 462 Internet, n = 464 Control, n = 460 All, n = 1386 
Male, n (%) 321 (69.5) 302 (65.1) 306 (66.5) 929 (67.0) 
Age, mean (r SD), years 43 (8.8) 43 (8.4) 43 (8.7) 43 (8.6) 
BMI, mean (r SD), kg/m2 29.5 (3.5) 29.6 (3.4) 29.6 (3.7) 29.6 (60.4) 
3DUWLFLSDQWV¶FKDUDFWHULVWLFVLQDOOGLHWJURXSVZHUHKLJKHUPHQDJHG\HDUVDQGKDGPHDQ%0,
kg/m2 and mean weight 93.2 kg, approximately. 
Number analyzed ITT: Did not report, completers 263 in phone group, 263 in Internet group and 266 in 
control group 
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Van Wier 2011 (continued) 
Results  
Outcomes and estimation 
Table 2: Body weight at baseline and 2-year follow-up 
 Phone Internet Control 
 Baseline Follow-up Baseline Follow-up Baseline Follow-up 
Multiply imputed datasets      
Body weight n = 453  n = 450  n = 448  
Mean (r SD), kg 93.6 (14.0) 92.1 (13.7) 92.9 (14.4) 91.0 (14.4) 93.0 (13.4) 92.0 (13.2) 
ZHLJKWORVV
n (%) 
- 100 (22.1) - 101 (22.4) - 71 (15.9) 
Complete cases       
Body weight n = 263  n = 241  n = 241  
Mean (r SD), kg 92.3 (13.0) 90.9 (13.3) 91.5 (13.7) 89.6 (13.9) 91.3 (12.4) 90.6 (12.9) 
ZHLJKWORVV
n (%) 
- 53 (20.2) - 51 (19.4) - 35 (13.2) 
At 2-year follow-XSSDUWLFLSDQWV¶PHDQZHLJKWORVVLQSKRQHJURXSNJDQG,QWHUQHWJURXSNJ
ZDVJUHDWHUWKDQWKRVHLQ&RQWUROJURXSNJDVZHOODVLQFRPSOHWHFDVHVSDUWLFLSDQWV¶PHDQ
weight loss in phone group (1.4 kg, 1.5%) and Internet group (1.9 kg, 2.0%) was greater than those in Control 
group (0.7 kg, 0.8%).  
Table 3: Differences between intervention groups in body weight 
Variable 
Multiply imputed datasets Complete cases 
Difference (95% CI) p-value Difference (95% CI) p-value 
Body weight 0-24 mo, kg     
Phone vs control -0.4 (-1.4 to 0.7) 0.448 -0.8 (-1.5 to 0.03) 0.059 
Internet vs control -0.9 (-2.0 to 0.3) 0.112 -1.2** (-1.9 to -0.4) 0.004 
Internet vs phone -0.5 (-1.2 to 0.2) 0.142 -0.4 (-1.2 to 0.4) 0.314 
Body weight 6-24 mo,* kg     
Phone vs control 0.5 (-1.3 to 2.3) 0.470 0.4 (-0.4 to 1.1) 0.360 
Internet vs control -0.7 (-1.7 to 0.3) 0.162 -0.6 (-1.4 to 0.1) 0.096 
Internet vs phone -1.0** (-1.7 to -0.3) 0.009 -1.0** (1.7 to 0.4) 0.009 
*Adjusted for baseline body weight, **Significant difference at p < 0.05 
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Van Wier 2011 (continued) 
Results  
Outcomes and estimation (continued) 
Comparing weight loss programmes among groups, there were statistically significant differences between 
Internet and control groups (p = 0.004) and Internet and phone groups (p = 0.009). 
Adverse events Did not report 
Discussions  
Interpretation Introduction 
- Reviewed the prevalence of overweight adults in Netherlands, proportion of overweight 
adults increased between 1990 and 2009, health risk factors related obesity  
- Reviewed the relevant studies about systematic review in the US emphasized on the 
effectiveness of weight loss, types of programme and advantages of the programme 
- Described the matter of this study: No studies providing phone counselling in a-long term 
treatment and no additional knowledge on how the effectiveness of telecommunication 
weight loss interventions was superior than others 
- Explained 2 aims of this study  
 Methods 
Randomisation sequence was generated by using blocks of 18 from the eligible employees 
to one of the three study groups following number and opaque envelopes. 1386 employees 
were randomised. 462 employees were allocated to phone group, 464 allocated to Internet 
group 460 to control group. 
Randomisation was implemented by statisticians. Blinding was not applicable. 
Comparison of 3 groups: Phone, internet and control groups  
 Assessing outcomes: Measured weight with a digital scale (Seca 770, Seca GmbH & Co, 
Hamburg, Germany). Weight value should be valid, however there was no report of 
measuring height so that this value could be bias because of over or under estimation. 
Provider: Counsellor 
 Statistical methods: Reported power calculation, p-value, tests used and programme 
analysed 
There was 90% power calculation to detect a mean weight loss of sample size between 2 
groups in or to scanning whether or not participants randomised were enough to see an 
effect and to prepare for sufficient participants if they declined to participate during the 
study. 
 Results 
- Reported SDUWLFLSDQWV¶IORZDQGQXPEHURIH[FOXVLRQUDQGRPLVDWLRQDOORFDWLRQGURSRXW
and completers, and presented values in mean weight with SD and 95% CI in multiply 
imputed datasets and complete cases 
- All groups reported statistically significant differences at p < 0.05. 
- Comparing weight loss programmes among complete cases, weight loss in the Internet 
group was 1.2 kg (95% CI: -1.5 to 0.4) and in the phone group 0.8 kg (95% CI: -1.5 to 0.03) 
compared with control groups. 
 Discussion 
The authors summarised main findings of this study and referred to reasons of determining 
effectiveness of phone and e-mail on weight control counselling. Consequently, counselling 
was described.  
The authors also explained reasons of selecting employees and the matter of this study, and 
discussed results found by complete-case analysis. However, there were few studies of 
weight reduction have done in the work setting for 6 months but no studies in this setting for 
18 months. As a consequence, results of this study could not compare to other previous 
studies. They confirmed that there was no significant difference in weight loss between 
usual care and phone counselling.  
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Van Wier 2011 (continued) 
Discussions  
Interpretation 
(continued) 
Discussion (continued) 
Discussion is acceptable because the authors summarised and discussed by following the 
primary and secondary aims. They proposed the further aim will be evaluating the effects of 
the intervention on WC, diet and physical activity.  
Generalisability Did not report 
Other evidence General comments 
Limitations: The rate of loss to follow-up and missing weight data 
Strengths: A theory-based intervention was adapted to the Dutch occupational setting, the 
broad selection criteria, the objective of measuring weight for the majority of participants, 
the substantial sample size and the long-term study. 
Future work: Methods to improve retention 
Funding  The Netherlands organisation for Health Research and Development supported the study 
funds within the Prevention Programme, the Netherlands Heart Foundation and 
Body@Work. 
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Womble 2004113 
Article identification: 1/2004 5HYLHZHU¶VLQLWLDOV66 9HULILHU¶VLQLWLDOV+% 
Author and year: Womble 2004 Country: US 
Objectives Assessed the efficacy of eDiet.com (a commercial Internet weight loss programme) to 
improving weight, cardiovascular health and quality of life 
Methods  
Participants Inclusion criteria: Women aged 18-65 years with BMI 27-40 kg/m2. 
 Exclusion criteria: If participants  
- Had type 1 or 2 DM, BP > 140/90 mm Hg, history of cerebrovascular, cardiovascular, 
kidney or liver disease 
- Used medications e.g. steroids  
- Had SUHJQDQF\RUODFWDWLRQZHLJKWORVVRILQLWLDOZHLJht and/or use of anorectic 
agents in the last 6 months, psychosocial contraindications e.g. bulimia nervosa, major 
depression or other psychiatric illness 
 Settings and/or locations: University of Pennsylvania 
 Duration: 1 year  
 Recruitment methods: Recruited participants via telephone calls.  
Participants were interviewed by a clinical psychologist  
158 Eligible via phone: 65 Ineligible, 93 Eligible via clinic visit (46 Ineligible) 
 Sample size: 47 participants randomised  
Study design Randomisation-sequence generation: Randomised controlled trial conducted from 
February 2001 to September 2002. No further description 
 Allocation concealment: No description. 47 participants randomised.  
23 participants were assigned to eDiets.com, and 24 participants were assigned to LEARN 
(Weight loss manual). 
 Implementation: Did not report 
 Blinding: Did not report 
 Statistical methods: 7KHSHUFHQWDJHRISRZHUFDOFXODWLRQZDVZLWKĮOHYHO
8VLQJ6WXGHQW¶VWWHVWVIRULQGHSHQGHQWVDPSOHVZDVWRFRPSDUHGLIIHUHQFHVEHWZHHQ
groups at baseline whilst repeated-measures ANOVA was to evaluate weight change over 
time. A last-observation-carried-forward (LOCF) analysis, a baseline-carried-forward 
(BCF) analysis and a completers analysis were used to present in this study. Data analysis 
used SPSS V11.5. 
Intervention Internet weight loss programme: Virtual visit with dietician 
BMI 27-35 kg/m2 with meal plan ~1200-1300 kcal/d, BMI > 35 kg/m2 with meal plan 
1300 - 1400 kcal/d 
Assisted purchasing appropriate foods 
Provided social support: On-line meeting by professional, on-line bulletin board, fitness 
instructors, 24 h/d help desk, e-mail reminders about the programme and their goals, bi-
weekly diet and fitness e-mail newsletter, allowed members to find a buddy 
Met a psychologist at baseline, weeks 8, 16, 26 and 52: 20 minutes/set  
Recorded food intake daily during the first 16 weeks 
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Womble 2004 (continued) 
Methods  
Comparison/ 
Control 
Weight loss manual: Given a copy of LEARN Program for Weight Management 2008 
A 243-page book: Provided 16 step-by-step lessons for modifying eating, activity and 
thinking habit 
Instructed women to consume a 1200-to-1500-kcal/d self-selected diet of conventional 
table foods, kept daily records of food intakes and the number of calorie consumed 
Encouraged physical activity by walking up to 30 min/day 
Practiced other weight control behaviours  
Outcomes Primary outcome measures: Weight change 
Secondary outcome measures: Cardiovascular health and quality of life not extracted here 
Results  
Participant flow 158 participants were eligible. 65 participants excluded.  
93 participants were eligible via clinic visit. 46 participants excluded. 
47 participants randomised. 23 participants were assigned to eDiets.com, and 24 
participants were assigned to LEARN (Weight loss manual). 
At week 16, 15 participants completed in eDiets.com, and 16 participants completed in 
Weight loss manual. 
At week 52, 8 participants each lost to follow-up in eDiets.com and in Weight loss 
manual. 
Baseline data 7DEOH3DUWLFLSDQWV¶EDVHOLQHFKDUDFWHULVWLFV* 
 Variables eDiets.com, n = 23 Weight loss manual, n = 24 
 Age, years 44.2 (9.3) 43.3 (11.1) 
 Weight, kg 93.4 (12.6) 87.9 (10.8) 
 BMI, kg/m2 33.9 (3.2) 33.0 (3.0) 
 
*Values shown are mean (r SD), There were no statistically significant differences between 
the two groups. 
 All participants were women. Participants¶FKDUDFWHULVWLFV in both eDiet.com and weight 
loss manual aged approximately 43.8 years with mean weight 90.7 kg and mean BMI 33.5 
kg/m2. 
Number analyzed ITT: 23 participants were assigned to eDiets.com, and 24 participants were assigned to 
LEARN (Weight loss manual). 
Completers: 15 participants in eDiets.com, 16 participants in weight loss manual 
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Womble 2004 (continued)  
Results  
Outcomes and estimation 
Table 2: Percentage of weight reduction for participants at week 16 and 52, mean (r SD) 
Condition LOCF (%) BCF (%) Completers only (%) 
eDiets.com, n 23 23 15 
  Week 16 0.9 (3.2) 0.9 (3.1) 1.3 (3.3) 
  Week 52 1.1 (4.0) 1.3 (3.3) 2.1 (3.9) 
Weight loss manual, n 23 23 16 
  Week 16 3.6 (4.0) 3.2 (5.5) 4.0 (3.7) 
  Week 52 4.0 (5.1) 3.1 (4.6) 4.4 (5.0) 
At 16 weeks with LOCF DQDO\VLVSDUWLFLSDQWV¶PHDQZHLJKWFKDQJHLQH'LHWVFRPZDVORZHUWKDQWKRVH
in the weight loss manual (3.6%) as well as at 52 weeks, weight in eDiets.com (1.1%) was lower than those in the 
weight loss manual (4.0%), respectively. 
At 16 weeks with %&)DQDO\VLVSDUWLFLSDQWV¶PHDQZHLJKWFKDQJHLQH'LHWVFRPZDVORZHUWKDQWKRVHLQ
the weight loss manual (3.2 %) as well as at 52 weeks, weight in eDiets.com (1.3%) was lower than those in the 
weight loss manual (3.1%), respectively. 
At 16 weekVZLWKFRPSOHWHUVDQDO\VLVSDUWLFLSDQWV¶PHDQZHLJKWFKDQJHLQH'LHWVFRPZDVORZHUWKDQ
those in the weight loss manual (4.0%) as well as at 52 weeks, weight in eDiets.com (2.1%) was lower than those 
in the weight loss manual (4.4%), respectively. 
Weight loss between groups at 16 and 52 weeks was statistically significant difference (p < 0.05). This study 
showed that eDiets.com was lower weight loss than the weight loss manual group. Although a commercial 
Internet weight loss improved weight, this programme lost weight less than a traditional behavioural weight 
control programme at the same period. 
Adverse events Did not report 
Discussions  
Interpretation Introduction 
- Reviewed the ratio of US overweight and obese adults and discovering the successful 
weight loss interventions in the public health and found that group behavioural weight loss 
programme was broadly, however, those people concern about type of the programme, 
time of being in the weight loss programme and how convenience the clinic visit will be.  
- Reviewed the recent study about the weight loss programme conditions such as group 
meeting, length of treatment and setting 
- Described the matter of this study: No studies of the commercial Internet weight loss 
programme presented results from RCT  
- Hypothesis was individuals who participated in Internet programme lost more weight 
than manual programme 
- Explained objectives of this study  
 Methods 
Randomised controlled trial: No report of how to generate randomisation sequence, 
however, 47 participants were randomised. 23 participants were allocated to eDiets.com, 
and 24 participants were allocated to LEARN (Weight loss manual). Implementation and 
blinding were not applicable. 
Comparison of 2 groups: eDiets.com and LEARN (Weight loss manual). At baseline, no 
statistically significant differences. 
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Womble 2004 (continued)  
Discussions  
Interpretation 
(continued) 
Methods (continued) 
Assessing outcomes: Measured weight without shoes to the nearest 0.1 kg. Weight value 
should be valid, however there was no report of measuring height so that this value could 
be bias because of over or under estimation. 
Provider: A clinical psychologist, family physician 
 Statistical methods: Reported power calculation, p-value, tests used, programme analysed, 
and 3 analyses of LOCF; BCF and completers, however, confidence intervals were 
unavailable. 
Power calculation could help this study for: 1) Detecting a difference among groups to 
scan whether or not participants randomised were enough to see an effect and 2) preparing 
for sufficient participants if they declined to participate during the study. 
 Results 
- 5HSRUWHGSDUWLFLSDQWV¶IORZQXPEHURIHOLJLEOHSDUWLFLSDQWH[FOXVLRQUDQGRPLVDWLRQ
completion and loss to follow-up  
- Reported values in mean weight with SD 
- Both groups reported statistically significant differences at p < 0.05. 
- $WZHHNVZLWK/2&)DQDO\VLVSDUWLFLSDQWV¶PHDQZHLJKWFKDQJHLQH'LHWVFRPr 
3.2%) was lower than those in the weight loss manual (3.6 r 4.0%) as well as at 52 weeks, 
weight in eDiets.com (1.1 r 4.0%) was lower than those in the weight loss manual (4.0 r 
5.1%), respectively. Participants in the manual group significantly lost more weight than 
those in eDiets.com.  
 Discussion 
The authors summarised main findings in terms of the successful weight loss and 2 factors 
related were convenience (time and travel) and structure (type of programme). Based on 
other previous evidences, this study was compared to the manual weight loss programme 
(LEARN) and found that results were similar success in weight reduction.  
As 2 factors mentioned, it seemed to limit the potential benefits of eDiets.com were 1. The 
PLQLPDOXVHRIWKHVHUYLFHV'HSHQGHGRQSDUWLFLSDQWV¶FRQYHQLHQW and 2. Structure 
concern: Did not follow step-by-step as LEARN approach. 
The authors also concluded that this study was the first evaluation of a commercially-based 
Internet weight loss programme. However, consumers were less likely to clinically achieve 
weight loss which provided mainly details in diets and exercise. 
Generalisability Did not report 
Other evidence General comments 
Recommendation for further study: Larger sample size in both men and women, needed to 
assess other internet-based weight loss programmes, always obtained counting number of 
times of participants log on to the web site including length of visits 
Using a commercially-based Internet weight loss programme was not as successful as a 
weight loss manual. The reason was that the Internet programme mostly provided the 
information about diet and exercise as well as the traditional weight loss programme. 
Funding  The North American Association for the Study for the Study of Obesity and NIH 
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Appendix 6 Ethical approval to the pilot study 
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Appendix 7 Four forms of BPWLP  
 
Figure A7.1 Customer record form   
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Figure A7.2 Repeat supply record 
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 Figure A7.3 Consultation checklist 
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Figure A7.4 :HLJKWORVVFKDUWDQG&XVWRPHU¶VFRQVXOWDWLRQQRWHV 
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Appendix 8 Testing normal distribution 
 
 
Figure A8.1 Tests of normality for weight data with Histograms 
 
Figure A8.2 Tests of normality for weight data with Normal Q-Q Plot 
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Figure A8.3 Tests of normality for weight data with Detrended Normal Q-Q Plots 
 
 
 
Figure A8.4 Tests of normality for BMI data with Histograms 
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Figure A8.5 Tests of normality for BMI data with Normal Q-Q Plot 
 
 
 
Figure A8.6 Tests of normality for BMI data with Detrended Normal Q-Q Plots 
  
Appendices 
 
392 
 
Appendix 9 1XPEHURIFOLHQWV¶YLVLWDQGVXSSO\
orlistat  
 
Table A9.1 Number of visits and orlistat supply at the particular time point (n = 120)  
Follow-up visit at 
Attended for follow-
up visits Orlistat supply  
n  %  n %  
1 month 
2 months* 
3 months 
4 months* 
5 months* 
6 months 
7 months* 
8 months* 
9 months 
10 months* 
11 months* 
12 months 
13 months* 
14 months* 
15 months 
16 months* 
17 months* 
18 months 
19 months* 
20 months* 
116 
103 
111 
98 
99 
46 
27 
23 
20 
10 
10 
9 
1 
1 
1 
1 
1 
1 
1 
1 
17.0 
15.1 
16.3 
14.4 
14.6 
6.8 
4.0 
3.4 
2.9 
1.5 
1.5 
1.3 
0.15 
0.15 
0.15 
0.15 
0.15 
0.15 
0.15 
0.15 
116 
102 
94 
51 
49 
41 
27 
23 
20 
10 
10 
9 
1 
1 
1 
1 
1 
1 
1 
1 
20.8 
18.3 
16.8 
9.1 
8.7 
7.3 
4.8 
4.0 
3.4 
1.8 
1.8 
1.6 
0.2 
0.2 
0.2 
0.2 
0.2 
0.2 
0.2 
0.2 
Total 680 100.0 559 100.0 
*Clients purchasing three months supply of orlistat did not need to attend for these follow-ups. 
 
  
Appendices 
 
393 
 
Appendix 10 Agreement was extracted from the 
contract with Boots UK Limited 
 
Schedule One ± Description of Project 
PROJECT TITLE: Weight management  
 
Academic Supervisor: Dr Helen Boardman 
Academic Co-supervisor: Prof Tony Avery 
Industrial Supervisor: Julie Hanmer 
This project aims to investigate weight management services and treatments 
primarily through an evaluation of a pharmacist-led weight management service 
where orlistat is supply via a Patient Group Direction (a private service provide 
by Boots). 
The first phase of this study will evaluate the Boots Pharmacy Weight Loss 
Programme. The primary outcome for the study will be the weight loss and 
reduction in BMI achieved after three months in the programme. The study will 
also include a description of the clients who participate in the programme, 
determination of how long clients continue with the programme and description 
of factors which influence length of time in the programme.  
Data will be collected from paper records held in Boots Pharmacies selected to 
include a range of locations. Data will be collected from the initial assessment 
visit and follow-up visits, and will include demographics, biometric 
measurements, details of the assessment of inclusion and exclusion critera, 
supplies of orlistat, dates of visits and comments about progress and side-
effects. 
Data analysis will consist of frequency counts with percentages to describe the 
data. Effectiveness of the service in reducing weight and BMI will be tested using 
paired t-tests and an evaluation of the clinical relevance of any changes.  
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Schedule Two Materials 
 
 
Data collection  
 
The Student shall not be given direct access to customer records held in store. 
To comply with the requirements of the Data Protection Act 1998, only 
anonymised copies of the paper records held in Boots Pharmacies (i.e. the 
customer record forms for customers treated under the Boots Pharmacy Weight 
Management programme) shall be provided to the Student. The records shall be 
collated by a Boots employee and all patient identifiers shall be blanked out prior 
to photocopying. A second check shall be carried out by another Boots employee 
to ensure that the photocopies are fully anonymised, before being provided to 
the Student. 
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Letters for data collectors 
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Appendix 11 Data collection  
 
Table A11.1 Completeness of data for blood pressure and blood glucose and doctor referral  
Value of data set 1XPEHURIFOLHQWV¶BP 
and BG recorded  
% 
Blood pressure level recorded (mmHg, n = 545)* 
  90/60 - 129/84 (normal BP-review 1 yr) 
  130/85 - 139/89 (normal upper range-accept but recommend 
view 1 yr) 
 
233  
114 
 
42.8 
21.0 
  140/89 for BPWLP (refer to GP-recheck 2 wks) 198  36.2 
Completeness (n = 557) 
  Both pharmacist checks and had BP values 
  No pharmacist checks but had BP values 
  Clients declined to be measured by pharmacists 
 
507  
38  
12  
 
91.0 
6.8 
2.2 
Doctor referral (mmHg, n = 198) 
  No referral although BP < 140/85 
  5HIHUWRGRFWRULI%3 
  Refer to doctor if SBP < 140, DBP > 89 
  5HIHUWRGRFWRULI6%3'%3d 89 
 
146  
30  
16  
6  
 
73.7 
15.2 
8.1 
3.0 
Blood glucose level recorded (n = 524) 
  < 5.6 mmol/L 
  5.6 mmol/L  
 
306  
218  
 
58.4 
41.6 
Completeness (n = 557) 
  Both pharmacist checks and had BG values 
  No pharmacist checks but had BG values 
  Clients declined to be measured by pharmacists 
 
479  
45  
35 
 
86.0 
8.0 
6.0 
Doctor referral (mmol/L, n = 218) 
  No referral although BG < 5.6 
  Refer to doctor if BG  
 
158  
60  
 
72.5 
27.5 
*Level and action from BP:/3623¶V 
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Appendix 12 Medicines prescribed and purchased 
over the counter 
 
Table A12.1 Name of medicines prescribed and purchased over the counter (n = 557 clients) 
1. Medicines for obesity-related health risks (n)* 
Diuretics (38) 
Bendrofluazide, Bendroflumethiazide (2.5, 5 
mg), Furosemide 40 mg, Co-amiofruse 2.5 mg, 
Indapamide 2.5 mg 
Anti-arrhythmic drugs (1) Rythmodan, Flecainide 
Beta-adrenoceptor blocking drugs (28) 
Beta blockers, Atenolol 25 mg (Tenoretic), 
Propranolol, Pindolol, Metoprolol, Nebivolol, 
Sotalol 
Hypertension and heart failure (73) 
BP medicines, Doxazosin (1, 2 mg), Tamsulosin, 
Micadis, Co-tenidone 
Losartan (Cozarr), Irbesartan 150 mg (Aprovel ), 
Candesartan (4, 8 mg), Valsartan 80 mg, 
Perindopril (Coversyl), Olmesartan 10 mg, 
Telmisartan 80 mg 
Lisinopril (Lisprinol), Ramipril 15 mg (Tritace), 
Enalapril 10 mg, Perindopril 
Methyldopa, Accuretic 
Nitrates, calcium-channel blockers and other 
antianginal drugs (39) 
Trinitrate, Isosorbide mononitrate, Glyceryl 
Trinitrate, Ikorel 10 mg 
Verapamil 120 mg, Diltiazem 180 mg 
Nifedipine (Adalat, Coracten), Nifedipine MR 
60, Amlodipine 5 mg (Istin), Lacidipine (Motens) 
Antiplatelet drugs (1) Aspirin (75, 300 mg), Dipyridamole 
Lipid-regulating drugs (44) 
Statins, Atorvastatin (Lipitor 10, 40 mg), Crestor 
(Rosuvastatin 20 mg), Simvastatin (Ezatimibe 40 
mg) 
Bezafibrate (Bezalip), Fenofibrate 
Bronchodilators (87) 
Asthma medications, Salbutamol (Ventolin), 
Salmeterol, Blue inhaler (Terbutaline/ Bricanyl), 
Combivent, Serevent, Spiriva inhaler, Ipratopium 
bromide 
*Many clients had more than one medicine, prescribed or OTC. 
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Table A12.1 (continued)  
1. Medicines for obesity-related health risks (continued) 
Cortocosteroids (9) 
Flixotide accuhaler 100 mcg, Seratide inhaler, 
Becotide, Foradil inhaler 
Beconase, Beclazone 100, Becloforte, 
Beclomethasone (Beclazone, Qvar 50 inhaler), 
Singulair, Prednisolone 
Symbicort, Pulmicort inhaler (400 mg), 
Rhinocort nasal spray 
Drugs used in diabetes (10) Metformin 500 mg, Glicazide 
Thyroid and antithyroids drugs (32) Thyroid drug, Thyroxine (Levothyroxine 50, 175 
mcg) 
Drugs affecting bone metabolism (2) Fosamax 
Drugs for genitor-urinary disorders (2) Trimethoprim, Tolterodine 
Cytotoxic drugs (1) Herceptin 
Drugs used in rheumatic diseases and gout (8) 
Diclofenac (Voltarol, Diclomax, Arthrotec 
Forte), Ibuprofen (400 mg), Naproxen, Arthrotec 
75, Mefenamic acid  
Azathiopine, Glucosamine (and Chondroitin), 
Sulfasalazine, Methotrexate 
Drugs used in neuromuscular disorders (1) Methocarbamol 
  
2. Vitamins (79) 
Multivitamin, Vitamin (supplement), Evening 
primrose oil, Cod liver oil, Calcium tabs, 
Cholecalciferol tablets (Vitamin D, Adcal D3, 
Calcichew), Calcium and Vitamin D, Vitamin B 
complex, Vitamin A, C and E, Zinc, Magnesium 
and Calcium, Osteocare, Multibionta 50+, Ivonne 
supplement 
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Table A12.1 (continued)  
3. Other medicines (n)* 
Sex hormone (46) 
Hormone Replacement Therapy (HRT, Estrapak), 
Estraderm (25, 50 mcg), Premarin (625 mg), 
Propecia, Elleste solo 1 mg, Kliovance, 
Femodene, Evorel, Hormone patches, Avodart, 
Tibolone, Primera, Dianette, Femoston 
Antibacterial drugs (13) 
Antibiotics, Tetracycline 250 mg, 
Oxytetracycline, Minocycline 50 mg, 
Erythromycin 
Anagesics (132) 
Tramadol, Paracetamol (Panadol, Co-codamol, 
Kapake, Tylex, Solpadol), Solpadeine, 
Paracetamol/Dihydrocodeine (Co-dydramol, 
Remedeine), Paracodeine, Sumatriptan, Movelat 
gel, Migraleve, Paramax (Paracetamol and 
metoclopramide) 
Drugs acting in nausea and vertigo (2) Cinnarizine 15 mg, Betahistine 16 mg 
Antihistamines, hyposensitisation and allergic 
emergencies (35) 
Antihistamine, Cetirizine 10 mg, Piriton, 
Avomine, Loratadine (Claritin), Xyzal (Hay 
tablets), Telfast, Nizatidine, Desloratadine 
(Neoclarityn) 
Hypnotics and anxiolytics (4) Zopiclone 7.5 mg, Temazepam 
Antidepressant drugs (42) 
Fluoxetine (Prozac), Citalopram 20 mg 
(Cipramil), Sertraline (Zoloft, Lustral 50, 100 
mg), Fluvoxamine 100 mg, Camcolit 400 mg, 
Cipralex 10 mg, Paroxetine, Venlafaxine 
(Effexor or Efexor), Mirtazapine, Escitalopram, 
Amitriptyline 
Drugs used in psychoses and related disorders (2) Loxapine 10 mg, Lithium carbonate 
Anti-epileptic drugs (13) 
Pregabalin, Carbamazepine 200 mg (Tegretol), 
Phenytoin, Mysoline, Frisium, Gabapentin, 
Trihexylphenidyl, Epilim 300 mg, Depakote 100 
mg, Topiramate, Acetazolamide 
Drugs used in parkinsonism and related disorders 
(1) 
Mirapexin (For restless leg syndrome-RLS) 
Anti-coagulant (2) Warfarin (3, 6 mg) 
Antispasmodics and other drugs altering gut 
motility (1) 
Colpermin, Mebeverine 135 mg (Fybogel) 
Antisecretory drugs and mucosal protectants (42) 
Nexium 40 mg, Omeprazole, Buccastem, 
Lansoprazole, Rabeprazole (Pariet), Gaviscon, 
Ranitidine, Mesalazine, Pantoprazole (Protium 20 
mg), Peptac 
*Many clients had more than one medicine, prescribed or OTC. 
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Table A12.1 (continued)  
3. Other medicines (continued) 
Acute diarrhoea (1) Loperamide 2.5 mg  
Laxatives (1) Macrogols (Movicol) 
Antifungal drugs (1) Terbinafine 
Contraceptives (30) 
Contraceptive pill, Microgynon 30, Noriday, 
Logynon, Cerazette, OTC oral contraceptive, 
Yasmin, Depo injection, Mirena, Orthogynol, 
Ovranette 
Sex hormones and hormone antagonists in 
malignant disease (1) 
Arimidex 
Nutrition and blood (6) Iron tabs (Ferrous sulphate 200, 500 mg), Folic 
acid 
Others (37) 
Sage drops, Garlic capsule, Eye drops acute 
infection, Cider vinegar tablet, Adios, Kalms 
(Herbal sedative), Mineral supplement, Confit 
wiki (Preserved food), Nasal drops, Liquifilm 
tears, Omega 3-6-9, Star flower oil, Ymea, Red 
clover, Semper acne, Horse chestnut, Smoking 
patches, Pregnacare, Chinese medicines for 
weight loss, Cranberry caps, Fish oil, Tumeric, 
3RWDVVLXP&DSVDLFLQFUHDP6W-RKQ¶VZRUW4
Ginko, Aloe vera juice 
Medicines discontinued (1) Reductil 10 mg 
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Table A12.2 Name of medicines prescribed and purchased over the counter for 74 clients 
with BMI < 30 kg/m2 
1. Medicines for obesity-related health risks (n)* 
Diuretics (2) Bendrofluazide, Bendroflumethiazide (2.5 mg)  
Beta-adrenoceptor blocking drugs (3) Atenolol 25 mg (Tenoretic)  
Hypertension and heart failure (8) 
BP medicines, Losartan (Cozarr), Irbesartan 150 
mg (Aprovel ), Lisinopril (Lisprinol), Ramipril 
15 mg (Tritace)  
Nitrates, calcium-channel blockers and other 
antianginal drugs (1) 
Nifedipine  
Antiplatelet drugs (3) Aspirin (75 mg)  
Lipid-regulating drugs (6) Crestor (Rosuvastatin 20 mg), Simvastatin (Ezatimibe 40 mg) 
Bronchodilators (10) Asthma medications, Salbutamol (Ventolin), Serevent, Spiriva inhaler  
Cortocosteroids (6) 
Seratide inhaler, Becotide, Becloforte, 
Beclomethasone (Qvar 50 inhaler), Prednisolone, 
Symbicort  
Drugs used in diabetes (2) Metformin 500 mg  
Thyroid and antithyroids drugs (5) Thyroid drug, Thyroxine (Levothyroxine 50, 175 
mcg) 
Drugs affecting bone metabolism (2) Fosamax 
Drugs used in rheumatic diseases and gout (11) Diclofenac, Ibuprofen (400 mg), Glucosamine  
  
2. Vitamins (7) 
Multivitamin, Vitamin (supplement), Cod liver 
oil, Cholecalciferol tablets (Vitamin D, Adcal 
D3, Calcichew), Calcium and Vitamin D, 
Vitamin C  
*Many clients had more than one medicine, prescribed or OTC. 
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Table A12.2 (continued)  
3. Other medicines (n)* 
Sex hormone (7) Hormone Replacement Therapy (HRT), Estraderm (25 mcg), Premarin (625 mg), Evorel  
Antibacterial drugs (1) Antibiotics  
Anagesics (9) 
Paracetamol (Panadol, Co-codamol), 
Paracetamol/Dihydrocodeine (Co-dydramol, 
Remedeine), Sumatriptan, Migraleve  
Drugs acting in nausea and vertigo (2) Cinnarizine 15 mg, Betahistine 16 mg 
Antihistamines, hyposensitisation and allergic 
emergencies (6) 
Antihistamine, Loratadine (Claritin), Nizatidine, 
Desloratadine (Neoclarityn) 
Hypnotics and anxiolytics (1) Zopiclone 7.5 mg  
Antidepressant drugs (7) Fluoxetine (Prozac), Citalopram 20 mg (Cipramil), Sertraline (Zoloft), Amitriptyline 
Anti-epileptic drugs (1) Gabapentin  
Drugs used in parkinsonism and related disorders 
(1) 
Mirapexin (For restless leg syndrome-RLS) 
Antispasmodics and other drugs altering gut 
motility (1) 
Colpermin, Mebeverine 135 mg (Fybogel) 
Antisecretory drugs and mucosal protectants (8) Nexium 40 mg, Omeprazole, Lansoprazole, Gaviscon, Peptac 
Contraceptives (2) Contraceptive pill, Orthogynol  
Nutrition and blood (2) Iron tabs (Ferrous sulphate 200, 500 mg)  
Others (2) Chinese medicines for weight loss, Tumeric  
*Many clients had more than one medicine, prescribed or OTC. 
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Appendix 13 &OLHQW¶Vvisit and orlistat supply  
 
Table A13.1 Number of visits and orlistat supply at the particular time point (n = 557)  
Visit Follow-up visit at 
Attended for 
follow-up visits Orlistat supply  
n  %  n %  
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
1 month 
2 months* 
3 months 
4 months* 
5 months* 
6 months 
7 months* 
8 months* 
9 months 
10 months* 
11 months* 
12 months 
13 months* 
14 months* 
15 months 
16 months* 
17 months* 
18 months 
19 months* 
20 months* 
21 months 
22 months* 
23 months* 
24 months 
468 
181 
207 
72 
41 
67 
25 
15 
21 
8 
4 
11 
3 
2 
5 
1 
2 
4 
1 
- 
2 
- 
- 
1 
41.0 
16.0 
18.0 
6.3 
3.6 
6.0 
2.2 
1.3 
1.8 
0.7 
0.3 
0.9 
0.3 
0.2 
0.4 
0.1 
0.2 
0.3 
0.1 
- 
0.2 
- 
- 
0.1 
444 
90 
115 
36 
18 
41 
10 
5 
13 
5 
2 
6 
- 
- 
3 
1 
1 
4 
1 
- 
2 
- 
- 
- 
55.7 
11.3 
14.4 
4.5 
2.3 
5.1 
1.3 
0.7 
1.6 
0.7 
0.2 
0.8 
- 
- 
0.4 
0.1 
0.1 
0.5 
0.1 
- 
0.2 
- 
- 
- 
Total 1,141 100.0 797 100.0 
*Clients purchasing three months supply of orlistat did not need to attend for these follow-ups.  
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Appendix 14 Testing normality for outcomes and 
characteristics data 
 
 
 
Figure A14.1 Tests of normality for weight data with Histograms, Normal Q-Q Plot and 
Detrended Normal Q-Q Plots 
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Figure A14.2 Tests of normality for BMI data with Histograms, Normal Q-Q Plot and 
Detrended Normal Q-Q Plots 
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Figure A14.3 Tests of normality for age with Histograms, Q-Q plot and detrended normal Q-
Q plots  
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Figure A14.4 Tests of normality for length of treatment with Histograms, Q-Q plot and 
detrended normal Q-Q plots 
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Figure A14.5 Tests of normality for systolic BP with Histograms, Q-Q plot and detrended 
normal Q-Q plots 
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Figure A14.6 Tests of normality for diastolic BP with Histograms, Q-Q plot and detrended 
normal Q-Q plots 
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Figure A14.7 Tests of normality for random BG with Histograms, Q-Q plot and detrended 
normal Q-Q plots 
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Appendix 15 Customer questionnaire survey  
Pre-test questionnaire 
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Post-test questionnaire booklet 
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Appendix 16 Validity evaluation form 
 
 
 
 
Your views of Weight Loss Programme Questionnaire 
 
We would like you provide some of your opinion or feedback from the questionnaire. Please 
read each statement and decide 9 whether you answer yes, no or not sure. 
 
Comprehension from Weight Loss Programme Questionnaire  
 
 Yes No  Not sure 
1. Do the questions appear to be relevant?    
2. Do the questions appear to be reasonable?    
3. Do the questions appear to be unambiguous?    
4. Do the questions appear to be clear?    
5. Do the questions have a good layout?     
6. Does it appear to be a sequence of questions?    
7. Is its content comprehensive?    
 
8. Other opinion or feedback please specify 
 
 
 
 
 
 
 
 
Thank you very much for your information 
 
 
   
